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Abstract	  
Context:	  	  
The	  human	   foetal	   adrenal	   (HFA)	   is	   an	   integral	   component	  of	   the	   foeto-­‐placental	   unit	   and	  
important	   for	   the	  maintenance	   of	   pregnancy.	   Low	   kisspeptin	   levels	   during	   pregnancy	   are	  
associated	   with	   miscarriage,	   and	   kisspeptin	   and	   its	   receptor	   are	   expressed	   in	   the	   HFA.	  
However,	  the	  role	  of	  kisspeptin	  in	  foetal	  adrenal	  function	  remains	  unknown.	  	  
	  
Objective:	  	  
The	   objective	   of	   this	   work	   was	   to	   determine	   the	   role	   of	   kisspeptin	   signaling	   in	   the	  
developing	  HFA.	  	  	  
	  
Methods:	  
Experiments	  using	  H295R	  adrenocortical	  cells	  and	  primary	  HFA	  cells	  as	  in	  vitro	  models	  of	  the	  
foetal	  adrenal	  were	  conducted.	  The	   spatiotemporal	  expression	  of	   the	  kisspeptin	   receptor,	  
Kiss1R	   in	   the	   HFA	   was	   examined.	   The	   production	   of	   dehydroepiandrosterone	   sulphate	  
(DHEAS)	   from	   HFA	   cells	   after	   kisspeptin	   treatment,	   alone	   or	   in	   combination	   with	  
adrenocorticotropic	  hormone	  or	  corticotropin-­‐releasing	  hormone	  was	  compared.	  	  
	  
The	   association	   of	   plasma	   kisspeptin	   levels	   with	   HFA	   size	   was	   analysed	   in	   a	   longitudinal	  
clinical	  study.	  Thirty-­‐three	  healthy	  pregnant	  women	  were	  recruited	  at	  their	  12-­‐week	  routine	  
antenatal	   ultrasound	   scan.	   Serial	   measurements	   of	   foetal	   adrenal	   volume	   (FAV)	   and	  
maternal	   kisspeptin	   levels	   at	   four	   antenatal	   visits	   (∼20,	   28,	   34,	   and	   38	  weeks’	   gestation)	  
were	   collected.	   Outcomes	   of	   pregnancy	   were	   recorded,	   including	   neonatal	   auxology	   and	  
complications	   in	   the	   postnatal	   period.	  Neoantal	   adrenal	   remodeling	  was	   characterized	   by	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serial	  measurements	  of	  adrenal	  volume	  postnatally.	  	  
	  
Results:	  
Expression	  of	  Kiss1R	  was	  present	  in	  the	  HFA	  from	  8	  weeks	  after	  conception	  to	  term	  and	  was	  
shown	   in	   the	   inner	   foetal	   zone.	   Kisspeptin	   significantly	   increased	   DHEAS	   production	   in	  
H295R	   and	   second-­‐trimester	   HFA	   cells.	   Serial	   measurements	   of	   kisspeptin	   confirmed	   a	  




Together,	  these	  studies	  demonstrate	  that	  kisspeptin	  plays	  a	  key	  role	  in	  the	  regulation	  of	  the	  
HFA,	  and	  thus	  the	  foeto-­‐placental	  unit,	  particularly	  in	  the	  second	  trimester	  of	  pregnancy.	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  wpc	  
	  
Figure	  24.	  	   Immunofluorescence	  co-­‐localisation	  studies	  at	  12	  wpc	  	  	  
	  
Figure.	  25.	  	   Immunofluorescence	  studies	  of	  the	  human	  foetal	  adrenal	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  at	  	  38	  wpc.	  	  
	  
Figure	  26.	  	   Immunofluorescence	   studies	   of	   the	   human	   foetal	   adrenal	   at	  
early,	  mid	  and	  late	  gestation.	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foetal	  tissue.	  
	  
Figure.	  28.	  	   Kiss1R	  expression	  in	  the	  HFA	  	  
	  
Figure.	  29.	  	   Human	  	  foetal	  	  adrenal	  tissue	  in	  	  primary	  culture.	  	  
	  
Figure.	  30.	  	   The	   appearances	   of	   human	   foetal	   adrenocortical	   cells	  
maintained	  in	  culture.	  
	  
Figure	  31.	  	   Monolayer	  of	  human	  	  foetal	  	  adrenal	  cells	  	  from	  	  9wpc	  tissue	  	  
in	  	  primary	  culture.	  	  
	  
Figure	  32.	  	   Immunofluorescence	   	   studies	   	   showing	   	   that	   	   cells	   	   cultured	  	  
from	  human	  foetal	  tissue	  	  are	  	  steroidogenic	  	  factor	  positive.	  
	  
Figure	  33.	  	   Morphologic	   and	   functional	   changes	   of	   HFA	   cells	   in	   primary	  
culture	  over	  time	  
	  
Figure	  34.	  	   Time-­‐dependent	  effects	  of	  kisspeptin	  on	  DHEAS	  production	  in	  
H295R	  cells.	  	  
	  
Figure	  35.	  	   Kisspeptin	  dose	  response	  studies.	  	  
	  


























	   27	  
primary	  HFA	  cells.	  	  
	  
Figure	  37.	  	   Effect	  of	  kisspeptin,	  ACTH,	  CRH	  treatments	  on	  DHEAS	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  production	  (measured	  by	  ELISA)	  by	  H295R	  and	  primary	  cells.	  
	  
Figure	  38.	  	   Effect	   of	   kisspeptin	   on	   DHEAS	   production	   (measured	   by	   LC-­‐
MS/MS)	  by	  H295R	  and	  primary	  cells.	  
	  
Figure	  39.	  	   Foetal	   adrenal	   gland	   volumes	   and	   kisspeptin	   levels	   at	   four	  
antenatal	  visits.	  
	  
Figure	  40.	  	   Postnatal	  neonatal	  adrenal	  gland	  involution.	  
	  
Figure	  41.	  	   Sequential	  maternal	  kisspeptin	  levels	  and	  foetal	  adrenal	  gland	  
volumes.	  Three	  participants	  developed	  pre-­‐eclampsia.	  
	  
Figure	  42.	  	   Sequential	  maternal	  kisspeptin	  levels	  and	  foetal	  adrenal	  gland	  
volumes.	  Two	  participants	  delivered	  pre-­‐term.	  
	  
Figure	  43.	  	   Foetal	   adrenal	   gland	  volumes	  and	  kisspeptin	   levels	   at	   the	  1st	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List	  of	  Abbreviations	  
	  
AC	   	   abdominal	  circumference	  
ACTH	   	   adrenocorticotropic	  hormone	  
AFP	   	   alphafoetoprotein	  
AGP	   	   adrenogonadal	  primordium	  
AHC	   	   adrenal	  hypoplasia	  congenital	  
AngII	   	   Angiotensin	  II	  
AP	   	   adrenal	  primordium	   	   	  
ARC	   	   arcuate	  nucleus	  
AS	   	   antisense	  	  
AT1	   	   angiotensin	  1	  
AVPV	   	   anteroventral	  periventricular	  nucleus	  
BPD	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Brdu	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BMI	   	   body	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  index	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   complementary	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   corticotropin-­‐releasing	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Ct	  	   	   cycle	  threshold	   	   	  
CYP	   	   Cytochromes	  P450	  
DAX1	   	   dosage-­‐sensitive	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  congenital	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   chromosome	  factor	  
DHEA	   	   dehydroepiandrosterone	  
DHEAS	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DZ	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   extracellular	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Edu	   	   5-­‐ethynyl-­‐2ʹ′-­‐deoxyuridine	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   estimated	  foetal	  weight	  
ELISA	   	   enzyme-­‐linked	  immunosorbent	  assay	  
Em	  LSCS	   Emergency	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  section	  
FAdE	   	   foetal	  adrenal-­‐specific	  enhancer	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  adrenal	  volume	  
FGF	   	   fibroblast	  growth	  factor	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FZ	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GA	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GAPDH	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  3-­‐phosphate	  dehydrogenase	  
GC-­‐MS	  	   gas	  chromatography–mass	  spectrometry	  
Gli1	   	   Glioma-­‐Associated	  Oncogene	  Homolog	  1	  
GnRH	   	   gonadotropin-­‐releasing	  hormone	  
GOI	   	   gene	  of	  interest	  
GPCR	   	   G-­‐protein	  coupled	  receptor	  
GR	   	   glucocorticoid	  receptor	  
hCG	   	   Human	  chorionic	  gonadotropin	  
HDBR	   	   Human	  Developmental	  Biology	  Resource	  
HDL	   	   high	  density	  lipoprotein	  
HFA	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  foetal	  adrenal	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Hh	   	   Hedgehog	  
ICH	   	   Institute	  of	  Child	  Health	  
IGF	   	   Insulin-­‐like	  growth	  factor	  2	  
IHH	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  hypogonadotropic	  hypogonadism	  
IOL	   	   induction	  of	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kD	   	   kilodalton	  
KISS1R	  	   Kisspeptin	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LC-­‐MS/MS	   liquid	  chromatography–tandem	  mass	  spectrometry	  
LDL	   	   Low	  density	  lipoprotein	  
MC2R	   	   melanocortin	  receptor	  type	  2	  
MEC	   	   meconium	  	  
mRNA	   	   messenger	  RNA	  
MTA	   	   Material	  transfer	  agreement	  	  
NNU	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  unit	  
NRES	   	   National	  Research	  Ethics	  Service	  
NTC	   	   no	  template	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   phosphate	  buffer	  saline	  
PE	   	   pre-­‐eclampsia	  
PlGF	   	   Placental	  growth	  factor	  
PKA	   	   protein	  kinase	  A	  
PKC	   	   protein	  kinase	  C	  
POMC	   	   Pro-­‐opiomelanocortin	  
PRA	   	   plasma	  renin	  activity	   	  
PROM	   	   prolonged	  rupture	  of	  membranes	  
PTCH1	  	   Protein	  patched	  homolog	  1	  receptor	  
QMUL	   	   Queen	  Mary	  University	  of	  London	  
qPCR	   	   quantitative	  reverse	  transcriptase	  polymerase	  chain	  reaction	  
REC	   	   Research	  ethics	  committee	  
RLH	   	   Royal	  London	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RNA	   	   Ribonucleic	  acid	  
S	   	   	   Sense	  
SD	   	   standard	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SDS	   	   standard	  deviation	  score	  
SER	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  endoplasmic	  reticulum	  
SF1	   	   steroidogenic	  factor	  1	  
SHH	   	   sonic	  hedgehog	  
SMO	   	   Smoothened	  
SLOS	   	   Smith	  Lemli	  Opitz	  syndrome	  
StAR	   	   Steroidogenic	  acute	  regulatory	  protein	  
SULT2A1	   sulphotransferase	  enzyme	  
SVD	   	   spontaneous	  vaginal	  delivery	  
TZ	   	   transitional	  zone	  
UCL	   	   University	  College	  London	  
USS	   	   ultrasound	  scan	  
Wpc	   	   weeks	  postconception	  
	  
ZG	   	   zona	  glomerulosa	   	  
	  
ZF	   	   zona	  fasciculata	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ZR	   	   zona	  reticularis	  
	  
3βHSD	  	   3β	  hydroxysteroid	  dehydrogensase	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1.1 History	  of	  adrenal	  medicine	  
Despite	   their	   importance,	   anatomists	   neglected	   the	   adrenal	   glands	   for	  many	   years.	   Their	  
discovery	   and	   description	   is	   generally	   attributed	   to	   the	   Italian	   anatomist	   Bartolomeo	  
Eustachius	   in	   1563.	   The	   uniqueness	   of	   the	   human	   foetal	   adrenal	   (HFA)	   was	   largely	  
overlooked	   until	   1911	   when	   Stella	   Starkel	   and	   Leslaw	  Wagrzynowski,	   two	   Polish	  medical	  
students,	   described	   the	   foetal	   zone	   (FZ)	   for	   the	   first	   time.	   The	   paper	   appeared	   in	   the	  
German	  Archiv	   für	  mikroskopische	  Anatomie	   und	   Entwicklungsgeschuchte,	  and	   its	   original	  
title	   was	   "Beitrag	   zur	   Histologie	   der	   Nebeniere	   bei	   Feten	   und	   Kindern"	   ("Contribution	   to	  
histology	  of	  adrenals	  of	  foetuses	  and	  children").	  The	  studies	  were	  performed	  on	  100	  adrenal	  
glands	  obtained	  from	  foetuses	  (from	  6	  months	  of	  gestation)	  and	  children	  up	  to	  the	  age	  of	  
five.	   They	   described	   the	   FZ	   as	   a	   "medullary	   zone",	   also	   as	   "immature	   cortex",	   which	  
undergoes	  involution	  in	  first	  years	  of	  life.	  At	  the	  same	  time,	  Elliott	  and	  Armour	  published	  on	  
“The	   development	   of	   the	   cortex	   in	   the	   human	   suprarenal	   gland	   and	   its	   condition	   in	  
hemicephaly”	   also	   describing	   the	   unique	   FZ	   1.	   The	   transient	   FZ	   is	   not	   present	   in	   most	  
mammals.	  It	  appears	  to	  be	  unique	  to	  humans	  and	  a	  few	  higher	  primates.	  
	  
The	   true	   biological	   role	   of	   the	   adrenal	   gland	   only	   really	   became	   apparent	  when	   Addison	  
described	  the	  effects	  of	  adrenal	  insufficiency	  in	  the	  middle	  of	  the	  19th	  Century,	  and	  animal	  
studies	   by	   Brown-­‐Séquard	   reported	   the	   consequences	   of	   adrenalectomy.	   Harvey	   Cushing	  
was	   the	   first	   physician	   to	   report	   the	   classic	   features	   of	   steroid	   hormone	   excess	   in	   1932.	  
During	  that	  decade	  it	  became	  clear	  that	  the	  adrenal	  gland	  produced	  two	  broad	  categories	  of	  
steroids	   –	   termed	   “glucocorticoids”	   and	   “mineralocorticoids”.	   Subsequently,	   the	  
laboratories	   of	   Reichstein	   and	   Kendall	   were	   successful	   in	   isolating	   and	   characterising	   the	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structure	  of	  several	  key	  adrenal	  steroids,	  for	  which	  they	  jointly	  received	  the	  Nobel	  Prize	  for	  
Medicine	  in	  1950.	  More	  recently,	  advances	  in	  molecular	  genetics	  have	  helped	  to	  elucidate	  
the	  pathological	  basis	  of	  many	  adrenal	  conditions.	  
	  
An	  appreciation	  of	  human	  adrenal	  development	  is	  essential	  to	  properly	  understand	  adrenal	  
physiology,	   as	   well	   as	   the	   pathological	   basis	   of	   many	   congenital	   adrenal	   disorders.	  
Furthermore,	   understanding	   the	   regulation	   of	   adrenal	   development	   will	   enlighten	   the	  
emerging	   critical	   role	   the	   foetal	   adrenal	  plays	   as	   a	   component	  of	   the	   foeto-­‐placental	   unit	  
during	  pregnancy.	  
	  
1.2 The	  human	  adrenal	  gland	  	  
1.2.1 Adrenal	  structure	  
The	  adrenal	  glands	  are	   located	  anterior	  and	  superior	   to	   the	  upper	  pole	  of	   the	  kidney	  and	  
comprised	  of	   an	  outer	   cortex	   and	   inner	  medulla	   (Fig.	   1).	   These	   are	  embryonically	   distinct	  
tissues,	   the	   cortex	   arising	   from	   the	   intermediate	   mesoderm,	   while	   the	   medulla	   is	  
established	  from	  neuroectoderm.	  Adult	  human	  adrenals	  weigh	  8-­‐10	  g	  and	  90%	  is	  made	  up	  
of	  the	  cortex.	  The	  medulla	  secretes	  catecholamines	  under	  conditions	  of	  stress	  that	  function	  
as	  “fight	  or	  flight”	  hormones	  2.	  The	  adrenal	  cortex,	  unlike	  the	  medulla,	  is	  essential	  for	  life	  as	  
it	  is	  the	  principal	  steroid	  producing	  organ	  in	  the	  body	  3.	  Adrenal	  failure	  or	  insufficiency	  can	  
lead	  to	  disrupted	  electrolyte	  balance,	   impaired	  carbohydrate	  metabolism,	  and	   in	  the	  most	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Fig.	  1a.	  Anatomy	  and	  structure	  of	  the	  human	  adult	  adrenal	  gland.	  
	  
The	  adrenals	  are	  located	  at	  the	  upper	  poles	  of	  the	  kidneys	  (Yates	  et	  al	  2014).	  
	  
Fig.	  1b.	  The	  zones	  of	  the	  human	  adrenal	  cortex	  
	  
The	  adult	  adrenal	  has	  three	  recognisable	  cortical	  zones,	  the	  zona	  glomerulosa	  (ZG),	  the	  zona	  
fasciculata	  (ZF)	  and	  the	  zona	  reticularis	  (ZR)	  which	  surrounds	  the	  medulla	  5	  
	  
Enclosing	   the	   adrenal	   gland	   is	   a	   capsule	   of	   fibroblasts	   and	   myofibroblasts	   (Fig.	   1a),	  
containing	  an	  arterial	   plexus,	  which	   sends	   trabeculae	   into	   the	  underlying	   cortex.	  Capsular	  
cells	  are	  flattened	  with	  elongated	  nuclei	  arranged	  in	  the	  plane	  of	  the	  capsule.	  The	  cortex	  has	  
three	  distinct	   concentric	   zones,	  named	   from	  outer	   to	   inner	  as	   the	   zona	  glomerulosa	   (ZG),	  
zona	   fasciculata	   (ZF),	   and	   zona	   reticularis	   (ZR)	   6.	   Each	   zone	   can	  be	  distinguished	  easily	  on	  
conventional	  staining	  by	  cell	  size	  and	  morphology.	  The	  narrow	  ZG,	  which	  makes	  up	  to	  15%	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low	  lipid	  content.	  Mineralocorticoids	  such	  as	  aldosterone	  are	  synthesised	  in	  the	  ZG	  and	  are	  
responsible	  for	  regulating	  salt/water	  balance	  and	  blood	  volume	  3,7.	  Beneath	  the	  ZG	  is	  the	  ZF	  
(Fig.	   1b),	   which	   contains	   lipid-­‐rich	   polygonal	   epithelial	   cells	   arranged	   in	   radial	   columns	  
separated	  by	  fenestrated	  capillaries.	  The	  human	  ZG	  is	  arranged	  in	  discrete	  clusters	  such	  that	  
some	  cords	  of	  ZF	  extend	  between	  them	  as	  far	  as	  the	  capsule	  8,9.	  The	  mitochondria	  of	  ZF	  cells	  
have	  tubulovesicular	  cristae.	  Glucocorticoids	  such	  as	  cortisol	  (corticosterone	  in	  rodents)	  are	  
secreted	  by	  the	  ZF	  3,	  and	  have	  crucial	  effects	  on	  metabolism,	  the	  cardiovascular	  system	  and	  
the	   immune	   system.	   The	   innermost	   zone	   is	   the	   ZR,	   comprised	   of	   polyhedral	   cells	   with	  
prominent	   lysosomes	   (Fig.	  1b).	   In	  humans	  and	  higher	  primates	   the	  ZR	  synthesises	  adrenal	  
androgens	   such	   as	   dehydroepiandrosterone	   (DHEA)	   and	   its	   sulphate,	  
dehydroepiandrosterone	   sulphate	   (DHEAS),	   also	   known	   as	   C19	   steroids	   3.	   These	   are	  
precursor	   sex	   hormones	   released	   into	   the	   blood	   stream,	   and	   taken	   up	   by	   the	   testis	   and	  
ovaries	  to	  produce	  testosterone	  and	  oestrogen.	  
	  
1.2.2 Adrenal	  Steroidogenesis	  
Steroidogenesis	  is	  dependant	  on	  the	  delivery	  of	  cholesterol	  to	  mitochondria	  and	  its	  catalysis	  
by	   cytochrome	   P450	   (CYP)	   mixed	   function	   oxidases	   and	   short-­‐chain	   dehydrogenases.	   	   A	  
series	   of	   reactions	   take	   place	   in	   the	   inner	   membrane	   of	   mitochondria	   or	   in	   the	   smooth	  
endoplasmic	  reticulum	  (SER)	  with	  intermediate	  compounds	  shuttling	  back	  and	  forth	  10.	  The	  
human	   adrenal	   cortex	   produces	  mineralocorticoids,	   glucocorticoids	   and	   androgens	   in	   the	  
ZG,	  ZF	  and	  ZR	  respectively,	  the	  products	  being	  dependent	  on	  the	  zone-­‐specific	  expression	  of	  
steroidogenic	  enzymes	  and	  the	  stimulus.	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The	  initial	  substrate	  cholesterol	  is	  synthesised	  de	  novo	  from	  acetate,	  or	  obtained	  from	  high-­‐
density	   lipoproteins	   (HDLs)	   internalised	   from	   the	   circulation	   by	   scavenger	   receptor	   B1,	   or	  
low-­‐density	   lipoproteins	   (LDLs)	   internalised	   by	   LDL	   receptor-­‐mediated	   endocytosis	   11.	  
Cholesterol	  is	  cleaved	  from	  its	  esterified	  form	  by	  hormone-­‐sensitive	  lipase	  (HSL),	  previously	  
known	  as	  cholesterol	  ester	  hydrolase.12	  Hormones,	  such	  as	  ACTH,	  stimulate	  the	  activity	  of	  
this	  intracellular	  neutral	  lipase	  13	  and	  free	  cholesterol	  is	  then	  transported	  from	  the	  outer	  to	  
the	   inner	   mitochondrial	   membrane	   by	   steroidogenic	   acute	   regulatory	   protein	   (StAR).	  
Following	   translocation,	   cholesterol	   is	   converted	   into	   steroids	   through	  sequential	   catalysis	  
by	  a	  series	  of	  enzymes	  (Fig.	  2).	  The	  first	  and	  only	  rate-­‐limiting	  step	  involves	  the	  conversion	  
of	   hydrophobic	   cholesterol	   to	   hydrophilic	   21-­‐carbon	   pregnenolone	   by	   P450	   side	   chain	  
cleavage	   (CYP11A1)	   enzyme.	   Pregnenolone	   is	   then	   translocated	   to	   the	   SER	   where,	   in	  
humans,	   it	   is	   converted	   to	  17OH	  pregnenolone	  by	  17α-­‐hydroxylase	   (CYP17)	   in	   the	  ZF	  and	  
ZR,	   but	   not	   in	   the	   ZG	   where	   CYP17	   is	   not	   expressed.	   3β-­‐hydroxysteroid	   dehydrogenase	  
(3βHSD)	   converts	   17OH	   pregnenolone	   to	   17OH	   progesterone	   in	   the	   ZF	   and	   ZR,	   and	  
pregnenolone	   to	   progesterone	   in	   the	   ZG.	   21-­‐hydroxylase	   (CYP21)	   converts	   progesterone	  
and	   17OH	   progesterone	   to	   11-­‐deoxycorticosterone	   and	   11-­‐deoxycortisol,	   respectively.	  
These	   compounds	   are	   transported	  back	   to	   the	   inner	  mitochondrial	  membrane	  where	   the	  
final	   steps	   of	   steroidogenesis	   take	   place.	   11β-­‐hydroxylase	   (CYP11B1)	   converts	   11-­‐
deoxycortisol	   to	   cortisol	   in	   the	   ZF.	   In	   the	   ZG,	   11-­‐deoxycorticosterone	   is	   converted	   to	  
aldosterone	  by	  aldosterone	  synthase	  (CYP11B2).	  	  
	  
CYP17	  acts	  as	  both	  a	  17α-­‐hydroxylase	  and	  a	  17,20-­‐lyase.	  Cytochrome	  b5,	  expressed	  in	  the	  
ZR,	  promotes	  the	  lyase	  activity	  that	  cleaves	  two	  carbon	  atoms	  to	  produce	  DHEA	  from	  17OH	  
pregnenolone,	  such	  that	  in	  the	  ZR	  cortisol	  production	  is	  suppressed	  and	  adrenal	  androgens	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form	   instead	   14.	   DHEA	   can	   be	   sulphated	   to	   DHEAS	   by	   the	   enzyme,	   sulphotransferase,	  
SULT2A1,	  or	  converted	  to	  androstenedione	  by	  3βHSD	  
	  
Fig.	  2.	  Adrenal	  steroidogenesis	  	  
	  
The	   major	   steroid	   products	   secreted	   by	   the	   adrenal	   cortex,	   mineralocorticoids,	  
glucocorticoids	   and	   adrenal	   androgens,	   are	   synthesised	   via	   a	   complex	   cascade	   of	  
sequential	  reactions	  catalysed	  by	  steroidogenic	  enzymes	  (Yates	  et	  al	  2014).	  	  	  
	  
1.3 Human	  adrenal	  development	  	  
1.3.1 Embryology	  
The	  adrenal	  cortex	  develops	  from	  a	  thickening	  of	  the	  intermediate	  mesoderm	  known	  as	  the	  
gonadal	   ridge,	   in	   contrast	   to	   the	   adrenal	  medulla,	  which	   derives	   from	   the	   ectoderm.	   The	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adrenal	   gland	   appears	   as	   the	   bipotential	   adrenogonadal	   primordium	   (AGP)	   at	   28-­‐30	   days	  
post	   conception	   (dpc)	   in	   humans	   15	   due	   to	   expression	   of	   the	   transcription	   factor,	  
steroidogenic	   factor	  1	   (SF1,	  NR5A1),	  a	  nuclear	   receptor	  essential	   for	  adrenal	  development	  
and	  steroidogenesis	  (Fig.	  3).	  
	  
Fig.	   3.	   Hemi-­‐cross-­‐section	   of	   a	   5-­‐week	   human	   embryo	   showing	   the	   locations	   of	   the	  
adrenal	  primordia	  (suprarenal	  cortices)	  and	  gonadal	  ridges.	  
	  
Steroidogenic	  factor	  1	  (SF1)	  is	  involved	  in	  testicular	  and	  ovarian	  development.	  SRY	   is	  the	  
single	  critical	  regulator	  of	  testicular	  embryogenesis.	  Inactivation	  of	  the	  DAX1	  gene	  leads	  to	  
adrenal	  hypoplasia.	  The	  steroidogenic	  acute	  regulatory	  protein	  (StAR)	  is	  the	  rate-­‐limiting	  
factor	  for	  adrenal	  steroidogenesis.	  16.	  
	  
The	  gonadal	  cells	  migrate	  caudally.	  Those	  cells	  that	  are	  more	  medial,	  expressing	  the	  highest	  
levels	  of	  SF1,	  migrate	  in	  a	  retroperitoneal	  fashion	  to	  the	  upper	  pole	  of	  the	  mesonephros	  to	  
form	  the	  adrenal	  primordium	  at	  33	  dpc.	  At	  about	  48	  dpc	  sympathetic	  neural	  crest	  cells	  start	  
migrating	  to	  the	  area	  where	  the	  adrenal	  primordium	  (AP)	  is	  developing.	  These	  cells	  persist	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as	  clusters	  scattered	  throughout	  the	  foetal	  adrenal	  until	  birth,	  following	  which	  they	  coalesce	  
and	  differentiate	  into	  the	  catecholamine-­‐producing	  chromaffin	  cells	  of	  the	  adrenal	  medulla.	  
Following	   the	   neural	   crest	   invasion,	   the	   adrenal	   primordium	   becomes	   encapsulated	  
resulting	   in	   the	   formation	  of	   a	   distinct	   organ	   just	   above	   the	  developing	   kidney.	   By	   50–52	  
dpc,	  within	  the	  cortex,	  there	  are	  two	  distinct	  zones.	  The	  inner	  zone,	  referred	  to	  as	  the	  foetal	  
zone	   (FZ)	   contains	   large	   polyhedral,	   eosinophilic	   cells	   with	   high	   levels	   of	   expression	   of	  
steroidogenic	   enzymes.	   The	   smaller	   outer	   zone,	   the	   definitive	   zone	   (DZ),	   is	   composed	   of	  
small,	   tightly	   packed	   basophilic	   cells	   with	   much	   lower	   levels	   of	   steroidogenic	   enzyme	  
expression.	  A	  third	  cortical	  zone,	  known	  as	  the	  transitional	  zone	  (TZ),	  becomes	  identifiable	  
from	  around	  14	  weeks	  post	  conception	  (wpc).	  This	  TZ	  is	  located	  between	  the	  DZ	  and	  the	  FZ	  
and	  contains	  cells	  whose	  histological	  appearance	  shares	  features	  of	  both17.	  
	  
Following	  encapsulation	  the	  foetal	  adrenal	  grows	  rapidly,	  undergoing	  tremendous	  change	  as	  
pregnancy	   progresses	   (Fig.	   4a).	   This	   is	   largely	   due	   to	   an	   increase	   in	   size	   of	   the	   FZ,	  which	  
accounts	   for	  80-­‐90%	  of	  the	  mass	  of	  the	  gland	  by	  mid-­‐gestation	  18,19.	  Growth	  of	  the	  HFA	   is	  
most	  rapid	  from	  the	  2nd	  trimester	  and	  by	  18	  weeks	  the	  gland	  is	  approaching	  the	  size	  of	  the	  
kidney	  (Fig.	  4a).	  The	  fastest	  growth	  occurs	  during	  the	  last	  6	  weeks	  of	  gestation,	  mainly	  due	  
to	   an	   enlarging	   FZ.	   The	   foetal	   adrenal	   forms	  0.4%	  of	   body	  weight	   at	   term,	  weighing	   3-­‐5g	  
with	  a	  relative	  size	  10-­‐	  to	  20-­‐fold	  that	  of	  the	  adult	  adrenal	  20.	  The	  main	  function	  of	  the	  foetal	  
adrenal	   during	   pregnancy	   is	   steroidogenesis,	   specifically	   increasing	   C19	   androgen	  
production	   (Fig.	   4b),	   and	   brief	   key	   periods	   of	   increased	   cortisol	   secretion.	   These	   steroids	  
have	  crucial	  roles	  in	  maintaining	  intra-­‐uterine	  homeostasis	  and	  in	  maturation	  of	  the	  foetus	  
in	  preparation	  for	  extra-­‐uterine	  life.	  FZ	  cells	  robustly	  express	  cytochrome	  P450	  17α	  (CYP17),	  
which	   converts	   pregnenolone	   to	   DHEA.	   DHEA	   is	   sulphated	   by	   the	   enzyme	   SULT2A1	   to	  
DHEAS,	  which	   is	   subsequently	   aromatised	   by	   the	   placenta	   to	   oestrogens.	   20.	   FZ	   cells	   also	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produce	   other	   sulphated	   Δ5	   steroids,	   including	   pregnenolone	   sulphate	   and	   17α-­‐
hydroxypregnenolone	  sulphate	  but	  their	  functional	  role	  is	  unclear	  15,20.	  
	  
Fig.	  4.	  Growth	  and	  functional	  development	  of	  the	  foetal	  adrenal	  	  
	  
(4a)	  Size	  of	  the	  adrenal	  gland	  and	  its	  component	  parts	  in	  utero,	  during	  infancy,	  and	  during	  
childhood.	  (Adapted	  from	  Bethune	  JE,	  The	  Adrenal	  Cortex:	  A	  Scope	  Monograph,	  Upjohn,	  
1974.)	  Photograph	  of	  an	  18-­‐week	  foetal	  kidney	  with	  adrenal	  21	  
	  
(4b)	   Zonation	   of	   the	   foetal	   adrenal.	   As	   pregnancy	   progresses,	   the	   growth	   of	   the	   foetal	  
adrenal	   is	   paralleled	   by	   increasing	   steroid	   production,	   principally	   DHEAS	   from	   the	   FZ	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1.3.2 Postnatal	  development	  
The	  HFA	  continues	  to	  undergo	  significant	  remodeling	  during	  neonatal	  and	  pubertal	  periods.	  
Immediately	   after	   birth	   the	   FZ	   rapidly	   involutes	   and	   remodels	   by	   a	   process	   involving	  
apoptosis	   of	   cells	   in	   the	   inner	   region	   of	   the	   FZ,	   and	   there	   is	   a	   concomitant	   decrease	   in	  
adrenal	  androgen	  secretion	  15.	  The	  weight	  of	  the	  adrenal	  gland	  drops	  by	  50%	  within	  the	  first	  
2	   weeks	   after	   birth	   23.	  Whether	   the	   timing	   of	   foetal	   adrenal	   involution	   is	   determined	   by	  
gestation	  or	  by	  birth	  is	  controversial.	  FZ	  androgen	  production	  has	  been	  reported	  to	  persist	  
in	   infants	   born	   prematurely	   24,	   and	   involution	   of	   the	   FZ	   may	   therefore	   be	   linked	   to	  
maturation	   rather	   than	   the	   event	   of	   birth	   itself.	   In	   contrast,	   a	   more	   recent	   study	   has	  
demonstrated	  a	  similar	  pattern	  of	  rapid	  adrenal	  involution,	  with	  size	  of	  the	  adrenal	  gland,	  as	  
measured	  by	  ultrasonography,	  decreasing	  to	  its	  normal	  infantile	  size	  within	  the	  first	  2	  weeks	  
after	  birth	  in	  all	  neonates	  examined,	  regardless	  of	  their	  gestational	  age	  at	  birth	  20.	  The	  FZ	  is	  
absent	   by	   6	   months	   of	   age	   in	   most	   cases.	   Cells	   with	   ZR	   morphology	   are	   detectable	   in	  
humans	   from	  around	  3	  years	  of	  age	  until	  a	  continuous	  ZR	   forms	  at	  around	  6	  years	  of	  age	  
and	   adrenal	   androgen	   synthesis	   recommences,	   a	   stage	   referred	   to	   as	   adrenarche	   25.	   The	  
exact	  mechanisms	  for	  ZR	  growth	  and	  the	  factors	  regulating	  adrenarche	  remain	  elusive.	  The	  
adult	  cortex	  develops	  from	  the	  DZ	  and	  TZ,	  giving	  rise	  to	  the	  ZG	  and	  ZF,	  respectively.	  
	  
1.3.3 Theories	  of	  growth	  and	  zonation	  of	  the	  adrenal	  cortex	  	  
It	   has	   long	  been	   thought	   that	  undifferentiated,	  pluripotent	   stem	  cells	   exist	   in	   the	  adrenal	  
cortex	   to	  maintain	  homeostasis	   in	   the	  adult.	  The	  precise	  origin	  of	  adrenocortical	   cells	  has	  
been	   debated	   over	   the	   years	   and	   their	   origin	   remains	   ambiguous.	   The	   adrenal	   cortex,	   as	  
well	  as	  having	  a	  constant	  turnover	  of	  cells	  to	  replace	  dying	  cells,	   is	  a	  highly	  dynamic	  organ	  
that	   undergoes	   rapid	   changes	   in	   response	   to	   hormonal	   demand	   and	   surgical	   injury,	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following	  which	  it	  demonstrates	  remarkable	  regenerative	  capacity.	  A	  number	  of	  theories	  of	  
the	   origin	   of	   the	   cells	   of	   the	   different	   adrenocortical	   zones	   have	   been	   proposed	   but	   the	  
weight	   of	   evidence	   favours	   the	   centripetal	   migration	   hypothesis	   20.	   This	   postulates	   that	  
there	   is	   a	   continual	   production	   of	   new	   cortical	   cells	   at	   the	   periphery	   of	   the	   gland	   that	  
migrate	  under	  mitotic	  pressure	   to	   the	   inner	   cortical	  medulla	  boundary	  where	   they	  die	   20.	  
Early	   lineage-­‐tracing	   studies	   26,	   transgenic	   studies	   27,28,	   and	   genetic	   lineage	   tracing	  
experiments	  29,30	  have	  provided	  direct	  evidence	  for	  the	  centripetal	  migration	  hypothesis.	  
	  
Intravital	  dye-­‐labeling	  experiments	   supported	  by	  observations	   from	  enucleation	   studies	   in	  
rodents	   these	   cells	   originate	   in	   the	   capsule.	   Proliferation	   studies	   and	   lineage	   tracing	  
experiments	  in	  mice	  propose	  sub	  capsular/DZ	  pools	  as	  the	  site	  of	  progenitor	  stem	  cells	  that	  
differentiate	  as	   they	  move	   centripetally	   through	   the	  gland,	  with	   the	   implication	   that	   they	  
change	   identity	  as	   they	  move	  between	  zones	   29,30.	  An	  alternative	   theory	   is	   that	   there	   is	   a	  
population	   of	   stem	   cells	   in	   the	   foetal	   zone	   or	   transitional	   zone	   that	   can	  migrate	   in	   both	  
directions	  to	  supply	  foetal	  and	  definitive	  zone	  cells.	  A	  combination	  of	  these	  concepts	  may	  be	  
correct,	   with	   the	   foetal	   zone	   contributing	   to	   subscapular	   progenitor	   cells	   during	  
development,	   that	   then	   differentiate	   through	   the	   various	   zones	   to	   maintain	   stable	   cell	  
populations	  in	  the	  mature	  gland	  31.	  	  Some	  conditions	  associated	  with	  adrenal	  hypoplasia	  (for	  
example,	  IMAGe	  syndrome,	  X-­‐linked	  AHC)	  may	  reflect	  a	  defect	  in	  progenitor	  cell	  expansion	  
during	  early	  foetal	  development.	  	  
	  
Zubair,	   et	   al	   using	   the	   FAdE-­‐Cre	  mouse	  model,	   observed	   proliferating	   cells	   in	   a	   scattered	  
pattern	   throughout	   the	   adrenal	   gland	   until	   E13.5	   At	   later	   time	   points,	   these	   cells	   were	  
ordered	   in	   the	   periphery	   of	   the	   adrenal	   gland.	   Similar	   to	   the	   developing	   human	   adrenal	  
cortex,	   the	   mouse	   FZ	   is	   first	   encapsulated	   by	   surrounding	   cells	   of	   the	   intermediate	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mesoderm.	  Following	  encapsulation	  a	  second	  group	  of	  cells	  emerge	  as	  the	  densely	  packed	  
DZ	  or	  definitive	  (adult)	  cortex.	  Sf1	   is	  activated	  by	  FAdE	  only	  in	  the	  FZ	  before	  E14.5	  but	  this	  
enhancer	  does	  not	  activate	  Sf1	  expression	  in	  the	  DZ.	  Zubair	  et	  al	  traced	  the	  fate	  of	  FZ	  cells	  
during	  development	  and	  demonstrated	   that	  all	  DZ	  cells	   are	  derived	   from	  FAdE-­‐expressing	  
cells	   of	   the	   foetal	   adrenal.	   To	   complement	   these	   experiments,	   Zubair	   et	   al	   also	   utilized	   a	  
tamoxifen-­‐inducible	  FAdE-­‐cre	  mouse	  model.	  DZ	  staining	  was	  only	  observed	  when	  tamoxifen	  
was	  administrated	  early	  in	  embryogenesis	  (E11.5-­‐E12.5).	  When	  tamoxifen	  was	  administered	  
after	  E14.5,	  no	  LacZ-­‐positive	  cells	  were	  found.	  These	  results	  are	  consistent	  with	  the	  absence	  
of	  FAdE	  activity	  during	   later	  developmental	  stages	  and	  support	   the	  conclusion	  that	   the	  FZ	  
gives	   rise	   to	   the	   DZ	   32.	   In	   contrast,	   studies	   focused	   on	   a	   downstream	   activator	   of	   the	  
hedgehog	   pathway,	   Glioma-­‐Associated	   Oncogene	   Homolog	   1	   (Zinc	   Finger	   Protein)	   (Gli1)	  
provide	  evidence	  that	  the	  adrenal	  capsular	  cells	  also	  give	  rise	  to	  the	  DZ.	  Gli1-­‐expressing	  cells	  
are	   specifically	   located	   in	   the	   adrenal	   capsule	   and	   do	   not	   express	   Sf1.	   King	   et	   al	  
demonstrated	   that	   this	   subpopulation	   of	   cells	   is	   capable	   of	   giving	   rise	   to	   Sf1-­‐expressing,	  
differentiated	   adrenocortical	   cells	   during	   embryonic	   development30.	   However,	   these	   data	  
are	   in	   conflict	   with	   lineage	   tracing	   experiments	   using	   FAdE-­‐LacZ	   reporter	   mouse	   that	  
revealed	  that	  all	  DZ	  cells	  arise	  from	  FZ	  cells.	  These	  apparently	  conflicting	  observations	  may	  
reflect	   two	   temporally	  distinct	   lineages	  of	   the	  definitive	  cortex.	  Wood	  et	  al	  demonstrated	  
that	   FZ	   cells	   that	   once	   expressed	   Sf1	   under	   control	   of	   the	   FAdE	   enhancer	   gave	   rise	   to	   a	  
subset	   of	   capsular	   cells.	   These	   FZ	   cell	   successors	  within	   the	   adrenal	   capsule	   express	  Gli1,	  
suggesting	  some	  FZ	  cells	  can	  evolve	   into	  Sf1-­‐negative	  capsular	  cells	  which	   in	  turn	  can	  give	  
rise	  to	  the	  underlying	  DZ	  /adult	  cortex	  33.	  Recent	  lineage	  tracing	  studies	  have	  revealed	  that	  
adrenal	   maintenance	   likely	   involves	   cell	   conversion	   of	   ZG	   cells	   into	   ZF	   cells	   34,	   with	   cells	  
being	  displaced	  in	  a	  centripetal	  fashion.	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Several	  lines	  of	  evidence	  suggest	  that	  β-­‐catenin	  plays	  an	  important	  role	  in	  adrenal	  zonation	  
and	  maintenance.	  	  Activation	  of	  the	  β-­‐catenin	  pathway	  is	  restricted	  to	  the	  ZG	  35	  and	  ectopic	  
expression	   leads	   to	   the	   activation	   of	   ZG	   markers	   in	   ZF	   cells	   36.	   Vidal	   et	   al	   37	   identified	  
members	  of	   the	  R-­‐spondin	   (Rspo)	   gene	   family	   to	  be	  expressed	   from	  E12.5	  onward	  within	  
mesenchymal	   cells	   surrounding	   the	   forming	   adrenal.	   R-­‐spondins	   are	   signaling	   molecules	  
that	  positively	  regulate	  the	  β-­‐catenin	  signaling	  pathway.	  This	  study	  showed	  capsular	  RSPO3	  
signals	   to	   the	   underlying	   steroidogenic	   compartment	   to	   induce	   β-­‐catenin	   signaling	   and	  
imprint	  glomerulosa	  cell	   fate.	  Shh	   in	  turn	  signals	  back	  to	  recruit	  capsular	  cells	   to	   form	  the	  
adrenal	   cortex,	   at	   least	   during	   development.	   This	   study	   therefore	   identifies	   the	   adrenal	  
capsule	  as	  a	  crucial	  signaling	  center	  that	  is	  continuously	  required	  for	  proper	  zonation.	  	  
	  
1.3.4 Regulation	  of	  adrenal	  development	  	  
Our	   knowledge	   about	   the	   factors	   and	   underlying	   mechanisms	   that	   control	   adrenal	  
development	   is	   limited	   at	   present.	   Based	   on	   human	   and	   animal	   models	   of	   disordered	  
development	  and	  studies	  of	  gene	  expression	  during	  early	  human	  adrenal	  development,	  it	  is	  
recognised	  that	  an	  array	  of	  transcription	  factors	  and	  signalling	  molecules	  are	  necessary	  for	  
foetal	  adrenal	  growth	  and	  functional	  development.	  	  
	  
1.3.4.1 Genetic	  regulation	  of	  adrenal	  development	  
The	   timing	  of	   gene	  expression	   is	   critical	   in	   the	   regulation	  of	   adrenal	   development.	  Genes	  
involved	  in	  the	  formation	  of	  the	  intermediate	  mesoderm	  and	  urogenital	  ridge	  (Odd-­‐skipped	  
related	  1	  (Odd1),	  Wilms’	  tumor	  1	  (WT1),	  Sal-­‐like	  1	  (Sall1),	  Pre-­‐B-­‐cell	  leukaemia	  transcription	  
factor	  1	   (Pbx1),	  Wingless-­‐type	  MMTV	   integration	   site	   family,	  member	  4	   (Wnt4),	   Forkhead	  
box	  D1	  and	  D2	  (FoxD1	  and	  FoxD2))	  affect	  kidney,	  adrenal	  and	  gonadal	  development;	  those	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affecting	   AGP	   development	   (steroidogenic	   factor	   1	   (SF1),	   dosage-­‐sensitive	   sex	   reversal,	  
adrenal	  hypoplasia	  congenital	  (AHC),	  X-­‐chromosome	  factor	  (Dax-­‐1),	  and	  Insulin-­‐like	  growth	  
factor	   receptor	   1	   (IGFR1)),	   affect	   both	   adrenal	   and	   gonadal	   development;	   there	   are	   also	  
those	  that	  specifically	  affect	  adrenal	  development	  (CBP/p300-­‐interacting	  transactivator	  with	  
Glu/Asp-­‐rich	  C-­‐terminal	  domain,	  2	  (Cited2),	  Wnt/B-­‐catenin	  signalling	  pathway	  genes)	  31.	  
	  
Of	  all	   the	  molecules	   regulating	  AGP	  development,	   the	  genes	  encoding	  SF1	   (also	  known	  as	  
NR5A1)	   and	  DAX-­‐1	   (dosage-­‐sensitive	   sex	   reversal,	   adrenal	   hypoplasia	   congenital	   (AHC),	   X-­‐
chromosome	  factor)	  have	  emerged	  as	  pivotal.	  These	  genes	  show	  coordinated	  expression	  in	  
adrenal	  cortex,	  testis,	  ovary,	  hypothalamus,	  and	  pituitary	  tissues	  38.	   In	  the	  absence	  of	  SF-­‐1	  
expression,	   the	   adrenal	   gland	   does	   not	   form	   15.	   Severe	   disruption	   of	   SF-­‐1	   in	   humans	   can	  
cause	   adrenal	   dysfunction,	   although	   must	   pathogenic	   variants	   in	   SF-­‐1	   in	   humans	   cause	  
impaired	   testicular	   development	   and	   Leydig	   cell	   dysfunction	   rather	   than	   adrenal	  
insufficiency.	   Sf1	   haploinsufficiency	   (Sf1+/-­‐)	   results	   in	   delayed/incomplete	   adrenal	  
development	   in	   mice,	   while	   overexpression	   of	   Sf1	   causes	   aberrant	   proliferation	   and	  
neoplasia	   in	   the	  mouse	  adrenal.	   Several	   studies	   indicate	   that	  while	  Wilms	   tumor	  1	   (WT1)	  
regulates	  Sf1	  expression	  in	  the	  AGP,	  CBP/P300-­‐Interacting	  transactivator,	  with	  Glu/Asp-­‐Rich	  
carboxy-­‐terminal	   domain,	   2	   (CITED2)	   expression	   in	   the	   AGP	   is	   necessary	   for	   proper	  
differentiation	   of	   the	   adrenal	   primordial	   (AP	   or	   foetal	   zone-­‐	   FZ)	   15.	   The	   foetal	   adrenal-­‐
specific	  enhancer,	   (FAdE)	   in	   the	  SF-­‐1	   locus	   that	  directs	   transgene	  expression	   to	   the	   foetal	  
adrenal	   cortex	   was	   discussed	   above	   32.	   It	   was	   demonstrated	   that	   this	   enhancer	   is	  
autoregulated	  by	  SF-­‐1	  and	  acts	  as	  a	  critical	   regulator	  of	  Sf1	  gene	  expression	   in	  the	  mouse	  
adrenal	   primordium.	   Sf1	   subsequently	   regulates	   itself	   by	   maintaining	   FAdE-­‐mediated	   Sf1	  
expression	  in	  the	  AP.	  After	  E14.5	  in	  mice,	  FAdE	  is	  no	  longer	  utilized.	  In	  the	  emerging	  DZ,	  Sf1	  
regulation	  is	  shifted	  to	  a	  different	  definitive	  enhancer	  that	  has	  not	  yet	  been	  characterized.	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In	  humans,	  however,	  no	  similar	  FADE	  or	  DZ	  enhancers	  have	  yet	  been	  confirmed	  15.	  	  
	  
SF1	   upregulates	   Dax1,	   which	   in	   turn	   represses	   SF1	   transcriptional	   activity	   and,	   hence,	  
steroidogenesis.	   It	   is	   unclear	   how	   disruption	   of	   SF1	   and	   its	   negative	   regulator	   can	   cause	  
similar	  defects,	  but	   it	  may	  be	   that	   very	   fine	   control	  of	   SF1	  activity	   is	   required	   for	  adrenal	  
development.	  However,	  Dax1	  can	  function	  as	  a	  co-­‐activator	  for	  SF1	  transcriptional	  activity	  in	  
steroidogenic	   cells	  when	   expressed	   at	   high	   levels,	   and	   perhaps,	   the	   pleiotropic	   effects	   of	  
these	  factors	  and	  not	  a	  simple	  consequence	  of	  their	  coactivity	  complicate	  the	  observations	  
in	   vivo.	   Pathogenic	   variants	   or	   deletions	   of	  DAX1	   in	   humans	   are	   well	   established	   as	   the	  
cause	   of	   X-­‐linked	   adrenal	   hypoplasia	   congenita	   (AHC)	   39.	   Knockdown	   of	   Dax1	   results	   in	  
premature	  differentiation	  of	  mouse	  adrenocortical	  progenitor	  cells.	  However,	  this	  occurs	  at	  
the	  expense	  of	  depleting	  this	  essential	  cell	  population,	  ultimately	  resulting	  in	  adrenal	  failure.	  
As	   such,	   Dax1	   plays	   an	   essential	   role	   in	   the	   maintenance	   of	   stem/progenitor	   cell	  
pluripotency.	  Sf1	  activates	  Dax1	   transcription	   in	  cooperation	  with	  paracrine	  Wnt	  signalling	  
and	   glucocorticoids	   that	   are	   synthesized	   in	   the	   differentiated	   adult	   cortex.	   Conversely,	  
ACTH,	   the	  well-­‐established	  glucocorticoid	   stimulator,	   has	  been	   shown	   to	  effect	   release	  of	  
Sf1	   complexes	   from	   the	   Dax1	   promoter,	   thus	   leading	   to	   effective	   inhibition	   of	   Dax1	  
transcription	  40,41.	  This	  is	  predicted	  to	  promote	  the	  response	  of	  Sf1-­‐positive	  progenitor	  cells	  
to	  ACTH	  and	  subsequently	  initiate	  steroidogenesis.	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1.3.4.2 Signalling	  pathways	  involved	  in	  adrenal	  development	  
Sonic	   hedgehog	   (Shh)	   is	   a	   member	   of	   the	   vertebrate	   hedgehog	   (Hh)	   family	   of	   secreted	  
ligands,	  and	  performs	  a	  multitude	  of	  crucial	  roles	  during	  embryonic	  development	  and	  is	  also	  
required	  in	  the	  adult	  for	  tissue	  maintenance,	  differentiation,	  and	  the	  regulation	  of	  stem	  cell	  
populations.	   Secreted	   Hh	   ligands	   bind	   to	   the	   12-­‐pass	   transmembrane	   protein	   Patched-­‐1	  
(Ptch1),	   which	   relieves	   the	   inhibition	   it	   exerts	   on	   the	   G	   protein-­‐coupled	   receptor	  
smoothened	  (Smo)	  and	  allows	   it	  to	  prevent	  the	  processing	  of	  the	  Gli	   transcription	  factors.	  
Full-­‐length	   Gli3	   and	   Gli2	   act	   as	   transcriptional	   activators.	   Gli1,	   which	   only	   acts	   as	   a	  
transcriptional	  activator,	   is	  not	  expressed	   in	   the	  absence	  of	  Hh,	  but	   is	  upregulated	  by	   the	  
pathway.	  Shh	  signalling	  is	  required	  for	  normal	  adrenal	  development	  at	  a	  later	  stage	  than	  SF1	  
and	   DAX1,	   and	   is	   expressed	   in	   the	   adrenal	   primordium	   in	   cells	   just	   beneath	   the	   capsule	  
29,42,43.	  Shh	  expression	  marks	  cortical	  progenitors	  42	  and	  Shh	  expressing	  cells	  give	  rise	  to	  all	  
steroidogenic	  cells	   in	  cortical	   zones.	  Homozygous	  deletion	  of	  Shh	   in	  mice	   is	  embryonically	  
lethal.	   Analysis	   of	   the	   adrenal	   gland	   at	   14.5	   and	   16.5	   dpc	   in	   Shh-­‐/-­‐	   embryos,	   however,	  
indicates	  that	  the	  adrenal	  primordium	  forms	  but	  is	  much	  smaller	  than	  in	  the	  wild	  type	  29,43.	  
	  
Holoprosencephaly	   is	   a	   consequence	   of	   the	   inactivation	   of	   the	   Hh	   pathway,	  with	   defects	  
observed	   in	   SHH	   44,	   PTCH1,	   and	  GLI2,	   and	   is	   often	   associated	  with	   adrenal	   hypoplasia	   45.	  
Smith–Lemli–Opitz	   syndrome	   (SLOS),	   a	   condition	   with	   defects	   in	   7-­‐dehydrocholesterol	  
reductase,	  (required	  for	  the	  formation	  of	  cholesterol),	  is	  associated	  with	  abnormalities	  that	  
overlap	  with	  those	  seen	  in	  cases	  of	  impaired	  Hh	  signalling,	  including	  holoprosencephaly	  46.	  
SLOS	  is	  also	  associated	  with	  adrenal	  insufficiency	  47.	  This	  may	  be	  due	  to	  the	  requirement	  of	  
cholesterol	   as	   the	   substrate	   for	   steroidogenesis,	   or	   may	   be	   linked	   to	   two	   observations	  
regarding	   Hh	   signalling.	   First,	   Hhs	   are	   covalently	   linked	   to	   cholesterol	   48,	   the	   only	   such	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proteins	  known	  to	  undergo	  this	  modification,	  which	  is	  critical	  for	  their	  signalling	  and	  second,	  
7-­‐dehydrocholesterol,	  which	  accumulates	  in	  the	  plasma	  of	  SLOS	  patients	  can	  be	  transported	  
out	  of	  the	  cell	  by	  Ptch1	  and	  act	  as	  a	  negative	  regulator	  of	  Smo	  49.	  
	  
Fibroblast	  growth	  factor	  (FGF)	  signalling	  controls	  early	  developmental	  processes	  such	  as	  cell	  
movement	   during	   gastrulation,	   mesodermal	   and	   neuroectoderm	   formation,	  
anterior/posterior	   patterning,	   and	   organogenesis	   50.	   FGFs	   are	   a	   large	   family	   of	   secreted	  
glycoproteins	   that	  bind	   to	   four	   signalling	   FGF	   receptors,	   FGFR1–4.	   FGF	   signalling	   interacts	  
with	   SF1	   and	   Shh	   signalling	   51.	   Fgfr2	   and	   Fgfr4	   are	   expressed	   in	   the	   developing	   adrenal	  
cortex.	   Embryos	   with	   a	   global	   Fgfr2	   IIIb	   deletion	   have	   hypoplastic	   adrenal	   glands	   51,	   and	  
deletion	  of	  both	   isoforms	  of	  FGFR2	  from	  steroidogenic	  tissue	  recapitulates	  this	  phenotype	  
and	   causes	   male-­‐to-­‐female	   sex	   reversal,	   implying	   that	   FGFR2	   is	   not	   necessary	   for	   AGP	  
formation	  but	  is	  required	  for	  the	  subsequent	  growth	  and	  development	  of	  the	  adrenal	  	  
gland	  52.	  
	  
Epidermal	   growth	   factor	   (EGF)	   stimulates	   proliferation	   of	   both	   the	   foetal	   and	   definitive	  
zones.	   The	   foetal	   adrenal	   expresses	   high	   levels	   of	   IGF-­‐2	   mRNA	   and	   protein,	   which	   are	  
responsive	   to	   ACTH	   53.	   	   IGF-­‐2	   augments	   ACTH-­‐stimulated	   expression	   of	   steroidogenic	  
enzymes	   and	   stimulates	   steroid	   hormone	   production	   in	   foetal	   adrenal	   cortical	   cells.	   The	  
pattern	  of	  enzyme	  maturation	  in	  the	  foetal	  adrenal	  suggests	  that	  cortisol	  production	  by	  the	  
definitive	   zone	   does	   not	   occur	   de	   novo	   from	   cholesterol	   until	   30	  weeks	   of	   gestation,	   but	  
some	  production	  using	  progesterone	  as	  precursor	  probably	  occurs	  earlier	  53.	  
	  
CDKN1C	   (Cyclin	   Dependent	   Kinase	   inhibitor	   1	   C,	   P57KIP2)	   is	   a	   paternally	   imprinted	   gene,	  
located	  on	  chromosome	  11p.15,	  and	  encoding	  for	  the	  CDKN1C	  protein,	  an	  inhibitor	  of	  cell	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cycle	   progression.	   Variations	   in	   CDKN1C	   or	   its	   genomic	   imprinting	   can	   lead	   to	   adrenal	  
pathology	   54.	   Loss-­‐of-­‐function	   of	   CDKN1C	   results	   in	   Beckwith-­‐Wiedemann	   syndrome,	   an	  
overgrowth	   syndrome	   with	   increased	   susceptibility	   to	   adrenal	   carcinoma.	   IMAGe	  
(intrauterine	   growth	   restriction,	   metaphyseal	   dysplasia,	   AHC,	   and	   genital	   anomalies)	  
syndrome	   is	   a	   rare	   multisystem	   disorder	   54	   that	   mirrors	   the	   features	   of	   Beckwith	  
Wiedemann	   syndrome	   and	   is	   caused	   by	   gain-­‐of-­‐function	   mutations	   in	   CDKN1C.	   Most	  
affected	  individuals	  are	  born	  small	  and	  develop	  skeletal	  abnormalities.	  Males	  present	  with	  
genital	   malformations	   including	   micropenis	   and	   undescended	   testicles	   and	   urethra	  
anomalies,	   but	   the	   most	   clinically	   important	   condition	   of	   the	   syndrome	   is	   adrenal	  
insufficiency,	  which	  shortly	  after	  birth	  causes	  salt	  wasting,	  hypoglycemia,	  and	  shock	  due	  to	  
loss	  of	  both	  mineralocorticoid	  and	  glucocorticoid	  synthesis	  and	  can	  be	  life-­‐threatening	  54.	  
	  
1.3.5 Models	  to	  study	  adrenal	  development	  	  
A	  number	  of	  in	  vitro	  cell	  models	  are	  available	  to	  study	  adrenal	  development.	  These	  differ	  in	  
terms	  of	  capacity	  for	  cell	  growth,	  response	  to	  agonists	  and	  steroidogenic	  capacity.	  Each	  may	  
also	  have	  changing	  properties	  in	  culture	  over	  time.	  	  
	  
The	   human	   adrenal	   carcinoma	   cell	   line	   NCI-­‐H295	   was	   isolated	   from	   an	   adrenocortical	  
carcinoma	  of	  a	  48-­‐year-­‐old	  Afro-­‐Caribbean	  female	  patient	  55.	  This	  was	  the	  first	  adrenal	  cell	  
line	  to	  express	  all	  enzymes	  required	  for	  steroidogenesis	  and	  to	  retain	  steroidogenic	  capacity	  
56.	   H295	   cells	   are	   aneuploid	   and	   hypertriploid,	   with	   the	  modal	   number	   of	   chromosomes	  
being	  62,	  held	  by	  approximately	  30%	  of	  cells.	  This	  original	  line	  grows	  slowly	  in	  suspension,	  
with	   a	   doubling	   time	   of	   approximately	   5	   days	   57.	   They	   produce	   their	   own	   cholesterol	   for	  
steroidogenesis,	   and	   like	   the	   tumour	   from	   which	   they	   originated,	   mainly	   produce	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androgens,	  with	  low	  mineralocorticoid	  and	  glucocorticoid	  synthesis,	  making	  them	  analogous	  
to	  the	  foetal	  adrenal,	  with	  pluripotent	  capabilities	  55.	  Like	  adrenocortical	  cells	   in	  vivo,	   they	  
respond	   to	   second	  messenger	   pathways	   56.	   AngII	   increases	   intracellular	   calcium	   levels	   via	  
AT1	   activation,	   and	   this	   along	   with	   PKC	   signalling	   preferentially	   induces	   CYP11B2	  
transcription	   to	   produce	   aldosterone	   58.	   Potassium	   ions	   also	   cause	   increased	   intracellular	  
calcium	  levels,	  and	  aldosterone	  release	  59.	  This	  response	  is	  identical	  to	  AngII	  and	  potassium	  
ion	   stimulation	   of	   the	   ZG.	   However,	   this	   strain	   demonstrates	   minimal	   response	   to	  
stimulation	   with	   ACTH,	   which	   may	   in	   part	   be	   due	   to	   low	   expression	   levels	   of	   the	   ACTH	  
receptor,	  MC2R	  60.	  The	  cAMP	  (cyclic	  adenosine	  monophosphate)	  pathway	  can	  be	  activated	  
by	   forskolin,	  which	  acts	  at	  adenylate	  cyclase	  and	  also	  activates	   the	  protein	  kinase	  A	   (PKA)	  
pathway.	  This	  results	  transcription	  of	  CYP17	  and	  CYP11B1	  and	  hence	  production	  of	  cortisol	  
61.	  Chronic	  treatment	  with	  forskolin	  promotes	  production	  of	  androgens	  62.	  	  
	  
A	   strain	   of	   H295	   cells,	   named	   H295R,	  was	   selected	   for	   their	   shorter	   population	   doubling	  
time	   of	   ~2	   days	   (the	   original	   line	   grows	   slowly	   in	   suspension	  with	   a	   doubling	   time	   of	   ~5	  
days),	  and	  their	  ability	  to	  grow	  in	  an	  adherent	  monolayer	  57.	  Both	  strains	  can	  be	  grown	   in	  
50%	   (v/v)	  Dulbecco’s	  Modified	  Eagles	  Medium,	  50%	   (v/v)	  Nutrient	  Mixture	   F-­‐12	  Ham,	  2%	  
(v/v)	  Ultroser	  G	  (a	  bovine	  derived	  serum	  substitute	  to	  increase	  growth	  rate	  and	  help	  retain	  
steroidogenic	  capacity),	  1%	  (v/v)	  ITS	  containing	  1mg/ml	  insulin,	  0.55mg/ml	  transferrin,	  and	  
0.5µg/ml	   sodium	   selenite,	   and	   1%	   (w/v)	   Pen/Strep	   (5000U/ml	   penicillin	   and	   5mg/ml	  
streptomycin).	   H295R	   cells	   produce	   mainly	   androgens	   with	   low	   glucocorticoid	   and	  
mineralocorticoid	  production,	  making	  them	  analogous	  to	  the	  foetal	  adrenal	  with	  pluripotent	  
capacity	   55.	   Therefore	   this	   cell	   line,	   established	   in	   our	   laboratory,	   was	   selected	   for	   the	  
preliminary	  studies	  described	  later.	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Alternatives	   include	   the	   use	   of	   animal	   models	   or	   primary	   cultures	   of	   HFA	   cells.	   The	  
developing	  human	  adrenal	  contains	  the	  unique	  inner	  FZ.	  Rodent	  models	  have	  been	  used	  to	  
study	   adrenal	   physiology	   and	   pathology.	   The	  murine	   foetal	   adrenal	   contains	   the	   inner	   X	  
zone,	   which	   has	   been	   proposed	   as	   analogous	   to	   the	   FZ	   of	   the	   human,	   although	   there	   is	  
strong	  evidence	  that	  this	  is	  not	  the	  case	  63.	  The	  X	  zone	  persists	  until	  puberty	  in	  males,	  and	  
the	  first	  pregnancy	  in	  females,	  in	  contrast	  to	  the	  FZ,	  which	  involutes	  rapidly	  after	  birth	  in	  the	  
neonatal	   period.	   The	   X	   zone	   is	   of	   unknown	   function	   and	   crucially	   does	   not	   produce	  
androgens.	  	  
	  
1.3.6 Foetal	  adrenal	  steroidogenesis	  
Steroid	   production	   from	   the	   foetal	   adrenal	   has	   important	   roles	   in	   the	   maintenance	   of	  
intrauterine	  homeostasis	  and	   in	   the	  maturation	  of	   the	   foetus	   in	  preparation	   for	  postnatal	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Fig.	  5.	  Steroidogenic	  enzyme	  expression	  in	  the	  human	  foetal	  adrenal	  zones	  (adapted	  from	  
21).	  
	  
Transcription	   of	   steroidogenic	   genes	   is	   tightly	   regulated	   resulting	   in	   differences	   in	   the	  
zonal	   activity	   of	   these	   enzymes	   20.	   During	   most	   of	   gestation,	   the	   foetal	   adrenal	   lacks	  
HSD3B2,	   preventing	   cortisol	   and	   aldosterone	   synthesis	   and	   directing	   steroid	   production	  
toward	  DHEAS	  production.	  DHEAS	  biosynthesis	  requires	  only	  three	  enzymes,	   localised	  in	  
the	   mitochondria	   (CYP11A),	   endoplasmic	   reticulum	   (CYP17,	   17α-­‐hydroxylase/17-­‐20-­‐
lyase),	  and	  cytosol	  (SULT2A1).	  Levels	  of	  these	  enzymes	  are	  very	  high	  in	  the	  HFA	  and	  vary	  
in	  their	  expression	  within	  each	  adrenal	  zone20.	  
	  
The	  principal	  output	  from	  the	  foetal	  adrenal	  during	  pregnancy	  is	  DHEA	  from	  the	  FZ,	  which	  is	  
then	   sulphated	   to	   dehydroepiandrosterone	   DHEAS	   by	   the	   enzyme	   sulphotransferase	  
(SULT2A1).	   The	   DZ/TZ	   contributes	   only	   a	   small	   fraction	   of	   total	   foetal	   adrenal	   steroid	  
production.	   Studies	   using	   immunohistochemistry	   have	   defined	   zonal	   differences	   in	   foetal	  
adrenal	  expression	  of	  steroidogenic	  enzymes	  (Fig.	  5).	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The	   TZ	   produces	   cortisol,	   with	   an	   early	   peak	   from	   8-­‐9	   wpc	   coinciding	   with	   transient	  
expression	  of	  type	  2	  3β-­‐hydroxysteroid	  dehydrogenase	  (HSD3B2)	  64.	  HSD3B2	  is	  the	  enzyme	  
needed	   for	   the	   conversion	   of	   Δ5	   to	   Δ4	   steroids	   (specifically	   pregnenolone	   and	   17α-­‐
hydroxypregnenolone	   to	   progesterone	   and	   17α-­‐hydroxyprogesterone,	   respectively).	   The	  
hypothalamic-­‐pituitary-­‐adrenal	  axis	  is	  sensitive	  to	  glucocorticoid-­‐mediated	  feedback	  at	  this	  
time;	  46,XX	  foetuses	  with	  steroidogenic	  defects	   (e.g.,	   in	  CYP21	  or	  CYP11)	   lack	  cortisol	  and	  
have	  an	  elevated	  ACTH	  drive	  that	  results	  in	  excess	  production	  of	  foetal	  androgens	  at	  a	  time	  
when	   the	   genital	   and	   scrotal	   folds	   are	   sensitive	   to	   androgen	   exposure,	   resulting	   in	  
virilization	  of	   female	  genitalia	   64.	  Cortisol	   can	   retard	   foetal	  and	  placental	  growth	  and	  so	   is	  
converted	   to	   biologically	   inactive	   cortisone	   by	   the	   enzyme	   11β-­‐hydroxysteroid	  
dehydrogenase	  type	  2	   (11βHSD2)	   in	  placental	  and	  foetal	   tissues.	   	   In	  this	  way	  the	  foetus	   is	  
protected	  from	  high	  levels	  of	  cortisol	  in	  utero.	  Levels	  of	  circulating	  cortisone	  in	  the	  foetus	  at	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Fig.	  6.	  Patterns	  of	  change	  of	  foetal	  plasma	  adrenocorticotropic	  hormone	  (ACTH),	  cortisol,	  
cortisone,	   and	   dehydroepiandrosterone	   sulphate	   (DHEAS)	   during	   gestation	   and	   in	   the	  
neonatal	  period.	  
	  
The	  trend	  of	  average	  values	  is	  shown	  for	  each	  hormone	  in	  nanomoles	  per	  liter.	  Note	  the	  
broken	  scale	  for	  DHEAS	  16	  
	  
As	   term	   approaches,	   expression/activity	   of	   11βHSD2	   drops	   and	   selected	   foetal	   tissues	  
including	  liver	  and	  lung	  express	  11βHSD1,	  so	  that	  maternal	  glucocorticoids	  are	  available	  to	  
the	   foetus	   to	  promote	   the	  maturation	  of	   foetal	  organs,	   including	   the	   lung	  and	  brain.	   This	  
increase	  in	  foetal	  cortisol	  production	  has	  an	  important	  role	  for	  extra-­‐uterine	  survival.	  Mice	  
lacking	   glucocorticoid	   receptor	   function	   manifest	   enlarged	   and	   disorganized	   adrenal	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cortices,	  adrenal	  medullary	  atrophy,	  lung	  hypoplasia,	  and	  defective	  gluconeogenesis	  15	  	  They	  
appear	  normal	  at	  birth	  but	  are	  not	  viable.	  
	  
The	   DZ	   expresses	   the	   enzymes	   needed	   for	   the	   production	   of	   aldosterone	   but	   does	   not	  
express	  17-­‐hydroxylase	  or	  SULT2A1.	  The	  HFA	  is	  capable	  of	  aldosterone	  secretion	  near	  term,	  
and	  foetal	  plasma	  aldosterone	  concentrations	  in	  infants	  who	  are	  born	  by	  caesarean	  section	  
are	   3-­‐	   or	   4-­‐fold	   higher	   than	   maternal	   levels	   6565.	   Vaginal	   delivery	   and	   maternal	   salt	  
restriction	   increase	   concentrations	   in	   both	  mother	   and	   infant.	   The	   increased	   aldosterone	  
concentrations	   in	   the	   foetus	  are	  a	   result	  of	   increased	   foetal	   adrenal	   secretion	  and	  persist	  
during	   the	   first	   year	   of	   extrauterine	   life.	   However,	   there	   is	   a	   poor	   correlation	   between	  
plasma	  renin	  activity	  (PRA)	  and	  aldosterone	  concentrations	  in	  cord	  blood	  66.	  	  
	  
During	   most	   of	   gestation,	   the	   foetal	   adrenal	   lacks	   HSD3B2,	   preventing	   cortisol	   and	  
aldosterone	   synthesis	   and	   directing	   steroid	   production	   toward	   DHEAS	   production.	   High	  
expression	   of	   SULT2A1	   in	   the	   FZ	   accounts	   for	   sulphation	   of	   most	   of	   the	   Δ5	   steroids	  
produced,	   including	   DHEA	   and	   pregnenolone.	   DHEAS	   biosynthesis	   requires	   only	   three	  
enzymes,	   localised	   in	   the	   mitochondria	   (CYP11A),	   endoplasmic	   reticulum	   (CYP17),	   and	  
cytosol	   (SULT2A1).	   Levels	   of	   these	   enzymes	   are	   very	   high	   in	   the	   HFA	   and	   vary	   in	   their	  
expression	   within	   each	   adrenal	   zone.	   Large	   amounts	   of	   cholesterol	   are	   required	   as	   a	  
precursor	   for	   steroid	   production	   and	   they	   are	   obtained	   through	   low-­‐density	   lipoprotein	  
receptors	  on	  the	  cell	  surface	  as	  well	  as	  intracellular	  synthesis	  of	  cholesterol	  from	  acetate.	  As	  
in	   the	  adult	   adrenal,	   cholesterol	  use	   for	   steroids	   is	   tightly	   controlled	  by	   the	  expression	  of	  
StAR,	  which	  regulates	  transport	  of	  cholesterol	  to	  the	  inner	  mitochondrial	  membrane,	  where	  
CYP11A	  converts	   it	   to	  pregnenolone.	  DHEA	   is	  sulphated	   in	  the	  FZ	  to	  DHEAS,	  which	   is	   then	  
converted	  by	  placental	  aromatase	  to	  oestrogens.	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1.4 The	  foeto-­‐placental	  unit	  
Successful	   pregnancy	   entails	   the	   timely	   birth	   of	   an	   appropriately	  mature	   foetus.	   Complex	  
genetic,	   cellular,	   and	   hormonal	   interactions	   are	   necessary	   to	   facilitate	   implantation,	  
placentation,	  embryonic	  development	  and	   foetal	  maturation,	  parturition	  and	   transition	   to	  
extra-­‐uterine	   life.	   Human	   pregnancy	   involves	   an	   orchestra	   of	   autocrine,	   paracrine	   and	  
endocrine	   networks	   that	   coordinate	  maternal-­‐placental-­‐foetal	   communication.	   The	   foetal	  
endocrine	   milieu	   is	   largely	   independent	   of	   maternal	   hormones	   because	   the	   placenta	   is	  
impermeable	  to	  most	  peptide	  hormones.	  Hormones	  larger	  than	  0.7-­‐1.2	  kD	  have	  little	  or	  no	  
access	   to	   the	   foetal	   compartment	   67.	   Unique	   features	   of	   the	   foeto-­‐placental	   endocrine	  
environment	   include	  a	  growing	  spectrum	  of	  placental	  hormones	  and	  growth	  factors	  and	  a	  
variety	   of	   foetal	   endocrine	   adaptations	   to	   the	   intrauterine	   environment,	   and	   the	   foetal	  
adrenal	  cortex	  is	  prominent	  among	  these.	  	  
	  
Oestrogens	  modulate	  many	   intrauterine	  processes	   throughout	   gestation,	   and	   the	  balance	  
between	  oestrogens	  and	  progesterone	  in	  utero	  is	  thought	  to	  be	  critical	  to	  the	  maintenance	  
of	  pregnancy,	  foetal	  maturation	  and	  the	  onset	  of	  parturition	  68.	  It	  is	  important	  to	  note	  that	  
early	   increased	   exposure	   to	   progesterone	   can	   advance	   the	   endometrium,	   resulting	   in	  
asynchrony	   of	   embryo	   development	   to	   endometrial	   development	   and	   reduction	   of	  
implantation	   69,70. Generally,	   however,	   progesterone	   maintains	   pregnancy	   by	   promoting	  
uterine	   quiescence.	   Any	   disruption	   of	   progesterone	   synthesis	   or	   action	   during	   pregnancy	  
rapidly	   induces	   abortion	   or	   delivery	   71.	   In	   contrast,	   oestrogens	   oppose	   this	   and	   promote	  
myometrial	  contractility	  of	  the	  uterus	  and	  regulate	  cervical	  ripening	  to	  facilitate	  parturition.	  
	  
The	   placenta	   produces	   vast	   amounts	   of	   oestrogens	   in	   the	   form	   of	   oestradiol,	   oestrone,	  
oestriol	  and	  oestetrol.	  The	  oestrogen	  products	   released	   from	  the	  placenta	  depend	  on	   the	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nature	  of	  the	  substrate	  available.	  Oestradiol	  is	  the	  primary	  oestrogen	  circulating	  at	  term.	  In	  
addition,	  however,	  significant	  levels	  of	  oestriol	  and	  oestetrol	  are	  also	  found	  in	  the	  maternal	  
circulation	   and	   they	   increase	   particularly	   late	   in	   gestation.	   These	   hydroxylated	   forms	   of	  
oestrogen	  are	  produced	  in	  the	  placenta	  using	  substrates	  from	  the	  combined	  efforts	  of	  the	  
foetal	   adrenal	   gland	   and	   liver.	   Though	   the	   primary	   site	   of	   oestrogen	   biosynthesis	   is	   the	  
placenta,	  the	  placenta	  lacks	  the	  cytochrome	  P450	  enzyme	  CYP17	  and	  accordingly	  is	  unable	  
to	  synthesise	  oestrogens	  de	  novo	  20.	  Placental	  oestrogen	  biosynthesis	  relies	  on	  a	  supply	  of	  
C19	  androgens,	  mainly	  DHEA	  and	  its	  sulpho-­‐conjugate,	  DHEAS,	  derived	  principally	  from	  the	  
foetal	   and	  maternal	   adrenal	   cortex	   20,53,68.	   The	   foetal	   adrenal	   cortex	   contributes	  a	  greater	  
proportion	  of	  substrates	   for	  placental	  oestrogen	  synthesis	   68.	   It	  has	   long	  been	  known	  that	  
women	   pregnant	   with	   an	   anencephalic	   foetus	   have	   much	   lower	   levels	   of	   circulating	  
oestrogens	   72,73.	   Pointing	   to	   the	   characteristic	   absence	   of	   the	   FZ	   of	   the	   adrenal	   cortex	   in	  
anencephaly,	  Frandsen	  and	  Stakeman	  72	  postulated	  that	  the	  normal	  foetal	  adrenal	  produces	  
a	   substance	   that	   serves	   as	   a	   precursor	   for	   oestrogen	   biosynthesis	   by	   the	   placenta.	   This,	  
together	   with	   the	   finding	   of	   high	   levels	   of	   DHEAS	   in	   cord	   blood	   of	   normal	   newborns,	  
suggested	   that	   foetal	   adrenal	   cortex	   is	   the	   principal	   source	   of	   placental	   oestrogen	  
precursors.	   Confirmation	   was	   provided	   by	   Diczfalusy’s	   group	   who	   demonstrated	   that	  
radiolabeled	   DHEAS	   that	   had	   perfused	   through	   the	   placenta	  was	   converted	   to	   oestradiol	  
74,75	  
	  
In	  the	  placenta	  the	  sulphate	  moiety	  is	  removed	  from	  DHEAS	  by	  the	  sulphatase	  enzyme,	  and	  
DHEA	  is	  then	  converted	  to	  androstenedione	  and	  testosterone	  by	  the	  actions	  of	  3β-­‐	  and	  17β-­‐
hydroxysteroid	   dehydrogenase	   (3β-­‐	   and	   17β-­‐HSD)	   enzymes,	   which	   are	   subsequently	  
aromatised	  respectively	  to	  oestrone	  and	  oestradiol	  (Fig.	  6).	  Placental	  17β-­‐HSD	  is	  considered	  
to	   prevent	   passage	   of	   excessive	   oestrogens	   to	   the	   foetus	   by	   catalyzing	   inactivation	   of	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oestradiol	   to	   oestrone	   76.	   Oestriol	   production	   increases	   as	   pregnancy	   progresses	   and	  
exceeds	  the	  production	  rates	  of	  oestrone	  and	  oestradiol	  by	   late	  gestation	  20.	  The	  placenta	  
lacks	  the	  16α-­‐hydroxylase	  enzyme	  and	  can	  only	  produce	  oestriol	  from	  a	  16α-­‐hydroxylated	  
C19	  precursor	  (Fig.	  7).	  16α-­‐hydroxy	  DHEAS	  is	  produced	  principally	  by	  the	  foetal	  liver	  (and	  to	  
a	  limited	  extent	  by	  the	  foetal	  adrenal).	  Placental	  oestriol	  production	  therefore	  reflects	  foetal	  
adrenal	   steroidogenic	   activity.	  Oestetrol	   is	   produced	  after	   15α-­‐	   and	  16α-­‐hydroxylation	  by	  
the	  foetal	  liver	  but	  placental	  production	  of	  this	  oestrogen	  is	  limited	  and	  its	  roles	  unknown.	  	  
	  
Fig.	  7.	  Pathways	  for	  the	  biosynthesis	  of	  placental	  oestrogens	  
	  
	  
At	   term	   nearly	   60%	   of	   the	   total	   DHEA	   used	   by	   the	   placenta	   for	   oestradiol	   and	   oestrone	  
synthesis	   is	   derived	   from	   the	   foetal	   adrenal,	   whereas	   40%	   is	   derived	   from	   the	   maternal	  
adrenal	  20,21,68,77.	  Furthermore,	  90%	  of	  16	  α-­‐hydroxyl	  DHEAS,	  used	  as	  a	  substrate	  for	  oestriol	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together	  as	  a	  foeto-­‐placental	  unit	  (Fig.	  8).	  Hence	  appropriate	  development	  and	  function	  of	  
the	  foetal	  adrenal	  is	  critical	  for	  the	  maintenance	  of	  a	  pregnancy,	  enabling	  foetal	  maturation	  
to	  ensure	  future	  perinatal	  survival.	  	  
	  
	  
Fig.	  8.	  Foeto-­‐placental	  unit.	  	  
	   	  
	  
The	   foetal	   adrenal	   is	   almost	   solely	   dedicated	   during	   the	   majority	   of	   gestation	   to	   the	  
production	  of	  dehydroepiandrosterone	  sulphate,	  DHEAS.	  This	  C19	  androgen	  is	  aromatised	  
in	  the	  placenta	  enabling	  the	  production	  of	  oestrogens.	  	  
	  
HFA	   function	   is	   programmed	  by	   the	   steroidogenic	   enzyme	  expression	   pattern	   to	   produce	  
DHEA	  and	  pregnenolone	  and	  their	  sulphate	  conjugates.	  Much	  of	  the	  DHEA	  is	  converted	  to	  
16-­‐hydroxy-­‐DHEAS	  by	   the	   foetal	  adrenal	  and	   foetal	   liver.	  This	  programming	   is	  designed	  to	  
provide	  DHEA	  substrate	  for	  placental	  oestrone	  and	  oestradiol	  production:	  16-­‐hydroxy-­‐DHEA	  
undergoes	  metabolism	  to	  oestriol	   in	   the	  placenta.	  Foetal	  DHEAS	  production	  and	  maternal	  
oestriol	  concentrations	   increase	  progressively	  to	  term;	  DHEAS	  production	  approximates	  to	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200	  mg/day	   near	   term	   78.	   	   In	   pregnant	   baboons	   with	   placental	   oestrogen	   production	  
suppressed	  by	  administration	  of	  an	  aromatase	   inhibitor,	   the	  volume	  of	   the	   foetal	   zone	  of	  
the	   foetal	   adrenal	   increased	   markedly	   79.	   This	   effect	   was	   reversed	   by	   administration	   of	  
inhibitor	   plus	   oestrogen,	   suggesting	   that	   oestrogen	   selectively	   suppresses	   foetal	   zone	  
growth	  and	  development	  during	  the	  second	  half	  of	  primate	  pregnancy.	   It	   is	  proposed	  that	  
this	   represents	   a	   feedback	   system	   to	   regulate	   secretion	   of	   foetal	   adrenal	   DHEA,	   thereby	  
maintaining	  normal	  foetal-­‐placental	  function	  and	  development	  79	  
1.5 Hormonal	  regulation	  of	  adrenal	  development	  	  
1.5.1 ACTH	  and	  the	  foetal	  hypothalamic-­‐pituitary-­‐adrenal	  axis	  
A	  major	  stimulus	  to	  foetal	  adrenal	  function	  is	  foetal	  pituitary	  ACTH.	  ACTH	  is	  a	  39	  amino	  acid	  
peptide	  secreted	  from	  the	  anterior	  pituitary	  gland	  under	  control	  of	  corticotropin-­‐releasing	  
hormone	   (CRH)	   80.	   	   CRH	   neurons	   projecting	   from	   the	   paraventricular	   nucleus	   onto	  
proopiomelanocortin	   (POMC)-­‐containing	  neurons	   in	  the	  hypothalamic	  arcuate	  nucleus	  can	  
also	   stimulate	   POMC	   release	   which	   is	   cleaved	   to	   form	   ACTH	   81.	   ACTH	   binds	   to	   the	  
transmembrane	   receptor	   melanocortin	   receptor	   2	   (MC2R)	   specifically	   in	   adrenocortical	  
cells.	  MC2R	  is	  a	  7-­‐transmembrane	  G	  protein-­‐coupled	  receptor	  (GPCR),	  and	  binding	  of	  ACTH	  
causes	   the	  α–subunit	   of	   the	   stimulatory	   heterotrimeric	  G	  protein	   (Gαs)	   to	   associate	  with	  
adenylate	  cyclase.	  This	  generates	  cyclic	  adenosine	  monophosphate	   (cAMP),	   leading	  to	   the	  
activation	  of	  downstream	  signalling	  pathways	  including	  activation	  of	  protein	  kinase	  A	  (PKA).	  
PKA	   phosphorylates	   and	   activates	   cholesterol	   ester	   hydrolases	   and	   StAR,	   increasing	   the	  
amount	  of	  cholesterol	  delivered	  to	  the	  inner	  mitochondrial	  membrane.	  cAMP	  also	  induces	  
transcription	  of	  StAR,	  CYP11A1	  and	  CYP17	  to	  promote	  cortisol	  production	  82,83.	   In	  a	  typical	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negative	   feedback	   loop,	   glucocorticoids	   inhibit	   further	   ACTH	   secretion	   at	   both	   the	  
hypothalamic	  and	  pituitary	  level	  84.	  	  
	  
ACTH	  has	  been	  prposed	  to	  be	  the	  most	  potent	  stimulus	  of	  the	  adrenal	  cortex,	  and	  most	  of	  
the	   knowledge	   on	   its	  mechanism	  of	   action	   derives	   from	   studies	   on	   the	   adrenal	   cortex	   or	  
ACTH	   receptor-­‐expressing	   cells	   85.	   However	   several	   observations	   suggest	   ACTH	   is	   not	   the	  
sole	   factor	   that	   stimulates	   adrenal	   growth.	   ACTH	   is	   involved	   in	   various	   aspects	   of	   the	  
dynamic	  organization	  of	  the	  adrenal	  cortex,	  namely	  cell	  migration	  and	  proliferation.	  While	  
ACTH	  has	  been	  shown	  to	  stimulate	  proliferation	  of	  cells	  in	  vivo,	  it	  is	  not	  a	  mitogen	  in	  vitro.	  It	  
has	   been	   shown	   that	   ACTH	   clearly	   inhibits	   the	   growth	   of	   adrenal	   cells	   in	   vitro86	   and	  
furthermore,	   treatment	   of	   rats	   with	   antiserum	   raised	   against	   ACTH,	   although	   decreasing	  
serum	   corticosteroid	   concentration,	   does	   not	   result	   in	   adrenal	   atrophy	   87.	   The	   trophic	  
actions	   of	   ACTH	  may	   therefore	   be	  mediated	   by	   locally	   produced	   growth	   factors,	   such	   as	  
insulin-­‐like	   growth	   factor	   2	   (IGF2),	   fibroblast	   growth	   factor	   beta	   (βFGF,	   FGF2)	   15	   and	  
epidermal	  growth	   factor	   (EGF),	   that	  act	   in	  an	  autocrine	  and/or	  paracrine	   fashion	   20.	  ACTH	  
results	   from	   proconvertase	   (PC)	   PC1/3	   cleavage	   of	   the	   proopiomelanocortin	   (POMC)	  
precursor	   and	   may	   be	   further	   cleaved	   by	   proconvertase	   2	   to	   generate	   α-­‐melanocyte-­‐
stimulating	  hormone	  (α-­‐MSH)	  (amino	  acids	  1–13	  of	  ACTH)	  88.	  There	   is	   	  mounting	  evidence	  
that	  proliferation	  is	  more	  likely	  to	  be	  mediated	  by	  other	  POMC-­‐related	  peptides.	  	  
	  
The	  structure	  of	  POMC	  was	  revealed	  in	  the	  late	  1970s	  and	  the	  discovery	  that	  the	  precursor	  
contained	   other,	   previously	   uncharacterized,	   peptides	   resulted	   in	   further	   lines	   of	   work	  
including	  elucidation	  of	  the	  role	  of	  the	  N-­‐terminal	  16K	  fragment	  or	  pro-­‐γ-­‐MSH	  89.	  In	  humans,	  
the	  16K	  fragment	  is	  a	  76-­‐residue	  peptide	  with	  the	  sequence	  of	  γ3-­‐MSH	  at	  its	  C-­‐terminal,	  and	  
the	  peptide	   is	  referred	  to	  as	  pro-­‐γ-­‐MSH	  (or	  N-­‐POMC(1–76))	   89.	  Further	   investigations	  have	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shown	  that	  the	  active	  domain	  of	  POMC-­‐derived	  peptide	  is	  a	  small	  fragment,	  N-­‐POMC	  (50–
74)	   (also	   named	   γ3-­‐melanocyte-­‐stimulating	   hormone,	   γ3-­‐MSH)	   89.	   Several	   studies	   have	  
demonstrated	  that	  this	  peptide	  is	  one	  of	  the	  principal	  processed	  products	  secreted	  from	  the	  
pituitary	  corticotroph	  cell	  into	  the	  circulation	  90,91,	  however	  though	  evidence	  strongly	  points	  
to	   a	   role	   for	   pro-­‐γ-­‐MSH	   in	   the	   regulation	   of	   adrenal	   growth,	   the	   underlying	  mechanisms	  
remain	  unclear	  89.	  
	  
Hypophysectomy	   of	   experimental	   animals	   results	   in	   adrenocortical	   atrophy,	   while	   excess	  
ACTH	   states	   such	   as	   Cushing’s	   disease	   cause	   adrenocortical	   hyperplasia	   20.	   The	  Pomc	   null	  
mouse,	  in	  a	  similar	  way	  to	  hypophysectomised	  animals,	  could	  provide	  a	  model	  to	  investigate	  
the	   role	   of	   different	   POMC	   peptides	   in	   adrenal	   function.	   Pomc-­‐null	   mice	   are	   born	   with	  
normal	   adrenal	   glands	   92	   but	   soon	   after	   birth	   the	   gland	   atrophies,	   indicating	   the	  
requirement	   for	   POMC	   peptides	   for	   adrenal	   maintenance	   and	   growth	   93.	   Studies	   of	   the	  
adrenals	   in	   Pomc	   null	   mice	   94	   have	   shown	   that	   the	   adrenals	   subsequently	   underwent	  
atrophy	  after	  birth	  due	  to	  a	  lack	  of	  cellular	  proliferation	  rather	  than	  apoptosis.	  It	  has	  been	  
reported	  that	  when	  Pomc	  null	  mice	  were	   injected	  on	  a	  daily	  basis	   for	  a	  period	  of	  10	  days	  
with	  a	  high	  dose	  of	  ACTH(1–24)	   (around	  10,000	  times	  basal	   levels),	  an	   increase	   in	  adrenal	  
size	  and	  also	  restoration	  of	  corticosterone	  but	  not	  aldosterone	  levels	  was	  seen	  95.	  However,	  
examination	   of	   the	   adrenals	   showed	   that	   the	   increase	   in	   size	   was	   a	   result	   of	   cellular	  
hypertrophy	  with	  no	  evidence	  of	  any	  hyperplasia.	  Stimulation	  of	  the	  adrenals	  in	  young	  Pomc	  
null	  mice	  with	   lower	  doses	  of	  ACTH	  did	  not	  result	   in	  secretion	  of	  corticosterone,	  although	  
the	   adrenals	   at	   this	   stage	   appeared	   relatively	   normal,	   expressing	  both	   the	  ACTH	   receptor	  
and	   components	   of	   the	   steroidogenic	   pathway	   94.	   Most	   significantly,	   the	   authors	  
transplanted	  single	  adrenals	  from	  9-­‐day-­‐old	  Pomc	  null	  mice	  into	  bilateral	  adrenalectomised	  
wild-­‐type	   littermates,	   exposing	   the	   mutant	   adrenals	   to	   physiological	   levels	   of	   all	   of	   the	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POMC	   peptides.	   After	   3	   months,	   it	   was	   noted	   the	   transplanted	   adrenal	   appeared	  
histologically	  normal	  and	  fully	   functional	  producing	  normal	   levels	  of	  both	  aldosterone	  and	  
corticosterone.	  This	  result	  demonstrates	  that	  when	  exposed	  to	  all	  the	  POMC	  peptides,	  the	  
mutant	  adrenals	  can	  become	  fully	  functional	  glands	  94.	  In	  a	  reconstitution	  experiment,	  Pomc	  
null	   mice	   were	   injected	   with	   synthetic	   N-­‐POMC(1–28)	   (twice	   daily)	   or	   supraphysiological	  
concentrations	   of	   ACTH(1–24)	   (daily)	   either	   alone	   or	   in	   combination	   93.	   Treatment	   with	  
ACTH	   alone	   again	   resulted	   in	   adrenal	   cellular	   hypertrophy	   with	   no	   cell	   proliferation,	   as	  
shown	  previously	  95.	  However,	  treatment	  with	  N-­‐POMC(1–28)	  alone	  had	  no	  apparent	  effect	  
on	   the	   adrenals.	   When	   both	   peptides	   were	   administered	   together,	   the	   adrenals	   were	  
identical	   to	  when	  treated	  with	  ACTH	  alone	  93.	  These	  results	  might	  contradict	  a	   role	   for	  N-­‐
terminal	   peptides	   in	   adrenal	   growth,	   however	   the	   doses	   of	   peptides	   used	   in	   were	  
supraphysiological,	  and	  a	  more	  subtle	  effect	  might	  have	  been	  seen	  if	  the	  two	  peptides	  were	  
administered	   together	   in	   physiological	   concentrations.	   Furthermore,	   although	   the	   N-­‐
POMC(1–28)	  used	   in	   the	  study	  has	  been	  shown	  previously	   to	  be	  biologically	  active	   96,	   the	  
disulfide	  bridge	  arrangements	   in	  N-­‐POMC	  are	  known	  to	  be	  unstable	  97	  and	  rearrangement	  
could	  have	  occurred	  rendering	  the	  peptide	  inactive,	  as	  found	  in	  N-­‐POMC(1–36)	  89.”	  
	  
ACTH,	  secreted	  by	  the	  foetal	  pituitary,	  is	  nonetheless	  proposed	  by	  many	  to	  be	  the	  primary	  
regulator	   of	   foetal	   adrenocortical	   development.	   The	   foetal	   pituitary	   adrenal	   axis	   is	  
postulated	  to	  become	  functional	  at	  50-­‐52	  dpc,	  with	  cytoplasmic	  ACTH	  discernible,	  coinciding	  
with	   the	   onset	   of	   adrenal	   steroidogenic	   enzyme	   expression	   64.	   In	   vivo	   ACTH	   stimulates	  
steroid	   production	   by	   activating	   StAR	   and	   increasing	   delivery	   of	   substrate	   cholesterol	   to	  
P450scc	  98.	  In	  vitro	  ACTH	  is	  known	  to	  promote	  both	  hypertrophy	  and	  production	  of	  DHEAS	  
and	   cortisol	   by	   foetal	   adrenal	   cells	   99	   Furthermore,	  Mesiano	   et	   al	   have	   shown	   that	   foetal	  
adrenal	   cells	   respond	   to	   ACTH	   by	   secreting	   growth	   factors	   that	   appear	   to	   stimulate	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hyperplasia	  of	  the	  foetal	  zone	  100	  .	  In	  vivo,	  excess	  ACTH	  is	  clearly	  involved	  in	  driving	  the	  high	  
androgen	  levels	  seen	  in	  foetuses	  affected	  with	  CAH.	  The	  HPA	  axis	  clearly	  functions	  early	  in	  
foetal	  life	  but	  the	  early	  development	  of	  the	  foetal	  adrenal	  in	  humans	  appears	  to	  be	  ACTH-­‐
independent.	   Normal	   adrenal	   development	   is	   observed	   before	   8-­‐13	   wpc	   in	   anencephalic	  
foetuses,	   presumed	   to	   have	   markedly	   reduced	   ACTH101,102.	   Thus	   ACTH	   may	   affect	   the	  
function	   of	   the	   foetal	   adrenal	   at	   early	   gestation,	   but	   not	   its	   structural	   development.	   It	   is	  
likely	  that	  other	  factors	  are	  necessary	  to	  stimulate	  the	  substantial	  amount	  of	  foetal	  adrenal	  
steroidogenesis,	  particularly	  during	  the	  last	  months	  of	  gestation.	  Growth	  and	  rising	  steroid	  
production	  by	  the	  foetal	  adrenal	  during	  pregnancy	  are	  not	  paralleled	  by	  increasing	  levels	  of	  
foetal	   plasma	  ACTH	   (Fig.	   8).	   A	   possible	   explanation	   for	   this	   paradox	   is	   that	   there	  may	   be	  
gestational	   age-­‐dependent	   alterations	   in	   responsiveness	   of	   the	   foetal	   adrenal	   tissue	   to	  
ACTH.	  Alternatively	  there	  may	  be	  additional	  regulators	  of	  foetal	  adrenocortical	  growth	  and	  
steroiodgenic	  function.	  The	  fact	  that	  ACTH	  levels	  do	  not	  increase	  significantly	  during	  the	  2nd	  
and	  3rd	  trimesters	  103,104	  makes	  it	  likely	  that	  growth	  and	  differentiation	  of	  the	  foetal	  adrenal	  
glands	   are	   influenced	   by	   placenta-­‐derived	   factors	   during	   this	   time.	   This	   hypothesis	   is	  
supported	  by	   the	  observation	   that	   the	   in	   the	  postpartum	  period	   the	   FZ	   rapidly	   involutes,	  
suggesting	  that	  placental	  factors,	  which	  are	  pregnancy	  specific,	  are	  likely	  to	  act	  to	  maintain	  
the	  FZ	  in	  utero.	  
	  
1.5.2 Placental	  CRH	  
As	  described	  previously,	  hypothalamic	  CRH	  stimulates	  expression	  and	  processing	  of	  POMC	  
by	   pituitary	   corticotropes	   and	   the	   secretion	   of	   ACTH.	   The	   human	   placenta,	   foetal	  
membranes	   and	   decidua	   also	   express	   CRH	   that	   is	   identical	   to	   hypothalamic	   CRH	   105.	  
However,	  unlike	  hypothalamic	  CRH,	  placental	  CRH	  gene	  expression	  and	  production	  can	  be	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stimulated	  by	  glucocorticoids	   106.	   This	  positive	   feed-­‐forward	   system	   is	  a	  unique	   feature	  of	  
placental	  CRH,	  and	  indicates	  a	  distinct	  role	  in	  pregnancy.	  	  	  
	  
Placental	  CRH	  production	  is	  restricted	  to	  primates,	  and	  predominantly	  enters	  the	  maternal	  
circulation	  but	  is	  also	  released	  in	  the	  foetal	  circulation	  107.	  The	  foetal	  adrenal	  and	  pituitary	  
express	   CRH	   receptors	   and	   transcripts	   encoding	   two	   isoforms	   (CRH-­‐R1α	   and	   –R2α)	   have	  
been	  detected	   in	   the	   foetal	   adrenal	   108–110.	  CRH	  can	  directly	   stimulate	   cortisol	   and	  DHEAS	  
production	   in	   vitro	   by	   isolated	   human	   foetal	   adrenocortical	   primary	   culture	   cells	   111	   by	  
elevating	  the	  mRNA	  levels	  of	  steroidogenic	  acute	  regulatory	  protein	  and	  other	  steroidogenic	  
enzymes,	   including	  3β-­‐HSD2,	   CYP21	   and	  CYP11B1.	   In	   addition,	   CRH	   enhances	   the	   adrenal	  
response	  to	  ACTH	  further	  and	  can	  stimulate	  expression	  of	  the	  receptor	  for	  ACTH	  in	  isolated	  
DZ/TZ	  cells	   in	   vitro	   112,113.	   This	   suggests	  CRH	  could	  affect	   foetal	   adrenal	   responsiveness	   to	  
ACTH,	  thereby	   indirectly	  promoting	  steroidogenesis,	  and	  driving	  the	  production	  of	  cortisol	  
and	  DHEA/DHEAS	  113.	  	  
	  
The	   circulating	   levels	   of	   CRH	   increase	   1000-­‐fold	   as	   pregnancy	   progresses	   105	   and	   reach	  
values	   of	   0.5	   to	   1	  nmol/L	   at	   term;	   normal	   values	   in	   nonpregnant	  women	   are	   lower	   than	  
0.01	  nmol/L.	   Maternal	   plasma	   CRH	   levels	   are	   low	   in	   the	   first	   trimester,	   rising	   from	  mid-­‐
gestation	   to	   term.	   In	   the	   last	   12	  weeks	  of	   gestation.	   CRH	  plasma	   levels	   rise	   considerably,	  
peaking	  during	  labor	  and	  then	  falling	  precipitously	  after	  delivery	  114,115.	  Umbilical	  cord	  blood	  
levels	   and	   amniotic	   fluid	   levels	   of	   CRH	   are	   similarly	   increased	   in	   late	   gestation	   103.	   Foetal	  
CRH	  levels	  are	  lower	  than	  those	  in	  maternal	  circulation	  (50	  versus	  1000	  picomolar)	  but	  are	  
still	  quite	  substantial	  compared	  with	  levels	  in	  men	  and	  nonpregnant	  women.	  CRH	  is	  the	  only	  
trophic	  hormone	  releasing	   factor	  to	  have	  a	  specific	  serum	  binding	  protein.	   It	  appears	  that	  
during	  most	  of	  pregnancy	  CRH-­‐binding	  protein	  (CRH-­‐BP)	  binds	  most	  of	  the	  circulating	  CRH	  in	  
	  
	   71	  
the	   foetal	  and	  maternal	  compartment,	  which	   likely	  serves	   to	   tightly	  control	   the	  activity	  of	  
placental	  CRH	  21.	  At	  the	  end	  of	  pregnancy,	  there	  is	  increased	  bioavailability	  of	  CRH,	  due	  to	  a	  
fall	   in	   levels	  of	   its	  binding	  protein.	  This	  results	   in	  an	  exponential	   increase	   in	  maternal	  CRH	  
levels	  from	  35	  weeks	  gestation	  to	  term	  105,116.	  Post-­‐partum,	  CRH	  normalises	  to	  non-­‐pregnant	  
levels	  within	  24	  hours	  of	  delivery	   in	  keeping	  with	  the	  fact	  that	  the	  placenta	   is	  the	  primary	  
source	  105,116.	  The	  step	  rise	  and	  peak	  in	  CRH	  has	  been	  proposed	  as	  an	  initiator	  of	  parturition,	  
by	   forming	  a	   feed-­‐forward	   loop	  that	   leads	  to	   increased	  productions	  of	  cortisol	  and	  DHEA/	  
DHEA-­‐S	  in	  the	  HFA	  116.	  Indeed,	  women	  who	  had	  idiopathic	  preterm	  deliveries	  were	  seen	  to	  
have	  higher	  mid-­‐pregnancy	  CRH	  levels	  than	  those	  who	  delivered	  at	  term,	  and	  CRH	  has	  been	  
used	  as	  a	  marker	  for	  risk	  of	  prematurity	  105.	  It	  could	  be	  postulated	  that	  CRH,	  via	  regulation	  
of	   adrenal	   androgen	  production	  and	  hence	  placental	   oestrogen	   synthesis,	  may	  determine	  
the	  length	  of	  pregnancy	  by	  enabling	  activation	  of	  parturition.	  Post-­‐partum,	  CRH	  normalises	  
to	  non-­‐pregnant	  levels	  within	  24	  hours	  of	  delivery	  in	  keeping	  with	  the	  fact	  that	  the	  placenta	  
is	  the	  primary	  source	  105,116.	  
	  
The	  rise	  in	  CRH	  levels	  with	  a	  surge	  late	  in	  the	  3rd	  trimester,	  however	  are	  not	  in	  keeping	  with	  
the	   rapid	   growth	   and	   profuse	   adrenocortical	   steroid	   production	   evident	   from	   the	   1st	  
trimester	  with	  increasing	  levels	  from	  the	  2nd	  trimester	  to	  term.	  Although	  placental	  CRH	  and	  
foetal	  pituitary	  ACTH	  play	  important	  roles,	  it	  is	  postulated	  that	  another	  locally	  produced	  or	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Previously	   proposed	   regulators	   ACTH	   and	   CRH	   do	   not	   fully	   explain	   the	   pattern	   of	   early	  
dramatic	   growth	   and	   increasing	   steroid	   production	   demonstrated	   by	   the	   human	   foetal	  
adrenal.	  This	  may	  suggest	  another	  factor	  with	  a	  role	  in	  regulating	  growth	  and	  functional	  
development	  of	  the	  human	  foetal	  adrenal	  gland.	  	  
1.6 Is	  kisspeptin	  a	  novel	  regulator	  of	  adrenocortical	  development?	  
1.6.1 Kisspeptin	  peptides	  
Kisspeptins	  are	  a	   family	  of	  peptides	  encoded	   for	  by	   the	  Kiss1	   gene	  on	   chromosome	  1	   117.	  
This	   family	   of	   peptides	   show	   an	   Arg-­‐Phe-­‐NH2	   motif	   at	   the	   carboxyl	   (C)-­‐terminus,	  
characteristic	  of	  the	  extensive	  RF-­‐amide	  peptide	  superfamily.	  Post-­‐translational	  cleavage	  of	  
the	   full-­‐length	   protein	   results	   in	   shorter	   biologically	   active	   fragments	   118,119	   (Fig.	   10).	   The	  
largest	  of	   these,	   kisspeptin	   (KP)-­‐54	  was	   initially	   identified	   in	  1996	  because	  of	   its	   ability	   to	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suppress	   the	   metastatic	   potential	   of	   malignant	   melanoma	   cells,	   hence	   it	   was	   termed	  
metastin	  117,118,120.	  The	  most	  abundant	  kisspeptin	  in	  the	  human	  circulation	  is	  kisspeptin-­‐54,	  
which	  can	  be	  further	  cleaved	  to	  14,	  13,	  and	  10	  amino	  acid	  peptides	  (Fig.	  10).	  
	  




Proteolytic	   processing	   of	   the	   full-­‐length	   145	   amino	   acid	   kisspeptin	   protein	   results	   in	  
shorter	  fragments	  of	  the	  carboxyl	  (C)-­‐terminus	  region	  of	  the	  molecule	  with	  54	  (KP-­‐54),	  14	  
(KP-­‐14),	  13	  (KP-­‐13)	  and	  10	  (KP-­‐10)	  amino	  acids.	  	  
	  
1.6.2 Kisspeptin	  receptor	  
Kisspeptins	  are	  the	  endogenous	  ligands	  for	  a	  G-­‐protein	  coupled	  receptor,	  discovered	  4	  years	  
later	   than	   kisspeptin,	   and	   originally	   known	   as	   GPR54	   (subsequently	   KISS1R	   in	   humans)	  
118,119,121,122.	  KISS1R	  was	   initially	  cloned	   from	  rat	  brain	   tissue	  as	  an	  orphan	  receptor	  with	  a	  
sequence	  similar	  to	  the	  galanin	  receptors,	  although	  it	  is	  unresponsive	  to	  galanin	  ligands	  121.	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All	  kisspeptins	  are	  able	  to	  bind	  KISS1R	  with	  KP-­‐10	  having	  maximal	  activity	  at	  receptor	  level	  
119.	   The	   literature	   contains	   inconsistencies	   regarding	   the	   terminology	   applied	   to	   the	  
kisspeptin	  gene	  and	  its	  products.	  However,	  an	  agreed	  nomenclature	  has	  been	  proposed	  123.	  
In	  this	  work,	  the	  terminology	  suggested	  will	  be	  utilised,	  with	  KISS1	  and	  KISS1R	  denoting	  the	  
kisspeptin	   and	   kisspeptin	   receptor	   gene	   in	   humans,	   and	   Kiss1	   and	   Kiss1r	   denoting	   the	  
kisspeptin	   and	   kisspeptin	   receptor	   gene	   in	   non-­‐primate	   species,	   respectively.	   The	   term	  
‘kisspeptins’	  is	  also	  widely	  used	  for	  the	  product	  of	  both	  human	  and	  non-­‐human	  genes	  124.	  
	  
1.6.3 Kisspeptin	  signalling	  	  
The	   mechanisms	   of	   action	   of	   kisspeptin	   are	   not	   fully	   elucidated.	   The	   major	   intracellular	  
signalling	  pathway	  recruited	  by	  Kiss1R	  is	  the	  Gq	  pathway,	  which	  activates	  phospholipase	  C	  
to	  hydrolyse	  phosphatidyl	  inositol	  bisphosphate	  to	  inositol	  triphosphate	  and	  diacyl	  glycerol,	  
which	  mobilises	   intracellular	   calcium	  and	  activates	  protein	   kinase	  C	   respectively	   122,125.	   	   A	  
recent	  study	  showed	  that	  the	  intracellular	  calcium	  release	  is	  biphasic,	  the	  first	  phase	  being	  
rapid	  with	  the	  second	  phase	  being	  slower.	  The	  slower	  phase	  is	  maintained	  by	  internalization	  
and	  recycling	  of	  the	  receptor	  to	  prevent	  desensitization	  126.	  
	  
1.6.4 Tissue	  distribution	  of	  kisspeptin	  and	  its	  receptor	  	  
Tissue	   distribution	   of	   Kiss1R	   and	   Kiss1	   often	   coincides.	   The	   kisspeptin	   receptor	   has	   been	  
shown	   to	   be	   present	   in	   the	   human	   placenta	   and	   brain	   118,	   with	   quantitative	   reverse	  
transcriptase-­‐polymerase	   chain	   reaction	   demonstrating	   its	   abundance	   in	   the	   cerebellum,	  
pituitary,	  cerebral	  cortex	  and	  brain	  stem	  117,119,122.	  Central	  expression	  of	  kisspeptin	  and	   its	  
receptor	   have	   been	   demonstrated	   in	   two	   major	   neuronal	   populations	   within	   the	  
	  
	   75	  
hypothalamus	  of	  rodents:	  in	  the	  arcuate	  nucleus	  (ARC)	  and	  the	  anteroventral	  periventricular	  
nucleus	   (AVPV)	   127.	   In	  humans	  and	  primates,	  kisspeptin	  mRNA	   is	  predominantly	  expressed	  
within	  the	  infundibular	  nucleus	  (equivalent	  of	  the	  ARC	  in	  this	  order	  of	  mammals)	  128.	  
	  
	  In	   humans	   peripheral	   expression	   of	   KISS1	   and	   KISS1R	   genes	   is	   observed	   throughout	   the	  
body,	   in	   the	  placenta,	   testis,	  ovary,	  small	   intestine,	  pancreas,	   liver,	  as	  well	  as	   the	  vascular	  
system	  117,118,129.	  Peripheral	  expression	  of	  both	  is	  highest	  in	  the	  placenta	  130.	  	  
	  
1.6.5 Regulatory	  roles	  for	  kisspeptin	  in	  utero	  
Kisspeptin-­‐expressing	  neurons	  exist	  in	  human	  foetuses	  131.	  Both	  Kiss1r	  and	  Kiss1	  have	  been	  
identified	  in	  the	  hypothalamus	  of	  mice	  from	  embryonic	  day	  13.5	  onwards	  as	  well	  as	  the	  pre-­‐
optic	  area	  132,133.	  The	  presence	  of	  both	  the	  kisspeptin	  receptor	  and	  its	  ligand	  suggests	  that,	  
this	   system	   is	   active	   from	   early	   developmental	   periods.	   Interestingly,	   this	   time	   point	  
correlates	   with	   GnRH	   neuron	   migration	   into	   the	   preoptic	   area.	   Although	   conflicting	  
evidence	   has	   been	   presented	   regarding	   whether	   kisspeptin	   stimulates	   GnRH	   neuron	  
number	  132,	  in	  vitro	  and	  in	  vivo	  studies	  have	  shown	  that	  kisspeptin	  influences	  GnRH	  neuron	  
growth	  133.	  
	  
Sex	   differentiation	   is	   initiated	   during	   embryonic	   development,	   and	   although	   female	  
gonadogenesis	  occurs	  autonomously,	  male	  development	  requires	  foetal	  testicular	  function	  
with	   androgen	   synthesis	   134.	   The	   testosterone	   surge	   is	   thought	   to	   be	   critical	   to	   external	  
genitalia	  masculinization.	   Clarkson	  et	   al	   showed	   that	   kisspeptin	  neurons	   are	   implicated	   in	  
activating	   GnRH	   neurons	   in	   the	   male	   mouse	   during	   the	   perinatal	   period,	   and	   that	   the	  
subsequent	   GnRH	   surge	   generates	   testosterone	   necessary	   for	   ensuring	   sexual	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differentiation	   of	   the	   male	   mouse	   brain	   135.	   Kisspeptin	   neurons	   lie	   in	   close	   proximity	   to	  
GnRH	  neurones	  suggesting	  a	  likely	  role	  in	  the	  testosterone	  surge	  136.	  
	  
1.6.6 Regulatory	  roles	  for	  kisspeptin	  in	  the	  hypothalamic-­‐pituitary-­‐gonadal	  axis	  
GnRH	   secretion	   is	   crucial	   for	   the	   hypothalamic–pituitary–gonadal	   axis,	   with	   increased	  
pulsatility	  stimulating	  pubertal	  development	  137.	  Kisspeptin	  has	  been	  shown	  to	  be	  a	  potent	  
stimulator	  of	  GnRH	  release	  in	  vitro	  and	  in	  vivo,	  and	  it	  has	  been	  shown	  to	  play	  a	  critical	  role	  
in	   the	   onset	   of	   puberty.	   Administration	   of	   kisspeptin	   to	   rodents	   increases	   circulating	  
gonadotrophins,	  with	  this	  effect	  being	  notably	  absent	  in	  Kiss1r–/–	  mice	  138,	  suggesting	  that	  
kisspeptin	  stimulates	  the	  hypothalamic–pituitary	  axis.	  	  
	  
Two	  seminal	  papers,	  provided	  evidence	  that	  kisspeptin	  influences	  pubertal	  development.	  De	  
Roux	  et	  al	  139	  looked	  at	  a	  series	  of	  patients	  with	  isolated	  hypogonadotrophic	  hypogonadism	  
(IHH),	   a	   condition	   characterised	   by	   inadequate	   gonadotrophin	   secretion	   in	   isolation	   and	  
without	  anosmia.	  The	  authors	  were	  able	  to	  identify	  a	  mutation	  affecting	  the	  KISS1R	  using	  a	  
genome-­‐mapping	  strategy	  as	  the	  responsible	  genetic	  basis	  for	  their	  presentation.	  This	  paper	  
was	  followed	  by	  that	  of	  Seminara	  et	  al,	  who	  used	  linkage	  analysis	  and	  genetic	  screening	  in	  a	  
large	   consanguineous	   family	   with	   IHH,	   and	   an	   unrelated	   patient	   with	   IHH,	   to	   identify	  
mutations	  in	  KISS1R	  140.	  They	  then	  went	  on	  to	  develop	  a	  mouse	  model	  with	  KISS1r-­‐deficient	  
mice.	  	  
	  
Simultaneous	   to	   the	   human	   genetic	   discoveries,	   Kiss1R-­‐	   deficient	  mice	  were	   found	   to	   be	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sexually	   immature	   with	   an	   absence	   of	   pubertal	   development.	   The	   animals	   possessed	   a	  
phenotype	   with	   small	   gonads,	   and	   impaired	   spermatogenesis	   or	   no	   coordinated	   follicle	  
maturation,	  presumably	  secondary	  to	  their	  low	  sex	  steroids	  in	  the	  setting	  of	  low	  circulating	  
gonadotropins	   140.	   The	   administration	   of	   exogenous	   GnRH	   corrected	   the	   HH	   phenotype,	  
which	  is	  consistent	  with	  the	  view	  that	  kisspeptin	  acts	  by	  stimulating	  endogenous	  GnRH.	  
	  
These	   landmark	   findings	   have	   paved	   the	   way	   for	   a	   number	   of	   other	   studies	   examining	  
mutations	  in	  the	  human	  kisspeptin	  receptor	  141–146.	  Tenenbaum-­‐Rakover	  et	  al	  146	  evaluated	  a	  
small	   series	   of	   patients	   presenting	   with	   IHH,	   all	   being	   homozygous	   for	   a	   single	  mutation	  
leading	  to	  a	   leucine	  substitution	  with	  proline,	  which	  was	  found	  to	   inhibit	  KISS1R	   signaling.	  
Patients	   were	   found	   to	   have	   LH	   pulses	   at	   normal	   frequency,	   but	   lower	   amplitude	   than	  
expected.	   All	   patients	   responded	   to	   exogenous	   GnRH	   stimulation,	   although	   there	   was	  
reduced	  pituitary	  response	  in	  KISS1R-­‐mutated	  patients.	  The	  authors	  concluded	  that	  KISS1R-­‐
mutated	  patients	  have	  delayed	  pubertal	  maturation	  of	  the	  gonadotrophic	  axis,	  rather	  than	  a	  
total	  absence	  of	  pubertal	  maturation,	  with	  pituitary	  and	  gonadal	  function	  remaining	  intact.	  	  
	  
The	   IHH	   phenotype	   has	   been	   observed	   in	   patients	  with	   heterozygous	   kisspeptin	   receptor	  
mutations	  147,	  and	  more	  recently,	  an	  inactivating	  mutation	  in	  the	  kisspeptin	  gene	  in	  humans	  
with	   absent	   progression	   of	   puberty	   has	   also	   been	   reported	   148.	   Here,	   a	   loss-­‐of-­‐function	  
mutation	  affecting	  KISS1	  was	  responsible	   for	  the	  presentation	  of	   IHH	   in	  a	   family	  with	  four	  
affected	   members.	   These	   findings	   suggest	   that	   both	   the	   kisspeptin	   receptor	   and	   a	  
functioning	   kisspeptin	   peptide	   are	   necessary	   in	   order	   for	   kisspeptin	   signaling	   to	   regulate	  
normal	   pubertal	   development.	   Patients	   with	   homozygous	   or	   compound	   heterozygous	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mutations	   in	   Kiss1R	   fail	   to	   undergo	   spontaneous	   pubertal	   development	   and	   less	   than	   30	  
patients	   to	   date	   have	   been	   described	   in	   the	   literature.	   Subsequently	   Teles	   et	   al.	   149	  
identified	  an	  activating	  autosomal	  dominant	  mutation	   in	  the	  kisspeptin	  receptor	  gene	   in	  a	  
girl	  with	  precocious	  puberty.	  	  
	  
Findings	  from	  clinical	  research	  have	  been	  supported	  by	  several	  animal	  studies.	  Funes	  et	  al	  
generated	  a	  mutant	  mouse	  with	  disruption	  of	   the	  Kiss1r	   receptor	   150.	   Phenotypic	   analysis	  
showed	  that	  both	  male	  and	  female	  knockout	  mice	  had	  abnormalities	  in	  the	  development	  of	  
external	  and	  internal	  genitalia	  and	  altered	  organ	  weight-­‐and-­‐body	  weight	  ratios.	  Lapatto	  et	  
al	   151	   used	   targeted	   deletion	   to	   establish	   whether	   the	   phenotype	   of	   Kiss1	   and	   Kiss1r	  
knockout	  mice	  would	  differ,	  revealing	  that	  although	  all	  Kiss1	  and	  Kiss1r	  knockout	  mice	  have	  
abnormal	  sexual	  maturation,	  a	  subpopulation	  of	  Kiss1	  knockout	  females	  appeared	  to	  have	  a	  
phenotype	   more	   similar	   to	   wild-­‐type	   controls	   151.	   The	   authors	   postulated	   that	   although	  
additional	   factors	   could	   be	   at	   play,	   including	   genetic	   polymorphisms,	   these	   findings	  
indicated	  that	  mutations	  affecting	  the	  Kiss1	  gene	  could	  still	  allow	  a	  near-­‐normal	  progression	  
in	  rodents	  towards	  sexual	  maturity.	  It	  is	  unclear	  whether	  rodent	  studies	  can	  be	  extrapolated	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1.6.7 Regulatory	  roles	  for	  kisspeptin	  in	  pregnancy	  	  
Recent	  evidence	  suggests	  that	  kisspeptin	  may	  play	  a	  role	  in	  several	  vital	  processes	  necessary	  
for	  ensuring	  a	  successful	  pregnancy.	  Implantation	  has	  been	  demonstrated	  as	  requiring	  Kiss1	  
function	   to	   ensure	   adequate	   adhesion	   in	   rodents.	   Calder	   et	   al	   described	   that	   in	  Kiss1–/–	  
knockout	  mice,	  a	  failure	  of	  embryo	  implantation	  was	  observed	  due	  to	  a	  lack	  of	  adhesion	  and	  
penetration	  152.	  This	  was	  found	  to	  be	  a	  function	  of	  uterine	  dysfunction,	  as	  evidenced	  by	  the	  
fact	  that	  the	  Kiss1+/–	  embryos	  created	  could	  be	  successfully	  implanted	  in	  wild-­‐type	  female	  
mice.	  
	  
Following	   embryo	   implantation,	   decidualisation	   occurs,	   characterised	   by	   stromal	   cell	  
proliferation	  and	  differentiation.	  Zhang	  et	  al	  reported	  uterine	  expression	  of	  Kiss1	  and	  Kiss1r	  
mRNA	  was	  significantly	  greater	  with	  decidualisation	  153.	  Downregulation	  of	  Kiss1	  expression	  
using	   a	   siRNA	   against	   Kiss1	   was	   found	   to	   prevent	   the	   increase	   of	   Kiss1	   and	   Kiss1r	  
demonstrated	   in	   vitro	   in	   a	   stromal	   cell	   culture	   model.	   Although	   the	   process	   of	  
decidualisation	  is	  different	  in	  humans,	  occurring	  before	  implantation	  in	  contrast	  to	  the	  post-­‐
implantation	  process	  occurring	   in	  rodents	  153	  the	  findings	  suggested	  a	  possible	  mechanism	  
underlying	   the	   relationship	   between	   kisspeptin	   and	   placental	   function.	   Evidence	   has	   also	  
demonstrated	   that	   not	   only	   does	  Kiss1	   and	  Kiss1r	  mRNA	   expression	   increase,	   but	   that	   in	  
rodents	  during	  implantation,	  a	  functional	  kisspeptin	  signalling	  system	  exists.	  
	  
Having	  previously	  demonstrated	  phosphorylation	  of	  mitogen-­‐activated	  protein	  kinases	  p38	  
and	   ERK1/2	   to	   be	   a	  marker	   of	   activation	   of	   Kiss1r,	   Fayazi	   et	   al	   reported	   that	   exogenous	  
administration	  of	  kisspeptin-­‐54	  on	  day	  4	  of	  pregnancy	  in	  mice	  led	  to	  significant	  activation	  of	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kisspeptin	  receptors	  with	  only	  a	  weak	  response	  seen	  in	  the	  uteri	  of	  non-­‐pregnant	  mice	  154	  .	  
The	   authors	   suggested	   that	   these	   observations	   supported	   the	   notion	   that	   kisspeptin	  
signalling	   is	   important	   in	   regulating	   the	   pregnant	   uterine	   endothelium.	   Although	  
extrapolation	  of	  these	  findings	  from	  a	  small	  study	  in	  rodents	  to	  humans	  is	  limited,	  studies	  in	  
man	  also	  suggest	  that	  kisspeptin	  is	  influential	  in	  pregnancy.	  
	  
The	   highest	   levels	   of	   peripheral	   kisspeptin	   expression	   however,	   have	   been	  described	   in	   a	  
prime	  location	  at	  the	  foeto-­‐maternal	  interface	  comprised	  of	  the	  syncytiotrophoblast	  cells	  of	  
the	  placenta	  130.	  Kiss1R	  has	  been	  identified	  in	  both	  the	  villous	  and	  the	  invasive	  extravillous	  
cytotrophoblasts	   130,	   suggesting	   an	   important	   role	   for	   kisspeptin	   in	   the	   regulation	   of	  
trophoblast	  invasion	  during	  placentation.	  	  Using	  placental	  tissue	  from	  the	  first	  trimester	  and	  
full-­‐term	  delivery	  pregnancies,	  Bilban	  et	  al	   found	  placental	  expression	  of	  KISS1	  gene	  to	  be	  
29-­‐fold	   higher	   in	   the	   first	   trimester	   human	   placentas	   compared	  with	   full-­‐term	   placentas.	  
This	  study	  interestingly	  showed	  that	  kisspeptin-­‐10	  appeared	  to	  block	  trophoblast	  migration,	  
acting	  as	  an	  inhibitor	  of	   implantation.	  The	  authors	  purported	  that	  expression	  of	  kisspeptin	  
and	   its	   receptor	   is	   greatest	   during	   the	   first	   trimester	   when	   cytotrophoblast	   invasion	   is	  
maximal,	   thereby	   supporting	   the	   notion	   that	   kisspeptin	   plays	   a	   regulatory	   role	   in	  
placentation.	  	  
	  
Given	   that	   placentation	   is	   crucial	   to	   pregnancy	   outcomes,	   it	  might	   follow	   that	   kisspeptin	  
expression	   levels	   alter	   with	   placental	   pathology.	   On-­‐going	   studies	   have	   proceeded	   to	  
investigate	   the	   potential	   link	   between	   kisspeptin	   levels	   and	  placental	   dysfunction	   such	   as	  
pre-­‐eclampsia	   155,	  and	   intrauterine	  growth	  restriction	  156.	  Cetkovic	  et	  al.	   	   157	   found	  plasma	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kisspeptin	  levels	  to	  be	  significantly	  lower	  in	  pregnant	  women	  with	  diabetes	  mellitus	  type	  1,	  
gestational	   diabetes,	   hypertension,	   pulmonary	   embolism,	   and	   placental	   dysfunction	  
compared	  with	  healthy	  pregnant	  controls.	  
	  
Circulating	  kisspeptin	  levels	  are	  low	  in	  males	  and	  non-­‐pregnant	  females	  (<2	  pmol/l)	  but	  rise	  
dramatically	  by	  940-­‐fold	  in	  the	  first	  trimester,	  and	  over	  7000-­‐fold	  in	  the	  third	  trimester	  158.	  
Levels	  fall	  rapidly	  by	  5	  days	  post	  partum,	  suggesting	  a	  placental	  source	  of	  the	  peptide	  (Fig	  
11)	  158	  
	  




Levels	  of	  circulating	  kisspeptin	  rise	  up	  to	  7000-­‐fold	  during	  pregnancy,	  falling	  rapidly	  post	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In	   support	   of	   a	   placental	   source,	   plasma	   kisspeptin	   levels	   are	   increased	   in	   patients	   with	  
gestational	  trophoblastic	  neoplasia	  and	  fall	  after	  chemotherapy	  treatment	  159.	  Furthermore,	  
in	   pregnancies	   complicated	   by	   pre-­‐eclampsia,	   kisspeptin	   levels	   are	   reportedly	   lower,	  
possibly	  reflecting	  placental	  dysfunction	  160.	  
	  
Not	  only	  does	  circulating	  kisspeptin	  appear	  to	  correlate	  with	  placental	  function	  of	  ongoing	  
pregnancies,	   but	   also	   evidence	   has	   been	   provided	   that	   kisspeptin	   levels	   are	   lower	   in	  
pregnancies	   that	   subsequently	  miscarry.	  Park	  et	  al.	   	  were	   the	   first	  group	   to	  suggest	  a	   link	  
between	   kisspeptin	   and	  miscarriage	   161.	   They	   observed	   that	   levels	   of	   placental	   kisspeptin	  
expression	  are	   lower	   in	  women	  with	  recurrent	  miscarriage	  when	  compared	  with	  placental	  
tissue	   in	  electively	   terminated	  pregnancies,	   although	  no	  matching	   for	  gestational	  age	  was	  
performed.	   Furthermore,	   maternal	   plasma	   kisspeptin-­‐10	   levels	   are	   lower	   in	   women	   with	  
early	   pregnancy	   bleeding,	   suggesting	   a	   possible	   association	   with	   abortus	   imminens	   162.	  	  
Jayasena	  et	  al	  showed	  that	  circulating	  kisspeptin	  at	  antenatal	  booking	  correlated	  with	  risk	  of	  
miscarriage	   163,	   with	   gestation-­‐corrected	   kisspeptin	   being	   60%	   lower	   in	   women	   with	   a	  
singleton	  pregnancy	   compared	  with	   unaffected	   singleton	  pregnancies.	   The	   relationship	   of	  
kisspeptin	  with	  miscarriage	  was	  also	  demonstrated	  in	  twin	  pregnancies,	  where	  death	  of	  one	  
foetus	   was	   associated	   with	   a	   lower	   kisspeptin	   level	   than	   those	   without	   complications.	  
Kisspeptin	   was	   also	   found	   to	   have	   a	   higher	   diagnostic	   performance	   with	   respect	   to	  
miscarriage	  compared	  with	  human	  chorionic	  gonadotrophin	  (hCG),	  using	  receiver	  operator	  
characteristic.	  Therefore	  there	  is	  compelling	  evidence	  to	  suggest	  that	  decreased	  kisspeptin	  
may	   be	   a	   novel	   biomarker	   of	   placental	   dysfunction	   in	   pregnancy	   and	   may	   also	   identify	  
asymptomatic	   pregnant	  women	   at	   greater	   risk	   of	  miscarriage.	   However,	   the	  mechanisms	  
underlying	  these	  associations	  are	  unknown.	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Pregnancy	   outcome	   data	   is	   of	   particular	   relevance	   given	   the	   rarity	   of	   human	   mutations	  
reported	  in	  KISS1	  /	  KISS1R.	  All	  the	  patients	  carrying	  homozygous	  or	  compound	  heterozygous	  
mutations	   in	   this	   signaling	   system	   are	   living	   testimonials	   to	   their	   ability	   to	   establish	  
functioning	  placentas	  during	  early	  gestation.	  The	  low	  frequency	  of	  human	  mutations	  in	  the	  
Kiss1-­‐Kiss1R	  pathway	  may	  suggest	  an	  evolutionary	  critical	  role	  in	  reproduction	  and	  species	  
propogation	   that	  might	  have	  undergone	  negative	   selection.	   	   Brioude	  et	   al	   142	   described	  a	  
male	   patient	   with	   IHH	   found	   to	   carry	   two	   recurrent	   mutations	   in	   the	   compound	  
heterozygous	   state.	   Pulsatile	   GnRH	   administration	   restored	   pulsatile	   LH	   secretion	   and	  
testosterone	  production.	  Later,	   long-­‐term	  combined	  Gn	  therapy	   induced	  spermatogenesis.	  
3	  successive	  pregnancies	  resulted	  in	  2	  miscarriages	  and	  1	  live	  birth.	  Miscarriages	  have	  also	  
been	  reported	  in	  this	  context	  by	  Pallais	  et	  al	  suggesting	  mutations	  in	  KISS1R	  may	  affect	  the	  
maintenance	  of	  pregnancy	  164 . 	  
	  
To	  date	  only	  one	   report	  exists	   in	   the	   literature	  of	  a	   female	  patient	  homozygous	   for	   the	  a	  
missense	  KISS1R	  mutation	  successfully	  conceiving	  and	  carrying	  a	  pregnancy	  to	  term	  164.	  This	  
patient	   underwent	   pulsatile	   GnRH	   therapy,	   with	   successful	   ovulation	   induction.	   She	  
subsequently	  switched	  to	  exogenous	  gonadotropin	   therapy	  and	  had	  multiple	  conceptions,	  
one	   ectopic	   and	   one	   miscarriage	   of	   twin	   pregnancy	   at	   6	   months,	   followed	   by	   two	  
uncomplicated	   pregnancies	   of	   healthy	   term	   babies.	   Although	   much	   remains	   to	   be	  
discovered	  regarding	  the	  intricacies	  of	  the	  role	  of	  kisspeptin	  during	  gestation,	  it	  is	  clear	  that	  
it	  has	  an	  important	  function	  in	  the	  maintenance	  of	  pregnancy.	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1.7 Thesis	  Rationale	  
HFA	  development	  and	  function	  is	  complex	  and	  poorly	  understood.	  Although	  placental	  CRH	  
and	  foetal	  pituitary	  ACTH	  play	   important	  roles,	  other	   locally	  produced	  or	  placenta-­‐derived	  
factors	  must	  also	  be	   involved.	   Interestingly,	   there	   is	  50-­‐fold	  higher	  expression	  of	  Kiss1R	   in	  
the	  HFA	  compared	  to	  the	  adult	  adrenal	  and	  Kiss1R	  expression	  has	  been	  confirmed	  in	  the	  DZ	  
and	   TZ	   of	   the	   HFA	   165.	   Additionally,	   kisspeptin	   has	   been	   shown	   to	   stimulate	   aldosterone	  
production	  in	  cultured	  human	  adrenocortical	  H295R	  cells	  165.	  Therefore,	  the	  HFA	  may	  be	  an	  
important	  target	  for	  the	  high	  levels	  of	  circulating	  kisspeptin	  in	  pregnancy.	  	  
	  
The	  objective	  of	  this	  project	  was	  to	  determine	  the	  role	  of	  kisspeptin	  in	  the	  developing	  HFA	  
and	  investigate	  the	  hypothesis	  that	  kisspeptin	  is	  a	  novel	  regulator	  of	  human	  adrenocortical	  
development	  and	   function,	  acting	  directly	  via	   its	   receptor,	  Kiss1R,	   in	   the	   foetal	  adrenal	   to	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The	  following	  research	  questions	  were	  proposed:	  
1. What	  is	  the	  spatio-­‐temporal	  expression	  of	  Kiss1R	  in	  the	  developing	  human	  
foetal	  adrenal	  (HFA)	  cortex?	  
2. Is	  expression	  of	  Kiss1R	  mRNA	  /	  protein	  regulated	  by	  its	  ligand?	  
3. Can	  kisspeptin	  directly	  stimulate	  the	  production	  of	  DHEAS	  in	  vitro?	  
4. Is	  there	  a	  correlation	  between	  maternal	  serum	  kisspeptin	  concentrations	  and	  
foetal	  adrenal	  growth	  in	  vivo?	  
	  
The	   first	   section	   of	   this	   thesis	   aims	   to	   qualitatively	   and	   quantitatively	   elucidate	   Kiss1R	  
expression	  in	  the	  developing	  foetal	  adrenal.	  The	  spatio-­‐temporal	  expression	  of	  Kiss1R	  in	  the	  
developing	  HFA	  cortex	  will	  be	  examined	  primarily	  by	  immunohistochemical	  analysis	  of	  HFA	  
sections	   aged	   8	   weeks	   post-­‐conception	   (wpc)	   to	   term.	   Quantitative	   reverse-­‐transcriptase	  
PCR	  (qPCR)	  will	  be	  performed	  on	  1st	  and	  2nd	  trimester	  HFA	  cDNA	  to	  examine	  expression	  of	  
Kiss1R	  with	  increasing	  gestational	  age.	  
	  
The	  second	  section	  aims	  to	  investigate	  the	  effects	  of	  kisspeptin	  on	  foetal	  adrenal	  function,	  
using	  two	   in	  vitro	  cell	  models	  comprising	  a	  human	  adrenocarcinoma	  cell	   line	  (H295R	  cells)	  
and	   primary	   HFA	   cell	   cultures.	   These	   models	   will	   be	   used	   to	   interrogate	   the	   effect	   of	  
kisspeptin	  on	  receptor	  (Kiss1R)	  expression	  and	  on	  production	  of	  DHEAS	  compared	  to	  other	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The	   final	   section	   aims	   to	   ascertain	   whether	   a	   correlation	   exists	   between	   foetal	   adrenal	  
growth	   and	   circulating	  maternal	   kisspeptin	   by	   studying	   a	   longitudinal	   cohort	   of	   pregnant	  
women	   who	   have	   serial	   measurements	   of	   serum	   kisspeptin	   and	   foetal	   adrenal	   volume	  
performed	  during	  pregnancy.	  
	  
The	  overall	  aim	  of	  this	  work	  was	  to	  advance	  the	  understanding	  of	  the	  regulation	  of	  human	  
adrenal	  development.	  As	  the	  foetal	  adrenal	  is	  a	  key	  component	  of	  the	  foeto-­‐placental	  unit,	  
understanding	   the	   regulation	   of	   adrenocortical	   development	   may	   offer	   insights	   into	   the	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2 MATERIALS	  AND	  METHODS	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2.1 Ethical	  approvals	  	  
2.1.1 Ethical	  approval	  for	  use	  of	  foetal	  adrenal	  tissues	  
Adrenal	   tissue	   blocks	   were	   obtained	   from	   Finland	   from	   human	   foetuses	   following	  
therapeutic	   termination	   of	   pregnancy/miscarriage/stillbirth	   or	   neonatal	   death.	   Ethical	  
approval	  was	  obtained	  from	  the	  ethics	  committee	  of	  Oulu	  University	  Hospital,	  Finland	  and	  a	  
permit	   to	   study	   human	   autopsy	   tissues	   and	   resection	   material	   was	   obtained	   from	   the	  
Finnish	   National	   Authority	   for	  Medicolegal	   Affairs.	   Use	   of	   the	   tissue	   for	   this	   project	   was	  
granted	   ethical	   approval	   by	   the	   Brighton	   and	   Sussex	   NRES	   Committee	   (Rec	   Reference:	  
12/LO/1755,	  December	   2012;	  Appendix	   1).	   A	  MTA	  between	   the	  University	   of	   Kuopio	   and	  
QMUL	  was	  set	  up	  to	  allow	  samples	  to	  be	  transferred	  between	  institutions	  for	  further	  studies	  
(Appendix	   2).	   Cryosections	   of	   frozen	  HFA	   tissue	  were	   also	   obtained	   from	   the	  HDBR	   (ICH,	  
Newcastle)	   and	   a	  MTA	   between	   Newcastle	   and	   QMUL	   (Appendix	   3)	   and	   UCL	   and	   QMUL	  
(Appendix	  4)	  was	  set	  up	  to	  allow	  samples	  to	  be	  transferred	  between	  instituitions	  for	  further	  
studies.	  The	  HDBR	  was	  established	  in	  1999	  in	  line	  with	  the	  ethical	  guidelines	  laid	  out	  in	  the	  
Polkinghorne	  Report	  (Review	  of	  the	  Guidance	  on	  the	  Research	  Use	  of	  Foetuses	  and	  Foetal	  
Material,	  1989).	  	  More	  recently,	  they	  have	  been	  licensed	  as	  a	  tissue	  bank	  at	  each	  site	  by	  the	  
Human	   Tissue	   Authority.	  	   Donations	   of	   tissue	   are	   made	   entirely	   voluntarily	   by	   women	  
undergoing	  termination	  of	  pregnancy.	  Donors	  are	  asked	  to	  give	  explicit	  written	  consent	  for	  
the	   foetal	   material	   to	   be	   collected,	   and	   only	   after	   they	   have	   been	   counselled	   about	   the	  
termination	  of	   their	  pregnancy.	  The	  HDBR	  can	  provide	  embryonic/foetal	  material	   from	  26	  
post-­‐conception	   days	   (Carnegie	   stage	   12),	   up	   to	  14	   post-­‐conception	   weeks.	   The	   tissue	   is	  
held	  at	   the	   Institute	   for	  Child	  Health,	  London.	   It	   is	   intended	  for	  use	  primarily	  by	  academic	  
researchers.	  The	  HDBR	  Joint	  Steering	  Committee	  is	  responsible	  for	  the	  overall	  management	  
of	   the	  project.	  Tissue	  samples	  arrived	  at	   the	  HDBR.	  The	  head	  of	   the	  HDBR	  at	   ICH	   (Dianne	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Gerelli)	  logged	  these	  samples	  and	  an	  identifying	  code	  number	  was	  assigned	  to	  each	  sample.	  
The	  samples	  did	  not	  have	  any	  identifiable	  patient	  details	  attached	  to	  them.	  The	  gestational	  
age	  of	  the	  foetal	  tissue	  will	  be	  available.	  Study	  investigators	  were	  then	  notified	  that	  material	  
was	  available	  for	  the	  study.	  	  
2.1.2 Ethical	  approval	  for	  clinical	  studies	  
Subjects	  gave	  written	  informed	  consent,	  and	  ethical	  approval	  for	  these	  studies	  was	  obtained	  
from	   the	   Brighton	   and	   Sussex	   NRES	   Committee	   (Rec	   Reference:	   12/LO/1755,	   December	  
2012;	  Appendix	  1).	  Studies	  were	  performed	  in	  accordance	  with	  the	  Declaration	  of	  Helsinki.	  
Clinical	  studies	  were	  carried	  out	  in	  collaboration	  with	  teams	  from	  the	  Foetal	  Medicine	  Unit,	  
Neonatal	  Unit	  and	  Radiology	  department	  at	  Barts	  Health	  NHS	  Trust,	  the	  Faculty	  of	  Medicine,	  
Imperial	  College	  London,	  and	  the	  Steroid	  Lab,	  King’s	  College	  London.	  	  
	  
2.2 Cell	  culture	  
The	   human	   adrenocortical	   carcinoma	   cell	   line	   H295R	   (CRL-­‐2128)	  was	   obtained	   from	   Ian	  
Mason,	  University	  of	  Edinburgh.	  Primary	  culture	  of	  HFA	  cells	  were	  established	  as	  detailed	  
later,	   from	   tissue	   obtained	   from	   the	   Human	   Developmental	   Biology	   Resource	   (HDBR),	  
Institute	  of	  Child	  Health	  (ICH),	  London,	  and	  University	  of	  Newcastle.	  H295R	  cells	  and	  primary	  
cells	  were	  grown	  at	  37°C	  with	  5%	  CO2	  in	  50%	  (v/v)	  DMEM,	  50%	  (v/v)	  Nutrient	  Mixture	  F12	  
Ham,	   with	   2%	   (v/v)	   Ultroser	   G	   (BioSepra),	   1%	   (v/v)	   ITS	   (containing	   1mg/ml	   insulin,	  
0.55mg/ml	   transferrin,	   and	   0.5µg/ml	   sodium	   selenite),	   and	   1%	   (w/v)	   Pen/Strep	   62.	   All	  
chemicals	  were	  obtained	  from	  Sigma	  Aldrich	  unless	  otherwise	  stated.	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2.2.1 Trypsinisation	  
All	  reagents	  were	  warmed	  to	  37oC	  before	  use.	  Media	  was	  removed	  from	  the	  culture	  flask	  or	  
dish	   and	   cells	   washed	   with	   DPBS	   (Dulbecco’s	   Phosphate	   Buffered	   Saline).	   Trypsin-­‐EDTA	  
(0.5g/l	  trypsin,	  0.2g/l	  Ethylenediaminetetraacetic	  acid;	  Invitrogen)	  was	  added	  for	  30	  seconds	  
and	   then	   removed.	   Cells	   were	   then	   left	   for	   2-­‐5	  minutes	   until	   all	   were	   detached	   used	   to	  
detach	  the	  cells	  for	  2-­‐5	  minutes.	  Fresh	  media	  was	  then	  added	  to	  the	  cells	  to	  neutralise	  the	  
trypsin	   and	  pipetted	  until	   no	   cell	   clumps	  were	   visible.	   The	   suspension	  was	   centrifuged	   at	  
800	  rpm	  for	  1	  minute	  to	  pellet	  the	  cells,	  which	  were	  then	  resuspended	  in	  fresh	  media	  and	  
plated	  at	  the	  desired	  density.	  	  
2.2.2 Freezing	  down	  cells	  
Cells	  were	  grown	  until	   confluent,	   then	   trypsinsed,	  and	   transferred	   to	  a	  15ml	  Falcon	   tube.	  
They	   were	   then	   centrifuged	   at	   800	   rpm	   for	   5	  minutes	   and	   the	  media	   removed.	   The	   cell	  
pellet	  was	  then	  resuspended	  in	  a	  freezing	  solution	  containing	  90%	  (v/v)	  FBS	  and	  10%	  (v/v)	  	  
DMSO	   (Dimethyl	   Sulphoxide).	   1ml	   of	   cells	   for	   each	   10cm	   plate	   was	   then	   cooled	   at	   a	  
maximum	  of	   1oC/min	   to	   -­‐80°C	   in	   1ml	   cryotubes.	   Tubes	  were	   then	   transferred	   to	   a	   liquid	  
nitrogen	  tank	  for	  long-­‐term	  storage.	  
2.2.3 Counting	  cells	  –	  Haemocytometer	  
After	   trypsinising,	   a	   50µl	   sample	   of	   cells	   was	   removed	   and	   injected	   into	   the	  
haemocytometer	  channel.	  Cells	  were	  counted	  in	  four	  corners	  of	  one	  of	  the	  grids	  on	  the	  slide	  
(Fig.	   12)	   using	   the	   Leica	  DMIL	   light	  microscope	  with	   10x	  objective.	   If	  more	   than	  500	   cells	  
were	   counted,	   the	   cell	   stock	  was	   diluted	   and	   another	   sample	   taken.	   If	   there	  were	   fewer	  
than	  200	  cells,	  all	  four	  corners	  of	  both	  grids	  were	  counted.	  The	  following	  calculations	  were	  
then	  made:	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𝑛𝑢𝑚𝑏𝑒𝑟  𝑜𝑓  𝑐𝑒𝑙𝑙𝑠  𝑐𝑜𝑢𝑛𝑡𝑒𝑑
𝑛𝑢𝑚𝑏𝑒𝑟  𝑜𝑓  red  𝑐𝑜𝑟𝑛𝑒𝑟𝑠  𝑐𝑜𝑢𝑛𝑡𝑒𝑑   =   𝑛𝑢𝑚𝑏𝑒𝑟  𝑜𝑓  𝑐𝑒𝑙𝑙𝑠 100𝑛𝑙	  
	  
𝑛𝑢𝑚𝑏𝑒𝑟  𝑜𝑓  𝑐𝑒𝑙𝑙𝑠 100𝑛𝑙  ×  10! =   𝑛𝑢𝑚𝑏𝑒𝑟  𝑜𝑓  𝑐𝑒𝑙𝑙𝑠 𝑚𝑙	  (y)	  
	  




Fig.	  12.	  Haemocytometer	  Grid	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2.3 Primary	  culture	  of	  human	  foetal	  adrenal	  cells	  
2.3.1 Material	  
Human	   embryonic	   and	   foetal	   material	   was	   provided	   by	   the	   Joint	   MRC/Wellcome	   Trust	  
[grant	   #	   099175/Z/12/Z]	   Human	   Developmental	   Biology	   Resource	   (www.hdbr.org),	   with	  
appropriate	  maternal	  consent	  and	  approval	  from	  the	  local	  National	  Health	  Authority	  Ethics	  
Committee.	  The	  experimental	  protocol	  for	  this	  research	  was	  approved	  by	  the	  Brighton	  and	  
Sussex	  REC.	  The	  samples	  were	  transported	  from	  the	  clinic	  to	  the	  HDBR	  resource	  and	  were	  
staged,	   dissected	   and	   stored	   at	   37°C	   in	   serum-­‐free	   DMEM/F12	   media	   with	   1%	   (w/v)	  
Pen/Strep.	  The	  age	  of	  the	  foetal	  samples	  were	  estimated	  following	  the	  guidelines	  of	  Hern	  166	  
and	  the	  embryos	  were	  staged	  using	  the	  Carnegie	  Staging	  classification	  system	  167.	  A	  snip	  of	  
tissue	  from	  each	  sample	  was	  taken	  to	  perform	  cytogenetic	  analysis	  to	  determine	  the	  mitotic	  
karyotype.	   All	   samples	   had	   a	   normal	   male	   or	   female	   karyotype.	   Samples	   were	   then	  
transported	  to	  our	  lab	  within	  24	  hours.	  	  
2.3.2 Collagenase	  digestion	  and	  establishment	  of	  primary	  cultures	  
Samples	  were	  washed	  in	  5	  ml	  of	  washing	  media	  (fresh	  DMEM	  F12,	  1%	  (w/v)	  Pen/Strep)	  and	  
then	  removed	  and	  placed	  in	  petri	  dish	  with	  2-­‐3	  ml	  of	  filtered	  digestion	  media	  (DMEM	  F12,	  
1%	   (w/v)	   Pen/Strep,	   2mg/ml	   collagenase).	   Surrounding	   fat	   tissue	   was	   removed	   and	   the	  
gland	  dissociated	  using	  a	  sterile	  scalpel	  blade.	  The	  tissue	  in	  this	  digestion	  media	  was	  placed	  
in	   a	   50	   ml	   falcon	   and	   a	   further	   10	   ml	   of	   digestion	   media	   was	   added.	   The	   mixture	   was	  
pipetted	  using	  a	  1	  ml	  pipette	  and	  allowed	  to	  incubate	  in	  a	  shaking	  water	  bath	  at	  370C	  for	  1.5	  
hours.	   Every	   15	  minutes	   the	  mixture	  was	  pipetted	  using	   a	   1	  ml	   pipette.	   The	  mixture	  was	  
then	  centrifuged	  at	  800	  rpm	  for	  5	  minutes	  and	  the	  supernatant	  removed.	  The	  cell	  pellet	  was	  
then	  resuspended	  in	  10	  ml	  of	  fresh	  DMEM	  F12	  media	  containing	  2%	  (v/v)	  Ultroser	  and	  1%	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(w/v)	  Pen/Strep.	  The	  cell	   suspension	  was	   filtered	  over	  a	   cell	   strainer	   (40	  μm)	  and	   the	  cell	  
strainer	  was	  then	  washed	  with	  a	  further	  10	  ml	  of	  media.	  Cells	  were	  then	  counted	  as	  above	  
and	  plated	  at	  the	  desired	  density.	  All	   flasks	  or	  plates	  were	   incubated	  for	  at	   least	  48	  hours	  
before	  the	  first	  media	  change.	  
	  
2.4 DHEAS	  Enzyme	  immunoassay	  	  
H295R	  or	  primary	  cells	  were	   seeded	   into	  6-­‐well	  plates	  and	  grown	  until	  60-­‐70%	  confluent.	  
They	   were	   then	   incubated	   in	   serum-­‐free	  media	   (DMEM	   F12,	   1%	   (w/v)	   Pen/Strep)	   for	   24	  
hours.	  Fresh	  serum-­‐free	  media	  containing	  one	  of	  the	  following	  treatments	  was	  then	  added:	  
	  
100	  nM	  Kisspeptin	  
10	  nM	  CRH	  
1	  nM	  ACTH	  
10	  µM	  Forskolin	  
Serum-­‐free	  media	  (untreated	  control)	  
	  
The	   doses	   and	   time	   period	   were	   chosen	   following	   dose-­‐response	   and	   time	   course	  
preliminary	   studies.	   In	   vivo	   it	   is	   estimated	   that	   the	   level	   of	   kisspeptin	   in	   the	   maternal	  
circulation	  reaches	  a	  peak	  of	  ~10	  nM	  158.	  Studies	  of	  cord	  blood	  levels	  suggest	  the	  kisspeptin	  
in	   the	   foetal	   circulation	   reaches	  a	  peak	  of	  ~1	  nM	  at	   term.	   In	   the	  maternal	   circulation	   the	  
level	   of	   CRH	   reaches	   a	   peak	   of	   ~1	   nM	   and	   is	   therefore	   10-­‐fold	   lower	   than	   circulating	  
kisspeptin.	  The	  kisspeptin	  concentration	  used	  in	  experiments	  was	  supraphysiological	  (100x	  
maternal	   circulating	   concentrations).	   This	   was	   decided	   on	   the	   basis	   of	   dose	   and	   time	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response	  studies,	  which	  showed	  a	  significant	  increase	  in	  DHEAS	  after	  24	  hours,	  compared	  to	  
untreated	   H295R	   cells	   with	   10nM	   (p<0.01)	   and	   100nM	   (p<0.05).	   Only	   100nM	   kisspeptin	  
produced	   a	   significant	   increase	   in	  DHEAS	   compared	   to	   no	   treatment	   in	   8-­‐10wpc	   (p<0.05)	  
and	  15-­‐20	  HFA	  (p<0.0001)	  cells.	  Although	  the	  concentrations	  of	  kisspeptin	  and	  CRH	  used	  in	  
these	   in	   vitro	   experiments	   are	   higher	   than	   physiological	   concentrations,	   the	   ratio	   of	  
kisspeptin	  to	  CRH	  is	  preserved	  in	  order	  to	  ensure	  that	  any	  findings	  can	  be	  extrapolated	  to	  an	  
in	  vivo	  situation.	  
	  
At	  the	  end	  of	  each	  experiment,	  the	  total	  protein	  content	  of	  the	  cells	  was	  measured,	  or	  the	  
cells	  were	  harvested	  to	  purify	  RNA.	  The	  media	  were	  collected	  for	  measurement	  of	  DHEAS	  by	  
enzyme	   linked	   immunosorbent	  assay	   (ELISA)	   from	  a	   commercial	   source.	   The	  DHEAS	  ELISA	  
Kit	  (Demeditec	  Diagnostics,	  Kiel)	  was	  used.	  The	  range	  of	  the	  assay	  is	  between	  0	  –	  10	  µg/ml.	  
The	   intra-­‐	   and	   inter-­‐assay	   coefficients	   of	   variation	   for	   all	   assays	   were	   <5	   and	   10%	  
respectively.	  The	  assay	  procedure	  was	  carried	  out	  according	   to	   the	  supplier’s	   instructions.	  
Each	  run	  included	  a	  standard	  curve:	  
	  
Standard	  0	   0	  µg/ml	  
Standard	  1	   0.1	  µg/ml	  
Standard	  2	   0.5	  µg/ml	  
Standard	  3	   1.0	  µg/ml	  
Standard	  4	   2.5	  µg/ml	  
Standard	  5	   5.0	  µg/ml	  
Standard	  6	   10.0	  µg/ml	  
(1	  µg/ml	  =	  2.6	  µmol/l)	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Each	   microtitre	   well	   supplied	   was	   coated	   with	   a	   polyclonal	   anti-­‐DHEAS	   antibody.	   The	  
enzyme	   conjugate	   supplied	   was	   horseradish	   peroxidase.	   The	   substrate	   solution	   was	  
tetramethylbenzidine	   (TMB).	   Stop	   solution	   contained	  1	   nM	  acidic	   solution.	  Wash	   solution	  
(40x	   concentrated)	   contained	   5-­‐bromo-­‐5-­‐nitro-­‐1,3-­‐dioxane	   and	   2-­‐methyl-­‐2H-­‐isothiazol-­‐3-­‐
one.	  Deionised	  water	  was	  added	  to	  the	  concentrated	  wash	  solution	  prior	  to	  use	  to	  obtain	  a	  
1x	  concentration	  of	  solution	  that	  was	  stable	  at	  room	  temperature	  for	  2	  weeks.	  	  
	  
The	   desired	   number	   of	   Microtitre	   wells	   was	   secured	   in	   the	   holder	   and	   25	   µl	   of	   each	  
standard,	  control	  and	  samples	  were	  dispensed	  into	  appropriate	  wells.	  Following	  this	  200	  µl	  
of	   enzyme	   conjugate	  was	   dispensed	   into	   each	  well	  with	   thorough	  mixing	   for	   10	   seconds.	  
The	  plate	  was	  incubated	  for	  60	  minutes	  at	  room	  temperature.	  The	  contents	  of	  the	  well	  were	  
briskly	  shaken	  out	  and	  each	  well	  was	  rinsed	  3	  times	  with	  diluted	  wash	  solution.	  Wells	  were	  
struck	  sharply	  on	  absorbent	  paper	  to	  remove	  residual	  droplets.	  100	  µl	  of	  substrate	  solution	  
was	   added	   to	   each	   well	   followed	   by	   a	   15-­‐minute	   incubation	   at	   room	   temperature.	   The	  
enzymatic	   reaction	  was	   then	   stopped	   by	   adding	   50	   µl	   of	   stop	   solution	   to	   each	  well.	   The	  
absorbance	  of	  each	  well	  at	  450	  nm	  was	  determined	  within	  10	  minutes	  of	  adding	  the	  stop	  
solution	  using	  the	  Perkin	  Elmer	  Wallac	  Victor2	  1420	  Microplate	  reader.	  
	  
2.5 RNA	  Extraction	  
Cells	  grown	   in	  6-­‐well	  plates	  were	  washed	  with	  cold	  PBS	  (Phosphate	  Buffered	  Saline),	   then	  
detached	   using	   a	   cell	   scraper	   and	   transferred	   to	   1.5ml	  microfuge	   tubes.	   They	  were	   then	  
centrifuged	  at	  1200rpm	  for	  5	  minutes	  to	  form	  a	  pellet,	  and	  the	  PBS	  aspirated.	  The	  cells	  were	  
lysed	   using	   350µl	   of	   buffer	   RLT	   from	   the	   Qiagen	   RNeasy	   mini	   kit,	   containing	   β-­‐
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mercaptoethanol.	  Cells	  grown	  in	  12-­‐well	  plates	  were	  also	  washed	  with	  cold	  PBS,	  but	   lysed	  
directly	  in	  the	  wells	  by	  the	  addition	  of	  350µl	  buffer	  RLT	  for	  20	  minutes	  at	  4°C	  with	  agitation.	  
The	  lysates	  were	  then	  transferred	  to	  1.5ml	  microfuge	  tubes.	  RNA	  from	  foetal	  adrenal	  tissue	  
along	  with	  all	  other	  cell	  culture	  samples	  were	  extracted	  as	  described	  in	  the	  Qiagen	  RNeasy	  
mini	   kit.	   The	   RNA	   concentration	  was	   determined	   by	  measuring	   the	   optical	   density	   of	   the	  
samples	  at	  260nm	  wavelength	  using	  the	  Nanodrop	  ND-­‐1000	  spectrophotometer.	  
	  
2.5.1 DNase	  treatment	  
2µg	  RNA,	  5µl	  10X	  Turbo	  DNase	  buffer	  (20	  mM	  HEPES	  pH	  7.5,	  10	  mM	  CaCl2,	  10	  mM	  MgCl2,	  1	  
mM	  DTT	  and	  50%	  (v/v)	  glycerol;	  Ambion,	  Life	  Technologies),	  0.5µl	  RNase	  inhibitor	  (40u/µl;	  
Promega),	  and	  1µl	  Deoxyribonuclease	  (Turbo	  DNase	  2	  units/µl;	  Ambion,	  Life	  Technologies)	  
were	   added	   to	   a	   1.5ml	  microfuge	   tube,	   and	   RNase	   free	   water	   (Qiagen)	   added	   to	   a	   final	  
volume	  of	  50µl.	  Samples	  were	  then	  briefly	  vortexed	  and	  centrifuged,	  and	  incubated	  at	  37°C	  
for	  15	  minutes.	  DNase	   treatment	  cleaves	  and	   fragments	  any	  genomic	  DNA	  contamination	  
within	   the	   samples.	   The	   RNase	   inhibitor	   prevents	   RNases	   degrading	   the	   RNA	   during	   the	  
treatment.	  
2.5.2 Phenol	  extraction	  
An	   amount	   of	   phenol	   –	   pH	   4.7	   equal	   to	   the	   volume	   of	   each	   sample	   was	   added	   (50µl),	  
vortexed	  for	  30	  seconds,	   then	  centrifuged	  for	  1	  minute	  at	  14,000rpm.	  The	  upper	  aqueous	  
layer	  was	  then	  removed	  into	  a	  new	  1.5ml	  microfuge	  tube,	  and	  the	  organic	  and	  inter-­‐	  phases	  
discarded.	   Phenol	   is	   an	   organic	   solvent	   acid	   used	   to	   denature	   and	   remove	   protein	  
contaminants	  from	  the	  RNA.	  The	  pH	  of	  phenol	  determines	  the	  segregation	  of	  DNA	  and	  RNA	  
between	  the	  organic	  phase	  and	  the	  aqueous	  phase.	  Acid	  phenol	  leaves	  RNA	  in	  the	  aqueous	  
	  
	   97	  
phase.	  As	  the	  pH	  decreases,	  the	  concentration	  of	  protons	  increases.	  DNA	  carries	  a	  negative	  
charge	   because	   of	   the	   phosphate	   groups	   in	   its	   sugar-­‐phosphate	   backbone,	   which	   are	  
neutralized	   in	   acid	  by	  protonation.	   In	   this	   case,	  DNA	  dissolves	   in	   the	  organic	   phase.	  RNA,	  
however,	  is	  not	  neutralized	  in	  acid	  because,	  even	  though	  it	  also	  has	  a	  negative	  charge,	  it	  has	  
exposed	   nitrogenous	   bases	   (as	   it	   is	   single-­‐stranded),	   which	   form	   hydrogen	   bonds	   with	  
water,	  thus	  keeping	  it	  in	  the	  aqueous	  phase.	  An	  acid	  pH	  also	  minimizes	  RNase	  activity.	  
	  
2.5.3 RNA	  precipitation	  
To	  precipitate	  out	  RNA	   from	  the	   residual	  phenol,	  3M	  sodium	  acetate	  buffer	   -­‐	  pH5.3	   (BDH	  
Chemicals)	  was	  added	  at	  an	  amount	  equal	  to	  1/10th	  of	  the	  volume	  of	  RNA	  (5µl),	  along	  with	  
2µl	   glycogen	   (5mg/ml;	   Ambion)	   and	   125µl	   ethanol	   (2	   ½	   times	   the	   volume	   of	   RNA).	   The	  
samples	  were	  then	  incubated	  at	  -­‐20°C	  for	  1	  hour	  or	  -­‐80°C	  for	  20-­‐30	  minutes.	  After	  leaving	  
for	  the	  allotted	  time	  the	  samples	  were	  centrifuged	  for	  10	  minutes	  at	  4°C	  and	  14,000	  rpm	  to	  
pellet	  the	  precipitate.	  The	  supernatant	  was	  then	  aspirated	  and	  the	  pellet	  washed	  with	  70%	  
ethanol	  to	  dissolve	  the	  sodium	  acetate.	  Samples	  were	  centrifuged	  again	  at	  4°C	  and	  14,000	  
rpm	  for	  5	  minutes,	  and	  the	  ethanol	  aspirated.	  
2.6 First	  strand	  cDNA	  synthesis	  
To	  each	  2µg	  pellet	  of	  RNA,	  12.5µl	  RNase	  free	  water	  and	  0.25µl	  Random	  primers	  (500µg/ml;	  
Promega)	   were	   added.	   They	   were	   vortexed	   to	   dissolve	   the	   RNA,	   and	   centrifuged	   briefly	  
before	   being	   heated	   to	   80°C	   for	   10	  minutes	   to	   denature	   the	   hydrogen	   bonds	  within	   the	  
single	  stands	  of	  RNA.	  Samples	  were	  then	  cooled	  on	  ice	  for	  1-­‐2	  minutes	  to	  allow	  the	  random	  
primers	  to	  anneal	  within	  the	  secondary	  structure	  of	  the	  RNA,	  and	  given	  a	  quick	  centrifuge	  to	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ensure	  pooling	  of	  any	  condensation.	  At	  this	  point,	  1µl	  was	  removed	  from	  each	  sample	  and	  
placed	   in	   separate	   PCR	   tubes	   for	   use	   as	   negative	   reverse	   transcription	   (RT)	   controls.	   A	  
master	  mix	  containing	  4µl	  5X	  MMLV	  RT-­‐buffer	  (Promega),	  2µl	  DTT	  (Dithiothreitol	  0.1M),	  1µl	  
dNTPs	   (deoxynucleoside	   triphosphates	   10mM	   A+C+G+T;	   Promega),	   0.5µl	   RNase	   inhibitor	  
(40u/µl),	  and	  1µl	  MMLV	  RT-­‐enzyme	  (200u/µl;	  Promega)	  per	  sample	  was	  created,	  and	  8.5µl	  
added	   to	   each	   tube	   (total	   volume	   now	   20µl).	   Samples	   were	   then	   vortexed	   and	   briefly	  
centrifuged,	  then	  incubated	  at	  37°C	  for	  1	  hour	  to	  allow	  reverse	  transcription	  to	  occur.	  After	  
incubation	  20µl	  of	  distilled	  water	  was	  used	  to	  dilute	  each	  sample	  1	  in	  2.	  cDNA	  was	  stored	  at	  
-­‐20°C.	  
2.7 Polymerase	  chain	  reaction	  
Each	  10µl	  reaction	  contained	  1µl	  cDNA,	  0.5µl	  dNTPs	  (10mM	  A+C+G+T),	  1µl	  primers	  (10µM	  
Forward+Reverse)	   (Table	   1),	   2µl	   10X	   PCR	   buffer,	   15.25µl	   H2O,	   and	   0.25µl	   Taq	   DNA	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Standard	  Program:	  
Cycles	   	   Temperature	   Time	   	  
1	   	   94°C	   5	  minutes	  
strand	  separation	  =	  denaturation	  of	  the	  hydrogen	  bonds	  within	  the	  
double	  stranded	  cDNA	  
25	  
	  
94°C	   30	  seconds	   further	  strand	  separation	  
55°C	   30	  seconds	  
annealing	   -­‐	   allows	   the	   primers	   to	   bind	   to	   a	   section	   of	   the	   single	  
stands	  of	  DNA	   for	  which	   they	  have	  been	   specifically	  designed.	   This	  
temperature	   may	   vary	   slightly	   depending	   on	   the	   Tm	   (melting	  
temperature)	  of	  the	  primers	  
72°C	   30	  seconds	  
Extension	   -­‐	   Taq	   DNA	   polymerase	   binds	   to	   the	   primers	   and	   uses	  
dNTPs	   as	   building	   blocks	   to	   enzymatically	   synthesise	   a	  
complementary	   strand	   of	   DNA.	   The	   newly	   formed	   PCR	   product	  
contains	   one	   strand	   of	   parental	   cDNA,	   and	   one	   newly	   synthesised	  
strand.	  This	  process	   if	  repeated	  25-­‐35	  times	  to	  amplify	  the	  piece	  of	  
DNA	  between	  the	  forward	  and	  reverse	  primer	  sequences	  
1	   	   72°C	   7	  minutes	   further	  elongation	  
1	   	   4°C	   ∞	   Preservation	  
2.7.1 Gel	  electrophoresis	  
After	   the	   cDNA	   has	   been	   amplified,	   samples	   were	   combined	   with	   5µl	   of	   loading	   dye	  
(Fermentas)	  and	  run	  on	  a	  1-­‐2%	  (w/v)	  agarose	  gel.	  The	  loading	  dye	  increases	  the	  density	  of	  
the	  DNA	  solution	  to	  contain	   it	  within	  the	  wells	  of	   the	  gel.	  The	  percentage	  gel	  depends	  on	  
the	   size	   of	   the	   piece	   of	   cDNA	   that	   has	   been	   amplified,	   as	   higher	   molecular	   weights	   are	  
separated	   more	   easily	   on	   lower	   percentage	   gels.	   The	   gel,	   containing	   0.5µg/ml	   ethidium	  
bromide,	  was	  placed	  in	  an	  electrophoresis	  chamber	  containing	  1X	  TAE	  buffer	  (Tris-­‐acetate-­‐
	  
	  100	  
EDTA	   buffer;	   National	   Diagnostics),	   and	   an	   electrical	   current	   passed	   through	   it.	   The	   PCR	  
products	  were	  visualised	  using	  a	  transilluminator.	  
	  
2.7.2 Oligonucleotide	  design	  
The	   relevant	   sequence	   of	   the	   gene	   of	   interest	   was	   established	   using	   Ensembl	  
(http://www.ensembl.org/index.html).	  Primer	  sequences	  for	  cDNA	  traverse	  intronic	  regions.	  
The	  following	  guidelines	  were	  then	  used	  for	  PCR	  primer	  design:	  
1. Oligonucleotide	  length	  of	  between	  18	  to	  30	  nucleotides	  	  
2. GC	  content	  should	  be	  between	  40-­‐60%	  	  
3. Primer	  pairs	  should	  have	  similar	  Tm	  (melting	  temperature)	  values,	  where	  the	  Tm	  can	  
be	  estimated	  as	  follows:	  Tm	  =	  2oC	  x	  (number	  of	  A	  and	  T	  residues)	  +	  4oC	  x	  (number	  of	  
G	  and	  C	  residues).	  
4. Complementary	  sequences	  within	  a	  primer	  sequence	  and	  between	  pairs	  should	  be	  
avoided.	  	  
5. Runs	  of	  3	  or	  more	  Gs	  or	  Cs	  should	  be	  avoided	  at	  the	  3’	  end.	  
6. Complementarity	  of	  2	  or	  3	  bases	  at	  the	  3’	  ends	  of	  primer	  pairs	  should	  be	  avoided	  to	  
reduce	  primer-­‐dimer	  formation.	  
The	   stock	   primer	   solution	   was	   stored	   at	   -­‐20oC.	   To	   avoid	   repeat	   freeze-­‐thawing,	   small	  






Table	  1:	  Primer	  sequences	  for	  PCR	  






Sequence	   Product	  
Length	  
(bps)	  
Human	  GAPDH	  F	   62.5	   58-­‐60	   TGCACCACCAACTGCTTAG	   177	  
Human	  GAPDH	  R	   63.0	   GGATGCAGGGATGATGTTC	  
Reverse	  complement	   	   GAACATCATCCCTGCATCC	  
Human	  Kiss1R	  F	   64.7	   58-­‐60	   TGGTACGTGACGGTGTTCC	   206	  
Human	  Kiss1R	  R	   64.2	   GCCTTCGCACTGTACAACCT	  
Reverse	  complement	   	   AGGTTGTACAGTGCGAAGGC	  
	  
	  
2.7.3 Gel	  purification	  
	  
After	  cutting	  out	  a	  band	  of	  PCR	  product	  from	  the	  agarose	  gel,	  a	  volume	  of	  6M	  NaI	  (sodium	  
iodide)	  three	  times	  that	  of	  the	  gel	  was	  added,	  and	  heated	  to	  55°C	  for	  5min	  to	  dissolve	  the	  
agarose.	   10µl	   of	   glass	  milk	   (silica	   in	   suspension	   in	   3M	  NaI)	   was	   then	   used	   to	   absorb	   the	  
nucleic	  acid	   for	  5	  minutes	  at	   room	  temperature,	  and	  a	  pellet	  of	  PCR	  product	  collected	  by	  
centrifugation	  for	  15	  seconds	  at	  14,000rpm.	  The	  supernatant	  was	  aspirated,	  and	  the	  pellet	  
washed	   twice	   with	   New	   Wash	   containing	   50mM	   NaCl	   (sodium	   chloride),	   10mM	   TrisHCl	  
pH7.5	   (Tris	  Base;	   Fisher	  BioReagents,	  HCl;	  BDH	  chemicals),	  50%	   (v/v)	  ethanol,	   and	  7.5mM	  
EDTA	   (ethylenediamenetetraacetic	   acid)	   to	   remove	   impurities.	   The	   pellet	   was	   then	  
resuspended	   in	   10µl	   distilled	   H2O,	   heated	   to	   55°C	   for	   2	   minutes,	   and	   centrifuged	   for	   1	  
	  
	  102	  
minute	   at	   14,000rpm,	   to	   elute	   the	   PCR	   product	   from	   the	   silica.	   The	   supernatant	   was	  
transferred	  to	  a	  new	  tube,	  and	  either	  sent	  for	  sequencing,	  or	  made	  up	  to	  50µl	  with	  distilled	  
H2O	  for	  use	  in	  real-­‐time	  qPCR.	  1	  μl	  of	  sample	  was	  re-­‐run	  on	  1%	  (w/v)	  agarose	  gel	  to	  confirm	  
efficient	  purification.	  PCR	  products	  were	  stored	  at	  -­‐20oC.	  
2.8 Sequencing	  
PCR	  products	  were	  sequenced	  using	  the	  ABI	  Prism	  Big	  Dye	  sequencing	  kit	  and	  an	  ABI	  3730	  
automated	  DNA	  sequencer	  (Applied	  Biosystems,	  Foster	  City,	  CA),	  carried	  out	  by	  the	  Genome	  
Centre	  at	  the	  William	  Harvey	  Research	  Institute,	  QMUL.	  This	  is	  based	  on	  the	  Sanger	  dideoxy-­‐
mediated	  chain	  termination	  method	  168,	  which	  requires	  a	  DNA	  template,	  a	  DNA	  primer,	  DNA	  
polymerase,	   conventional	   dNTPs	   and	   modified	   nucleotides	   that	   terminate	   DNA	   strand	  
elongation	   (ddNTPs).	   The	   double	   stranded	   DNA	   fragment	   is	   denatured	   into	   single	   DNA	  
strands	   and	   a	   primer	   complementary	   to	   the	   known	   DNA	   sequence	   binds	   to	   the	   single	  
stranded	  DNA	  template.	  DNA	  polymerase	  then	  binds	  to	  the	  primer	  and	  a	  new	  strand	  of	  DNA	  
incorporating	  free	  nucleotides,	  complementary	  to	  the	  target	  DNA	  sequence,	  is	  synthesised.	  
The	  terminating	  nucleotides	  of	   the	  ddNTPs	  are	   fluorescently	   labelled	  and	  modified	  to	   lack	  
the	   3’OH	   group	   required	   for	   the	   formation	   of	   the	   phosphodiester	   bond	   between	   two	  
nucleotides	   thus	   terminating	   each	   DNA	   strand	   at	   the	   point	   of	   inclusion.	   This	   process	   is	  
repeated	  many	  times	  thus	  generating	  many	  fragments	  of	  different	  lengths	  that	  all	  terminate	  
in	   fluorescently	   labelled	   bases,	   corresponding	   to	   A,	   T,	   G	   and	   C.	   The	   reaction	   is	   then	  
transferred	   into	   thin	   glass	   capillaries	   where	   application	   of	   an	   electrical	   charge	   moves	  
negatively	   charged	   particles	   through	   a	   gel	  matrix	   and	  DNA	   fragments	   are	   then	   separated	  
according	   to	   size.	   Finally	   a	   laser	   is	   used	   to	   excite	   the	   chain	   terminating	   fluorescent	   base,	  




Analysis	   of	   sequence	   chromatograms	   was	   carried	   out	   using	   BioEdit	  
(http://www.mbio.ncsu.edu/BioEdit/).	   BioEdit	   is	   a	   freeware	  biological	   sequence	  alignment	  
editor	   and	   analysis	   program	   for	   Windows	   95/98	   NT.	   The	   program	   enables	   the	   user	   to	  
compare	  the	  DNA	  sequence	  to	  a	  reference	  sequence,	  enabling	  identification	  of	  differences	  
between	  2	  or	  more	  sequences	  by	  eye.	  
2.9 Real-­‐time	  qPCR	  	  
A	   DNA	   template	   is	   replicated,	   as	   in	   normal	   PCR,	   but	   then	   quantified	   in	   real	   time	   by	   the	  
detection	   of	   fluorescence.	   The	   amount	   of	   fluorescence	   recorded	   is	   proportional	   to	   the	  
amount	   of	   DNA	   amplified,	   so	   DNA	   copy	   numbers,	   and	   therefore	   mRNA	   levels	   can	   be	  
determined.	  The	  Ct	  value	  is	  the	  threshold	  cycle	  value,	  and	  the	  point	  at	  which	  amplification	  is	  
first	  detectable	  above	  background	   fluorescence.	  A	   lower	  Ct	   indicates	  a	  greater	  amount	  of	  
amplification	  target	  in	  the	  starting	  DNA.	  The	  Ct	  is	  measured	  during	  the	  exponential	  phase	  of	  
replication,	   before	   a	   plateaux	   is	   reached,	   and	   is	   best	   recorded	   just	   as	   the	   fluorescent	  
threshold	  has	  been	  met.	  A	  standard	  curve	  of	  known	  DNA	  concentrations	   for	  each	  gene	  of	  
interest	  (GOI)	  is	  used	  to	  calculate	  the	  DNA	  copy	  numbers	  from	  the	  Ct	  values.	  The	  quantity	  of	  
a	   reference	   RNA,	   such	   as	   GAPDH,	   is	   also	   determined	   to	   account	   for	   differences	   in	   the	  
amount	  of	  cDNA	  loaded.	  A	  sample	  containing	  H2O	  instead	  of	  cDNA,	  termed	  the	  no	  template	  
control	  (NTC),	  is	  measured	  to	  distinguish	  between	  actual	  gene	  expression	  and	  background.	  






The	  following	  criteria	  were	  used	  for	  results	  inclusion:	  
𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑  𝑐𝑢𝑟𝑣𝑒  𝑔𝑟𝑎𝑑𝑖𝑒𝑛𝑡 = −3.3  ± 0.3	  	  
(This	  is	  the	  number	  of	  cycles	  expected	  between	  each	  standard	  with	  a	  serial	  dilution	  
of	  1	  in	  10).	  	  
	  
𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 = 100%  ± 10%	  	  
	  
𝑅! = 1− 0.03	  	  
(this	   indicates	   the	   relationship	   between	   the	   CT	   and	   the	   concentration	   of	   DNA	   and	  
should	  be	  linear	  (1)	  
	  
SYBRGREEN	   is	   a	   DNA-­‐binding	   dye	   that	   will	   fluoresce	   with	   light	   excitation	   when	   bound	   to	  
double	  stranded	  DNA.	  The	  amount	  of	  fluorescence	  is	  therefore	  directly	  proportional	  to	  the	  
concentration	  of	  amplified	  template.	  	  The	  emission	  intensity	  of	  fluorescence	  during	  the	  PCR	  













Fig.	  13a.	  Amplification	  plot	  (Applied	  Biosystems	  technical	  manual	  4309155)	  
	  
Reactions	  were	  run	  in	  duplicate	  or	  triplicate	  in	  a	  96-­‐well	  plate,	  including	  a	  NTC.	  Plates	  were	  
centrifuged	   at	   1500	   rpm	   to	   remove	   bubbles	   and	   ensure	   the	   reaction	  mixture	  was	   at	   the	  
bottom	   of	   the	   wells.	   Standard	   curves	   were	   created	   using	   serial	   dilutions	   of	   a	   known	  
concentration	  of	  DNA	  for	   the	  gene	  of	   interest	  and	  of	   the	   internal	  control	   (GAPDH).	   In	   the	  
initial	   cycles	   of	   PCR,	   there	   is	   little	   change	   in	   fluorescence	   signal	   and	   an	   increase	   in	  
fluorescence	  above	  baseline	  indicates	  the	  detection	  of	  an	  accumulated	  target.	  Amplification	  
plots	   are	   the	   plots	   of	   fluorescence	   signal	   versus	   cycle	   number.	   A	   fixed	   fluorescence	  
threshold	   is	   set	   in	   the	  region	  associated	  with	  exponential	  growth	  of	   the	  PCR	  product.	  The	  
threshold	  cycle	  (Ct)	   is	  defined	  as	  the	  fractional	  cycle	  number	  at	  which	  fluorescence	  passes	  
the	  fixed	  threshold.	  The	  higher	  the	  starting	  copy	  number	  of	  the	  nucleic	  target	  the	  sooner	  a	  
significant	   increase	  in	  fluorescence	  is	  observed.	  The	  no	  template	  control	  (NTC)	   is	  a	  sample	  
that	  does	  not	  contain	  template	  and	  is	  used	  to	  verify	  amplification	  quality.	  The	  Ct	  of	  the	  NTC	  
should	  be	  more	   than	  5	   cycles	   away	   from	   that	  of	   the	   target.	  Dissociation	   curve	   analysis	   is	  
	  
	  106	  
used	   to	   determine	   the	   melting	   temperature	   (Tm)	   of	   the	   PCR	   product.	   The	   Tm	   is	  
characteristic	  of	  the	  GC	  content,	  length	  and	  sequence	  of	  a	  DNA	  product	  and	  can	  be	  used	  to	  
establish	   that	   the	   correct	  DNA	  product	   has	   been	   amplified.	   The	   standards	   of	   the	   gene	  of	  
interest	   have	   the	   same	   Tm,	  with	   the	   NTC	  melting	   at	   a	   lower	   temperature.	   The	   standard	  
curve	  is	  generated	  from	  the	  Cts	  of	  the	  standards	  (Fig.	  13b).	  Adequate	  PCR	  efficiency	  has	  to	  
be	  achieved	  with	  a	  minimum	  of	  3	  replicates	  and	  a	  minimum	  of	  5	  logs	  of	  standard	  template	  
concentration.	  A	  slope	  of	  -­‐3.3	  +/-­‐	  10%	  reflects	  an	  efficiency	  of	  100%	  +/-­‐	  10%.	  A	  PCR	  reaction	  
of	   lower	   efficiency	   will	   have	   lower	   sensitivity.	   If	   the	   standard	   curve	   is	   of	   appropriate	  
efficiency	  it	  can	  then	  be	  used	  to	  extrapolate	  the	  quantity	  of	  the	  target.	  	  
	  
Fig.	   13b.	   Representative	   image	   of	   a	   standard	   curve	   generated	   from	   the	   Ct	   of	   the	  














This	  method	  of	  generating	  a	  fluorescent	  signal	  is	  cheap	  and	  easy	  to	  use,	  as	  the	  same	  dye	  can	  
be	  used	  for	  all	  genes.	  However,	  this	  does	  mean	  it	  lacks	  in	  specificity,	  so	  the	  quantity	  of	  only	  
one	  gene	  per	  well	  can	  be	  measured.	  Amplification	  in	  the	  NTC	  is	  also	  often	  seen,	  as	  it	  cannot	  
distinguish	   between	   real	   template	   and	   artefact	   bands,	   such	   as	   those	   created	   by	   primer-­‐
dimers.	  
	  
Each	   10	   µl	   reaction	   contained	   2	   µl	   cDNA	   template,	   5µl	   2X	   SYBRGREEN	   I	   master	   mix	  
(KapaBiosystems),	   0.2	   µl	   low	   ROX	   (KapaBiosystems),	   0.5	   µl	   primers	   (10	   µM	  
Forward+Reverse),	   and	   2.3	   µl	   sterile	   H2O.	   The	   2X	   SYBRGREEN	   I	   master	   mix	   contains	   the	  
SYBRGREEN	  I	  fluorescent	  dye,	  MgCl2,	  dNTPs,	  stabilisers,	  and	  DNA	  polymerase.	  ROX	  is	  used	  as	  a	  
reference	  dye	  as	  it	  does	  not	  intercalate	  with	  DNA	  and	  increases	  its	  fluorescence	  during	  the	  
PCR	   reaction.	   This	   is	   used	   as	   an	   internal	   reference	   to	   correct	   for	   inter-­‐well	   fluorescence	  















Using	  the	  MX4000	  real	  time	  thermocycler	  (Stratagene),	  a	  quantitative	  method	  was	  selected.	  
Quantitative	  fast	  cycle	  program:	  
	  
Cycles	   	   Temperature	   Time	   	  
1	   	   95°C	   3	  minutes	   strand	  separation	  	  
35	  
	  
95°C	   3	  seconds	  
annealing	   and	  
extension	  
60°C	   30	  seconds	  
72°C	   1	  second	  
1	   	   95°C	   1	  minute	  
dissociation	  melt	  1	   	   60°C	   30	  seconds	  
1	   	   95°C	   30	  seconds	  
	   	   	   	   	  
The	  dissociation	  melt	   separates	  double	  stranded	  DNA	  back	   to	   its	   single	  stranded	   form.	  As	  
different	   genes	   have	   different	   melting	   temperatures,	   the	   quality	   of	   the	   amplification	  
product	  can	  be	  assessed.	  All	  wells	  amplified	  with	  the	  same	  primers	  should	  contain	  the	  same	  
cDNA,	  with	   only	   one	   peak	   detected	   at	   a	   temperature	   corresponding	   to	   the	   amplification	  
product’s	  Tm.	  Primer-­‐dimers,	  or	  amplification	  of	  more	  than	  one	  DNA	  template	  may	  result	  in	  




The	  quantitative	  protocol	   displays	   all	  DNA	   copy	  numbers,	   but	   comparisons	  must	  be	  done	  
separately	  after	  dividing	  the	  GOI	  values	  by	  the	  reference	  gene	  values.	  
2.10 Protein	  analysis	  
2.10.1 Protein	  extraction	  for	  Western	  blotting	  
To	  prepare	  lysates,	  media	  was	  removed	  by	  pipetting	  and	  cells	  were	  washed	  in	  cold	  PBS.	  For	  
a	   6	   well	   plate	   cells	   were	   lysed	   in	   200	  µl	   RIPA	   buffer	   (Sigma-­‐Aldrich)	   containing	   protease	  
inhibitor	  (complete,	  Mini,	  EDTA-­‐free	  Protease	  Inhibitor	  Cocktail	  tablets,	  Roche).	  They	  were	  
then	  scraped	  off	  the	  plate	  and	  transferred	  to	  1.5	  ml	  eppendorf	  tubes.	  Tubes	  were	  left	  on	  ice	  
for	  30	  minutes,	  then	  centrifuged	  at	  13	  000	  rpm	  for	  12	  minutes	  at	  4oC	  to	  pellet	  cell	  debris.	  
Supernatant	   was	   collected	   and	   added	   to	   an	   equal	   volume	   of	   2x	   Laemmli	   buffer	   (Sigma-­‐
Aldrich),	  containing	  SDS	  and	  β-­‐ME,	  then	  boiled	  for	  10	  minutes	  to	  denature	  proteins	  prior	  to	  
gel	  loading.	  
	  
2.10.2 Bradford	  protein	  assay	  
The	  Bradford	  protein	  assay	  (Bradford,	  1979)	  was	  used	  to	  determine	  protein	  concentration	  
of	  cell	  lysates.	  The	  assay	  is	  based	  on	  the	  maximum	  absorbance	  shift	  from	  465nm	  to	  595nm	  
of	  Coomassie	  Brilliant	  Blue	  G-­‐250	   (5x)	   (Biorad)	  protein	   assay	  dye	  when	  bound	   to	  protein.	  
Serial	  dilutions	  of	  bovine	  serum	  albumin	  (BSA)	  (Sigma-­‐Aldrich)	  ranging	  from	  0	  –	  1mg/ml	  in	  
concentration	  were	  used	  as	  protein	  standards.	  The	  protein	  assay	  dye	  was	  diluted	  1	  in	  5	  with	  
PBS	  prior	  to	  the	  assay.	  10	  µl	  of	  standard	  or	  test	  sample	  were	  added	  in	  triplicate	  to	  each	  well	  
of	   a	   96	   well	   plate,	   together	   with	   200	  µl	   of	   protein	   assay	   dye.	   The	   samples	   were	   left	   to	  
incubate	  at	  room	  temperature	  for	  5	  minutes.	  Absorbance	  of	  each	  well	  at	  595	  nm	  (OD595)	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was	  determined	  using	  the	  Perkin	  Elmer	  Wallac	  Victor2	  1420	  Microplate	  reader.	  A	  standard	  
curve	  was	  produced	  by	  plotting	  the	  OD595	  against	  concentration	  of	  the	  BSA	  standard,	  and	  
the	   protein	   content	   of	   each	   sample	   was	   determined	   by	   extrapolating	   from	   the	   linear	  
equation	  as	  previously	  described	  (Bradford	  1979).	  
	  
2.10.3 Western	  blotting	  
A	  pre-­‐cast	  gel	  (SDS	  PAGE	  precast	  NuPage	  BisTris	  gels	  (w/v)	  4-­‐12%,	  10%	  or	  12%)	  (Invitrogen)	  
was	  briefly	  rinsed	  with	  distilled	  water	  and	  inserted	  into	  the	  gel	  tank.	  The	  tank	  was	  filled	  with	  
1x	  MOPS	  running	  buffer	  (50x	  3-­‐(N-­‐morpholino)	  propanesulphonic	  acid	  (50nM	  MOPS,	  50nM	  
Tris	  Base,	  0.1%	  (w/v)	  SDS,	  1mM	  EDTA	  pH	  7.7))	  to	  cover	  the	  gel	  and	  the	  comb	  removed	  the	  
protein	   ladder	   (Kaleidoscope	  prestained	  Protein	  Marker	   (Biorad)	  was	   loaded	   into	   the	   first	  
well	  of	  the	  gel	  (10	  µl	  for	  10	  well	  gel,	  8	  µl	  for	  15	  well	  gel).	  Samples	  prepared	  in	  2x	  Laemmli	  
buffer	  were	  centrifuged	  for	  1	  minute	  at	  13	  000	  rpm	  and	  loaded	  into	  adjacent	  wells,	  typically	  
between	  20-­‐30	  µl,	  depending	  on	  the	  protein	  content	  of	  the	   lysate.	  The	  gel	  was	  run	  for	  30	  
minutes	  at	  70V	  and	  an	  hour	  at	  160V.	  	  
	  
2.10.4 Semi-­‐dry	  transfer	  of	  proteins	  from	  gel	  to	  membrane	  
A	  square	  segment	  of	  0.1	  µm	  pore	  nitrocellulose	  membrane	  was	  cut	  to	  the	  dimensions	  of	  the	  
gel	   using	   extra	   thick	   filter	   paper	   (Biorad)	   as	   a	   template.	   The	   membrane	   was	   soaked	   in	  
transfer	  buffer	   (0.9%	  glycine	  (w/v),	  0.242%	  Tris	   (w/v),	  20%	  methanol	   (v/v))	   for	  10	  minutes	  
prior	   to	   the	   transfer	  procedure.	  A	  sandwich	  of	   filter	  paper-­‐membrane-­‐gel-­‐filter	  paper	  was	  
assembled	   in	   the	   transfer	   cell.	   First,	   filter	  paper	  was	  briefly	   soaked	   in	   transfer	  buffer	   and	  
placed	   on	   the	   transfer	   cell,	   pressed	   with	   a	   roller	   to	   remove	   excess	   buffer.	   Next	   the	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membrane	  was	  placed	  on	  top	  of	  the	  filter	  paper	  and	  then	  the	  gel	  was	  soaked	  and	  placed	  on	  
top	  of	  the	  membrane.	  	  Bubbles	  were	  removed	  by	  gently	  pressing	  the	  gel	  from	  the	  centre	  to	  
the	   corners.	   Finally	   the	   second	   filter	  paper	  was	   soaked	  and	  placed	  on	   top	  of	   the	  gel.	   The	  
sandwich	  was	  pressed	  again	  with	  the	  roller	  to	  remove	  excess	  buffer.	  The	  transfer	  cell	  (Trans-­‐
Blot	   SD	   semi-­‐dry	   transfer	   cell)	   (Biorad)	  was	   set	   to	   15V	   for	   40	  minutes	   for	   one	   blot	   or	   50	  
minutes	  for	  two	  blots.	  After	  transfer	  the	  gel	  was	  discarded	  and	  the	  membrane	  subjected	  to	  
Ponceau-­‐S	  staining	  to	  determine	  the	  efficiency	  of	  the	  transfer.	  	  
	  
2.10.5 Ponceau-­‐S	  staining	  
Ponceau-­‐S	   (0.2%	   (w/v)	   Ponceau-­‐S	   and	   1%	   (w/v)	   acetic	   acid)	   (Sigma-­‐Aldrich)	   is	   a	   dye	   that	  
reversibly	   stains	   protein	   bands	   without	   any	   adverse	   effects	   on	   the	   proteins.	   Staining	  
membranes	   with	   Ponceau-­‐S	   reveals	   any	   regions	   where	   the	   transfer	   has	   failed	   (seen	   as	  
bubbles)	  as	  well	  as	  the	  amount	  of	  protein	  loaded	  per	  lane	  and	  the	  efficiency	  of	  the	  transfer.	  
Membranes	  were	  placed	  in	  small	  containers,	  covered	  with	  Ponceau-­‐S	  and	  left	  on	  a	  shaker	  
for	  about	  two	  minutes.	  Ponceau-­‐S	  was	  removed	  and	  the	  membrane	  washed	  with	  PBS-­‐tween	  
(1x	   PBS	   +0.1%	   (v/v)	   Tween20)	   (Sigma-­‐Aldrich).	   After	   one	   wash,	   protein	   bands	   became	  
visible,	  and	  Ponceau-­‐S	  staining	  was	  then	  removed	  with	  further	  washes	  in	  PBS-­‐tween.	  	  
	  
2.10.6 Immunoblotting	  
A	  blocking	  buffer	  was	  prepared	  by	  dissolving	  5%	  (w/v)	  non-­‐fat	  dried	  powdered	  milk	  (Asda)	  
in	   PBS-­‐tween	   (0.1%	   (w/v)),	   and	   mixing	   by	   inversion.	   Nitrocellulose	   membranes	   were	  
transferred	  to	  50	  ml	  falcon	  tubes	  with	  10	  ml	  blocking	  buffer	  for	  one	  hour	  to	  prevent	  non-­‐
specific	  binding	  of	  the	  antibody.	  Tubes	  were	  rotated	  on	  a	  roller.	  After	  blocking,	  membranes	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were	   incubated	   in	   milk	   containing	   relevant	   dilutions	   of	   primary	   antibodies	   (Table	   2)	  
overnight	  at	  4oC.	  The	  following	  day,	  membranes	  were	  subjected	  to	  3x	  10	  minute	  washes	  in	  
PBS-­‐tween,	   incubated	   in	   milk	   containing	   fluorophore-­‐conjugated	   secondary	   antibodies	  
(Table	   2)	   (goat	   anti-­‐rabbit	   800	   1:5000,	   goat	   anti-­‐mouse	   680	   1:20	   000)	   (Odyssey)	   for	   one	  
hour	   and	   wash	   steps	   were	   repeated.	   Bands	   were	   detected	   using	   an	   Odyssey	   scanner	   at	  
wavelengths	  800	  and	  680.	  	  	  
	  
Table	  2.	  Antibodies	  used	  for	  western	  blotting	  
	  
Ab	   Antigen/Fluorophore	   Species	   Company	   Dilution	  
1°	    β-­‐actin	   Mouse	  
monoclonal	  
Sigma-­‐Aldrich	  	   1	  in	  10	  000	  
1°	   Kiss1R	   Rabbit	  polyclonal	   Alomone	  AKR-­‐001	   1	  in	  500	  
2°	   IRDye®680LT	   Goat	  anti-­‐mouse	   Li-­‐cor	   1	  in	  20	  000	  
2°	   IRDye®800CW	   Goat	  anti-­‐rabbit	   Li-­‐cor	   1	  in	  5000	  
2.11 Cytology	  
2.11.1 Fixation	  	  
Cells	  grown	  on	  cover	  slips	  were	  washed	  twice	  with	  ice	  cold	  PBS,	  and	  fixed	  for	  15	  minutes	  in	  
4%	  (w/v)	  PFA	  (paraformaldehyde;	  BDH	  Chemicals)	  on	  ice.	  	  
PFA	  holds	  the	  cells	  architecture	   in	  place	  by	  creating	  chemical	  cross-­‐links	  that	   join	  proteins	  




After	  fixation,	  cells	  were	  blocked	  with	  10%	  (v/v)	  normal	  donkey	  or	  goat	  serum	  in	  PBS-­‐triton-­‐
Na	   azide	   containing	   0.1%	   (w/v)	   triton	   X-­‐100	   and	   0.2%	   (w/v)	   Sodium	   azide	   (Fluka	  
BioChemika),	  then	  incubated	  overnight	  at	  room	  temperature	  with	  primary	  antibodies	  (Table	  
3),	   also	   in	   PBS-­‐triton-­‐Na	   azide.	   Residual	   unbound	   primary	   antibodies	   were	   removed	   by	  
washing	  the	  cells	  three	  times	  in	  PBS	  with	  0.1%	  (w/v)	  triton	  X-­‐100	  (PBS-­‐triton)	  for	  10	  minutes	  
each.	   Incubation	   with	   secondary	   antibodies	   (Table	   3)	   in	   PBS-­‐triton	   was	   carried	   out	   for	   3	  
hours	   at	   room	   temperature,	   before	   repeating	   the	   washes	   in	   PBS-­‐triton	   to	   remove	   any	  
unbound	  secondary	  antibodies.	  One	  drop	  of	  DAPI	  (4’,6-­‐diamidino-­‐2-­‐phenylindole)	  was	  then	  
added	  to	  each	  cover	  slip	  for	  less	  than	  1	  minute	  before	  being	  washed	  away.	  Cover	  slips	  were	  
transferred	  onto	  microscope	  slides,	  and	  secured	  with	   fluorescent	  mounting	  media	   (Dako).	  
Slides	   were	   visualised,	   and	   images	   taken	   using	   the	   Zeiss	   LSM510	   laser	   scanning	   confocal	  


















Table	  3.	  Antibodies	  used	  for	  immunofluorescence	  
Ab	   Antigen/Fluorophore	   Species	   Company	   Dilution	  
1°	   SF1	   Mouse	  
monoclonal	  
Invitrogen	  434200	   1	  in	  200	  
2°	   AF488-­‐Green	   Goat	  anti-­‐mouse	   Invitrogen	  A11029	   1	  in	  1000	  
1°	   Kiss1R	   Rabbit	  polyclonal	   Alomone	  AKR-­‐001	   1	  in	  100	  
2°	   CY3-­‐Red	   Donkey	   anti-­‐
rabbit	  
Jackson	   Immunoresearch	   711-­‐
165-­‐152	  
1	  in	  1000	  
1°	   SULT2A1	   Rabbit	  polyclonal	   Abcam	  38416	   1	  in	  200	  
2°	   CY3-­‐Red	   Donkey	   anti-­‐
rabbit	  
Jackson	   Immunoresearch	   711-­‐
165-­‐152	  
1	  in	  1000	  




Invitrogen	  MHCD5620	   1	  in	  1000	  
2.12 Histology	  
2.12.1 Sectioning	  and	  Mounting	  
10µm	   thick	   sections	   were	   cut	   from	   adrenals	   embedded	   in	   paraffin	   using	   the	   Leitz	   1512	  
microtome,	  and	  mounted	  on	  TESPA	  treated	  slides	  (3-­‐triethoxysilylpropylamine;	  VWR)	  by	  the	  
floating-­‐out	   technique.	   Briefly,	   a	   small	   amount	   of	   water	   was	   placed	   on	   the	   slides,	   and	  
ribbons	  of	   serial	   sections	   laid	   flat	  on	   the	  water.	  They	  were	  heated	   to	  approximately	  38°C,	  
and	   the	  water	   removed	  by	  pipetting	   from	  a	   corner	  or	   edge,	   leaving	   the	   sections	   to	  bond	  
with	  the	  adhesive	  coating	  (TESPA).	  The	  slides	  were	  then	  dried	  overnight	  at	  37°C	  to	  increase	  




As	   paraffin	   is	   insoluble	   in	   water,	   most	   staining	   techniques	   require	   it	   to	   be	   removed.	   To	  
deparaffinise,	  sections	  were	  washed	  three	  times	   in	  xylene,	  twice	   in	  100%	  ethanol,	  once	   in	  
90%	   (v/v)	   ethanol,	   once	   in	   70%	   (v/v)	   ethanol,	   once	   in	   50%	   (v/v)	   ethanol,	   and	   then	  
rehydrated	  by	  washing	  twice	  in	  H2O.	  Each	  wash	  lasted	  10	  minutes.	  	  
	  
2.12.3 Haematoxylin	  &	  Eosin	  (H&E)	  staining	  
Slides	   were	   washed	   for	   2	   minutes	   in	   haematoxylin	   (Lamb	   Laboratories),	   and	   2	   minutes	  
under	  running	  H2O.	  They	  were	  then	  immersed	  in	  acidic	  alcohol	  10	  times	  (75%	  (v/v)	  ethanol,	  
0.04%	   (v/v)	  HCl),	   followed	  by	   another	  2	  minutes	  under	   running	  H2O.	  After	   immersing	   the	  
slides	   10	   times	   in	   ammonia	   solution	   (0.084%	   (v/v)	   ammonium	   hydroxide),	   they	   were	  
subjected	  to	  5	  minutes	  under	  running	  H2O,	  10	  immersions	  in	  80%	  (v/v)	  ethanol,	  placed	  for	  
15	  seconds	  in	  Eosin	  (Lamb	  Laboratories),	  followed	  by	  two	  lots	  of	  10	  immersions	  in	  95%	  (v/v)	  
ethanol,	  two	  lots	  of	  10	  immersions	  in	  100%	  ethanol,	  and	  two	  10	  minute	  washes	  in	  xylene.	  
Excess	  xylene	  was	  wiped	  from	  the	  back	  and	  edges	  of	  the	  slides,	  and	  they	  were	  covered	  with	  
glass	   slips,	   using	  DPX	  mounting	  media	   (Lamb	   Laboratories)	   to	   preserve	   the	   staining.	   They	  
were	   visualised	   and	   imaged	   using	   the	   NanoZoomer-­‐2.0	   HT	   Digital	   Slide	   Scanner	  
(Hamamatsu)	   and	   Panoramic	   Viewer	   (3DHistech)	   software,	   and	   the	   Leica	   DMR	   Light	  





Tissue	   from	   early	   gestation	   (8	   –	   13	   wpc)	   was	   studied	   in	   collaboration	   with	   Achermann’s	  
group	  at	  ICH	  using	  material	  collected	  from	  the	  HDBR.	  Paraffin	  embedded	  wax	  sections	  were	  
studied	  both	  in	  our	  lab	  and	  at	  ICH.	  	  
	  
Paraffin	   sections	   were	   deparaffinised	   with	   three	   washes	   in	   xylene.	   Ethanol	   washes	   were	  
continued	  using	  100%,	  90%,	  70%	  and	  50%	  (v/v)	  solutions,	  followed	  by	  two	  washes	  with	  H2O	  
to	  rehydrate.	  The	  slides	  were	  then	  boiled	   for	  15	  minutes	   in	  10mM	  sodium	  citrate	  buffer	   -­‐	  
pH6	   (BDH	   Chemicals)	   to	   break	   cross-­‐links	   formed	   between	   proteins	   during	   paraffin	  
embedding,	   and	   unmask	   antigens	   and	   epitopes.	   	   Cryosections	   were	   left	   at	   room	  
temperature	   for	  10	  minutes.	  After	  a	  5-­‐minute	  wash	   in	  PBS-­‐triton,	   the	  slides	  were	  blocked	  
for	  30	  minutes	  with	  10%	  (v/v)	  normal	  goat	  serum.	  The	  primary	  antibody	  (or	  control	  solution)	  
(Table	   3)	   was	   applied	   overnight	   at	   room	   temperature,	   then	   any	   unbound	   removed	   by	  
washing	  three	  times	  in	  PBS-­‐triton.	  Negative	  controls	  were	  included	  in	  experiments	  to	  ensure	  
staining	   was	   specific.	   Controls	   comprised	   omission	   of	   the	   primary	   antibody,	   or	   pre-­‐
incubation	   of	   the	   primary	   antibody	   with	   its	   peptide	   antigen.	   Pre-­‐incubation	   required	  
addition	  of	  the	  blocking	  peptide	  (at	  a	  final	  concentration	  of	  1µg/ml)	  to	  a	  solution	  containing	  
the	  primary	  antibody,	  which	  was	   then	  agitated	  at	   room	  temperature	   for	  30	  minutes.	  This	  
was	   followed	   by	   2	   hours	   incubation	  with	   the	   secondary	   antibody	   (Table	   3).	   One	   drop	   of	  
4’,6’-­‐diamino-­‐2-­‐phenylindole	   (DAPI,	   Vector	   Laboratories,	   Peterborough,	   UK))	   was	   then	  
added	  to	  each	  cover	  slip	  for	  less	  than	  1	  minute	  before	  being	  washed	  away.	  Cover	  slips	  were	  
secured	  with	  fluorescent	  mounting	  media	  (Dako).	  Slides	  were	  visualised,	  and	  images	  taken	  




2.13 Non-­‐radioactive	  in	  situ	  hybridisation	  	  
2.13.1 RNA	  probe	  design	  and	  labelling	  	  
cDNA	  from	  foetal	  adrenal	  tissue	  was	  prepared	  as	  described	  above	  following	  RNA	  extraction	  
using	   RNeasy	   Mini	   kit	   (Qiagen),	   using	   random-­‐primed	   total	   RNA	   using	   Moloney	   Murine	  
Leukaemia	  Virus-­‐Reverse	  Transcriptase	  (MMLV-­‐RT),	  Promega).	  Kiss1R	  cDNA	  fragments	  were	  
PCR	  amplified	  using	  the	  following	  primers	  (Table	  4)	  
	  	  
Table	  4.	  Primers	  used	  for	  RNA	  probe	  design	  






Sequence	   Product	  
Length	  
(bps)	  
Human	  Kiss1R	  F	   61.9
9	  
58-­‐60	   CCCCTTCCTGAGTTCCACAG	   932	  
Human	  Kiss1R	  R	   61.9
8	  
GGCGAAGAGCAGGACCAC	  
Reverse	  complement	   	   GTGGTCCTGCTCTTCGCC	  
	  
2.13.2 RNA	  probe	  labelling	  	  
Amplified	  PCR	  products	  were	  cloned	  into	  the	  dual	  promoter	  vector	  pGEM-­‐T	  easy	  (Promega,	  
Southampton,	   UK)	   and	   linearized	   with	   the	   appropriate	   restriction	   enzymes.	   Digoxigenin	  
(DIG)-­‐labeled	  antisense	  and	  sense	  cRNA	  probes	  were	  synthesized	  by	  in	  vitro	  transcription	  in	  
the	  presence	  of	  DIG-­‐labeling	  mix	  ((Roche	  Diagnostics	  Ltd,	  West	  Sussex,	  UK)	  using	  ~1	  µg	  of	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linearized	   template	   and	   T7	   or	   SP6	   RNA	   polymerase	   (New	   England	   Biolabs).	   The	  
concentration	   and	   integrity	   of	   the	   RNA	   probe	   was	   analyzed	   by	   gel	   electrophoresis	   and	  
spectrophotometrically;	   the	   transcription	   reaction	   was	   diluted	   with	   diethylpyrocarbonate	  
(DEPC)-­‐treated	  H2O	  to	  a	  concentration	  of	  100ng/µl	  transcript,	  aliquoted,	  and	  stored	  at	  	  
-­‐80°C.	   The	   probe	   was	   used	   at	   a	   concentration	   of	   400ng/ml	   of	   hybridization	   buffer.	   The	  
probe	  was	  designed	  to	  include	  regions	  of	  low	  nucleotide	  identity	  with	  other	  related	  family	  
members	  or	  other	  sequences	  located	  in	  the	  NCBI	  nucleotide	  database.	  
	  
The	   in	   situ	   protocol	  was	   performed	  as	   in	  Guasti	  et	   al	   42.	   Cryosections	   of	  HFA	   tissue	  were	  
fixed	  in	  4%	  (w/v)	  PFA.	  All	  were	  then	  permeabilised	  with	  Proteinase	  K	  (Sigma	  Aldrich,	  Poole,	  
UK,	   5ug/ml	   in	   100mM	  Tris	  HCL	   pH	   7.5	   and	   50mM	  EDTA,	   pH	   8.0)	   for	   10	  minutes	   at	   37oC.	  
After	   re-­‐fixing	   in	   4%	   (w/v)	   PFA	   and	  3	  washes,	   sections	  were	  hybridized	  overnight	   at	   58°C	  
with	   either	   sense	   or	   antisense	   riboprobes	   in	   incubation	   buffer	   containing	   50%	   (v/v)	  
formamide,	  0.3M	  NaCl,	  10mM	  Tris-­‐HCL	  pH7.5,	  1mM	  EDTA,	  5%	  (w/v)	  dextran	  sulphate,	  1	  x	  
Denhardt’s	   solution,	  0.5mg/ml	  denatured	  salmon	  sperm	  DNA	  and	  0.02%	   (w/v)	  SDS.	  Slides	  
were	   then	   washed	   through	   a	   series	   of	   saline-­‐sodium	   citrate	   (SSC,	   National	   Diagnostic)	  
buffers	  (2x	  SSC,	  three	  times	  each	  for	  30	  min,	  and	  once	  each	   in	  1x	  SSC,	  0.2x	  SSC	  and	  0.05x	  
SSC	   for	   15	  min,	   respectively)	   at	   65°C.	   They	  were	   then	  washed	   in	   STE	   buffer	   (0.5M	  NaCl,	  
10mM	   Tris	   pH	   7.5,	   5mM	   EDTA)	   for	   10	   min	   at	   RT	   followed	   by	   treatment	   with	   RNase	   A	  
(QIAGEN,	   25ml	   of	   20mg/ml	   stock	   in	   50	   ml	   of	   STE	   buffer)	   for	   30	   minutes	   at	   37°C.	   After	  
washing	  the	  slides	  twice	  with	  Maleic	  Acid	  Buffer	  (MAB)	  (0.1M	  maleic	  acid,	  0.15	  NaCl,	  pH	  7.5,	  
0.1%	  (w/v)	  Tween)	  they	  were	  incubated	  with	  anti-­‐DIG	  alkaline	  phosphatase-­‐Fab	  fragments	  
(Roche	  Diagnostics	  Ltd,	  West	  Sussex,	  UK)	  diluted	  1:2000	  with	  0.5%	  (w/v)	  Blocking	  Reagent	  




After	  two	  washes	  with	  T-­‐PBS	  the	  slides	  were	  equilibrated	  in	  alkaline	  buffer	  (100mM	  Tris	  pH	  
9.5,	  100mM	  NaCl,	  50mM	  MgCl2,	  1%	  (w/v)	  Tween-­‐20)	   for	  10	  min	  before	  being	   incubated	  at	  
room	   temperature	   with	   NBT/BCIP	   (Roche	   Diagnostics	   Ltd,	   West	   Sussex,	   UK)	   in	   alkaline	  
buffer	  supplemented	  with	   levamisole	  (Vector	  Laboratories,	  Peterborough,	  UK;	  1drop/5ml).	  
Sections	  were	  checked	  every	  hour	  until	   there	  was	  adequate	  staining.	  Sections	  were	  finally	  
washed	   in	  T-­‐PBS	  and	  mounted	  with	  a	  glycerol-­‐based	  mounting	  medium	   (glycerol/PBS,	  3:1	  
v/v).	  	  
	  
2.13.3 Image	  acquisition	  	  
Images	   were	   acquired	   using	   a	   Leica	   DM5500B	   microscope	   (Leica,	   Nussloch,	   Germany),	  
equipped	  with	  a	  DCF295	  camera	  (Leica)	  and	  DCViewer	  software	  (Leica),	  and	  then	  processed	  
with	  Abode	  Photoshop	  CS6	  and	  Adobe	  Illustrator	  CS6.	  
2.14 Liquid	  chromatography-­‐tandem	  mass	  spectrometry	  	  
DHEAS	  was	  measured	   in	  the	  cell	  media	  by	  enzyme	   linked	   immunosorbent	  assay	   (ELISA,	  as	  
described	   above)	   (Demeditec	   Diagnostics,	   Kiel)	   and	   checked	   for	   some	   experiments	   by	  
analysis	  by	   liquid	  chromatography–tandem	  mass	  spectrometry	  (LC-­‐MS/MS).	  This	  work	  was	  
performed	  by	  collaborators	  at	  the	  Steroid	  Lab,	  King’s	  College	  Hospital	  (Dr	  Lea	  Ghataore,	  Dr	  
Norman	  Taylor).	  LC-­‐MS/MS	  is	  the	  gold	  standard	  method	  for	  quantifying	  steroid	  production.	  




2.14.1 Sample	  preparation	  	  
500μl	   of	   precipitation	   reagent	   (a	   cocktail	   of	   internal	   standards	   in	   acetonitrile,	   including	  
16,16	  d2	  DHA	  sulphate)	  was	  added	  to	  the	  samples,	  calibrators	  and	  internal	  quality	  controls	  
(500μl).	   The	   quality	   controls	   were	   created	   in-­‐house	   from	   a	   standard	   solution	   of	   DHA	  
sulphate	   diluted	   in	   charcoal-­‐stripped	   serum.	   	   Samples	   were	   vortexed	   (30	   seconds)	   and	  
centrifuged	   (13	  000rpm)	   for	  5	  minutes.	   The	   supernatant	  was	   transferred	   into	  glass	   tubes.	  
Bicarbonate	  solution	  (200μl,	  8%	  aq,	  v/v)	  and	  1ml	  of	  ethyl	  acetate	  was	  added	  and	  the	  tubes	  
were	  vortexed	  (30	  seconds)	  and	  centrifuged	  (13	  000	  rpm)	  for	  5	  minutes.	  The	  organic	  layer	  
was	   transferred	   into	   a	   glass	   tube	   and	   evaporated	   to	   dryness	   under	   nitrogen	   gas	   and	  
reconstituted	  in	  125μl	  of	  freshly	  prepared	  reconstitution	  solution	  (Mobile	  phase	  A:	  Mobile	  
phase	  B,	  65:35	  (v/v)).	  100μl	  was	  injected	  onto	  the	  liquid	  chromatography	  (LC)	  system.	  Using	  
the	  TSQ	  Vantage	  (ThermoFisher)	  in	  MS/MS	  positive	  APCI	  mode,	  m/z	  transitions	  271.1	  to	  105	  
&	  91	  were	  monitored.	  DHEA	  was	   also	   quantified	   in	   the	   same	   runs	   and	   remained	  near	   or	  
below	  detection	  limits,	  indicating	  that	  there	  was	  no	  significant	  desulphation	  during	  sample	  
processing.	  	  
	  
2.14.2 Liquid	  chromatography	  conditions	  
Eluents:	   Mobile	  Phase	  A:	  	   Water	  with	  0.1	  %	  (v/v)	  formic	  acid	  	  
	   	   Mobile	  Phase	  B:	  	  	   Methanol	  with	  0.1	  %	  (v/v)	  formic	  acid	  	   	  
Flow	  rate:	   	   	   	   0.4ml/min	  
Column:	  	  	  	  	  	  	  	  	  	  	   	   	   	   Accucore	  RP-­‐MS	  Column	  (100	  x	  2.1mm.	  2.6	  µm)	  
Column	  temperature:	  	   	   40	  ºC	  (maintained	  by	  Hot	  Pocket.	  ThermoScientific	  
Detector:	  	  	  	  	  	  	  	  	  MS/MS	  (positive	  APCI,	  2	  m/z	  transitions	  per	  analyte	  are	  monitored)	  	  
	  Model:TSQ	  Vantage	  (ThermoFisher)	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Capillary	  temperature	   400
o
C	  
Discharge	  current	  (mA)	   5.0	  
Sheath	  gas	   20	  
Auxillary	  gas	   5	  
Collision	  gas	  pressure	  (mTorr)	   1.5	  
Q1	  (FWHM):	   0.40	  
Q3	  (FWHM):	   0.70	  














2.14.4 DHEAS	  assay	  validation	  data	  	  
	  
Precision	  and	  accuracy	  
Concentration	  
nmol/L	  (n=6)	  
102	   204	   1697	   8148	  
Intra-­‐assay	  
Mean	   99.8	   187.3	   1840	   8080	  
Accuracy	  %	   97.9	   92	   108	   99	  
CV%	   5.3	   3.0	   3.8	   1.3	  
Inter-­‐assay	  
Mean	   102.3	   201.7	   1789.7	  
	  
7700.8	  
Accuracy	  %	   100.3	   98.9	   105.5	   94.5	  
CV%	   8.1	   3.7	   5.6	   4.7	  
	  
	  
Lower	  limit	  of	  quantification	  is	  35	  nmol/L	  
No	  carry	  over	  or	  carry	  under	  was	  detected	  













204	   1697	   5729	  
Post	  extraction	  1	  week	  @4C	  
Mean	   201.4	   1646	   5720	  
Accuracy	  %	   96.7	   97.0	   99.8	  
Post	  extraction	  1	  week	  @RT	  
Mean	   202.4	   1570	   5539.3	  
Accuracy	  %	   99.2	   92.5	   96.7	  
3	  freeze-­‐thaw	  cycles	  
Mean	   203.2	   1633	   5581	  
Accuracy	  %	   99.6	   96.2	   97.4	  
	  
2.15 Clinical	  study	  	  
2.15.1 Clinical	  study	  design	  and	  recruitment	  	  
A	   prospective	   observational	   study	   of	   patients	   with	   singleton,	   uncomplicated	   pregnancies	  
was	  undertaken	  in	  collaboration	  with	  the	  Foetal	  Medicine	  Unit	  at	  the	  Royal	  London	  Hospital	  
(Dr	   Rebecca	   Allen,	   Dr	   Shemoon	   Marleen,	   Mr	   Joseph	   Aquilina).	   Women	   attending	   their	  
routine	   antenatal	   ultrasound	   scan	   (USS)	   at	   ~12	   weeks	   gestation	   at	   the	   Royal	   London	  




I	  designed	  this	  clinical	  study	  with	  the	  intention	  that	  a	  case	  group	  of	  pregnant	  women	  who	  
go	   on	   to	   develop	   pre-­‐eclampsia	   (PE),	   and	   a	   control	   group	   of	   pregnant	   women	   with	  
uncomplicated	  normal	  pregnancies	  would	  be	  recruited	  in	  the	  first	  trimester.	  Pre-­‐eclampsia	  
is	  a	  condition	  associated	  with	  placental	  dysfunction,	  and	  therefore	  presumed	  lower	  levels	  of	  
placental	   hormones	   such	   as	   kisspeptin.	   As	   discussed	   previously	   the	   association	   of	   PE	   and	  
low	  maternal	  kisspeptin	  levels	  has	  been	  reported	  in	  the	  literature	  160.	  Biomarkers	  previously	  
described	   to	   be	   associated	  with	   the	   onset	   of	   PE,	   particularly	   early	   onset	   disease,	   include	  
placental	  growth	  factor	  (PlGF)	  and	  β-­‐hCG.	  PlGF	  is	  a	  polypeptide	  growth	  factor	  and	  a	  member	  
of	  the	  vascular	  endothelial	  growth	  factor	  (VEGF)	  family,	  which	  regulates	  the	  development	  of	  
placental	   villi	   during	   early	   gestation.	   This	   regulatory	   effect	   is	   essential	   for	   establishing	  
placental	   blood	   circulation	   to	   ensure	   a	   normal	   pregnancy	   outcome.	   In	   normal	   pregnancy	  
PlGF	  steadily	   increases	  during	  the	  first	   two	  trimesters	  and	  peaks	  at	  29-­‐32	  weeks	  and	  then	  
declines.	  Previous	  studies	  have	  reported	  PE	  in	  association	  with	  low	  placental	  growth	  factor	  
(PlGF)	   169,170.	   In	  PE,	  PlGF	   concentrations	   start	   to	  decrease	  9-­‐11	  weeks	  before	   the	  onset	  of	  
hypertension	  and	  proteinuria	  170.	  hCG	  is	  produced	  by	  the	  syncitiotrophoblast	  of	  the	  placenta	  
and	  consists	  of	  alpha	  and	  beta	  subunits.	  It	  has	  been	  postulated	  that	  low	  β-­‐hCG	  between	  10-­‐
14	  weeks	  may	  be	  a	  consequence	  of	  impaired	  placentation	  and	  a	  smaller	  placental	  mass	  and	  
that	   subsequently	   high	   2nd	   trimester	   levels	   may	   develop	   as	   a	   result	   of	   hypoperfusion–
related	   stimulation	   171,172.	   Several	   previous	   studies	   have	   reported	   an	   association	   between	  
increased	   2nd	   trimester	   levels	   of	   β-­‐hCG	   and	   adverse	   pregnancy	   outcomes	   including	   PE.	  
Other	  studies	  report	  that	  decreased	  levels	  of	  β-­‐hCG	  in	  the	  1st	  trimester	  were	  predictive	  of	  
PE	  171.	  Abnormal	  1st	  trimester	   levels	  of	  β-­‐hCG	  have	  also	  been	  reported	  as	  not	  significantly	  
associated	   with	   any	   adverse	   outcomes,	   including	   PE	   156,173.	   PE	   affects	   around	   5%	   of	  
pregnancies	  and	  is	  a	  major	  cause	  of	  maternal	  and	  perinatal	  morbidity	  and	  mortality	  174.	  It	  is	  
characterised	   by	   pregnancy	   induced	   hypertension,	   blood	   pressure	   ≥140/90mmHg,	   and	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protein	   in	   the	   urine	   (0.3g/24h)	   (+/-­‐	   pathological	   oedema)	   after	   20	  weeks	   gestation.	   PE	   is	  
associated	  with	  poor	  placentation	  and	  incomplete	  remodelling	  of	  the	  utero-­‐placental	  spiral	  
arteries.	  In	  pregnancies	  complicated	  by	  PE,	  placental	  abruption	  and	  birth	  of	  SGA	  neonates,	  
there	  is	  histological	  evidence	  of	  impaired	  trophoblastic	  invasion	  of	  the	  spiral	  arteries.	  PE	  is	  
typically	   diagnosed	   in	   the	   late	   2nd	   or	   early	   3rd	   trimester.	  More	   recently	   abnormal	   uterine	  
artery	  Doppler	   in	  the	  1st	   trimester	  was	  shown	  to	   identify	  a	  high-­‐risk	  group	  of	  women	  who	  
could	  be	  targeted	  for	  closer,	  more	  intensive	  antenatal	  surveillance	  and	  clinical	  management	  
175.	  The	  specificity	  for	  predicting	  early	  onset	  pre-­‐eclampsia	  using	  this	  screening	  method	  was	  
reported	   to	   be	   high.	   First	   trimester	   uterine	   artery	   Doppler	   is	   therefore	   a	   useful	   tool	   to	  
stratify	   women	   by	   risk	   status	   and	   target	   them	   for	   appropriate	   clinical	   management	   and	  
identify	   higher	   risk	   individuals	   for	   research	   purposes.	   A	   research	   study	   carried	   out	   by	  
collaborators	   in	   Foetal	   Medicine	   Unit	   at	   the	   Royal	   London	   Hospital	   in	   2011	   (Mr	   Joseph	  
Aquilina,	   unpublished)	   revealed	   that	   20%	   of	   women	   scanned	   at	   12	   weeks	   had	   abnormal	  
uterine	  artery	  Doppler	  measurements.	  Out	  of	   this	  group,	  35%	  of	   those	  with	  abnormal	  12-­‐
week	   Doppler	   measurements	   went	   on	   to	   develop	   PE.	   The	   remaining	   65%	   of	   women	  
screened	   have	   uncomplicated	   normal	   pregnancies.	   The	   design	   of	   this	   study	   incorporated	  
this	   information,	   anticipating	   that	   the	   finding	   of	   abnormal	   Doppler	   measurements	   at	   12	  
weeks	  would	  provide	  both	  a	  cohort	  of	  women	  with	  normal	  pregnancies	  and	  a	  cohort	  that	  go	  
on	  to	  develop	  PE.	  The	  advantage	  of	  using	  this	  starting	  point	  for	  selection	  and	  enrolment	  was	  
that	  both	  cohorts	  would	  receive	  exactly	  the	  same	  follow	  up	  during	  the	  course	  of	  the	  study.	  	  
	  
Eligible	   candidates	   were	   identified	   by	   Obstetric	   collaborators	   (Dr	   Rebecca	   Allen,	   Dr	  
Shemoon	   Marleen)	   at	   the	   12-­‐week	   antenatal	   booking	   visit	   as	   those	   with	   a	   singleton	  
pregnancy	   and	   a	   uterine	   artery	   pulsatility	   index	   >1.96	   on	  Doppler	   ultrasound.	   Participant	  
information	  sheets	  were	  produced	  (Appendix	  5)	  and	  written	  informed	  consent	  (Appendix	  6,	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consent	   forms)	   was	   obtained	   for	   all	   participants	   and	   translators	   were	   provided	   where	  
necessary.	   The	   GP	   of	   participants	   were	   notified	   of	   inclusion	   in	   the	   study	   with	   consent	  
(Appendix	  7,	  GP	  letter).	  
	  
2.15.2 Patient	  selection	  
Inclusion	  criteria:	  
1. Singleton	  pregnancy	  
2. PI	  >	  1.96	  on	  ultrasound	  at	  12	  weeks	  gestation	  
	  
Exclusion	  criteria:	  	  
1. Multiple	  pregnancy	  
2. Coexistent	  maternal	  medical	  conditions	  (pre-­‐existing	  hypertension,	  diabetes,	  thyroid,	  
adrenal	  or	  renal	  disease)	  
3. Congenital	  foetal	  abnormalities	  or	  chromosomal	  anomalies	  
4. Maternal	  infection	  (including	  HIV)	  
5. Maternal	  alcohol	  abuse	  
6. Heavy	  smoking	  (>10	  cigarettes	  daily	  prior	  to	  pregnancy;	  >5	  cigarettes	  daily	  during	  
pregnancy)	  	  




2.15.3 Source	  of	  patients	  	  
Subjects	   were	   recruited	   from	   the	   following	   cohort	   of	   patients:	   Pregnant	   women	   who	  
present	  to	  the	  antenatal	  clinic	  at	  the	  Royal	  London	  Hospital	  and	  had	  already	  consented	  to	  
have	  their	  routine	  12	  week	  scan	  performed	  by	  a	  senior	  obstetric	  doctor	  (collaborators	  from	  
the	   Foetal	   Medicine	   Unit,	   Royal	   London	   Hospital)	   as	   part	   of	   a	   study	   examining	   Doppler	  
measurements.	  Gestational	  age	  was	  established	  during	  the	  USS	  evaluation.	  
	  
2.15.4 Informed	  consent	  procedures	  
Written	  information	  about	  this	  study	  (Appendix	  5)	  was	  provided	  at	  12-­‐week	  scans	  by	  foetal	  
medicine	  collaborators	  (Dr	  Rebecca	  Allen,	  Dr	  Shemoon	  Marleen)	  once	  the	  patient	  has	  given	  
verbal	   consent	   to	   receive	   information	   about	   the	   study.	   If	   translation	   was	   required,	   the	  
information	   leaflet	   was	   translated	   using	   the	   Barts	   Health	   NHS	   Trust	   translation	   service.	  
Information	   about	   the	   study	   was	   given	   to	   the	   patient	   at	   least	   6	   weeks	   before	   written	  
consent	   was	   obtained	   in	   order	   to	   ensure	   adequate	   time	   for	   potential	   participants	   to	  
understand	  the	  commitment	  to	  the	  study	  and	  to	  address	  any	  questions	  they	  had.	  Written	  
informed	  consent	  (Appendix	  6)	  from	  those	  patients,	  who	  agree	  to	  participate	  in	  the	  study,	  
was	   obtained	  by	   a	  member	  of	   the	   research	   team	   (myself,	  Dr	  Muriel	  Meso,	  Miss	   Shezhan	  
Elahi)	  at	  the	  time	  of	  the	  anomaly	  scan	  at	  18-­‐22	  weeks.	  This	  followed	  adequate	  explanation	  
of	   the	  aims,	  methods,	  anticipated	  benefits	  and	  potential	  hazards	  of	   the	  study.	   It	  was	  also	  
made	  clear	  to	  the	  potential	  participant	  that	  they	  were	  free	  to	  refuse	  any	  involvement	  within	  
the	  study	  or	  alternatively	  withdraw	  their	  consent	  at	  any	  point	  during	  the	  study	  and	  for	  any	  
reason.	  The	  participants'	  GP	  was	  informed	  with	  consent	  of	  a	  participant’s	  involvement	  in	  the	  
study	   (Appendix	   7).	   The	   Consultant	   Clinician	   and	   Obstetric	   team	   responsible	   for	   the	  
patient’s	  antenatal	  care	  were	  also	  made	  aware	  of	  participation	  in	  the	  study	  by	  highlighting	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this	  in	  the	  patient’s	  medical	  records	  along	  with	  signed	  copies	  of	  the	  consent	  form	  and	  study	  
information	  leaflet.	  	  
	  
2.15.5 Premature	  withdrawal	  /	  loss	  to	  follow	  up	  
Any	  patients	  lost	  to	  follow	  up	  or	  who	  withdrew	  consent	  and	  no	  longer	  wished	  to	  participate	  
in	   the	  study	  at	  any	  stage	  were	   included	   in	   the	  data	  analysis.	  For	  patients	  who,	  during	   the	  
course	  of	  the	  study,	  no	  longer	  fit	  the	  initial	  inclusion	  criteria,	  the	  plan	  was	  to	  follow	  up	  as	  far	  
as	  possible	  as	  per	  the	  protocol	  and	  perform	  a	  subset	  analysis.	  Withdrawals	  were	  aimed	  to	  
be	  replaced	  if	  time	  permitted.	  	  
	  
2.15.6 Sample	  size	  
This	  clinical	  study	  was	  designed	  as	  a	  pilot	  study	  to	  assess	  the	  effect	  of	  placental	  dysfunction	  
with	  a	  postulated	  decrease	  in	  production	  of	  placental	  hormones	  and	  the	  subsequent	  impact	  
on	   the	   primary	   endpoint	   of	   foetal	   adrenal	   enlargement.	   It	  was	   therefore	   apparent	   that	   a	  
power	   calculation	   for	   this	   could	   only	   be	   performed	   retrospectively	   once	   the	   effect	   size	   is	  
known.	   	   Instead	   I	   carried	  out	  a	  power	   calculation	  of	   sample	   size	   to	  detect	  a	  difference	   in	  
maternal	   kisspeptin	   levels	   between	   normal	   pregnancies	   and	   those	   complicated	   by	   pre-­‐
eclampsia.	  	  
	  
A	  case-­‐control	  study	  176	  examining	  3rd	  trimester	  kisspeptin	  levels	  in	  a	  group	  of	  women	  with	  
pre-­‐eclampsia	   and	   a	   group	   with	   normal	   pregnancies	   carried	   out	   statistical	   power	  
calculations	   in	   order	   to	   detect	   a	   difference	   of	   600pmol/l	   and	   an	   estimated	   standard	  
deviation	  of	  500,	  a	  power	  of	  80%,	  and	  a	  difference	  detected	  at	  the	  5%	  significance	  level	  (1–β	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of	  0.8	  and	  α	  of	  0.05	  respectively).	  No	  statistically	  significant	  difference	  between	  the	  groups	  
was	   found.	   However	   the	   study	   was	   powered	   to	   detect	   a	   difference	   in	   plasma	   kisspeptin	  
concentrations	  of	  600	  pmol/l	  or	  greater,	  and	  therefore	  the	  relatively	  small	  number	  of	  pre-­‐
eclampsia	  patients	  (n=8)	  recruited	  into	  the	  study	  may	  not	  have	  allowed	  for	  the	  detection	  of	  
more	   subtle	   differences	   in	   kisspeptin	   between	   the	   groups.	   In	   this	   study,	   statistical	   power	  
calculations	   yield	   sample	   sizes	   of	   25	   controls	   and	   25	   experimental	   subjects	   in	   order	   to	  
detect	   a	   difference	   between	   kisspeptin	   levels	   in	   the	   two	   groups	   of	   400	   pmol/l	   with	   an	  
estimated	   standard	   deviation	   of	   500pmol/l,	   1–β	   of	   0.8	   and	   α	   of	   0.05.	   Assuming	   a	   10%	  
dropout	  rate	  in	  each	  cohort,	  28	  patients	  would	  need	  to	  be	  recruited	  in	  each	  group.	  The	  time	  
taken	   to	   recruit	   this	   sample	   number	   was	   based	   on	   figures	   obtained	   from	   a	   pilot	   study	  
carried	   out	   in	   the	   Foetal	  Medicine	   Unit/Antenatal	   Clinic	   at	   the	   Royal	   London	   Hospital	   in	  
2011	  (Mr	  Joseph	  Aquilina,	  unpublished).	  
	  
Time	  to	  recruit	  study	  sample	  number	  
	  
Time to recruit study sample number 
 




Abnormal Doppler finding at 12 weeks in 20% of all scans = 10 patients/week 
 
 
35% of patients with an     65% of patients with an 
abnormal 12 week Doppler go    abnormal 12 week Doppler go 
on to develop pre-eclampsia     on to have an normal pregnancy 




Time to recruit 28 patients    Time to recruit 28 patients 
=9-10 weeks      = 4-5 weeks 
	  
	  130	  
2.15.7 Primary	  endpoint	  
Correlation	  of	  placental	  kisspeptin	  (maternal	  kisspeptin	  levels)	  to	  foetal	  adrenal	  size.	  
	  
2.15.8 Secondary	  endpoints	  
1. Gestational	  age	  at	  end	  of	  pregnancy	  and	  outcome	  of	  pregnancy	  (to	  include	  miscarriage,	  
still	  birth,	  live	  birth).	  
2. Birth	  weight	  
3. Correlation	  of	  placental	  kisspeptin	  with	  other	  markers	  of	  placental	  function	  (hCG,	  PlGF)	  
4. Neonatal	  complications	  including	  respiratory	  distress	  syndrome,	  transient	  tachypnoea	  of	  
the	  newborn,	  neonatal	  death.	  
	  
2.15.9 Parameters	  that	  mark	  the	  end	  of	  the	  study	  
The	  outcome	  of	  infants	  of	  patients	  enrolled	  in	  the	  study	  was	  recorded.	  	  
Infants	   admitted	   for	   hospital	   care	   were	   followed	   up	   to	   discharge	   if	   this	   exceeded	   the	  
planned	  duration	  of	  neonatal	  follow	  up	  for	  this	  study	  (8	  weeks).	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2.15.10 Clinical	  protocol	  
Clinical	  management	  was	  directed	  by,	  and	  at	   the	  discretion	  of,	   the	  obstetric	  and	  neonatal	  
providers.	  Antenatal	  scans	  for	  the	  participants	  were	  performed	  in	  the	  Foetal	  Medicine	  Unit	  
by	  two	  Obstetric	  Fellows	  (Dr	  Rebecca	  Allen	  and	  Dr	  Shemoon	  Marleen),	  under	  the	  guidance	  
of	  the	  Lead	  for	  Foetal	  Medicine	  (Mr	  Joseph	  Aquilina).	  This	  collaborating	  team	  carrying	  out	  
all	  the	  study	  scans	  were	  also	  providing	  clinical	  antenatal	  care	  for	  the	  patients	  enrolled	  in	  the	  
study.	  They	  were	  therefore	  not	  blinded	  when	  performing	  scan	  measurements	  as	  this	  would	  
have	   been	   unethical	   and	   compromised	   patient	   safety	   and	   care.	   Serial	   measurements	   of	  
foetal	  adrenal	  size	  were	  performed	  at	  the	  time	  of	  the	  routine	  anomaly	  scan	  (18-­‐22	  weeks	  
gestation,	   visit	   1)	   and	   at	   3	   other	   time	   points:	   ~28,	   34	   and	   38	  weeks	   gestation	   (visits	   2-­‐4,	  
respectively)	  (Fig.	  14).	  Maternal	  plasma	  samples	  for	  kisspeptin	  (and	  other	  biomarkers,	  PlGF	  
and	  hCG)	  were	  taken	  at	  the	  time	  of	  the	  first	  USS	  only	  (collection	  at	  ~20	  weeks	  gestation	  as	  
part	  of	  a	  separate	  study	  conducted	  by	  Dr	  Rebecca	  Allen)	  and	  subjects	  were	  followed	  up	  until	  

















As	  far	  as	  possible	  each	  delivery	  was	  attended	  by	  one	  of	  the	  study	  investigators	  (myself,	  Dr	  
Muriel	   Meso,	   Miss	   Shezhan	   Elahi).	   At	   delivery,	   cord	   blood	   was	   obtained	   and	   stored.	  
Placental	  punch	  biopsies	  were	   taken,	  and	   the	  placenta	  was	  sent	   for	  histology	  as	  part	  of	  a	  
separate	   research	   study.	  With	   consent,	   each	   live	   infant	  of	   a	  mother	  enrolled	   in	   the	   study	  
was	  followed	  up	  during	  the	  1st	  week	  of	  life	  with	  a	  postnatal	  abdominal	  USS	  scan	  measuring	  
the	   adrenal	   gland	   and	   urine	   collection	   as	   soon	   as	   possible	   after	   delivery	   while	   still	   in	  
hospital,	  and	  again	  at	  ~5-­‐7	  days	  of	  life	  and	  with	  an	  USS,	  urine	  collection	  and	  a	  blood	  sample	  
(Fig.	   15).	   Routinely	   in	   the	   UK	   a	   Guthrie	   blood	   spot	   test	   is	   collected	   at	   5-­‐7	   days	   of	   life.	   If	  
consent	  is	  obtained,	  a	  whole	  blood	  sample	  was	  collected	  for	  storage	  at	  the	  same	  time	  that	  
the	  Guthrie	  is	  performed	  by	  the	  study	  investigators	  (myself,	  Dr	  Muriel	  Meso,	  Miss	  Shezhan	  
Elahi).	   The	   ultrasound	   scan	   and	   urine	   collection	   were	   repeated	   at	   6-­‐8	   weeks	   of	   life.	   The	  
postnatal	   scans	   were	   performed,	   using	   the	   same	   measurement	   technique	   as	   antenatal	  
foetal	   scans,	   in	   collaboration	  with	   the	   Royal	   London	   Hospital	   Radiology	   department.	   The	  
neonatal	   scans	   were	   all	   performed	   by	   one	   Consultant	   Paediatric	   Radiologist	   (Dr	   Kirsteen	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Macdonald).	   Post-­‐discharge,	   urine	   was	   collected	   at	   home	   overnight	   by	   parents	   the	   day	  
before	  their	  follow	  up	  appointment	  and	  stored	  in	  the	  fridge,	  or	  collected	  on	  the	  day	  of	  the	  
scan	  while	  in	  hospital.	  Urine	  collection	  involved	  a	  small	  plastic	  bag	  placed	  in	  the	  nappy	  and	  
affixed	  gently	  to	  the	  skin.	  Neonates	  who	  are	  admitted	  to	  the	  neonatal	  unit	  or	  who	  require	  
anything	  other	  than	  routine	  postnatal	  care	  were	  followed	  up	  until	  discharge.	  If	  the	  baby	  was	  
too	  unwell	  to	  undergo	  an	  USS,	  this	  was	  performed	  later	  when	  it	  was	  clinically	  safe	  to	  do	  so.	  	  	  
	  




For	  each	  infant,	  the	  following	  outcomes	  were	  recorded:	  
1.	  Outcome	  of	  pregnancy	  (stillbirth,	  miscarriage,	  live	  birth,	  neonatal	  death)	  
2.	  Gestation	  at	  birth	  









































































































































4.	  Complications	  of	  pregnancy	  /	  labour	  (e.g.	  intrauterine	  growth	  retardation)	  
5.	  Placental	  weight	  and	  morphology	  at	  delivery	  
6.	  Neonatal	  production	  of	  steroids	  (urine	  for	  steroid	  profile	  collected	  to	  be	  measured	  by	  LC-­‐
MS/MS	  at	  the	  Steroid	  Lab,	  Kings	  College	  Hospital)	  
7.	  Adverse	  neonatal	  outcomes	  (respiratory	  distress	  syndrome,	  transient	  tachypnoea	  of	  the	  
newborn,	  necrotizing	  enterocolitis).	  
	  
2.15.11 Kisspeptin	  RIA	  
Ten	  milliliters	  of	  blood	  were	  taken	  and	  collected	  into	  lithium-­‐heparin	  tubes	  (LIP,	  Cambridge,	  
UK)	  containing	  5,000	  kallikrein	  inhibitor	  units	  (0.2	  ml)	  of	  aprotinin	  (Trasylol;	  Bayer,	  Newbury,	  
UK)	  and	  stored	  on	  ice.	  After	  centrifugation,	  plasma	  was	  immediately	  separated	  and	  stored	  
at	  −20°C	  until	  measurement	  of	  kisspeptin	  IR	  in	  all	  subjects.	  Samples	  were	  stored	  at	  -­‐20°C	  for	  
between	   6	   and	   18	   months	   prior	   to	   kisspeptin	   measurements.	   Plasma	   kisspeptin	  
immunoreactivity	   (IR)	   was	   measured	   by	   collaborators	   using	   an	   established	   in-­‐house	  
radioimmunoassay	   at	   Imperial	   College	   London	   177.	   Antibody	   GQ2	   was	   raised	   in	   a	   sheep	  
immunized	  with	  synthetic	  human	  kisspeptin-­‐54	  (Bachem	  UK,	  Merseyside,	  UK)	  conjugated	  to	  
BSA	  by	  glutaraldehyde	  and	  used	  at	  a	  final	  dilution	  of	  1:	  3,500,000.	  Bioactivity	  of	  kisspeptin-­‐
54	  peptide	  was	  confirmed	  by	  stimulation	  of	  LH	  release	  in	  female	  mice.	  Vials	  of	  freeze-­‐dried	  
kisspeptin-­‐54	  were	   stored	   at	   -­‐20OC	   and	   reconstituted	   in	   0.9%	   (w/v)	   saline.	   The	   antibody	  
cross	   reacted	   100%	   with	   human	   kisspeptin-­‐54,	   kisspeptin-­‐14,	   and	   kisspeptin-­‐10	   and	   less	  
than	  0.01%	  with	  any	  other	   related	  human	  RF	  amide	  peptide,	   including	  prolactin	   releasing	  
peptide,	   RF	   amide-­‐related	   peptide	   (RFRP1),	   RFRP2,	   RFRP	   3,	   neuropeptide	   FF,	   and	  
neuropeptide	  AF.	  The	  125I-­‐kisspeptin-­‐54	  label	  was	  prepared	  using	  the	  iodogen	  method	  and	  
purified	  by	  reverse-­‐phase	  HPLC	  on	  a	  C18	  column	  (Waters,	  Milford,	  MA)	  over	  a	  15–45%	  90-­‐
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min	   gradient	   of	   acetonitrile	   (AcN)/water/0.1%	   (v/v)	   trifluoroacetic	   acid	   (TFA).	   The	   specific	  
activity	   of	   kisspeptin	   label	   was	   56	   Bq/fmol.	   The	   assay	   was	   performed	   in	   duplicate	   using	  
dilutions	  of	  neat	  plasma	  in	  0.7	  ml	  of	  0.06	  M	  phosphate	  buffer	  (pH	  7.2)	  containing	  0.3%	  (w/v)	  
BSA	  and	   incubated	   for	  3	  d	  at	  4	  C.	  Free	  and	  antibody-­‐bound	   label	  were	   then	  separated	  by	  
charcoal	  adsorption.	  The	  assay	  detected	  changes	  of	  2	  pmol/liter	  of	  plasma	  kisspeptin	  with	  a	  
95%	  confidence	   limit.	  The	   intraassay	  and	   interassay	  coefficients	  of	   variation	  were	  8.3	  and	  
10.2%,	  respectively.	  	  
	  
2.15.12 Maternal	  placental	  biomarker	  measurements	  	  
Ten	  mls	   of	  maternal	   blood	  was	   taken	   in	   gold	   top	   gel	   tubes	  with	   no	   additives.	   The	   blood	  
samples	  were	   allowed	   to	   clot	   and	   then	   centrifuged	  with	   removal	   of	   serum	   into	   aliquots,	  
which	  were	  stored	  at	  -­‐80oC	  until	  analysed.	  50μl	  samples	  were	  extracted	  for	  measurement	  
of	  PlGF	  and	  10	  μl	  for	  β-­‐hCG.	  Elecsys	  test	  kits	  from	  Cobas	  were	  used	  and	  analysed	  by	  a	  Roche	  
Cobas	  e601.	  The	  lower	  limit	  for	  detection	  was	  3pg/ml	  for	  PlGF,	  and	  <0.1iu/L	  for	  β-­‐hCG.	  Tests	  
of	   repeatability	  were	  performed	   to	   determine	  between	  batch	   imprecision	   and	   revealed	   a	  
coefficient	  of	  variation	  of	  3.89%	  for	  PlGF.	  These	  samples	  were	  analysed	  by	  the	  Biochemistry	  
laboratory	  at	  the	  Royal	  London	  Hospital	  as	  part	  of	  a	  separate	  collaborative	  study	  conducted	  
by	  Dr	  Rebecca	  Allen	  (Foetal	  Medicine	  Unit).	  
	  
2.15.13 Adrenal	  ultrasound	  measurements	  
	  
The	   gestational	   age	   was	   determined	   at	   the	   12-­‐week	   booking	   visit	   according	   to	   routine	  
methods	   of	   ultrasound	   guided	   crown-­‐rump	   length	   assessment.	   Following	   this	   serial	   3-­‐
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dimensional	  transabdominal	  ultrasound	  measurements	  took	  place	  at	  approximately	  20,	  28,	  
34	  and	  38	  weeks’	  gestation.	  Each	  scan	  was	  performed	  transabdominally	  by	  one	  of	  the	  two	  
collaborating	   senior	   foetal	   medicine	   fellows	   (Dr	   Rebecca	   Allen,	   Dr	   Shemoon	   Marleen).	  
Assessment	  of	   the	   foetal	   adrenal	   glands	  was	  done	  according	   to	   the	  method	  described	  by	  
Turan	  178	  along	  with	  foetal	  biometry,	  using	  the	  Voluson	  E8	  systems	  (Voluson	  Expert;	  General	  
Electric	   Healthcare	   Austria	   GmBH	   &	   Co;	   Zipf;	   Austria)	   equipped	   with	   a	   4-­‐8	   MHz	   array	  
transducer.	  FA	  depth,	  width	  and	  length	  parameters	  were	  obtained.	  For	  optimal	  visualisation	  
the	   foetal	   adrenal	   gland	   closest	   to	   the	   probe	  was	   selected	   for	   analysis	   and	   subsequently	  
assessed	  in	  the	  transverse,	  coronal	  and	  sagittal	  plane	  to	  obtain	  the	  gland	  length,	  width	  and	  
depth	  (Fig.	  16a,	  b).	  Based	  on	  these	  parameters	  a	  3D-­‐ultrasound	  model	  for	  the	  adrenal	  gland	  
volume	  was	  obtained	  using	   the	  VOCAL	   (Virtual	  Organ	  Computer-­‐Aided	  Analysis,	   4D	  View;	  
General	   Electric	   Medical	   System,	   Milwaukee,	   WI)	   software	   package.	   For	   accuracy	   each	  
Fellow	  reviewed	  all	  images	  separately	  before	  both	  calculated	  the	  volume	  independently.	  For	  
each	   participant	   the	   abdominal	   circumference	   (AC),	   femur	   length	   (FL)	   and	   biparietal	  
diameter	   (BPD)	   were	   also	   measured.	   Based	   on	   these	   parameters	   the	   estimated	   foetal	  
weight	  (EFW)	  was	  calculated	  for	  all	  gestational	  ages	  >20	  weeks	  using	  the	  GE	  ViewPoint	  6	  
software	   (ViewPoint	   Bildverarbeitung	  GmbH;	  Wessling,	   Germany).	  Women	  were	   followed	  
until	   the	   outcome	   of	   their	   pregnancy	   was	   known.	   Adrenal	   volume	   data	   were	   missing	   in	  








Fig.	  16a:	  Methodology	  of	  measurement	  of	  the	  whole	  adrenal	  gland	  	  
	  
1. Transverse	  measurements.	  Yellow	  arrow,	  adrenal	  gland;	  red	  arrow,	  spine.	  	  
2. Sagittal	  measurements.	  Yellow	  arrow,	  adrenal	  gland;	  red	  arrow,	  spine;	  green	  arrow,	  
kidney.	  
3. Transverse	  measurements	  to	  obtain	  foetal	  adrenal	  length	  were	  also	  obtained	  (not	  
shown).	  

















Fig.	  16b:	  Methodology	  of	  measurement	  of	  the	  foetal	  zone	  
	  
Ultrasound	  image	  of	  the	  A,	  transverse,	  B,	  coronal	  and	  C,	  sagittal	  plane,	  and	  corresponding	  
schematic	   images	   of	   adrenal	   gland	   and	   foetal	   zone	   were	   demonstrated.	   The	   adrenal	  
gland,	  kidney,	  and	  spine	  are	  marked	  by	  arrows.	  (Adapated	  from	  Turan	  et	  al.,	  2011).178	  
	  
2.15.14 Data	  handling	  and	  storage	  
Data	   was	   stored	   in	   accordance	   with	   local	   and	   national	   data	   protection	   regulations.	   	   The	  
Investigators	   had	   responsibility	   to	   ensure	   that	   patient	   anonymity	   is	   protected	   and	  
maintained.	  Information	  with	  regards	  to	  study	  patients	  was	  kept	  confidential	  and	  managed	  
in	   accordance	   with	   the	   Data	   Protection	   Act,	   NHS	   Caldicott	   Guardian,	   The	   Research	  





















Tissue	   samples	   from	   HDBR	   and	   Kuopio	   were	   annonymised	   with	   all	   patient	   identifiable	  
details	   removed.	   The	  data	  was	   stored	  on	  password-­‐protected	  databases	  on	   computers	   at	  
the	  William	  Harvey	  Research	  Institute.	  	  	  
	  
Data	  collected	  from	  the	  clinical	  study	  was	  pseudo-­‐anonymised.	  Patient	  details	  were	  coded	  
and	  data	  separated	  on	  input.	   Identifiable	   information	  collected	  from	  the	  subjects	   included	  
the	   hospital	   number,	   name	   and	   date	   of	   birth.	   This	   information	   was	   required	   in	   order	   to	  
process	   samples	   at	   the	   laboratory	   at	   the	   Royal	   London	   Hospital.	   Participants	   received	   a	  
unique	   identifying	   code	   and	   these	   codes,	   the	   key	   to	   the	   corresponding	   identifiable	  
information,	  and	  the	  personal	  information	  itself	  was	  stored	  on	  separate	  password	  protected	  
databases	  at	  the	  WHRI,	  QMUL.	  Only	  the	  PI	  of	  the	  study	  (Dr	  Helen	  Storr)	  had	  further	  access	  
to	   the	   database	   containing	   identifiable	   information	   and	   the	   key.	   The	   other	   study	  
investigators	  only	  had	  access	   to	   the	  database	  with	   the	  corresponding	  codes	  and	  data	  was	  
inputted	  and	  then	  analysed	  in	  this	  format.	  No	  patient	  identifiable	  details	  will	  be	  transferred	  
outside	  the	  European	  Union	  and	  participants	  had	  the	  right	  to	  revoke	  their	  authorisation	  for	  
the	  use	  of	  their	  information	  and	  data.	  Patient	  information	  was	  anonymised	  with	  regards	  to	  
publications	  relating	  to	  this	  study.	  
	  
2.15.15 Data	  analysis	  and	  statistics	  	  
In-­‐vitro	  data	  were	  evaluated	  using	  a	  paired	  two-­‐tailed	  Student’s	   t	   test	  or	  one-­‐way	  ANOVA	  
followed	   by	   a	   post-­‐hoc	   Tukey	   comparisons	   test	   (GraphPad	   Prism	   6,	   San	   Diego,	   CA).	   All	  
experiments	  were	  performed	   in	   triplicate	  and	   represent	  3	  or	  4	   independent	  experiments;	  
error	   bars	   depict	   the	   standard	   deviation	   of	   each	   individual	   experiment.	   Non-­‐parametric	  
continuous	  variables	  (FAV	  and	  kisspeptin	  levels)	  were	  analysed	  by	  a	  Kruskal–Wallis	  test	  with	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Dunn-­‐Bonferroni	   post	   hoc	   multiple	   comparison	   test	   correction.	  Continuous	   parametric	  
variables	   (FAV	   in	  male	  and	  female	  foetuses)	  were	  compared	  using	  student	  t-­‐test.	  R-­‐values	  
are	   Pearson's	   correlation	   coefficient	   (SPSS	   V.23	   Armonk,	   New	   York,	   USA:	   IBM	   Corp).	  
Statistical	   analysis	   of	   the	   clinical	   data	   was	   carried	   out	   by	   Dr	   Sumana	   Chatterjee	   (Clinical	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3 Results:	  Expression	  of	  Kiss1R	  in	  the	  developing	  human	  foetal	  
adrenal	  cortex	  
	   	  
	  




The	  main	  aim	  of	  this	  work	  was	  to	  obtain	  a	  detailed	  description	  of	  the	  expression	  of	  Kiss1R	  
within	   the	   developing	   HFA	   cortex.	   To	   date,	   only	   one	   previous	   study	   has	   examined	   foetal	  
adrenocortical	  expression	  of	  Kiss1R	   165.	  Quantitative	   reverse-­‐transcriptase	  PCR	   (qPCR)	  was	  
used	   to	   compare	  mRNA	   levels	   for	  Kiss1R	   between	   foetal	   and	  adult	   adrenal	   glands.	  Kiss1R	  
was	   reported	   to	   be	   significantly	   higher	   (50-­‐fold)	   in	  HFA	   than	   in	   human	   adult	   adrenals.	   In	  
addition,	   immunohistochemical	   studies	   carried	   out	   by	   this	   group	   demonstrated	   that	   the	  
Kiss1R	  protein	  is	  predominantly	  expressed	  in	  the	  outer	  DZ	  and	  TZ	  of	  HFA	  cortex	  from	  14-­‐36	  
weeks	  gestation	  (12wpc	  –	  34wpc).	  	  
	  
Early	  expression	  of	  Kiss1R	  in	  the	  developing	  HFA	  prior	  to	  14	  weeks	  gestation	  (12	  wpc)	  has	  
not	   previously	   been	   described.	   In	   this	   study,	   co-­‐localisation	   studies	   using	   markers	   of	  
zonation	   to	   further	   characterise	   the	   spatial	   expression	   of	   Kiss1R,	   and	   tissue	   from	   early	  
gestation	  (8wpc,	  10	  weeks	  gestation)	  to	  term	  (38wpc,	  40	  weeks	  gestation)	  were	  studied	  to	  
examine	   the	   temporal	   expression	   of	   Kiss1R.	   CD56	   (neural	   cell	   adhesion	   molecule)	   is	   an	  
adhesion	  molecule	  that	  belongs	  to	  the	  Ig	  superfamily	  of	  adhesion	  molecules	  and	  has	  roles	  in	  
axonal	   growth,	   migration,	   and	   guidance.	   CD56	   expression	   was	   originally	   thought	   to	   be	  
confined	   to	   neuronal	   and	  neuroendocrine	   tissues,	   however	   expression	  has	   been	  noted	   in	  
other	   tissues,	   most	   notably	   endocrine	   organs	   including	   human	   adrenocortical	   cells	   179.	  
Interestingly,	  the	  adult	  adrenal	  gland	  expresses	  CD56	  primarily	  in	  the	  zona	  glomerulosa	  179.	  
Late	  in	  gestation,	  the	  DZ,	  which	  also	  is	  immediately	  beneath	  the	  capsule,	  is	  analogous	  to	  the	  
zona	   glomerulosa	   in	   that	   it	   begins	   to	   express	   steroidogenic	   enzymes	   and	   produce	  
aldosterone.	  CD56	  expression	  has	  previously	  been	  observed	  by	   immunohistochemistry	  on	  
DZ	  cells	  17.	  CD56	  mRNA	  expression	  has	  also	  been	  detected	  among	  DZ	  cells	  but	  not	  selected	  
sections	  of	  FZ	  cells	  isolated	  by	  laser	  capture	  microdissection	  17.	  These	  findings	  indicate	  that	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CD56	  expression	  can	  be	  used	  as	  a	  marker	  of	  DZ	  cells.	  	  Search	  for	  a	  cell	  surface	  marker	  for	  FZ	  
cells	   led	   to	   the	   LDL	   (low	   density	   lipoprotein)	   receptor,	   as	   circulating	   LDL	   cholesterol	   is	   a	  
major	   precursor	   for	   adrenal	   steroid	   synthesis	   180.	   As	   the	   cells	   of	   the	   FZ	   are	   steroidogenic	  
beginning	  in	  early	  gestation,	  whereas	  those	  of	  the	  DZ	  are	  not,	   it	  can	  be	  predicted	  that	  the	  
LDL	   receptor	   might	   exhibit	   zonal	   expression	   in	   the	   HFA.	   Previous	   studies	   using	  
immunofluorescence	  have	  shown	  far	  greater	  expression	  of	  the	  LDL	  receptor	  on	  cells	  of	  the	  
FZ	   than	   the	   DZ.	   DZ	   cells	   would	   not	   be	   expected	   to	   express	   the	   LDL	   receptor	   early	   in	  
gestation	  given	  their	  lack	  of	  steroidogenic	  activity	  until	  close	  to	  term,	  however	  the	  evolution	  
to	  a	   steroid-­‐producing	  phenotype	   in	   the	  DZ	   is	   a	   limitation	  of	  using	   this	   as	   a	  marker	  of	   FZ	  
cells.	  SULT2A1,	  which	  converts	  DHEA	  to	  DHEAS,	  has	  been	  shown	  to	  localize	  to	  the	  TZ	  and	  FZ,	  
but	  not	  to	  the	  DZ	  20.	  Therefore,	  in	  these	  studies	  CD56	  was	  chosen	  as	  a	  marker	  of	  DZ/TZ	  cells	  
and	   SULT2A1	   was	   chosen	   as	   a	   marker	   of	   FZ	   cells.	   Steroidogenic	   factor-­‐1	   (SF1)	   a	   key	  
transcriptional	   activator	   of	   numerous	   genes	   involved	   in	   steroidogenesis,	   is	   expressed	   in	  
almost	  all	  adrenocortical	  cells	  in	  the	  DZ,	  TZ,	  and	  FZ	  181.	  SF1	  is	  expressed	  in	  the	  HFA	  from	  its	  
earliest	   stages	   of	   adrenal	   development,	   initially	   in	   the	   adrenogonadal	   precursors,	   and	  
subsequently	  in	  both	  the	  FZ	  and	  DZ	  of	  the	  gland	  182.	  SF1	  was	  therefore	  used	  in	  studies	  as	  a	  
spatio-­‐temporal	  marker	  of	  foetal	  adrenocortical	  cells.	  
3.2 Morphological	  study	  of	  the	  developing	  human	  foetal	  adrenal	  
H&E	  staining	  of	  HFA	  sections	  demonstrated	  the	  morphology	  and	  remarkable	  growth	  of	  the	  
gland	  (seen	  in	  comparative	  images	  from	  14	  wpc	  –	  38	  wpc,	  16	  –	  40	  weeks	  gestation)	  (Fig.	  17).	  	  
The	  large	  size	  of	  the	  foetal	  adrenal	  is	  evident	  when	  compared	  to	  the	  foetal	  kidney	  (Fig.	  17	  A,	  
arrow).	  The	  zonal	  architecture	  is	  evident	  in	  Fig.	  17	  and	  Fig.	  18.	  The	  cytoplasm	  of	  cells	  in	  the	  
outer	  definitive/transitional	  zones	  (DZ/TZ)	  exhibit	  some	  basophilia;	  in	  combination	  with	  the	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closely	  packed	  nuclei,	  this	  gives	  this	  part	  of	  the	  gland	  a	  blue	  appearance,	  in	  contrast	  to	  the	  
eosinophilic	  pink	  staining	  of	  the	  inner	  foetal	  zone	  (FZ)	  (Fig.	  18).	  
	  
An	  extensive	  body	  of	  evidence	  delineates	  essential	  roles	  for	  SF1	  in	  regulating	  adrenocortical	  
differentiation	  and	  function	  20.	  Immunofluorescence	  studies	  to	  localise	  steroiodogenic	  cells	  
in	   the	   foetal	  adrenal	  were	  carried	  out	   (Fig.	  19,	  HFA	  at	  11wpc	  shown).	   Localization	  of	  SF1-­‐
positive	   steroidogenic	   cells	   (green)	   was	   demonstrated,	   as	   previously	   described	   182,	  
throughout	   the	   foetal	   adrenal	   cortex	   (panel	  A).	  No	   immunoreactivity	  was	  detected	   in	   the	  






















































































































































































































































































































































































































































































































Fig.	   19.	   Immunofluorescence	   studies	   of	   11wpc	   HFA.	   Localization	   of	   SF1-­‐positive	  
steroidogenic	  cells	  (green)	  is	  demonstrated	  throughout	  the	  cortex	  using	  anti-­‐SF1	  antibody,	  
(panel	   a).	   No	   immunoreactivity	   detected	   in	   the	   negative	   controls	   where	   the	   primary	  
antibody	   (SF1)	  was	   omitted	   (panel	   b,	   SF1-­‐con).	   The	   adrenal	   cortex	   is	   surrounded	   by	   an	  




















3.3 Kiss1R	  is	  expressed	  from	  as	  early	  as	  10	  weeks	  gestation	  (8	  wpc)	  to	  term	  (38	  wpc,	  40	  
weeks	   gestation)	   throughout	   the	   human	   foetal	   adrenal	   cortex	   in	   all	   zones	   (DZ,	   TZ	  
and	  FZ).	  
The	  temporal	  and	  spatial	  expression	  of	  Kiss1R	  in	  the	  foetal	  adrenal	  cortex	  was	  characterised	  
by	   performing	   immunofluorescence	   studies	   on	   a	   series	   of	   tissue	   ranging	   from	   10	   to	   40	  
weeks	  gestation	  (8	  –	  38	  wpc).	  	  
	  
3.3.1 Kiss1R	   is	   expressed	   in	   the	   first	   trimester	   from	   10	  weeks	   gestation	   (8pcw)	   in	   the	  
developing	  adrenal	  cortex.	  
Kiss1R	   positive	   immunoreactivity	   in	   the	   HFA	   cortex	   was	   shown	   for	   the	   first	   time	   to	   be	  
present	   from	   as	   early	   as	   10	  weeks	   gestation	   (8wpc).	   Steroidogenic	   cells	   are	   identified	   by	  
SF1-­‐immunoreactivity	   throughout	   the	  HFA	   and	   there	   is	   co-­‐localization	   of	   SF1	   (green)	   and	  

























































































































































































3.3.2 Kiss1R	  is	  expressed	  in	  all	  zones	  of	  the	  foetal	  adrenal	  cortex	  	  
Kiss1R	   positive	   immunoreactivity	   in	   the	   HFA	   cortex	   was	   shown	   for	   the	   first	   time	   to	   be	  
present	   throughout	   the	   adrenal	   cortex,	   with	   expression	   in	   the	   inner	   FZ	   at	   all	   gestational	  
stages	  examined	   (Fig.	  21,	  high	  power	  of	   the	  FZ	  at	  11	  wpc)	  as	  well	  as	   the	  outer	  DZ	  and	  TZ	  
(Fig.	  22	  a-­‐c,	  11wpc	   shown).	  This	  expression	  was	   specific,	  with	  no	  Kiss1R	   immunopositivity	  
seen	   in	   the	  negative	  control	  where	  Kiss1R	  was	  preincubated	  with	   its	  peptide	  antigen	   (Fig.	  
23,	  panel	  b-­‐c,	   Kiss1R-­‐con).	  Co-­‐localisation	   studies	  using	  markers	  of	   zonation	   for	   the	  outer	  
DZ/TZ	  (CD56)	  and	  inner	  FZ	  (SULT2A1)	  revealed	  clear	  expression	  of	  Kiss1R	  in	  all	  zones	  of	  the	  
developing	  cortex	  (Fig.	  24).	  
	  
	  
Fig.	   21.	   Immunofluorescence	   studies	   of	   the	   human	   foetal	   adrenal	   (11	   wpc	   shown).	  
Localisation	  of	  Kiss1R	  (red)	  using	  anti-­‐Kiss1R	  anitibody	  (Alomone)	  is	  seen	  in	  the	  inner	  FZ.	  
Scale	  bar:	  100μm.	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3.3.3 Kiss1R	  expression	  persists	  in	  all	  zones	  of	  the	  foetal	  adrenal	  cortex	  throughout	  early	  
gestation	  to	  term	  (38	  wpc,	  40	  weeks	  gestation).	  
Kiss1R	   positive	   immunoreactivity	   in	   the	  HFA	   cortex	  was	   shown	   for	   the	   first	   time	   after	   36	  
weeks	  gestation	  (34	  wpc),	  with	  expression	  in	  the	  DZ	  and	  TZ	  as	  well	  as	  the	  inner	  FZ	  (Fig.	  26,	  
38	   wpc	   (40	   weeks	   gestation	   shown).	   This	   expression	   was	   specific,	   with	   no	   Kiss1R	  
immunopositivity	   seen	   in	   the	   negative	   control	   where	   Kiss1R	   was	   preincubated	   with	   its	  
peptide	   antigen	   (Fig.	   25,	   Kiss1R-­‐con,	   Fig.	   27	   panel	   e,	   Kiss1R-­‐con).	   Kiss1R	   expression	  
throughout	  all	  zones	  of	  the	  foetal	  adrenal	  cortex	  is	  therefore	  present	  from	  as	  early	  as	  8	  wpc	  
(10	  weeks	  gestation)	  and	  persists	  during	  mid-­‐gestation	   in	  the	  2nd	  and	   late-­‐gestation	   in	  the	  
3rd	  trimester	  to	  term	  (38	  wpc,	  40	  weeks	  gestation)	  (Fig.	  26).	  
	  
Fig.	   25.	   Immunofluorescence	   studies	   of	   the	   human	   foetal	   adrenal	   at	   38	  wpc	   (40	  weeks	  
gestation).	  Localisation	  of	  Kiss1R	  (red)	  using	  anti-­‐Kiss1R	  antibody	  (Alomone)	  in	  the	  DZ,	  TZ	  
and	   throughout	   the	   FZ.	   No	   immunoreactivity	   detected	   in	   the	   negative	   control	   with	  
antigen	   (Kiss1R)	   pre-­‐incubation,	   demonstrating	   specificity	   of	   the	   Kiss1R	   antibody.	   The	  





























Fig.	  26.	   Immunofluorescence	   studies	  of	   the	  human	   foetal	  adrenal	  at	  early,	  mid	  and	   late	  
gestation	  (panels	  a-­‐d,	  8	  wpc,	  11	  wpc,	  33	  wpc	  38	  wpc	  shown).	  Localisation	  of	  Kiss1R	  (red)	  
using	  anti-­‐Kiss1R	  antibody	  throughout	  the	  adrenal	  cortex	  at	  all	  gestational	  ages	  examined.	  
No	   immunoreactivity	   detected	   in	   the	   negative	   control	   with	   antigen	   (Kiss1R)	   pre-­‐
incubation	   demonstrating	   specificity	   of	   the	   Kiss1R	   antibody	   (panel	   e,	   Kiss1R-­‐con).	   The	  
adrenal	  cortex	  is	  surrounded	  by	  an	  outer	  capsule	  (dashed	  line).	  Scale	  bar:	  100μm.	  








































3.3.4 NR-­‐in	   situ	  hybridisation	  studies	  of	  Kiss1R	  expression	   in	   the	  human	   foetal	  adrenal	  
confirm	  localisation	  to	  all	  zones	  of	  the	  foetal	  adrenal	  cortex).	  
To	  further	  support	  my	  novel	  finding	  of	  Kiss1R	  expression	  throughout	  the	  adrenal	  cortex,	  the	  
mRNA	  expression	  pattern	  of	  genes	  encoding	  Kiss1R	  was	  determined	  using	  non-­‐radioactive	  
in	   situ	  hybridization	   (NR-­‐ISH).	  This	  approach	  was	  chosen	  as	   I	   failed	   to	  obtain	   reproducible	  
results	   on	   tissue	   sections	   with	   another	   commercially	   available	   antibody	   raised	   against	  
Kiss1R,	   used	   in	   a	   previous	   study	   by	   Nakamura	   et	   al	   (immunohistochemical	   studies	   not	  
shown).	  I	  therefore	  designed	  and	  tested	  antisense	  RNA	  probes	  for	  this	  gene,	  and	  confirmed	  
they	   specifically	   detect	   Kiss1R	   expression	   in	   previously	   documented	   embryonic	   locations	  
(Fig.	  27,	  panels	  h,	  i).	  In	  situ	  hybridization	  was	  performed	  on	  sections	  obtained	  from	  human	  
embryos	  and	  assayed	  with	  antisense	  (AS)	  and	  sense	  (S)	  probes.	  In	  the	  foetal	  adrenal	  tissues	  
analysed	   (Fig.	   27,	   panels	   a,	   c,	   e,	   f)	   Kiss1R	   transcripts	   localised	   to	   the	   DZ,	   TZ	   and	   FZ,	   in	  
keeping	  with	  previous	   immunofluorescence	  studies.	  No	  specific	   signal	  was	  obtained	  when	  
sections	  were	   treated	  with	   the	   sense	  probes	   (Fig.	   28,	   panels	   b,	   d).	  Kiss1R	  expression	  was	  
seen	  in	  foetal	  spinal	  cord	  and	  in	  the	  outer	  syncytiotrophoblasts	  of	  first	  trimester	  placental	  
villi	   (Fig.	   27,	   panel	   i)	   in	   keeping	  with	   numerous	  published	   studies	   119,122,161,183.	   Foetal	   lung	  





Fig.	  27.	  NR-­‐ISH	  studies	  of	  expression	  of	  Kiss1R	  transcript	  in	  human	  foetal	  tissue.	  
Kiss1R	   is	   localized	  throughout	  the	  developing	  human	  adrenal	  cortex	  (panels	  a,c,d,e).	  The	  
capsule	   (*)	   is	   unstained.	   At	   all	   ages	   examined	   the	   adrenocortical	   cells	   were	   strongly	  
positive	   for	  Kiss1R	   transcript	   (panel	   a,	   8wpc,	  panel	   c,	   f	   12wpc,	  panel	  e,	   38	  wpc	   shown).	  
Panel	   g	   is	   foetal	   lung	   tissue	   (12wpc)	  used	  as	   a	  negative	   control.	   Panel	  h	   is	   foetal	   spinal	  
cord	   (12wpc)	  and	  panel	   i	   is	   first	   trimester	  placental	  villi	   tissue	   (12	  wpc)	  used	  as	  positive	  
controls.	  Sections	  incubated	  with	  Kiss1R	  sense	  probe	  (panels	  b,	  HFA	  8wpc,	  panel	  d,	  HFA	  12	  
wpc)	  did	  not	  show	  any	  specific	  staining.	  Scale	  bars:	  100µm.	  
	  
3.3.5 Quantitative	  assessment	  of	  Kiss1R	  in	  the	  developing	  human	  adrenal	  cortex.	  
A	  quantitative	  assessment	  of	  Kiss1R	  in	  the	  HFA	  was	  compared	  to	  expression	  in	  the	  placenta,	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that	   of	   SULT2A1.	   SULT2A1	   (sulphotransferase)	   is	   highly	   expressed	   in	   the	   FZ	   of	   the	  
developing	   adrenal	   cortex,	   and	   the	   ZF	   of	   the	   adult	   adrenal,	   where	   it	   converts	   DHEA	   to	  
DHEAS.	  Quantitative	   reverse-­‐transcriptase	   PCR	   (qPCR)	   performed	  on	   1st	   and	   2nd	   trimester	  
HFA	  cDNA	  (8-­‐10wpc,	  11-­‐14wpc,	  15-­‐20wpc)	  showed	  an	  increase	  in	  both	  Kiss1R	  (Fig.	  28A)	  and	  
SULT2A1	   (Fig.	   28B)	   mRNA	   expression	   with	   increasing	   gestational	   age.	   Kiss1R	   mRNA	   was	  
significantly	   higher	   in	   11-­‐14wpc	   HFA	   (7.9-­‐fold,	   p<0.05)	   and	   15-­‐20	   wpc	   HFA	   (22.3-­‐fold,	  
p<0.0001)	   than	   placenta	   (Fig.	   28A).	   At	   8-­‐10wpc	  Kiss1R	   mRNA	  was	   3.7-­‐fold	   higher	   in	   HFA	  
than	   in	   human	   placenta,	   although	   this	   was	   not	   significant	   (Fig.	   29A).	   There	   was	   also	   a	  
significant	  increase	  in	  Kiss1R	  expression	  from	  8-­‐10wpc	  to	  15-­‐20wpc	  (5.9	  fold,	  p<0.0001)	  and	  
11-­‐14wpc	  to	  15-­‐20wpc	  (2.8-­‐fold,	  p<0.001).	  The	  2-­‐fold	  increase	  in	  Kiss1R	  expression	  between	  
8-­‐10wpc	  and	  11-­‐14wpc	  was	  not	  significant.	  SULT2A1	  mRNA	  was	  significantly	  higher	   in	  11-­‐
14wpc	  (7.3-­‐fold,	  p<0.05)	  and	  15-­‐20	  wpc	  HFA	  (9.4-­‐fold,	  p<0.01)	  than	  in	  human	  adult	  adrenal	  
(Fig.	   29B).	   At	   15-­‐20wpc	   SULT2A1	   mRNA	   was	   2.6-­‐fold	   higher	   in	   HFA	   than	   at	   8-­‐10wpc	  
(p<0.05).	   At	   8-­‐10wpc	   SULT2A1	   mRNA	   was	   3.6-­‐fold	   higher	   in	   HFA	   than	   in	   adult	   adrenal,	  
although	  this	  result	  was	  not	  significant	  (Fig.	  29B).	  The	  2.0-­‐	  and	  1.3-­‐fold	  increase	  in	  SULT2A1	  













Fig.	  28.	  A.	  Kiss1R	  qPCR	  was	  performed	  on	  cDNA	  obtained	  from	  3	  HFA	  samples	  from	  each	  
stage	   of	   development	   (8-­‐10wpc,	   11-­‐14wpc,	   15-­‐20wpc).	   Placental	   cDNA	   was	   used	   as	   a	  
positive	  control.	  Data	  points	  represent	  the	  mean	  +/-­‐	  SD	  from	  4	  independent	  experiments	  
performed	   in	   triplicate.	  B.	  SULT2A1	  qPCR	  was	  performed	  on	  cDNA	  obtained	   from	  3	  HFA	  
samples	  from	  each	  stage	  of	  development	  (8-­‐10wpc,	  11-­‐14wpc,	  15-­‐20wpc).	  Adult	  adrenal	  
cDNA	   was	   used	   as	   a	   positive	   control.	   Data	   points	   represent	   the	   mean	   +/-­‐	   SD	   from	   3	  
independent	   experiments	   performed	   in	   triplicate.	   D&E.	   Data	   are	   normalized	   to	  GAPDH	  
expression	   and	   presented	   as	   a	   proportional	   increase	   or	   decrease	   from	   the	   calibrator	  
(placenta	   and	   adult	   adrenal,	   normalized	   to	   a	   value	   of	   1	   for	   comparison).	   *p<0.05;	  
**p<0.01	  ***p<0.001;	  ****p<0.0001.	  
3.4 Discussion:	   Qualitative	   and	   quantitative	   expression	   studies	   of	   Kiss1R	   in	   the	  
developing	  human	  adrenal	  
Kisspeptin	  and	  its	  receptor,	  Kiss1R,	  are	  expressed	  in	  the	  central	  nervous	  system,	  pancreas,	  
adipose	  tissue,	   testes	  and	  spleen	  119,122.	  One	  other	  group	  has	  assessed	  the	  expression	  and	  




























































































































































mRNA	   in	   HFA	   tissue	   and	   Kiss1R	   protein	   expression	   in	   the	   definitive	   and	   the	   transitional	  
zones	   (DZ	   and	   TZ)	   of	   14-­‐36	   weeks	   gestation	   (12-­‐34	   wpc)	   HFA	   tissues	   by	  
immunohistochemistry.	   In	   keeping	  with	   this	   study	   I	   identified	   expression	   of	   Kiss1R	   in	   the	  
outer	  DZ/TZ.	  For	  the	  first	  time,	  I	  confirmed	  Kiss1R	  protein	  expression	  in	  the	  HFA	  cortex	  from	  
as	   early	   as	   8	   wpc	   (10	   weeks	   gestation)	   to	   term,	   38	   wpc	   (40	   weeks	   gestation),	   by	  
immunofluorescence.	   Interestingly,	   it	   was	   identified	   throughout	   the	   adrenal	   cortex,	   with	  
expression	  in	  the	  inner	  FZ	  as	  well	  as	  the	  outer	  DZ	  and	  TZ.	  The	  reason	  for	  this	  discrepancy	  is	  
unclear	   but	   may	   be	   accounted	   for	   by	   the	   different	   methodology	   and	   antibody	   used.	  
However,	  using	  a	  second	  method	  of	  NR-­‐in	  situ	  hybridisation,	  Kiss1R	  transcript	  was	  identified	  
in	  the	  inner	  FZ	  as	  well	  as	  DZ/TZ.	  	  
	  
My	   immunofluorescence	   and	   in-­‐vitro	   data	   concord	   as	   I	   had	   hypothesised	   that	   kisspeptin	  
stimulates	  DHEAS	  production	  from	  FZ	  cells.	  Consistent	  with	  this,	  SULT2A1	  is	  localized	  to	  the	  
FZ	   and	   converts	   DHEA	   to	   DHEAS.	   This	   suggests	   that	   the	   FZ	   may	   represent	   an	   important	  
target	  for	  kisspeptin	  during	  pregnancy.	  	  
	  
Quantitative	  evaluation	  shows	  that	  Kiss1R	  mRNA	  expression	   increases	  significantly	   in	  mid-­‐
gestation	  (11-­‐20	  wpc);	  therefore	  this	  may	  be	  a	  critical	  time	  point	  for	  the	  action	  of	  kisspeptin	  
on	  the	  FZ.	  The	  production	  of	  DHEAS	  begins	  at	  ~8-­‐10	  weeks	  gestation	  (6-­‐8wpc)	  but	  increases	  
considerably	  during	  the	  second	  and	  third	  trimesters	  20.	  The	  increase	  in	  Kiss1R	  expression	  in	  
mid-­‐gestation	  (11-­‐20	  wpc)	  is	  paralleled	  by	  an	  increase	  in	  SULT2A1	  mRNA	  expression.	  	  
	  
In	   conclusion,	   taken	   together,	   these	   data	   suggest	   that	   the	   FZ	   is	   an	   important	   target	   for	  




3.4.1 Limitations	  and	  future	  studies	  	  
Intriguingly,	  my	   spatio-­‐temporal	   studies	   confirm	   the	   previous	   report	   of	   Kiss1R	   expression	  
within	  the	  outer	  DZ/TZ	  from	  as	  early	  as	  8	  wpc.	  Its	  role	  here	  is	  unclear	  and	  further	  studies	  are	  
warranted.	  	  
	  
The	   persistent	   proliferative	   capacity	   of	   the	   DZ	   and	   the	   observation	   of	   centripetal	   cellular	  
turnover	  within	   the	   cortex	   support	   a	   centripetal	  model	   of	   adrenocortical	   cytogenesis	   and	  
suggests	   the	  possible	   existence	  of	   stem-­‐like	   cells	   in	   the	  outer	   zone	  of	   the	   gland	   53.	   It	   has	  
been	  proposed	  that	  undifferentiated	  sub-­‐capsular	  cells	  give	  rise	   to	   the	  rest	  of	   the	  adrenal	  
cortex.	   Cells	   capable	   of	   repopulating	   the	   adrenocortical	   steroidogenic	   zones	   might	   be	  
predicted	   to	   be	   undifferentiated	   and	   hence	   pluripotent.	   Further	   studies	   specifically	  
examining	  expression	  of	  Kiss1R	  in	  the	  sub-­‐capsular	  DZ/TZ	  cells	  would	  be	  useful	  to	  determine	  
whether	   Kiss1R	   is	   expressed	   in	   differentiated	   steroidogenic	   cells,	   or	   in	   relatively	  
undifferentiated	  steroidogenic	  cells	  (cells	  that	  express	  neither	  CYP11B1	  nor	  CYP11B2).	  
	  
It	   is	   clear	   from	   previous	   studies	   that	   Shh-­‐expressing	   cells	   serve	   as	   a	   genuine	   progenitor	  
population	   that	   contributes	   to	   the	   adrenal	   cortex	   homeostasis,	   as	   previously	   described.	  
Previous	  observations	   indicate	   in	   rodents	   that	   the	  Shh-­‐expressing	   sub-­‐capsular	  progenitor	  
cells	  and	  the	  capsular	  Gli-­‐expressing	  cells	  30,42	  are	  integral	  components	  of	  the	  adrenocortical	  
progenitor	  cell	  niche.	  SHH-­‐expressing	  cells	  are	  also	  observed	  in	  sub-­‐capsular	  clusters	  in	  the	  
human	  adult	  adrenal	  8,	  and	  this	  is	  likely	  to	  also	  be	  the	  case	  in	  the	  foetal	  adrenal.	  It	  could	  be	  
postulated	  that	  placental	  kisspeptin	  may	  regulate	  the	  Hh	  signalling	  pathway	  and	  in	  this	  way	  
regulate	  adrenal	  development.	  The	  spatio-­‐temporal	  expression	  of	  SHH-­‐expressing	  cells	  and	  
SHH-­‐signal-­‐receiving	   cells	   would	   be	   interesting	   to	   characterise	   using	   serial	   in	   situ	  
hybridisation	  with	  probes	  detecting	  SHH	  and	  GLI1	  RNA	  (due	  to	  lack	  of	  availability	  of	  a	  good	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anti-­‐SHH	  antibody).	  The	  spatio-­‐temporal	  expression	  of	  SHH	  and	  GLI-­‐1-­‐positive	  cells	  could	  be	  
compared	   to	   expression	   of	   Kiss1R.	   These	   studies	   would	   be	   useful	   and	   important	   as	   the	  
progenitor	   niche	   of	   the	   adrenal	   cortex	   is	   only	   just	   beginning	   to	   be	   characterized	   and	   the	  
underlying	  molecular	  mechanisms	  are	  still	  unknown.	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4 Results:	  Functional	  studies	  into	  the	  effects	  of	  kisspeptin	  on	  the	  human	  foetal	  adrenal	  
cortex	  using	  in	  vitro	  models	  	  
	  




The	  main	  aim	  of	   these	   studies	   is	   to	   investigate	   the	  effects	  of	   kisspeptin	  on	   foetal	   adrenal	  
function,	   using	   two	   in	   vitro	   cell	   models	   comprising	   a	   human	   adrenocarcinoma	   cell	   line	  
(H295R	  cells)	  and	  primary	  HFA	  cultures.	  These	  models	  will	  be	  used	  to	  interrogate	  the	  effect	  
of	   kisspeptin	   on	   receptor	   (Kiss1R)	   expression	   and	   on	   production	   of	   DHEAS	   compared	   to	  
other	  known	  regulators	  of	  steroidogenesis	  such	  as	  ACTH	  and	  CRH	  	  (measured	  by	  ELISA	  and	  
LC-­‐MS/MS).	   It	   is	   important	   to	   examine	   the	   possible	   regulation	   of	   adrenocortical	  
steroidogenesis	   to	   obtain	   a	   better	   understanding	   of	   function	   of	   the	   foetal	   adrenal	   during	  
pregnancy.	  To	  date	  only	  one	  study	  has	  examined	  whether	  kisspeptin	  is	  directly	  involved	  in	  
steroid	  production	  in	  the	  HFA	  165.	  Nakamura	  et	  al	  previously	  demonstrated	  that	  kisspeptin	  
increases	  aldosterone	  production	  (approximately	  2-­‐fold)	   in	  both	  foetal	  adrenocortical	  cells	  
and	  H295R	  adrenal	  cells.	  In	  addition,	  Kisspeptin	  increased	  angiotensin	  II	  (Ang	  II)-­‐stimulated	  
aldosterone	   production	   by	   approximately	   1.5-­‐fold.	   Kisspeptin	   also	   increased	   the	   ability	   of	  
the	  H295R	  cells	  to	  metabolize	  exogenously	  added	  pregnenolone	  to	  aldosterone	  but	  had	  no	  
effect	  on	  the	  expression	  of	  aldosterone	  synthase	  (CYP11B2).	  The	  authors	  suggested	  that	  the	  
high	   foetal/maternal	   levels	   of	   metastin	   seen	   during	   pregnancy	   might	   affect	   adrenal	  
production	   of	   aldosterone.	   The	   DZ/TZ,	   however	   contributes	   only	   a	   small	   fraction	   of	   total	  
foetal	   adrenal	   steroid	   production	   during	   gestation,	   and	   the	   DZ	   is	   capable	   of	   aldosterone	  
secretion	  only	  near	   term	  20.	  The	  effect	  of	  kisspeptin	  on	  adrenal	  production	  of	  DHEAS,	   the	  
largest	   steroid	  output	   from	   the	   foetal	   adrenal,	  has	  not	  previously	  been	   reported	  and	  was	  
the	  main	  focus	  of	  these	  functional	  studies.	  
	  
The	   H295R	   adrenocortical	   cell	   line	   was	   used	   as	   an	   in	   vitro	   model	   of	   the	   HFA	   to	   obtain	  
preliminary	   data.	   H295R	   cells	   can	   differentiate	   towards	   either	   a	   zG	   or	   zF-­‐like	   phenotype	  
when	   treated	  with	  angiotensin	   II	   (AngII)	  or	   forskolin	   (Fsk)	   respectively	   58,61.	  As	  part	  of	   the	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renin-­‐angiotensin-­‐aldosterone	   pathway,	   angiotensin	   II	   stimulates	   aldosterone	   production	  
via	   AT1	   receptors	   in	   the	   zona	   glomerulosa	   of	   the	   adrenal	   cortex	   184.	   It	   also	   stimulates	  
differentiation	  of	  H295R	  cells	  towards	  a	  zG-­‐like	  fate,	  characterized	  by	  increased	  production	  
of	  CYP11B2	  (aldosterone	  synthase)	  58.	  Activation	  of	  the	  HPA	  axis	  causes	  the	  release	  of	  ACTH	  
from	  the	  anterior	  pituitary,	  which	  acts	  on	  its	  receptor,	  MC2R,	  on	  the	  surface	  of	  zF/zR	  cells	  to	  
stimulate	   glucocorticoid	   release	   via	   intracellular	   cAMP	   production.	   Stimulating	   the	   cAMP	  
pathway	  in	  H295Rs	  leads	  to	  their	  differentiation	  towards	  a	  zF/zR-­‐like	  fate,	  characterised	  by	  
increased	   production	   of	   CYP11B1	   (11β-­‐hydroxylase)	   62.	   Forskolin	   can	   be	   used	   to	   directly	  
activate	  adenylate	  cyclase	  in	  this	  pathway,	  as	  H295R	  cells	  tend	  to	  be	  unresponsive	  to	  ACTH	  
185.	   Initial	   experiments	   sought	   to	   reproduce	   those	   of	   Nakamura	   et	   al,	   and	   to	   ensure	   that	  
H295R	   cells	   had	   retained	   their	   responsiveness	   to	   these	   compounds	   by	   examining	   their	  
steroidogenic	  function.	  
	  
Subsequently,	   due	   to	   limitiations	   of	   this	   cell	   line	   as	   a	   suitable	   model,	   as	   previously	  
described,	   primary	   cultures	   of	  HFA	   cells	  were	   established,	   and	  both	   in	   vitro	  models	  were	  
utilised	   in	   further	   functional	   studies.	   The	   direct	   effect	   of	   kisspeptin	   stimulation	   on	   Kiss1R	  
mRNA	   and	   protein	   expression	   was	   investigated	   using	   real-­‐time	   RT-­‐PCR.	   The	   direct	   and	  
indirect	  effects	  of	  kisspeptin	  on	  steroidogenesis	  were	  then	  examined.	  DHEAS	  was	  measured	  
in	  the	  cell	  media	  by	  enzyme	  linked	  immunosorbent	  assay	  (ELISA)	  and	  the	  assay	  quality	  was	  




4.2 Establishment	  of	  primary	  human	  foetal	  adrenal	  cell	  cultures	  	  
The	  importance	  of	  using	  primary	  cells,	  rather	  than	  cancer	  cell	  lines,	  for	  biological	  studies	  is	  
becoming	   widely	   recognised.	   Kisspeptin-­‐Kiss1R	   signalling	   plays	   diverse	   roles	   in	   human	  
physiology,	   including	  potential	   roles	   in	   pathological	  metastatic	   conditions	   183.	   Therefore	   it	  
was	   felt	   that	   the	   use	   of	   a	   tumour-­‐derived	   cell	   line	   as	   a	   model	   of	   the	   HFA	   may	   limit	  
extrapolation	  of	  any	   findings	   to	  an	   in	   vivo	   physiological	   situation.	   Furthermore	   the	  H295R	  
strain	  demonstrates	  minimal	  response	  to	  stimulation	  with	  ACTH,	  which	  may	  in	  part	  be	  due	  
to	  low	  expression	  levels	  of	  the	  ACTH	  receptor,	  MC2R.	  
	  
Cell	   culture	   systems	   allow	   the	   examination	   of	   cell	   populations	   in	   a	   functional	   state.	   To	  
simulate	  in	  vivo	  conditions	  as	  closely	  as	  possible	  freshly	  established	  cell	  strains	  are	  superior	  
to	   permanent	   cell	   lines.	   Primary	   cells	   cannot	   be	   cultured	   indefinitely	   due	   to	   the	   onset	   of	  
replicative	   senescence	   or	   aneuploidization.	   Hence,	   new	   cultures	   need	   to	   be	   established	  
regularly.	   The	   procedures	   for	   primary	   culture	   is	   well	   established,	   however	   can	   present	   a	  
challenge.	  At	  the	  time	  this	  work	  was	  carried	  out,	  primary	  HFA	  cell	  cultures	  were	  not,	  to	  my	  
knowledge,	  established	  at	  any	  other	  institution	  in	  the	  UK.	  Therefore	  this	  was	  an	  invaluable	  
resource,	   both	   within	   my	   institute	   and	   wider	   afield,	   as	   an	   in	   vitro	   model	   for	   studies	   of	  
adrenal	  disorders.	  
4.2.1 Establishment	  of	  primary	  cultures	  	  
As	   a	   result	   of	   collaboration	   with	   the	   MRC-­‐Wellcome	   HDBR	   in	   Newcastle	   and	   ICH,	   I	  
established	  primary	  HFA	  cell	  cultures	  in	  our	  laboratory.	  A	  series	  of	  fresh	  HFA	  tissue	  samples	  
from	  the	  HDBR	  ranging	  from	  8	  to	  17	  wpc	  (male	  and	  female	  sex)	  were	  obtained	  and	  	  primary	  
cell	   cultures	   were	   established	   successfully	   on	   each	   occasion	   (Table	   5	   and	   Fig.	   29).	   The	  
medium	  was	   removed	   and	   replaced	  with	   fresh	  medium	  after	   48	   hours	   of	   culture.	   At	   this	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time,	   about	   70-­‐80%	   of	   the	   cells	   had	   firmly	   attached	   and,	   thereafter,	   the	   medium	   was	  
replaced	  every	  2	  days.	  Cells	  formed	  a	  50%	  confluent	  monolayer	  4-­‐6	  days	  after	  plating,	  and	  a	  
90%	   confluent	   monolayer	   8-­‐10	   days	   after	   plating	   (Table	   5;	   Fig.	   30).	   These	   cultures	   were	  
maintained	  for	  periods	  of	  up	  to	  4	  weeks.	  	  
	  
	  
Fig.	  29.	  Human	  	  foetal	  	  adrenal	  tissue	  	  from	  	  9	  wpc,	  12	  wpc	  and	  17wpc	  in	  	  primary	  culture.	  	  
Human	  foetal	  adrenal	  cells	  shown	  at	  low	  magnification	  (x10)	  growing	  in	  media	  containing	  


















Table	  5	  Characteristics	  of	  human	  foetal	  adrenal	  tissue	  used	  for	  primary	  culture	  
Age	  
wpc	  

















CS23	   Abnormal	   10	   -­‐	   -­‐	   -­‐	   Abnormal	  
karyotype	  
CS23	   46,	  XY	   -­‐	   -­‐	   -­‐	   -­‐	   Infection	  of	  
primary	  
culture	  	  
8	   46,	  XY	   6	   9	   15	   22	   	  
8	   46,	  XX	   5	   8	   17	   19	   	  
9	   46,	  XX	   5	   9	   17	   23	   	  
9	   46,	  XX	   4	   10	   16	   21	   	  
9	   46,	  XY	   5	   9	   16	   19	   	  
10	   46,	  XY	   6	   9	   14	   16	   	  
11	   46,	  XY	   4	   8	   16	   21	   	  
12	   46,	  XX	   5	   9	   15	   22	   	  
13	   46,	  XX	   5	   8	   14	   19	   	  
15	   46,	  XY	   5	   9	   13	   18	   	  
16	   46,	  XX	   4	   9	   14	   17	   	  





Fig.	  30.	  The	  appearances	  of	  human	  foetal	  adrenocortical	  cells	  maintained	  in	  culture	  (cells	  
from	  HFA	  8wpc	  tissue	  shown	  growing	  in	  adherent	  conditions).	  Human	  foetal	  adrenal	  cells	  
shown	  at	  low	  magnification	  (x10)	  growing	  in	  media	  containing	  ultroser	  (adherent	  
conditions)	  on	  day	  1,	  3,	  5	  and	  9	  after	  plating.	  Cells	  were	  noted	  to	  have	  formed	  a	  50%	  
confluent	  monolayer	  4-­‐6	  days	  after	  plating,	  and	  a	  90%	  confluent	  monolayer	  8-­‐10	  days	  
after	  plating.	  Scale	  bar:	  100μm.	  
4.2.2 Morphology	  and	  functional	  development	  of	  HFA	  cells	  in	  culture	  	  
In	   addition	   to	   adrenocortical	   cells	   with	   steroidogenic	   appearances	   (rounded	   nuclei	   and	  
abundant	   lipid),	   a	   small	   proportion	   (<5%)	   of	   capsular	   fibroblast-­‐like	   cells	   with	   elongated	  
nuclei	  and	  multiple	  nucleoli	  were	  present	  in	  each	  primary	  culture	  of	  HFA	  cells.	  Fig.	  31	  is	  an	  
example	  of	   a	   typical	  monolayer	   found	   in	   these	   cultures	  on	  day	  5	   and	  day	  9	   after	  plating.	  
Preliminary	  data	   indicated	  that	   the	  mixed	  population	  of	  cells	   in	  culture	   included	  cells	   that	  
are	   SF1-­‐positive	   and	   therefore	   steroiodgenic	   (Fig.	   32).	   In	   primary	   culture	   cells	   initially	  









the	  first	  passage.	  These	  cells	  were	  steroidogenic,	  as	  indicated	  by	  SF1-­‐positivity	  detected	  by	  
immunofluorescence	  (Fig.	  33,	  HFA	  cells	  at	  9wpc	  shown,	  panel	  A),	  and	  production	  of	  DHEAS	  
following	  ACTH	  stimulation	  of	  cells,	  measured	  by	  ELISA	   (Fig.	  33,	  HFA	  cells	  at	  9wpc	  shown,	  
panel	  D,	  E).	  On	  subsequent	  passages	  cells	  rapidly	  lost	  lipid,	  spread,	  and	  assumed	  fibroblastic	  
shapes	  (Fig.	  33,	  HFA	  cells	  at	  9wpc	  shown,	  panel	  B).	  The	  morphologic	  changes	  seen	  appeared	  
to	   be	   due	   to	   fibroblastic	   overgrowth	   as	   the	   number	   of	   SF1-­‐positive	   cells	   detected	   by	  
immunofluorescence	  was	   significantly	   less	   (3-­‐fold	   reduction	   in	   the	  number	  of	  SF1-­‐positive	  
cells,	  p<0.01)	  following	  passage	  3,	  compared	  to	  passage	  1	  (Fig.	  34,	  HFA	  cells	  at	  9wpc	  shown,	  
panel	  C).	  The	  production	  of	  DHEAS	  by	  HFA	  cells	  was	   reduced	  2.6-­‐fold	   following	  passage	  3	  
compared	   to	  passage	  1,	  although	   this	  was	  not	   statistically	   significant	   (Fig.	  33,	  HFA	  cells	  at	  
9wpc	  shown,	  panel	  F).	  
	  
Fig.	  31.	  Monolayer	  of	  human	  	  foetal	  	  adrenal	  cells	  	  from	  	  9wpc	  tissue	  	  in	  	  primary	  culture.	  	  
Human	  	  foetal	  	  adrenal	  tissue	  	  from	  	  9wpc	  	  in	  	  primary	  culture.	  Human	  foetal	  adrenal	  cells	  
shown	  growing	  in	  media	  containing	  ultroser	  (adherent	  conditions)	  on	  day	  5	  (A,	  low	  power	  
x10,	  B,	  medium	  power	  x20,	  C,	  high	  power	  x40	  magnification)	  and	  day	  9	  (D,	  low	  power	  x10,	  




























Fig.	  32.	   Immunofluorescence	   	  studies	   	   showing	   	   that	   	  cells	   	   cultured	   	   from	  human	   foetal	  
tissue	   	   (9	  wpc)	   	   are	   	   steroidogenic	   	   factor	   (SF1)	   	   positive.	  Nuclear	   	   localisation	   	   of	   	   SF1	  
(green)	  	  using	  	  anti-­‐SF1	  	  antibody	  	   	  (panel	   	  A,	   	  B).	   	  No	  immunopositive	  staining	  is	  seen	  in	  
the	  negative	  control	  (primary	  antibody	  omitted)	  (panel	  D,	  SF1-­‐con).	  Immunopositivity	  for	  

























Fig.	  33.	  Morphologic	  and	  functional	  changes	  of	  HFA	  cells	  in	  primary	  culture	  over	  time	  
In	   primary	   culture,	   cells	   retained	   lipid	   and	   formed	   cohesive	   epithelial	   monolayers	   that	  
remained	   stationary	   up	   until	   the	   first	   passage	   (HFA	   at	   9wpc	   shown).	   These	   cells	   were	  
steroidogenic,	  as	   indicated	  by	  SF1-­‐positivity	  detected	  by	   immunofluorescence	   (panel	  A),	  
and	  production	  of	  DHEAS	  following	  ACTH	  stimulation,	  measured	  by	  ELISA	  (panel	  D,	  E).	  On	  
subsequent	  passages	  cells	  assumed	  fibroblastic	  shapes	  (panel	  B).	  Fibroblastic	  overgrowth	  
was	   evident	   as	   the	   number	   of	   SF1-­‐positive	   cells	   detected	   by	   immunofluorescence	   was	  
significantly	   less	   (3-­‐fold	   reduction,	   p<0.01)	   following	   passage	   3,	   compared	   to	   passage	   1	  
(panel	  C).	  Furthermore	  production	  of	  DHEAS	  by	  HFA	  cells	  was	  reduced	  2.6-­‐fold	  following	  
passage	  3	  compared	  to	  passage	  1,	  although	  this	  was	  not	  statistically	  significant	  (panel	  F).	  
Data	  points	  represent	  the	  mean	  +	  SD	  of	  values	  from	  3	  independent	  experiments	  run,	  and	  
















































































































































































































4.3 Functional	  studies	  using	  in	  vitro	  models	  of	  the	  human	  foetal	  adrenal	  	  
Initial	   experiments	   had	   shown	   the	   number	   of	   SF1-­‐positive	   HFA	   cells	   detected	   by	  
immunofluorescence	  was	  significantly	   less	   (3-­‐fold	   reduction	   in	   the	  number	  of	  SF1-­‐positive	  
cells,	  p<0.01)	  following	  passage	  3,	  compared	  to	  passage	  1	  (Fig.	  34,	  HFA	  cells	  at	  9wpc	  shown,	  
panel	  C),	  and	  the	  production	  of	  DHEAS	  by	  HFA	  cells	  was	  reduced	  2.6-­‐fold	  following	  passage	  
3	   compared	   to	   passage	   1,	   (Fig.	   33,	   HFA	   cells	   at	   9wpc	   shown,	   panel	   F).	   Therefore	   in	  
functional	   studies,	   cells	   from	   passage	   1,	   passage	   2,	   and	   passage	   3	   were	   included	   for	  
preliminary	  dose-­‐response	  studies.	  All	  other	   functional	  studies	  carried	  out	  and	   included	   in	  
the	  analyses	  that	  follow	  were	  performed	  using	  passage	  1	  cells	  only.	  
	  
4.3.1 Preliminary	  time	  course	  and	  dose-­‐response	  studies	  
Time	  course	  experiments	  examining	  the	  effect	  of	  kisspeptin	  on	  DHEAS	  production	  in	  H295R	  
cells	  were	  carried	  out.	  HFA	  cells	  were	  unavailable	  for	  use	  in	  these	  studies.	  A	  concentration	  
of	  100nM	  kisspeptin	  was	  selected	  for	  time	  course	  experiments	  following	  the	  studies	  using	  
H295R	  cells	  carried	  out	  by	  Nakamura	  et	  al	  165.	  At	  24	  hours,	  stimulation	  of	  cells	  resulted	  in	  a	  
significant	  increase	  in	  DHEAS	  production	  (Fig.	  34.	  Treatment	  of	  cells	  with	  kisspeptin	  resulted	  





Fig.	  34.	  Time-­‐dependent	  effects	  of	  kisspeptin	  on	  DHEAS	  production	  in	  H295R	  cells.	  	  
Cells	   were	   incubated	  with	   kisspeptin	   100nM	   or	   serum-­‐free	  media	   alone	   (basal	   control,	  
untreated	   cells),	   (-­‐)	   no	   treatment;	   (+)	   treatment	   added.	   Steroid	   level	   in	   the	  media	  was	  
determined	   by	   enzyme	   immunoassay	   and	   corrected	   for	   protein	   content.	   Data	   points	  
represent	   the	   mean	   +	   SD	   of	   values	   from	   3	   independent	   experiments	   run,	   and	   are	  
expressed	  as	  the	  fold	  over	  basal	  level	  (normalised	  to	  a	  value	  of	  1).	  **P<0.01.	  	  
	  
The	   kisspeptin	   concentration	   used	   in	   experiments	   was	   supraphysiological	   (100x	  maternal	  
circulating	  concentrations).	  This	  was	  decided	  on	  the	  basis	  of	  dose	  response	  studies,	  which	  
showed	   a	   significant	   increase	   in	   DHEAS	   compared	   to	   untreated	   H295R	   cells	   with	   10nM	  
(p<0.01)	   and	   100nM	   (p<0.05).	   Only	   100nM	   kisspeptin	   produced	   a	   significant	   increase	   in	  
DHEAS	  compared	  to	  no	  treatment	  in	  8-­‐10wpc	  (p<0.05)	  and	  15-­‐20	  HFA	  (p<0.0001)	  cells	  (Fig.	  
35	  A	  B	  and	  C,	   respectively).	  Using	   LC-­‐MS/MS	   (Fig.	   35	  D-­‐E)	   to	  measure	  DHEAS	  produced	  a	  
similar	  finding	  with	  100nM	  kisspeptin	  resulting	  in	  a	  significant	   increase	  (p<0.05)	  compared	  
to	  no	  treatment	  in	  H295R	  cells	  (D)	  and	  HFA	  8-­‐10wpc	  cells	  (E).	  LC-­‐MS/MS	  is	  the	  gold	  standard	  
method	   for	   quantifying	   steroid	   production;	   however	   mass	   spectrometry	   results	   were	  

































































































Fig.	  35.	  Kisspeptin	  dose	  response	  studies.	  	  
A-­‐C.	   DHEAS	   production	   (ELISA)	   by	   H295R	   and	   HFA	   cells	   following	   kisspeptin	   treatment.	  
H295R	  cells	  (A),	  8-­‐10wpc	  HFA	  cells	  (passage	  1,	  2	  and	  3)	  (B)	  and	  15-­‐20wpc	  HFA	  (passage	  1	  
and	  2)	  cells	  (C)	  were	  incubated	  with	  kisspeptin	  1nM,	  10nM,	  100nM,	  or	  no	  treatment	  (-­‐)	  for	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and	  expressed	  as	  the	  fold	  over	  basal	  level	  (normalised	  to	  a	  value	  of	  1).	  (-­‐),	  no	  treatment;	  
(+)	  treatment	  added.	  	  
D-­‐E.	  DHEAS	  production	   (LC-­‐MS/MS)	  by	  H295R	   (D)	  and	  8-­‐10wpc	  HFA	  cells	   (passage	  1)	   (E)	  
following	   24	   hours	   100nM	   kisspeptin	   treatment.	   Data	   points	   are	   mean	   +/-­‐	   SD	   derived	  
from	   3	   independent	   experiments	   run	   in	   triplicate	   and	   expressed	   as	   the	   fold	   over	   basal	  
level	  (normalised	  to	  a	  value	  of	  1).	  *p<0.05;	  **p<0.01;	  ****p<0.0001.	  
	  
4.3.2 The	   effect	   of	   kisspeptin	   treatment	   on	   Kiss1R	   mRNA	   and	   protein	   expression	   in	  
H295R	  and	  HFA	  cells	  (passage	  1)	  
Treatment	   of	   H295R	   adrenocortical	   cells	   with	   kisspeptin	   resulted	   in	   a	   significant	   (60%)	  
decrease	   in	   Kiss1R	   mRNA	   expression	   (Fig.	   36A;	   p<0.05).	   A	   significant	   decrease	   (34%)	   in	  
Kiss1R	  mRNA	  expression	  was	  also	  observed	   in	  15-­‐20	  wpc	  HFA	  cells	   (passage	  1)	   	   (Fig.	  36C;	  
p<0.05)	   but	   not	   8-­‐10	   wpc	   HFA	   cells	   (passage	   1)	   (16%	   decrease,	   Fig.	   36B)	   in	   response	   to	  
kisspeptin	  treatment.	  Kisspeptin	  treatment	  also	  resulted	  in	  a	  significant	  decrease	  in	  Kiss1R	  
protein	   levels	   in	   H295R	   adrenocortical	   cells	   (53.5%	   decrease	   from	   baseline;	   p<0.05)	   (Fig.	  
36D).	   Kiss1R	   protein	   expression	  was	   decreased	   in	   8-­‐10	  week	   HFA	   cells	   (passage	   1)	   (8.3%	  
reduction;	   Fig.	   36E)	   and	   15-­‐20	   week	   HFA	   cells	   (passage	   1)	   (8.9%	   reduction;	   Fig.	   37F)	   in	  











Fig.	   36.	   The	   effect	   of	   kisspeptin	   on	   Kiss1R	   expression	   in	   H295R	   and	   primary	   HFA	   cells	  
(passage	  1).	  	  
A-­‐F.	   The	   effect	   of	   kisspeptin	   treatment	   on	   Kiss1R	   mRNA	   and	   protein	   expression.	  
Treatment	  with	  100nM	  kisspeptin	  for	  24	  hrs	  significantly	  reduced	  Kiss1R	  mRNA	  expression	  
in	  H295R	  cells	  (A).	  This	  was	  also	  evident	  in	  HFA	  15-­‐20wpc	  cells	  (passage	  1)	  (C)	  but	  not	  8-­‐
10wpc	  cells	  (passage	  1)	  (B).	  Data	  are	  normalized	  to	  GAPDH	  expression	  and	  presented	  as	  a	  
proportional	   increase	  or	   decrease	   from	   the	   control	   (unstimulated	   cells,	   normalized	   to	   a	  
value	  of	  100	  for	  comparison).	  Data	  points	  represent	  the	  mean	  +/-­‐	  SD	  from	  3	  independent	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showed	  a	  significant	  reduction	  in	  Kiss1R	  protein	  following	  treatment	  of	  H295R	  cells	  with	  
100nM	  kisspeptin	  for	  24	  hours	  (D)	  but	  not	  8-­‐10wpc	  HFA	  cells	  (passage	  1)	  (E)	  or	  15-­‐20wpc	  
cells	   (passage	   1)	   (F).	   Data	   points	   represent	   the	   mean	   +/-­‐	   SD	   from	   3	   independent	  
experiments	  performed	  in	  triplicate.	  β-­‐actin	  was	  used	  as	  a	  loading	  control.	  *p<0.05.	  
	  
4.3.3 The	   effect	   of	   kisspeptin	   and	   known	   adrenal	   regulators	   on	   DHEAS	   production	  
(measured	  by	  ELISA	  and	  LC-­‐MS/MS)	  in	  H295R	  and	  HFA	  cells	  (passage	  1).	  
Kisspeptin	  significantly	  increased	  DHEAS	  secretion	  from	  H295R,	  8-­‐10wpc	  and	  15-­‐20wpc	  HFA	  
cells	   3.7-­‐fold	   (p<0.05,	   Fig.	   37A),	   2.7-­‐fold	   (p<0.05;	   Fig.	   37B)	   and	   4.0-­‐fold	   (p<0.05;	   Fig	   37C)	  
compared	  to	  untreated	  cells,	  respectively.	  DHEAS	  production	  from	  8-­‐10wpc	  and	  15-­‐20wpc	  
HFA	   cells	   following	   kisspeptin	   treatment	   was	   similar	   to	   that	   produced	   by	   ACTH	   (3.5-­‐fold	  
(p<0.01)	   and	   4.1-­‐fold	   (p<0.05)	   compared	   to	   untreated	   cells,	   respectively).	   Kisspeptin	  with	  
forskolin	  increased	  DHEAS	  secretion	  8.6-­‐fold	  from	  H295R	  cells	  compared	  to	  untreated	  cells	  
(p<0.0001)	  (Fig.	  37A),	  which	  was	  2.3-­‐fold	  (p<0.01,	  Fig.	  37A)	  and	  1.4	  fold	  	  (p<0.05,	  Fig.	  37A)	  
higher	  than	  kisspeptin	  or	  forskolin	  alone,	  respectively.	  Kisspeptin	  with	  ACTH	  also	  increased	  
DHEAS	   production	   4.5-­‐fold	   (p<0.001;	   Fig.	   37B)	   and	   9.1-­‐fold	   (p<0.0001,	   Fig.	   38C)	   from	   8-­‐
10wpc	  and	  15-­‐20wpc	  HFA	  cells	  compared	  to	  untreated	  cells,	  respectively.	  This	  was	  1.7-­‐fold	  
(p<0.05;	   Fig.	   37B)	   and	   2.3-­‐fold	   (p<0.01;	   Fig.	   37C)	   higher	   than	   with	   kisspeptin	   alone	   in	   8-­‐
10wpc	  HFA	  cells	  and	  15-­‐20wpc	  HFA	  cells,	  respectively	  and	  2.2-­‐fold	  (p<0.01;	  Fig.	  37C)	  higher	  
than	   with	   ACTH	   alone	   in	   15-­‐20wpc	   HFA	   cells.	   Consistent	   with	   these	   data,	   when	   the	   cell	  
media	   was	   analysed	   by	   LC-­‐MS/MS,	   there	   was	   a	   significant	   increase	   in	   DHEAS	   following	  
kisspeptin	   treatment	   from	  H295R	   (10-­‐fold)	  and	  8-­‐10wpc	  HFA	  cells	   (>50-­‐fold)	   (Fig.	  35D,	  E).	  	  
LC-­‐MS/MS	   measurement	   of	   steroids	   also	   clearly	   demonstrates	   shunting	   of	   metabolites	  
down	   the	   androgen	   pathway,	   with	   preferential	   production	   of	   DHEAS	   compared	   to	   other	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steroids	  in	  response	  to	  stimulation	  of	  H295R	  and	  HFA	  (8-­‐10wpc)	  cells	  by	  kisspeptin	  (Fig.	  38).	  
My	   ELISA	   data	   confirm	   that	   kisspeptin	   can	   significantly	   increase	   DHEAS	   production	   from	  
H295R	   and	   8-­‐10	   /	   15-­‐20wpc	   (10-­‐22	   weeks	   gestation)	   HFA	   cells.	   The	   increase	   of	   DHEAS	  
described	  with	   the	   LC-­‐MS/MS	  assay	   is	  much	  higher	   than	  with	   the	  one	  described	  with	   the	  
immunoassay.	  The	  greater	  increase	  for	  the	  HFA	  experiment	  when	  calculated	  as	  fold	  change	  
can	   be	   ascribed	   to	   the	   baseline	   values	   being	   much	   lower.	   	   The	   values	   before	   protein	  
correction	  for	  the	  DHEAS	  concentrations	  are	  compared	  in	  Table	  6	  below.	  HFA	  medium	  must	  
contain	  significant	  amounts	  of	  steroids	  that	  are	  read	  in	  the	  ELISA	  as	  DHEAS,	  whereas	  this	  is	  
not	  the	  case	  for	  H295R	  cells.	  	  Another	  possibility	  is	  that	  DHEAS	  might	  have	  been	  desulfated	  
however	   no	   evidence	  was	   found	   for	   this	   in	   practice	   and	   pre-­‐analytical	   steps	   verified	   the	  
specificity	  of	  the	  LC-­‐MS/MS	  assay	  for	  DHEAS.	  
	  
DHEAS	   production	   (measured	   by	   ELISA)	   by	   H295R,	   8-­‐10wpc	   and	   15-­‐20wpc	   HFA	   cells	  
following	  CRH	   treatment	  was	   similar	   to	   that	   produced	  by	  ACTH	  and	   kisspeptin	   treatment	  
alone	   (4.0-­‐fold	   (p<0.01),	   4.0-­‐fold	   (p<0.001)	   and	   2.5-­‐fold	   (p<0.05)	   compared	   to	   untreated	  
cells,	  respectively)	  (Fig.	  37D-­‐F).	  Compared	  to	  kisspeptin	  and	  CRH	  alone,	  treatment	  of	  H295R	  
cells	  with	  a	  combination	  of	  kisspeptin	  and	  CRH	  resulted	   in	  a	  significant	  decrease	  (2.6-­‐fold;	  
p<0.01	  and	  2.8-­‐fold;	  p<0.01)	  in	  DHEAS	  production,	  respectively	  (Fig.	  37D).	  The	  same	  pattern	  
was	   observed	   in	   8-­‐10wpc	   HFA	   cells	   (3.1-­‐fold	   (p<0.01)	   and	   4.7-­‐fold	   (p<0.001)	   decrease	   of	  
DHEAS	  (measured	  by	  ELSIA)	  compared	  to	  kisspeptin	  and	  CRH	  treatment	  alone,	  respectively)	  
(Fig	   37E)	   and	   15-­‐20wpc	   HFA	   cells	   (3.5-­‐fold	   (p<0.001)	   and	   2.2-­‐fold	   (p<0.05)	   decrease	   of	  





Fig.	   37.	   The	   effect	   of	   kisspeptin,	   ACTH	   and	   CRH	   treatments	   on	   DHEAS	   production	  
(measured	  by	  ELISA)	  by	  H295R	  and	  primary	  HFA	  cells	  (passage	  1).	  
A-­‐C.	   DHEAS	   production	   (ELISA)	   by	   H295R	   and	   HFA	   cells	   following	   kisspeptin	   and	   CRH	  
treatments.	  H295R	  cells	  were	   incubated	   for	  24	  hours	  with	  100nM	  kisspeptin	  and	  10mM	  
forskolin	   individually	  or	   together	   (A).	  8-­‐10wpc	  HFA	  cells	   (B)	  and	  15-­‐20	  wpc	  HFA	  cells	   (C)	  
were	   incubated	   for	   24	   hours	   with	   100nM	   kisspeptin	   and	   10nM	   ACTH	   individually	   or	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CRH	  treatments.	  H295R	  cells	   (D),	  8-­‐10wpc	  HFA	  cells	   (E)	  and	  HFA	  cells	  15-­‐20wpc	  (F)	  were	  
incubated	  for	  24	  hours	  with	  100nM	  kisspeptin	  or	  10nM	  CRH	  individually	  or	  together.	  Data	  
points	  are	  mean	  +/-­‐	  SD	  from	  3	  independent	  experiments	  run	  in	  triplicate	  and	  expressed	  as	  
the	   fold	   over	   basal	   level	   (normalized	   to	   a	   value	   of	   1).	   (-­‐),	   no	   treatment;	   (+),	   treatment	  
added.	  *p<0.05;	  **p<0.01;	  ***p<0.001;	  ****p<0.0001.	  
	  
	  
Fig.	   38.	   The	   effect	   of	   kisspeptin	   on	   steroidogenesis	   (measured	   by	   LC-­‐MS/MS)	   by	  H295R	  




















































Steroid	   production	   (LC-­‐MS/MS)	   by	   H295R	   and	   8-­‐10wpc	   HFA	   cells	   following	   24	   hours	  
100nM	  kisspeptin	   treatment.	  Data	   points	   are	  mean	   +/-­‐	   SD	  derived	   from	  3	   independent	  
experiments	   run	   in	   triplicate	   (11DF,	   11-­‐deoxycortisol,	   17OHP,	   17-­‐hydroxyprogesterone,	  
A4,	   androstenedione,	   P,	   progesterone,	   E,	   oestrogen,	   DHEA,	   dehydroepiandrosterone,	   T,	  
testosterone,	  DHEAS,	  dehydroepiandrosterone	  sulphate).	  	  
	  
	  
Table	  6.	  ELISA	  vs	  LCMS/MS	  data	  
H295R	  cell	  line	  























393.16	   551.5	   392.85	   445.8	   3.7	  
	   	   	   	   	   	  
Untreated	  
(LCMS)	  









HFA	  8-­‐10	  week	  (passage	  1,2,	  and	  3)	  































255.8	   270.1	   301.2	   275.7	   2.7	  
	   	   	   	   	   	  
Untreated	  
(LCMS)	  




86.5	   552.8	   312.5	   317.2	   93.5	  
	  
4.4 Discussion:	   Functional	   studies	   of	   kisspeptin	   stimulation	   in	   in	   vitro	   models	   of	   the	  
human	  foetal	  adrenal	  	  
KISS1R	   is	   a	   G-­‐protein	   coupled	   receptor	   (GPCR).	   Kisspeptin-­‐KISS1R	   signalling	   is	   best	  
characterized	   in	   GnRH	   neurons	   and	   in	   these	   cells,	   KISS1R	   undergoes	   both	   kisspeptin-­‐
triggered	   and	   kisspeptin-­‐independent	   signalling,	   internalization	   and	   recycling	   186.	   This	  
ensures	  a	  dynamic	  population	  of	  functional	  cell-­‐surface	  receptors	  and	  tight	  regulation	  of	  the	  
biochemical	  response.	  In	  HFA	  cells,	  kisspeptin	  treatment	  resulted	  in	  a	  significant	  decrease	  in	  
Kiss1R	  mRNA	  expression	   in	  adrenocortical	   tumor	   (H295R)	  and	  second	   trimester	  HFA	  cells.	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This	  was	  paralleled	  by	  a	  significant	  decrease	  in	  Kiss1R	  protein	  levels	  in	  H295R	  cells.	  This	  data	  
is	  novel	  and	  we	  hypothesise	  that	  high	  circulating	  kisspeptin	  levels	  may	  down-­‐regulate	  Kiss1R	  
expression	   in	   the	   HFA	   to	   regulate	   signaling	   and	   therefore	   ensure	   tight	   control	   of	  
steroidogenesis	   throughout	   pregnancy.	   This	   process	   of	   desensitisation	   is	   a	   recognized	  
phenomenon	  of	  many	  other	  GPCRs	  187	  as	  well	  as	  kisspeptin	  188.	  
	  
The	   kisspeptin	   effect	   on	   DHEAS	   production	   measured	   using	   immunoassay	   in	   all	   of	   the	  
studies	  perfomed.	   In	  a	  number	  of	  experiments	   the	  cell	  media	  was	  also	  analysed	  using	  LC-­‐
MS/MS.	  Quantification	  of	  hormonal	   steroids	   and	   their	   precursors	  using	   immunoassay	   can	  
be	   problematic,	   particularly	   for	   low	   concentration	   analytes	   due	   to	   assay	   interference	   by	  
other	   endogenous	   steroids.	   Mass	   spectrometry	   offers	   improved	   specificity	   over	  
immunoassay	  and	  can	  be	  highly	  sensitive.	  Gas	  chromatography	  mass	  spectrometry	  (GC-­‐MS)	  
with	   use	   of	   stable	   isotopically	   labelled	   internal	   standards	   is	   considered	   the	   gold	   standard	  
method	   for	   serum	  steroid	  analysis	   189.	   Liquid	   chromatography-­‐tandem	  mass	   spectrometry	  
(LC-­‐MS/MS)	   compares	   well	   to	   GC-­‐MS	   in	   terms	   of	   accuracy,	   precision	   and	   sensitivity	   but	  
allows	  simplified	  sample	  preparation	  189.	  Multi-­‐targeted	  steroid	  analysis	   (steroid	  panelling)	  
is	  adaptable	  for	  use	  in	  a	  number	  of	  matrices	  including	  cell	  media.	  LC-­‐MS/MS	  analyses	  of	  my	  
in	  vitro	  experiments	  clearly	  show	  the	  preferential	  production	  of	  DHEAS	  over	  other	  steroid	  
metabolites	  in	  response	  to	  kisspeptin	  stimulation	  of	  H295R	  and	  8-­‐10wpc	  HFA	  cells.	  
	  
Kisspeptin-­‐stimulated	   production	   of	   DHEAS	   by	   primary	   HFA	   cells	   and	   H295R	   cells	   was	  
comparable	  to	  stimulation	  with	  ACTH	  or	  CRH	  alone.	  Furthermore,	  kisspeptin	  in	  combination	  
with	  ACTH	  appears	  to	  augment	  this	  effect.	  In	  contrast,	  CRH	  in	  combination	  with	  kisspeptin	  
significantly	   decreased	   DHEAS	   production	   (see	   also	   later,	   Chapter	   5.5	   Discussion:	   Clinical	  
study).	   	   The	   independent	   agonist	   effects	   of	   kisspeptin	   and	   CRH	   on	   DHEAS	   production	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compared	  to	  their	  apparent	  antagonistic	  effect	  in	  combination	  is	  an	  interesting	  observation	  
and	   warrents	   further	   study.	   The	   combination	   of	   CRH	   and	   kisspeptin	  may	   result	   receptor	  
desensitization,	  which	  represents	  an	   important	  physiological	  process	  that	  prevents	  GPCRs,	  
such	   as	   Kiss1R,	   from	   overstimulation	   due	   to	   prolonged	   agonist	   exposure	   by	   signal	  
attenuation	  or	  termination	  190,191.	  The	  classical	  model	  of	  GPCR	  desensitization	  involves	  three	  
processes:	  (1)	  receptor	  phosphorylation	  and	  subsequent	  uncoupling	  of	  the	  receptor	  from	  its	  
cognate	   G	   protein,	   (2)	   receptor	   sequestration	   (internalization)	   to	   intracellular	  
compartments,	   and	   (3)	  downregulation.	  Additional	  possible	  mechanisms	   for	   the	  observed	  
reduction	   in	   DHEAS	   production	  when	   kisspeptin	   and	   CRH	  were	   administered	   together	   to	  
H295R	   and	   HFA	   cells,	   may	   be	   found	   by	   examining	   other	   reported	   in	   vivo	   hormone	  
interactions:	  	  
1)	  Direct,	  steroid-­‐independent	  down-­‐regulation	  of	  CRH	  mRNA	  expression	  by	  ACTH	  has	  been	  
demonstrated	   in	   central	   neurons,	   in	   both	   therapeutic	   and	   physiological	   contexts	   192.	  
Modulation	  of	  CRH	  synthesis	  may	  prove	  to	  be	  one	  of	  the	  mechanisms	  by	  which	  ACTH	  exerts	  
its	  profound	  and	  diverse	  effects	  on	  CNS	  function.	  In	  vivo	  placental	  synthesis	  of	  CRH	  may	  be	  
modulated	  in	  a	  similar	  manner	  by	  kisspeptin	  or	  vice	  versa.	  	  
2)	  Luteinizing	  hormone	  (LH),	   in	  synergy	  with	  follicle	  stimulating	  hormone	  (FSH),	  stimulates	  
normal	   follicular	   growth	   and	   ovulation.	   FSH	   is	   frequently	   used	   in	   assisted	   reproductive	  
technology	   (ART),	   however	   recent	   studies	   have	   shown	   that	   maturing	   follicles	   become	  
increasingly	   sensitive	   to,	   and	   ultimately	   dependent	   on,	   the	   presence	   of	   LH	   for	   their	  
development	   70.	   The	   ovary	   comprises	   of	   two	   cellular	   components,	   which	   are	   stimulated	  
independently	   by	   LH	   and	   FSH,	   leading	   to	   the	   production	   of	   ovarian	   steroids	   193.	   Ovarian	  
steroidogenesis	   in	  the	  preovulatory	  follicle	  takes	  place	  through	  LH	  receptors	  on	  theca	  and	  
FSH	   (possibly	   plus	   LH)	   receptors	   on	   granulosa	   cells	   194.	   Maintaining	   homeostasis	   often	  
requires	  conditions	  to	  be	  limited	  to	  a	  narrow	  range.	  The	  ovary	  has	  a	  minimum	  requirement	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level	   (threshold	   requirement)	   for	   FSH	  below	  which	   follicular	   development	  does	  not	   occur	  
195.	  Furthermore,	  it	  has	  been	  shown	  that	  FSH	  threshold	  is	  not	  fixed	  for	  any	  given	  follicle,	  but	  
depends	   on	   the	   developmental	   stage	   and	   varies	   over	   time	   196.	   The	   concept	   of	   the	   LH	  
therapeutic	  window	  may	  interplay	  with	  this	  and	  is	  an	  area	  of	  on-­‐going	  studies.	  Low	  levels	  of	  
LH	   impair	   follicular	   growth	   and	   oocyte	   maturation,	   and	   hence	   androgen	   and	   oestrogen	  
synthesis.	   High	   levels	   result	   in	   follicular	   atresia	   and	   compromise	   of	   oocyte	   development,	  
and	  suppression	  of	  granulosa	  cell	  proliferation.	   	   In	  ART	  one	  protocol	   for	  a	  poor	  responder	  
utilizes	  a	  GnRH	  analogue	  at	  the	  beginning	  of	  the	  cycle,	  resulting	  in	  a	  flare	  effect	  of	  FSH	  and	  
LH	  and	  augmenting	  the	  folliculogenesis	  already	  in	  progress	  70.	  Though	  follicles	  are	  recruited	  
with	   this	   method,	   the	   excess	   of	   LH	   in	   the	   early	   part	   may	   be	   deleterious	   to	   the	   growing	  
follicle.	   The	   experiments	   conducted	   in	   this	   work	   to	   examine	   the	   effect	   of	   kisspeptin	   and	  
CRH,	   alone	   and	   in	   combination,	   on	   DHEAS	   production,	   were	   based	   on	   preliminary	   dose-­‐
response	  and	  time	  course	  studies.	  Earlier	  or	  later	  time	  points,	  or	  different	  dose	  ratios	  of	  the	  
two	   hormones	   in	   combination	   may	   have	   resulted	   in	   increased	   or	   decreased	   DHEAS	  
production	  and	  this	  would	  be	  interesting	  to	  explore	  in	  future	  work.	  
	  
Thus	   kisspeptin	   may	   work	   in	   concert	   with	   CRH	   and	   ACTH	   to	   regulate	   HFA	   function	   and	  
therefore	  the	  balance	  of	  oestrogens	  during	  pregnancy.	  The	  placenta	  is	  the	  primary	  source	  of	  
oestrogen	  and	   the	  concentration	  of	  oestrogen	   increases	  with	  progressing	  gestational	  age.	  
The	   timing	   of	   these	   interactions	   may	   be	   critical	   as	   ACTH	   levels	   remain	   fairly	   steady	  
throughout	  pregnancy	   and	   circulating	   kisspeptin	   levels	   rise	   steadily	  between	   the	   first	   and	  
third	   trimesters.	   Consequently	   as	   pregnancy	   progresses,	   kisspeptin	   may	   work	   in	   tandem	  
with	   ACTH	   to	   enhance	   DHEAS,	   the	   production	   of	   oestrogens	   and	   the	   maintenance	   of	  
pregnancy.	   In	   support	   of	   this	   hypothesis,	   low	   levels	   of	   kisspeptin,	   particularly	   in	   early	  




In	  conclusion	  these	  data	  support	  the	  hypothesis	  that	  kisspeptin-­‐Kiss1R	  signalling	  may	  be	  a	  
key	  regulator	  of	  HFA	  steroidogenesis.	  
	  
4.4.1 Limitations	  and	  future	  studies	  
Within	  the	  time-­‐scale	  and	  remit	  of	  this	  study	  I	  was	  unable	  to	  explore	  the	  functional	  role	  of	  
Kiss1R	  expression	  seen	  in	  the	  outer	  DZ/TZ	  of	  the	  HFA.	  	  Nakamura	  et	  al	  previously	  reported	  
an	   increase	   in	  aldosterone	  production	   in	  vitro	   from	  H295R	  cells	   in	  response	  to	  stimulation	  
with	   kisspeptin	   165.	   In	   vivo	   DZ	   steroidogenesis	   occurs	   only	   late	   in	   the	   3rd	   trimester	   as	  
previously	  described.	  	  This	  suggests	  kisspeptin-­‐Kiss1R	  signalling	  in	  the	  outer	  cortex	  may	  be	  
important	  for	  other	  roles,	  such	  as	  growth	  and	  differentiation,	  early	  in	  adrenal	  development.	  
This	   hypothesis	   is	   supported	  by	   the	  observation	   that	   in	   the	  postpartum	  period	   the	   foetal	  
adrenal	   undergoes	   significant	   remodelling	  with	   involution	  of	   the	   large	   FZ,	   suggesting	   that	  
placental	   factors,	  which	  are	  pregnancy	  specific,	  are	   likely	  to	  act	  to	  maintain	  foetal	  adrenal	  
growth	  and	  differentiation	  in	  utero.	  	  
	  
Proliferation	   of	   isolated	   DZ	   and	   FZ	   cells	   could	   be	   assessed	   by	   an	   MTS	   assay	   where	  
absorbance	   readings	   are	   proportional	   to	   cellular	   metabolic	   activity.	   Methods	   of	   directly	  
labelling	   DNA	   in	   proliferating	   cells	   have	   been	   extensively	   reported	   including	   BrdU	   (5’-­‐
bromo-­‐2’-­‐deoxyuridine),	   that	   is	   incorporated	   into	   the	  proliferating	  DNA	  during	   S-­‐phase	  of	  
cell	  division	  197.	  The	  limitation	  is	  that	  its	  detection	  is	  lengthy	  and	  requires	  harsh	  treatment	  of	  
tissue	   sections	   to	   give	   access	   of	   anti-­‐BrdU	   antibody	   to	   nucleosides	   in	   genomic	   DNA.	   A	  
quicker,	   simpler,	   and	   highly	   sensitive	   method	   relying	   on	   incorporation	   of	   5-­‐ethynyl-­‐2ʹ′-­‐
deoxyuridine	   (EdU)	   into	   de	   novo	   DNA	   was	   subsequently	   developed	   198.	   EdU	   is	   a	   viable	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alternative	  for	  direct	  DNA	  labelling	  of	  proliferating	  cells	  	  and	  could	  be	  used	  to	  quantify	  the	  
effect	  of	  kisspeptin	  stimulation	  on	  proliferation	  of	  HFA	  cells,	  when	  compared	  to	  untreated.	  
Cells	  could	  be	  double	  labelled	  with	  Kiss1R	  antibody	  following	  EdU	  chemistry	  to	  determine	  if	  
proliferating	  cells	  are	  those	  that	  also	  express	  Kiss1R.	  	  
	  
To	   investigate	   the	   effect	   of	   kisspeptin	   on	   differentiation,	   the	   expression	   of	   zone-­‐specific	  
markers	   could	  be	  analysed	   in	  DZ	  and	  FZ	   cells	   by	  qPCR.	  Markers	  quantified	  might	   include:	  
CYP11B2	   (DZ),	   CD56	   (DZ),	   CYP11B1	   (TZ),	   and	   SULT2A1	   (FZ)	   at	   baseline	   and	   following	  
kisspeptin	   stimulation.	   An	   increase	   in	   expression	   of	   SULT2A1,	   for	   example,	   in	   DZ	   cells	  
following	  stimulation	  would	  indicate	  differentiation	  towards	  a	  FZ	  phenotype.	  	  
All	   my	   in	   vitro	   functional	   work	   using	   primary	   HFA	   cultures	   were	   limited	   by	   the	   age	   of	  
material	  available.	  Primary	  culture	  of	  late	  trimester	  HFA	  tissue	  is	  not	  possible	  due	  to	  ethical	  
and	  legal	  restrictions.	  In	  vitro	  studies	  of	  the	  role	  of	  kisspeptin	  and	  its	  interaction	  with	  other	  
pregnancy-­‐specific	   hormones	   in	   late	   pregnancy	   are	   difficult	   to	   conduct	   due	   to	   lack	   of	  
appropriate	   cell	   models.	   Furthermore,	   in	   vitro	   studies	   using	   cell	   lines	   and	   primary	   cell	  
culture	   may	   be	   limited	   in	   extrapolation	   to	   in	   vivo.	   Studies	   involving	   animal	   models	   are	  
complex	   and	   time-­‐consuming	   and	  may	   also	   be	   limited	   in	   extrapolation	   to	   in	   vivo	   due	   to	  
species-­‐specific	  differences	  in	  adrenal	  development.	  	  
	  
The	   adrenal	   cortex	   is	   a	   very	   dynamic	   organ,	   in	   which	   steroid	   secretion	   correlate	   with	  
morphology	   and	   structure	   according	   to	   external	   stimuli	   or	   surrounding	   environmental	  
conditions.	   All	   pathways	   implicated	   in	   steroidogenesis	   and	   adrenal	   growth	   are	   closely	  
interconnected	  and	  probably	  dependent	  on	  the	  extracellular	  matrix	  and	  the	  cytoskeleton.	  It	  
has	   been	   shown	   that	   the	   cell	   environment	   is	   important	   to	   dictate	   the	   nature	   of	   steroids	  
secreted,	   and	   even	   the	   activation	   of	   transcription	   factors	   199–202.	   For	   example,	   in	   isolated	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cells	   in	   culture,	   ACTH	   inhibits	   cell	   proliferation	   to	   favor	   steroid	   secretion	   203.	   It	   is	   now	  
relatively	   accepted	   that	   ACTH	   is	   preferentially	   a	   differentiation	   factor	   controlling	   steroid	  
secretion	   rather	   than	   a	   proliferation	   factor.	   However,	   ACTH	   favours	   cell	   survival	   when	  
viability	   is	   compromised,	   a	   protective	   effect	   occurring	   only	   when	   the	   adrenal	   glands	   are	  
intact.	   ACTH	   loses	   its	   protective	   effects	   when	   the	   adrenal	   architecture	   is	   disrupted	   204.	  
Quartering	   of	   the	   glands	   enhances	   basal	   apoptosis	   and,	   interestingly,	   abolishes	   ACTH-­‐
induced	   inhibition	   of	   apoptotic	   DNA	   fragmentation,	   without	   altering	   ACTH-­‐induced	  
corticosterone	  secretion.	  These	  data	  suggest	  that	  the	  global	  organ	  architecture	  is	  required	  
for	  modulation	  of	  adrenal	  cell	  survival	  by	  ACTH	  204.	  The	  precise	  mechanisms	  of	  interactions	  
between	  the	  ECM	  and	   integrin	  receptors	  with	  the	  cytoskeleton	  and	   intracellular	  kinases	   is	  
beginning	   to	  emerge	  but	   is	   yet	   to	  be	   correlated	  with	   in	   vivo	   physiology.	   The	   results	   from	  
primary	   cell	   experiments	   detailed	   in	   my	   work	   followed	   from	   initially	   disrupting	  
adrenocortical	  structure	  and	  separating	  the	  cells	  into	  a	  monolayer.	  The	  fact	  that	  significant	  
results	  were	  obtained	  in	  a	  monolayer	  may	  suggest	  that	  the	  effects	  in	  the	  intact	  organ	  may	  
be	  even	  greater	  than	  shown	  here.	  
	  
Emerging	   innovative	   in	  vitro	   techniques	  such	  as	  organoid	  culture	  and	  engineered	  ECM	  are	  
promising	   approaches	   to	   studying	   such	   a	   small	   yet	   complex	   organ	   like	   the	   foetal	   adrenal	  
gland.	   Organoid	   culture	   has	   emerged	   in	   recent	   years	   as	   a	   valuable	   tool	   to	   study	   several	  
aspects	   of	   stem	   cell	   biology,	   tissue	   morphogenesis,	   and	   lineage	   specification	   205,206.	  
Organoids	  are	  self-­‐organizing	  three-­‐dimensional	  structures	  that	  are	  derived	  from	  stem	  cells	  
and	  exhibit	  organotypic	  anatomic	  and	  functional	  features.	  Organoids	  can	  be	  grown	   in	  vitro	  
from	   pluripotent	   stem	   cells	   (embryonic	   stem	   cells	   and	   induced	   pluripotent	   stem	   cells)	   or	  
organ-­‐specific	   stem	  cells	   206.	  Organoid	  cultures	  have	  been	  established	   for	  different	  mouse	  
and	   human	   tissues,	   and	   have	   been	   proven	   to	   be	   valuable	   models	   for	   studying	   different	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aspects	   developmental	   biology	   such	   as	   tissue	   morphogenesis,	   organogenesis,	  
differentiation,	  heterotypic	  interactions	  between	  different	  cell	  types,	  and	  the	  effects	  of	  the	  
ECM	  on	  cell	  differentiation	  and	  behavior.	  However,	  a	  current	  limitation	  of	  organoid	  cultures	  
is	   the	  organoid	  dependence	  on	   a	   suitable	   three-­‐dimensional	  matrix.	   Engineered	   synthetic	  
ECM	   has	   emerged	   as	   an	   attractive	   approach	   to	   mimic	   the	   original	   three-­‐dimensional	  
microenvironment	  of	  a	  given	  organ	  or	  tissue	  207.	  
	   	  
	  
	  191	  






















Circulating	   kisspeptin	   levels	   increase	   dramatically	   during	   pregnancy	   158	   and	   have	   an	  
important	   role	   in	   placentation	   by	   regulating	   placental	   invasion	   into	   the	  maternal	   uterine	  
wall	   118,122,130.	  Circulating	  kisspeptin	   levels	  are	  reduced	   in	  women	  with	   intrauterine	  growth	  
retardation	  and	  preeclampsia	  155,156	  and	   low	  maternal	   levels	   in	  early	  pregnancy	  have	  been	  
associated	  with	  greater	  miscarriage	  risk	  163.	  Therefore,	  kisspeptin	  may	  be	  a	  novel	  endocrine	  
marker	  of	   functional	  placental	   tissue	  and	   low	  placental	  kisspeptin	  may	  be	  associated	  with	  
serious	   obstetric	   complications.	   The	   role	   of	   kisspeptin	   in	   pregnancy	   and	   the	  mechanisms	  
underlying	   these	   associations	   are	   unclear.	   A	   prospective	   observational	   study	   of	   patients	  
with	   singleton,	   uncomplicated	   pregnancies	   was	   undertaken.	   	   The	   aim	   of	   this	   was	   to	  
ascertain	  whether	  kisspeptin-­‐Kiss1R	  signalling	  might	  be	  a	  regulator	  of	  HFA	  function	  in	  vivo.	  
5.2 Participant	  demographics,	  progress	  and	  outcomes	  
33	  pregnant	  women	  of	  mean	  age	  26.8	  ±	  6.1	  yrs	  were	  recruited.	  The	  median	  gravidity	  and	  
parity	   of	   the	   women	   were	   1	   (range	   1-­‐4)	   and	   0	   (range	   0-­‐2),	   respectively.	   The	   participant	  
demographics	  are	  detailed	   in	  Table	  7	  and	  8.	  Two	  subjects	   (21	  and	  23)	  moved	  area	  before	  
completion	   of	   the	   study	   (after	   visits	   2	   and	   3,	   respectively).	   Two	   babies	   were	   born	  
prematurely	   at	   26	   and	   33	   weeks	   gestation	   (18	   and	   30,	   respectively)	   with	   normal	   birth	  
weights	  of	  950	  and	  1340g	  (BW	  SDS	  0.84	  and	  -­‐1.95),	  respectively	  (Table	  9).	  Three	  participants	  
(6,	   9	   and	   22)	   developed	   pre-­‐eclampsia.	  Maternal	   serum	  biomarkers	   of	   placental	   function	  
were	   not	   significantly	   different	   at	   visits	   1	   and	   2	   between	   those	  women	  who	   had	   normal	  
pregnancies	   and	   those	   who	   later	   developed	   complications	   including	   PE	   (Table	   10).	  
Interestingly,	   participant	   6	   was	   noted	   to	   have	   low	   PlGF	   50.61	   pg/ml	   at	   visit	   4,	   and	  
participant	   22	   was	   noted	   to	   have	   low	   PlGF	   76.17	   pg/ml	   at	   visit	   3.	   Both	   these	   women	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developed	  PE	  in	  the	  3rd	  trimester,	  and	  their	  infants,	  born	  at	  39.3	  and	  37.1	  weeks	  gestation	  
respectively	  were	  small	  for	  gestational	  age,	  BW	  2420	  and	  1720g	  (BW	  SDS	  -­‐2.42	  and	  -­‐3.30);	  
these	  two	  infants	  were	  both	  delivered	  following	  induction	  of	   labour	  for	  pre-­‐eclampsia	  and	  
intra-­‐uterine	   growth	   retardation	   (Table	   9).	   The	   remaining	   subjects	   had	   term	   deliveries,	  
mean	  gestation	  39.96	  ±	  1.18	  (range	  37.14	  -­‐	  42.14)	  and	  BW	  SDS	  -­‐0.71	  ±	  0.87	  (-­‐3.30	  -­‐	  0.57).	  	  
	  
Table	   7.	   Details	   of	   the	   participants,	   the	   timing	   of	   the	   antenatal	   assessments	   and	  
pregnancy	  outcome	  
Characteristic	   Mean	  ± 	  SD	   Range	   N	  
Age	  (years)	   26.8	  ±	  6.1	   17.0	  -­‐	  37.0	   33	  
BMI	   25.4	  ±	  5.3	   18.8	  -­‐	  41.1	   33	  






20.35	  ±	  0.68	  
28.07	  ±	  0.75	  
34.42	  ±	  0.75	  
38.09	  ±	  0.62	  
	  
19.29	  -­‐	  22.57	  
26.29	  -­‐	  29.86	  
33.00	  -­‐	  36.14	  






Gestation	  at	  delivery	  
(weeks)	  
39.33	  ±	  2.83	  
26.86	  -­‐	  42.14	   31	  
Birth	  weight	  (grams)	   3006	  ±	  650	   950	  -­‐	  3680	   31	  
Birth	  weight	  SDS	   -­‐0.698	  ±	  0.913	   -­‐3.30	  -­‐	  0.840	   31	  
	  
N=	  total	  number	  of	  subjects	  assessed
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5.3 Foetal	  adrenal	  volume	  and	  kisspeptin	  levels	  in	  pregnancy	  
Foetal	   adrenal	   volumes	   (FAV)	   increase	   steadily	   during	   pregnancy	   (Fig.	   39A	   &	   Table	   8).	  
Median	   FAVs	   were	   0.19	   cm3	   (IQR	   0.08-­‐0.48;	   n=31),	   0.52	   cm3	   (0.26-­‐1.53;	   n=32),	   1.52	   cm3	  
(0.94-­‐2.40;	   n=28)	   and	   2.16	   cm3	   (1.17-­‐7.87;	   n=23)	   at	   antenatal	   visits	   1-­‐4,	   respectively.	   The	  
range	   of	   FAVs	   increase	   as	   gestation	   advances	   but	   there	   are	   significant	   increases	   in	   FAV	  
between	  visits	  1	  and	  2	  (p<0.01),	  visits	  1	  and	  3	  (p<0.001),	  visits	  1	  and	  4	  (p<0.001)	  and	  visits	  2	  
and	  4	  (p<0.01).	  The	  difference	  in	  FAV	  between	  sequential	  visits	  is	  consistent	  with	  an	  overall	  
increase	  during	  pregnancy.	  Between	  antenatal	  visit	  1	  and	  2	   the	  median	   increase	   in	  FAV	   is	  
0.29	  cm3	  (IQR	  0.13-­‐1.14;	  n=31),	  0.61	  cm3	  (IQR	  -­‐0.06-­‐1.59;	  n=29)	  between	  antenatal	  visits	  2	  
and	  3,	  and	  0.41	  cm3	  (IQR	  -­‐0.13-­‐2.64;	  n=21)	  between	  antenatal	  visits	  3	  and	  4.	  The	  differences	  
in	  FAV	  between	  sequential	  visits	  were	  not	  statistically	  significant	  (Fig	  40A).	  
	  
Postnatally	   rapid	   involution	   of	   the	   adrenal	   is	   seen.	   Median	   FAVs	   were	   0.105	   cm3	   (IQR	  
0.0775-­‐0.3175;	   n=8),	   0.12	   cm3	   (0.07-­‐0.14;	   n=9),	   0.04	   cm3	   (0.037-­‐0.05;	   n=14)	   at	   postnatal	  
visits	  1-­‐3,	  respectively	  (Fig.	  41).	  There	   is	  a	  significant	  decrease	  postnatally	   in	  FAV	  between	  
visits	  1	  (days	  1-­‐2	  of	  life)	  and	  visit	  3	  (6-­‐8	  weeks	  of	  life)	  (p<0.01).	  In	  keeping	  with	  previous	  US	  
studies	   of	   the	   neonatal	   adrenal	   208,	   postnatal	   involution	   of	   the	   adrenal	   was	   seen	   in	   our	  
cohort	  of	  neonates	  and	  occurred	  following	  delivery,	  suggesting	  parturition	  itself	  is	  the	  basis	  
for	   foetal	   adrenal	   involution.	   The	   adrenals	   were	   seen	   to	   decrease	   in	   ultrasonographic	  
volume	   from	   d	   1	   to	   7	   of	   life,	   however	   this	   was	   not	   significant.	   A	   significant	   decrease	   in	  
adrenal	  volume	  was	  seen	  between	  the	  first	  day	  of	   life	  and	  ~2	  months	  of	   life,	  regardless	  of	  
gestational	   ages	   and	   sex.	   Thus,	   parturition	   itself	   would	   appear	   to	   be	   the	   basis	   for	   foetal	  
adrenal	   involution,	   further	   supporting	   a	   key	   role	   for	   placental	   factors	   in	   maintaining	   the	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foetal	  adrenal	  and	  generating	  adrenal	  androgens.	   It	  has	  been	  previously	   reported	   that	  on	  
day	  4	  of	  life	  the	  adrenal	  looses	  25%	  of	  its	  mass;	  at	  1	  month	  of	  age,	  it	  has	  lost	  50%,	  and	  at	  1	  
year	  it	  has	  lost	  75%	  of	  its	  birth	  mass	  98.	  The	  present	  findings	  disagree	  with	  previous	  reports	  
that	  involution	  of	  the	  adrenal	  is	  related	  to	  gestational	  age	  rather	  than	  birth	  24.	  The	  study	  by	  
Midgley	  et	  al	  used	  urinary	  levels	  of	  3β-­‐OH-­‐5ene	  steroids	  as	  a	  measure	  of	  urinary	  foetal	  zone	  
steroids	  and	   suggested	   that	   the	   foetal	   adrenals	  maintain	  high	  androgen	   levels	   for	  3–4	  wk	  
after	  term.	  In	  this	  study,	  in	  parallel	  to	  postnatal	  US	  measurements	  of	  the	  adrenal,	  urine	  had	  
been	  collected	  from	  neonates	  and	  stored	  for	  analysis	  of	  steroid	  metabolites	  by	  LC-­‐MS/MS	  
with	  the	  aim	  of	  documenting	   functional	  change	  over	   time.	  Unfortunately	  due	  to	  time	  and	  
resource	  pressures	  on	  a	   clinical	   service	   these	   samples	   are	   yet	   to	  be	  processed	  but	  would	  
form	  part	  of	  ongoing	  collaborative	  studies.	  
	  
Median	  kisspeptin	  levels	  were	  2822	  pmol/L	  (IQR	  1913-­‐0.48;	  n=33),	  3953	  pmol/L	  (2823-­‐5615;	  
n=31),	   4545	   pmol/L	   (3182-­‐6182;	   n=30)	   and	   3711	   pmol/L	   (2546-­‐4937;	   n=26)	   at	   antenatal	  
visits	   1-­‐4,	   respectively	   (Fig.	   39B).	   There	   is	   considerable	   overlap	   of	   kisspeptin	   levels	   as	  
gestation	  advances	  but	  significant	  increases	  are	  noted	  between	  visits	  1	  and	  2	  (p<0.05),	  visits	  
1	   and	   3	   (p<0.001),	   visits	   1	   and	   4	   (p<0.001)	   and	   visits	   2	   and	   4	   (p<0.01)	   (Fig.	   39B).	   The	  
difference	  in	  kisspeptin	  levels	  between	  sequential	  visits	  was	  analysed	  and	  while	  an	  increase	  
overall	  is	  seen	  in	  kisspeptin	  levels	  from	  visit	  1-­‐3,	  there	  is	  a	  decrease	  in	  levels	  from	  visit	  3	  to	  
4.	  Between	  antenatal	   visit	   1	   and	  2	   the	  median	   increase	   in	   kisspeptin	   is	   1311	  pmol/L	   (IQR	  
285.9-­‐2389;	  n=32),	  between	  antenatal	  visits	  2	  and	  3	  the	  median	  increase	  is	  620	  pmol/L	  (IQR	  
-­‐7.1-­‐1343;	   n=24),	   between	  antenatal	   visits	   3	   and	  4	   the	  median	  decrease	   in	   kisspeptin	   is	   -­‐
1135	  pmol/L	  (IQR	  -­‐2073—578.4;	  n=26).	  Significant	  decrease	  is	  noted	  between	  the	  difference	  




Three	   participants	   (6,	   9	   and	   22)	   developed	   pre-­‐eclampsia	   in	   the	   3rd	   trimester	   of	   their	  
pregnancy.	  Median	  FAVs	  were	  0.19	  cm3	  (IQR	  0.1-­‐1.32;	  n=3),	  0.24	  cm3	  (0.21-­‐0.44;	  n=3),	  5.03	  
cm3	   (0.95-­‐9.11;	   n=3)	   and	   4.81	   cm3	   (1.67-­‐7.95;	   n=3)	   at	   antenatal	   visits	   1-­‐4,	   respectively.	  
Median	  kisspeptin	   levels	   in	   this	   small	   sub-­‐group	  were	  1624	  pmol/L	   (IQR	  1680-­‐2383;	  n=3),	  
3273	  pmol/L	  (1098-­‐3718;	  n=3),	  2993	  pmol/L	  (1397-­‐4924;	  n=3)	  and	  3427	  pmol/L	  (2883-­‐3971;	  
n=3)	  at	  antenatal	  visits	  1-­‐4,	  respectively	  (Fig.	  41A).	  Due	  to	  the	  small	  sample	  size,	  further	  sub-­‐
group	  analysis	  was	  not	  conducted.	  	  
	  
Two	  participants	  (18	  and	  30)	  delivered	  preterm	  infants.	  Only	  one	  measurement	  of	  FAV	  (0.49	  
cm3)	  and	  one	  measurement	  of	  kisspeptin	  (3437	  pmol/L)	  were	  obtained	  for	  participant	  18	  at	  
visit	   1,	   as	   she	   subsequently	   delivered	   at	   26.8	   weeks	   gestation.	   The	   FAVs	   recorded	   for	  
participant	  30	  were	  1.17	  cm3,	  0.25	  cm3	  and	  0.8	  cm3	  at	  antenatal	  visits	  1-­‐3,	  respectively.	  The	  
kisspeptin	   levels	   at	   antenatal	   visits	   1-­‐3	  were	   1793	   pmol/L,	   3952	   pmol/L	   and	   2568	   pmol/,	  
respectively.	   She	   subsequently	   delivered	   at	   33.5	   weeks	   gestation	   (fig.	   42).	   There	   was	   no	  
striking	  difference	  between	  maternal	  serum	  levels	  of	  hCG	  or	  PlGF	  in	  these	  2	  participants	  and	  








	   	  
Fig.	  39.	  Foetal	  adrenal	  gland	  volumes	  and	  kisspeptin	  levels	  at	  four	  antenatal	  visits	  
Box	   and	  whisker	  plots	   (A)	   of	   foetal	   adrenal	   gland	   volumes	   (FAV;	   cm3)	   and	   (B)	  Maternal	  
serum	  kisspeptin	   (KP)	   levels	  at	   the	  4	  antenatal	  visits	   (visit	  1,	  19-­‐20	  weeks;	  visit	  2,	  26-­‐28	  
weeks;	   visit	   3,	   34-­‐35	   weeks;	   visit	   4,	   37-­‐40	   weeks).	   Box	   and	   whisker	   plots	   of	   (C)	   the	  
difference	   in	   FAV	   (cm3)	   and	   (D)	   Maternal	   serum	   kisspeptin	   levels	   between	   sequential	  
antenatal	  visits.	  Box	  plots	  show	  the	  median,	  upper	  and	  lower	  quartiles	  and	  interquartile	  



































































































































































































Fig.	   40.	   Postnatal	   neonatal	   adrenal	   gland	   involution.	   Box	   and	  whisker	   plots	   of	   neonatal	  
adrenal	  gland	  volumes	  (FAV;	  cm3)	  at	  3	  postnatal	  visits	  (visit	  1,	  day	  1	  of	  life;	  visit	  2	  day	  5-­‐7	  
of	  life;	  visit	  3	  6-­‐8	  weeks	  of	  life).	  Box	  plots	  show	  the	  median,	  upper	  and	  lower	  quartiles	  and	  































































































































































































































































































































































































































































































































































































































































































































































































































































5.4 Relationship	   between	   foetal	   adrenal	   volume	   and	   plasma	   kisspeptin	   in	   singleton	  
pregnancies	  	  
To	  corroborate	  the	  in	  vitro	  data,	  I	  assessed	  the	  association	  of	  the	  maternal	  kisspeptin	  levels	  
with	  the	  subsequent	  FAV	  increment	  at	  the	  four	  different	  time	  points.	  The	  statistical	  analysis	  
was	   performed	   by	   Dr	   Sumana	   Chatterjee	   (Fellow	   in	   Paediatric	   Endocrinology).	   The	  mean	  
increase	  in	  FAV	  between	  antenatal	  visits	  1	  and	  2	  correlated	  with	  the	  kisspeptin	  level	  at	  visit	  
1	   (r	   =	   0.41,	  P	   =	   0.026)	   (Fig.	   43)	   suggesting	   that	   the	   kisspeptin	   levels	   between	   19	   and	   20	  
weeks’	   gestation	   (17	   to	   18	   wpc)	  may	   influence	   FAV	   increase	   between	   19	   and	   28	   weeks’	  
gestation	  (17	  to	  26	  wpc).	  	  
	  
There	  was	  no	  significant	  difference	   in	   the	  mean	   rise	  of	  FAV	  between	   the	   first	  and	  second	  
antenatal	   visits	   in	   male	   0.83	   ±	   0.94	   (n	   =	   18)	   and	   female	   1.28	   ±	   1.38	   (n	   =	   12)	   infants,	  
respectively	  (P	  =	  0.30;	  95%	  CI,	  −0.42	  to	  1.31).	  There	  was	  no	  significant	  correlation	  between	  
FAV	   and	   estimated	   foetal	   weight	   (efw)	   between	   the	   first	   and	   second	   antenatal	   visits	   (r	  
−0.166;	  P	  =	  0.36).	  Therefore,	   the	  significant	  correlations	  between	  maternal	  kisspeptin	  and	  
FAV	  were	  independent	  of	  foetal	  sex	  and	  efw,	  suggesting	  that	  kisspeptin	  may	  be	  important	  
for	  FA	  development	  in	  mid-­‐pregnancy.	  	  
	  
There	   was	   no	   significant	   correlation	   between	   the	   maternal	   kisspeptin	   levels	   and	   the	  
subsequent	   FAV	   increment	   at	   the	   other	   antenatal	   time	   points.	   There	   was	   no	   significant	  
correlation	   between	   maternal	   hCG	   or	   PlGF	   at	   visits	   1	   or	   2	   and	   the	   subsequent	   FAV	  




at	   the	  4	  time	  points	  examined,	  although	  a	  complete	  data-­‐set	   for	  each	  participant	  was	  not	  
always	  available,	  limiting	  the	  analysis.	  
	  
Fig.	   43.	   Foetal	   adrenal	   gland	   volumes	   and	   kisspeptin	   levels	   at	   the	   1st	   and	   2nd	   antenatal	  
visits.	  
Scatter	  Plots	  showing	  (A)	  the	  correlation	  between	  the	  kisspeptin	  	  (KP)	  level	  at	  the	  1st	  visit	  
and	  the	  increase	  in	  FAV	  between	  the	  1st	  and	  2nd	  antenatal	  visits.	  r,	  pearson	  coefficient.	  
	  
5.5 Discussion:	  Clinical	  study	  
3-­‐D	  ultrasonography	  (3DUS)	  is	  an	  established	  and	  accurate	  method	  of	  assessing	  foetal	  organ	  
volumes.	   More	   recently	   it	   has	   been	   reported	   as	   a	   reliable	   technique	   to	   measure	   HFA	  
volume,	  with	  good	   intra-­‐	  and	   inter-­‐observer	  repeatability	  178,209.	  A	  previous	  cross-­‐sectional	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gestational	  age	  (GA)	  	  210.	   Interestingly,	  my	  data	  suggest	  that	  FAV	  was	  independent	  of	  both	  
GA	  and	  efw.	  This	  discrepancy	  may	  be	  explained	  by	  the	  fact	  that	  the	  data	  was	   longitudinal	  
and	  is	  therefore	  more	  likely	  to	  show	  true	  correlations.	  Chang	  et	  al	  observed	  larger	  FAVs	  than	  
those	  obtained	  in	  the	  current	  study	  210	  and	  two	  other	  groups	  report	  slightly	   lower	  FAVs	  at	  
comparable	  GAs	  178,209.	  These	  differences	  may	  be	  attributed	  to	  different	  methodologies	  and	  
inclusion	  criteria	  employed.	  Additionally,	  all	  three	  studies	  report	  cross	  sectional	  rather	  than	  
longitudinal	  data.	  Importantly,	  the	  FAV	  measurements	  in	  the	  current	  study	  are	  in	  agreement	  
with	  data	  obtained	  from	  a	  detailed	  postmortem	  study	  211.	  	  
	  
Circulating	  kisspeptin	  concentrations	   increase	  dramatically	  during	  pregnancy	  and	   its	   levels	  
reflect	  the	  amount	  of	  viable	  placental	  tissue	  158.	  Consequently	  a	  decline	  in	  the	  levels	  may	  be	  
associated	  with	  increased	  miscarriage	  and	  preeclampsia	  160,163.	  This	  was	  also	  demonstrated	  
in	  twin	  pregnacies	  where	  the	  death	  of	  one	  twin	  was	  associated	  with	  lower	  kisspeptin	  levels	  
163.	  Serial	  measurements	  of	  plasma	  kisspeptin	  in	  pregnant	  women	  have	  not	  previously	  been	  
undertaken	   but	   cross-­‐sectional	   data	   suggest	   that	   the	   levels	   increase	   as	   pregnancy	  
progresses	   158.	   I	   found	   a	   significant	   increase	   in	   circulating	   kisspeptin	   in	   pregnant	   females	  
between	  20	  and	  28	  weeks	  gestation	  which	  correlates	  with	  the	  second	  trimster	  rise	  in	  FAV.	  
This	  increase	  in	  FAV	  is	  independent	  of	  sex	  and	  efw.	  It	  also	  coincides	  with	  the	   in	  vitro	  data,	  
which	   shows	   a	   significant	   increase	   in	  Kiss1R	  mRNA	  expression	   in	   second	   trimester	   (13-­‐22	  
weeks)	   HFA	   cells,	   and	   DHEAS	   production	   from	  mid-­‐trimester	   (10-­‐22	   gestation)	   HFA	   cells	  
following	  kisspeptin	  treatment.	  	  
	  
Abnormal	  activation	  of	  the	  foetal	  HPA	  axis	  and	  enlargement	  of	  the	  FAV	  has	  been	  associated	  
with	  impending	  preterm	  birth	  178,212.	  The	  onset	  of	  parturition	  is	   likely	  to	  involve	  a	  complex	  
interplay	   between	   placental	   hormones.	   Intriguingly,	   my	   clincial	   study	   of	   serial	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measurements	  of	  kisspeptin	  levels	  revealed	  a	  general	  slight	  decline	  late	  in	  the	  3rd	  trimester	  
between	   ~34	   weeks	   and	   38-­‐40	   weeks	   gestation,	   prior	   to	   parturition.	   This	   has	   not	   been	  
previously	   reported	   and	  may	   concord	  with	  my	   in	   vitro	   data	  which	   showed	   that	   CRH	   and	  
kisspeptin	   together	   decrease	   DHEAS	   production.	   The	   relative	   concentrations	   of	   both	  
placental	  hormones	  may	  be	  extremely	  critical	  to	  the	  timing	  of	  parturition.	  Kisspeptin	  falling	  
towards	  the	  end	  of	  pregnancy	  and	  CRH	  rising	  from	  35	  weeks	  could	  be	  postulated	  to	  result	  in	  
a	  sharp	  rise	  in	  DHEAS	  production	  and	  hence	  oestrogen.	  The	  surge	  in	  oestrogen	  converts	  the	  
in	   utero	   environemnt	   to	   a	   contractile	   state,	   preparing	   for	   expulsion	   of	   the	   foetus.	   CRH	   is	  
proposed	  to	  play	  critical	  roles	  in	  foetal	  maturation	  and	  the	  onset	  of	  parturition	  as	  the	  levels	  
of	  CRH	  increase	  as	  pregnancy	  progresses	  and	  peak	  from	  35	  weeks	  gestation	  corresponding	  
with	  a	  fall	  in	  the	  level	  of	  cortisol	  binding	  protein	  105.	  It	  is	  possible	  that	  kisspeptin	  modulates	  
the	  effects	  of	  CRH	  in	  mid	  gestation	  however,	  its	  role	  in	  late	  pregnancy	  when	  change	  in	  CRH	  
levels	  is	  critical,	  warrants	  further	  investigation.	  
	  
5.5.1 Limitations	  and	  future	  studies	  
This	   study	   was	   designed	   to	   capture	   two	   cohorts	   of	   women	   (uncomplicated	   normal	  
pregnancy	  vs	  pregnancy	  later	  complicated	  by	  pre-­‐eclampsia)	  that	  would	  be	  serially	  followed	  
up	  from	  ~20	  weeks	  gestation.	  As	  had	  been	  intended	  in	  the	  original	  study	  design,	  this	  work	  
would	  be	  usefully	  extended	  by	  the	   inclusion	  of	  patients	  with	  pre-­‐eclampsia.	  Unfortunately	  
during	  the	  time	  scale	  of	  this	  project	  which	  included	  an	  extension	  to	  the	  recruitment	  period,	  
the	   projected	   numbers	   of	   participants	   who	   developed	   PE	   did	   not	   maerialise.	   This	   may	  
reflect	  a	  lower	  prevalence	  of	  PE	  (1.3%)	  in	  the	  local	  population	  compared	  to	  a	  few	  years	  ago	  
with	   the	   initial	   screening	   pilot	   study	   was	   undertaken.	   It	   may	   also	   be	   the	   case	   that	   the	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screening	   method	   utilised	   (uterine	   artery	   Doppler	   measurements	   at	   12	   weeks)	   is	   not	   as	  
sensitive	  or	  specific	  as	  the	  pilot	  data	  had	  indicated.	  	  
	  
A	  very	  small	  number	  of	  participants	  developed	  PE	  or	  delivered	  spontaneously	  preterm.	  Due	  
to	  the	  small	  sample	  size	  it	  was	  not	  possible	  to	  conduct	  meaningful	  subgroup	  analysis.	  Larger	  
scale	   clinical	   studies	   would	   be	   needed	   in	   order	   to	   ascertain	   outcomes	   of	   pregnancies	  
associated	  with	   abnormal	   kisspeptin-­‐Kiss1R	   signalling.	   Limitations	   to	  measuring	   kisspeptin	  
currently,	   utilising	   the	  method	   described	   in	   this	   study	   (mainly	   processing	   complexity	   and	  
expense	  of	  the	  test)	  does	  have	  implications	  however	  for	  its	  use	  in	  larger	  clinical	  trials.	  
	  
Further	   extensions	   to	   this	   clinical	   study	   would	   include	   simultneous	   measurements	   of	  
maternal	   oestrogens	   in	   blood	   or	   urine	   (specifically	   oestriol	   as	   a	  marker	   of	   foetal	   adrenal	  
steroidogenesis);	  ideally	  these	  should	  be	  measured	  in	  a	  normal	  cohort	  of	  pregnant	  women	  
and	  a	  cohort	  with	  placental	  dysfunction	  (and	  hence	  presumed	  lower	  levels	  of	  kisspeptin)	  as	  
this	  would	  be	  highly	  informative.	  Plasma	  concentrations	  of	  oestrone,	  oestradiol,	  and	  oestriol	  
increase	  as	  human	  pregnancy	  progresses,	  with	  daily	  excretion	  rates	  at	  term	  approximating	  
2,	   1,	   and	   40	   mg,	   respectively	   213,214.	   The	   assessment	   of	   foetoplacental	   function	   by	  
measurement	  of	  maternal	  oestrogens	  has	  been	  used	  previously	   215.	   Low	  serum	  oestradiol	  
concentrations	  during	  the	  first	  trimester	  increase	  risk	  of	  spontaneous	  miscarriage	  216and	  low	  
levels	   in	   the	  third	  trimester	  are	  associated	  with	  poor	  obstetric	  outcome	  217.	  The	  causes	  of	  
low	   oestrogen	   excretion	   may	   be	   due	   to	   failure	   of	   foetal	   steroidogenesis	   or	   in	   placental	  
dysfunction,	   or	   both,	   however	   it	   has	   previously	   been	   demonstrated	   that	   abnormal	   foetal	  
steroidogenesis	   rather	   than	   reduced	  placental	  metabolistm	   is	   the	  most	   common	  cause	  of	  
low	   oestrogen	   excretion	   of	   unknown	   aetiology	   218.	   Taken	   together,	   these	   observations	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suggest	   that	   oestrogen	   plays	   a	   critically	   important	   role	   in	   the	   maintenance	   of	   human	  
pregnancy.	  	  
	  
Progesterone	  and	  oestrogens	  are	  antagonistic	   in	   the	  parturition	  process	   219.	   Progesterone	  
promotes	   uterine	   quiescence	   by	   producing	   uterine	   relaxation,	   stabilizing	   lysosomal	  
membranes	  and	   inhibiting	  prostaglandin	  synthesis	  and	  release	  220.	  By	  contrast,	  oestrogens	  
destabilize	   lysosomal	   membranes,	   ripen	   the	   cervix,	   and	   increase	   the	   sensitivity	   of	   the	  
myometrium	  to	  oxytocin	  by	  augmenting	  prostaglandin	  biosynthesis.	   Interestingly,	   it	  would	  
appear	  that	  in	  human	  pregnancy,	  oestrogen	  is	  produced	  in	  considerable	  excess,	  suggesting	  
interplay	   between	   factors	   to	   maintain	   balance	   between	   drivers	   that	   cause	   uterine	  
quiescence	  and	  those	  that	  produce	  contractility	  and	  uterine	  emptying.	  
	  
If	   time,	   resources	   and	   cost	   permitted,	   ideally	   this	   study	   would	   have	   incorporated	   serial	  
masurement	  of	  other	  maternal	  hormones,	  such	  as	  CRH	  and	  ACTH,	  as	  well	  as	  progesterone.	  
Serum	  had	  been	   taken	  and	  saved	  with	   this	   intention	  as	   these	  data	  would	  provide	  a	  great	  
deal	   of	   information	   on	   the	   interplay	   in	   vivo	   between	   factors	   regulating	   foetal	   adrenal	  
development	  and	  the	  role	  these	  may	  play	  in	  the	  onset	  of	  parturition.	  
	  	  
The	  aim	  of	   this	  work	  overall	  was	   to	   improve	  understanding	  about	  normal	  human	  adrenal	  
development.	  	  
	  
It	   is	   hoped	   that	   this	   project	   will	   inform	   future	   studies	   into	   abnormalities	   of	   adrenal	  
development	  and	  function.	  Furthermore,	  postnatal	  remodeling	  of	  the	  neonatal	  adrenal	  and	  
how	  this	  impacts	  on	  adaptation	  to	  life	  ex-­‐utero	  is	  incompletely	  understood.	  In	  our	  cohort	  of	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infants,	  serial	  US	  measurements	  of	  the	  adrenal	  were	  carried	  out	  to	  document	  this	  process.	  A	  
significant	  decrease	  in	  adrenal	  volume	  was	  seen	  between	  the	  first	  day	  and	  the	  6-­‐8th	  week	  of	  
life.	  In	  parallel,	  urine	  had	  been	  stored	  for	  analysis	  of	  steroid	  metabolites	  by	  LC-­‐MS/MS	  with	  
the	  aim	  of	  documenting	  functional	  change	  over	  time.	  As	  previously	  stated,	  due	  to	  time	  and	  
resource	   pressures	   on	   a	   clinical	   service	   these	   samples	   would	   be	   processed	   as	   part	   of	  
ongoing	  collaborative	  studies.	  Involution	  of	  the	  adrenal	  would	  therefore	  be	  documented	  in	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6.1 Kisspeptin	  in	  pregnancy	  
Proteolytic	   processing	   of	   the	   full-­‐length	   145	   amino	   acid	   KP	   protein	   results	   in	   shorter	  
fragments	  of	  the	  molecule	  with	  54	  (KP-­‐54),	  14	  (KP14),	  13	  (KP-­‐13)	  or	  10	  (KP-­‐10)	  amino	  acids.	  
Bilban	   et	   al	   showed	   that	   first	   trimester	   placenta	   conditioned	   medium	   contained	   KP-­‐10,	  
13,14	  as	  well	  as	  KP-­‐54	  130.	  The	  common	  feature	  of	  all	  kisspeptins	  is	  a	  carboxyl	  (C)-­‐terminus	  
region,	  which	   is	  a	  ten-­‐residue	  peptide	  (KP-­‐10)	  necessary	  for	  receptor	  activation.	  KP-­‐10	  has	  
the	   highest	   potency	   to	   bind	   KISS1R	   and	   to	   trigger	   downstream	   signalling	   pathway	   and	   in	  
trophoblasts	   of	   early	   placenta,	   it	   was	   shown	   that	   only	   KP-­‐10	   was	   able	   to	   increase	  
intracellular	  Ca2+130.	  To	  date	  almost	  all	  the	  data	  on	  potential	  action	  of	  kisspeptins	  over	  vital	  
parameters	  of	  adrenocortical	  cells,	  and	  others	  such	  as	  cancer	  cells,	  has	  been	  derived	  from	  
the	  experiments	  in	  which	  synthetic	  KP-­‐10	  has	  been	  used.	  In	  pregnancy,	  it	  is	  serum	  levels	  of	  
placental-­‐derived	  kisspeptin-­‐54	  that	  have	  been	  measured	  in	  studies	  with	  reported	  rises	  up	  
to	   10,000-­‐fold	   above	   nonpregnant	   levels	   by	   the	   third	   trimester	   158.	   To	   have	   a	   better	  
understanding	  of	  functional	  activity	  of	  the	  native	  molecule,	  it	  is	  important	  to	  know	  how	  the	  
activity	  of	  cells	  is	  affected	  by	  the	  kisspeptins	  released	  from	  its	  physiological	  sources	  such	  as	  
placenta.	   Rasoulzadeh	   et	   al	   analysed	   the	   potential	   effects	   of	   placental	   kisspeptins	   and	  
synthetic	   KP-­‐10	   on	   proliferation,	   adhesion,	   invasion,	   migration,	   and	   pro-­‐inflammatory	  
cytokine	   production	   in	   breast	   cancer	   cells	   221.	   Their	   observations	   suggest	   that	   placental	  
kisspeptins	  differentially	  modulate	  vital	  parameters	  of	  breast	  cancer	  cells,	  possibly	  through	  
modulation	  of	  pro-­‐inflammatory	  cytokine	  production.	  Placental	  kispeptins	  were	  reported	  to	  
markedly	  reduce	  proliferation	  of	  breast	  cancer	  cells	  in	  a	  dose-­‐	  and	  time-­‐dependent	  manner	  
221.	   This	   observation	   may	   be	   due	   to	   cumulative	   effects	   of	   different	   placental	   kisspeptin	  
fragments	  working	   in	   concert.	   Indeed,	  activity	  of	   the	  proteins	   is	  extensively	   influenced	  by	  
their	  structure	  and	  it	  is	  highly	  probable	  that	  placental	  kisspeptins	  with	  native	  conformation	  
are	  more	   stable	   compared	   to	   synthetic	   polypeptides.	   In	   support	   of	   this	   hypothesis,	   their	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results	  showed	  that	  placental	  kisspeptins	  have	  higher	  potency	  to	  block	  cell	  proliferation	  and	  
retained	   its	   activity	   until	   72	   hours,	   when	   no	   anti-­‐proliferative	   activity	   for	   KP-­‐10	   was	  
observed	  221.	  Future	  extensions	  of	  my	   in	  vitro	  work	  therefore	  would	  ideally	  include	  culture	  
of	   1st,	   2nd	   and	   3rd	   trimester	   placental	   villous	   tissue	   explants.	   Culture	   supernantants	   could	  
then	  be	  collected	  and	  examined	  for	  the	  content	  of	  kisspeptins	  released	  from	  explants	  and	  
then	  utilized	  in	  experiments	  with	  adrenocortical	  cells.	  
6.2 The	  putative	  role	  of	  placental	  kisspeptin	  in	  foetal	  adrenal	  steroidogenesis	  	  
The	  mechanisms	   that	   regulate	  DHEAS	  production	   by	   the	   foetal	   adrenals	   are	   incompletely	  
understood.	   CRH	   has	   been	   shown	   to	   be	   as	   effective	   as	   ACTH	   at	   stimulating	   DHEAS	  
production,	   in	   HFA	   cells	   however,	   it	   has	   been	   shown	   to	   be	   less	   potent	   than	   ACTH	   at	  
stimulating	  cortisol	  production,	  indicating	  that	  its	  actions	  are	  preferentially	  directed	  toward	  
increasing	  DHEAS	  synthesis	  110.	  My	  data	   indicates	  that	  Kisspeptin-­‐stimulated	  production	  of	  
DHEAS	  by	  primary	  HFA	  cells	  and	  H295R	  cells	  was	  comparable	  to	  stimulation	  with	  ACTH	  or	  
CRH	   alone.	   This	   may	   be	   due	   to	   the	   heterogeneity	   of	   the	   SF1-­‐positive	   cells	   and	   further	  
experiments	  might	  examine	  SF1	  RNA	  and	  protein	  levels,	  Kiss1R	  RNA	  and	  protein	  levels,	  and	  
DHEAS	   production	   of	   cells	   treated	   with	   kisspeptin	   vs.	   ACTH/CRH.	  Measurement	   of	   other	  
steroids	  including	  cortisol	  and	  aldosterone	  would	  also	  be	  useful	  to	  ascertain	  whether	  there	  
is	  preferential	  output	  of	  androgens	  with	  kisspeptin,	  and	  if	  so	  if	  this	  is	  due	  to	  changes	  in	  the	  
regulation	  of	  steroidogenic	  enzymes.	  Kisspeptin	  may	  stimulate	  DHEAS	  more	  specifically	  than	  
ACTH	  or	  CRH,	   for	  example,	  by	   increasing	  abundance	  of	  cytochrome	  P450	  cholesterol	  side-­‐
chain	   cleavage	   and	   17alpha-­‐hydroxylase/17,20	   lyase	   but	   not	   3beta-­‐hydroxysteroid	  
dehydrogenase	   in	  adrenal	   cells.	  Alternatively	   it	  may	  alter	   cell	  number,	   indicating	   that	   it	   is	  
mitogenic	   for	   foetal	   adrenal	   cortical	   cells.	   These	   unanswered	   questions	   would	   form	   the	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basis	  of	  future	  work.	  
6.3 The	  putative	  role	  of	  placental	  kisspeptin	  in	  foetal	  adrenal	  growth	  	  
Kisspeptins	  appear	   to	  be	   regulators	  of	   invasion	  both	   in	  pathological	   conditions	   (tumours),	  
and	   in	   physiological	   situations	   including	   trophoblast	   invasion	   in	   pregnancy.	   The	   rapid	  
development	  of	  the	  foetal	  adrenal	  could	  be	  viewed	  as	  akin	  to	  the	  rapid	  growth	  of	  tumours	  
although	  this	  organ	   is	  non-­‐invasive.	  As	  such	  clear	   regulatory	  mechanisms	   for	  growth	  must	  
exist.	   The	   mechanisms	   by	   which	   kisspeptin	   may	   regulate	   adrenal	   growth	   have	   not	   been	  
studied	  to	  date	  but	  are	  likely	  to	  involve	  processes	  that	  are	  emerging	  in	  other	  tissues,	  such	  as	  
in	   tumour	   biology.	   For	   example,	   kisspeptin	   has	   been	   shown	   to	   inhibit	   matrix	  
metalloproteinase	   (MMP)	   expression	   and	   activity	   in	   vitro	   222,	   and	   MMPs	   are	   critically	  
involved	   in	   events	   taking	   place	   at	   the	   cell–extracellular	   membrane	   interface	   such	   as	   cell	  
division,	  migration	  and	  morphogenesis	  and	  ultimately	  regulate	  cell	  behavior	  223.	  	  
	  
Apoptosis	   appears	   to	   occur	   in	   the	   developing	  HFA	   cortex	   20.	   There	   is	   evidence	   of	   cellular	  
apoptosis,	  determined	  by	  morphological	  criteria,	  in	  the	  HFA	  primarily	  in	  the	  central	  portions	  
of	  the	  FZ	  23	  and	  studies	  have	  shown	  detection	  of	  apoptotic	  cells	  by	   in	  situ	  analysis	  of	  DNA	  
fragmentation	  and	  found	  that	  the	  labeling	  index	  of	  apoptotic	  nuclei	  is	  greater	  in	  the	  central	  
areas	   of	   the	   FZ	   than	   in	   the	   DZ	   19.	   Kisspeptin	  was	   originally	   discovered	   from	   a	  metastasis	  
tumour	  suppressor	  gene,	  KISS1	  117	  and	  it	  has	  been	  suggested	  that	  kisspeptin	  may	  suppress	  
metastasis	  by	   induction	  of	  apoptosis	   in	  cells,	   since	  metastatic	  spread	   is	  dependent	  on	  cell	  
growth	  224.	  However	  reports	   in	  the	   literature	  have	  been	  conflicting.	  Culturing	  recombinant	  
Chinese	  hamster	  ovary	  cells	  with	  KP-­‐10	  was	  shown	  to	  have	  a	  strong	  anti-­‐proliferative	  effect,	  
while	  no	  evidence	  of	  apoptosis	  was	  detected	  119.	  By	  contrast,	  in	  a	  more	  recent	  study	  using	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human	  mammary	  carcinoma	  cells,	   stimulation	  of	  KISS1R	  by	  KP-­‐10	  caused	  up-­‐regulation	  of	  
several	  genes	  involved	  in	  cell	  cycle	  progression	  (including	  cyclin	  dependent	  kinase	  inhibitor	  
1A	   (CDKN1A),	   Growth	   Arrest	   and	   DNA	   damage-­‐inducible	   45	   (GADD45A,	   GADD45B),	   and	  
Hypoxia-­‐inducible	   factor-­‐1α-­‐responsive	   DNA-­‐damage-­‐inducible	   transcript	   4	   (HIF1A-­‐
responsive	  DDIT4)),	  cell	  cycle	  arrest	  and	  apoptosis	  125.	   Interestingly	  a	  study	  by	  Ziegler	  et	  al	  
225showed	  a	  connection	  between	  the	  antiproliferative	  effect	  of	  kisspeptin	  and	  the	  nature	  of	  
KISS1R	   expression,	   with	   evidence	   for	   KISS1R	   mediated	   cellular	   mechanisms	   involved	   in	  
proliferation	  only	  detectable	  in	  cells	  with	  up-­‐regulated	  receptor	  expression.	  My	  results	  show	  
decreased	   expression	   of	   Kiss1R	   at	   mRNA	   and	   protein	   level	   at	   supraphysiological	  
concentrations	   of	   kisspeptin.	   In	   vivo	   the	   dramatic	   fold-­‐change	   in	   kisspeptin	   concentration	  
through	   gestation	  may	   result	   in	   changes	   in	   Kiss1R	   expression	   in	   foetal	   adrenal	   cells	   in	   a	  
spatio-­‐temporal	  manner,	  hence	  effecting	  a	  change	  in	  the	  postulated	  effects	  of	  kisspeptin	  on	  
cells.	   Further	   experiments	   in	   the	   H295R	   cell	   line	   and	   HFA	   cells	   would	   seek	   to	   examine	  
whether	  kisspeptin	  has	  a	  proliferative	  or	  anti-­‐proliferative	  effect	  these	  cells	  expressing	  Kis1R	  
endogenously.	  	  
	  
The	  rapid	  HFA	  growth	  is	  almost	  entirely	  due	  to	  enlargement	  of	  the	  FZ,	  and	  in	  contrast	  to	  the	  
DZ,	  mitotic	  figures	  in	  the	  FZ	  are	  scant.	  Collectively,	  the	  FZ	  appears	  to	  grow	  by	  hypertrophy	  
under	   limited	  cell	  proliferation	   20.	   In	   the	   foetal	   rhesus	  monkey,	   it	  has	  been	  demonstrated	  
that	  growth	  of	  the	  FZ	  occurs	  primarily	  by	  hypertrophy,	  in	  response	  to	  increased	  endogenous	  
ACTH	   secretion	  provoked	  by	  metyrapone	   treatment	   226.	   It	   is	   unknown	  whether	   kisspeptin	  
treatment	  of	  FZ	  cells	  would	  also	  result	  in	  hypertrophy.	  
	  
Additionally,	  the	  HFA	  is	  one	  of	  the	  most	  highly	  vascularized	  organs	  in	  the	  human	  foetus	  20.	  
The	  development	  of	  an	  extensive	  vasculature	  in	  this	  organ	  is	  essential	  for	  organ	  growth	  and	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delivery	   of	   tropic	   agents	   and	   steroid	   hormone	   precursors	   to	   the	   gland	   and	   secretion	   of	  
hormone	  products	  into	  the	  peripheral	  circulation.	  Angiogenesis,	  the	  formation	  of	  new	  blood	  
vessels	  from	  pre-­‐existing	  vascular	  beds,	  is	  considered	  an	  integral	  process	  for	  organ	  growth.	  
Because	  the	  HFA	  undergoes	  a	  phase	  of	  rapid	  growth	  in	  midgestation,	  angiogenesis	  likely	  is	  
essential	   for	   the	   rapid	   growth	   of	   the	   HFA.	   Angiogenesis	   is	   a	   common	   feature	   of	   both	  
implantation	  and	  cancer	  spread	   227	  and	   is	  of	  vital	   importance	   in	  establishing	   the	  placenta.	  
Kisspeptin	  and	  KISS1R	  expression	  have	  been	  reported	  in	  human	  aorta,	  coronary	  artery	  and	  
umbilical	   vein	  and	  kisspeptin	  acts	  as	  a	   vasoconstrictor	   (a	   crucial	  phase	   in	  angiogenesis)	   in	  
isolated	   coronary	   arteries	   129,	   suggesting	   a	   role	   in	   the	   vascular	   system.	   A	   potential	  
angiostatic	   effect	   of	   kisspeptin	   may	   also	   explain,	   at	   least	   in	   part,	   the	   anti-­‐metastatic	  
potential	   of	   this	   peptide	   given	   that	   angiogenesis	   is	   intimately	   involved	   in	   this	   process.	  
Detailed	   in	   vitro	   and	   in	   vivo	   studies	   to	   investigate	   the	  potential	   angiostatic	   effects	   and	   to	  
determine	  the	  molecular	  mechanisms	  underpinning	  such	  effects	  of	  kisspeptin	  are	  required.	  	  
6.4 New	  frontiers	  and	  challenges	  	  
Advances	   in	   foetal	   imaging,	   genomics,	   transcriptomics,	   proteomics,	   metabolomics,	   and	  
minimally	   invasive	   techniques,	   as	   well	   as	   a	   better	   understanding	   of	   the	   intra-­‐uterine	  
endocrine	  milieu	  and	  natural	  history	  of	  many	  diseases	  have	  revolutionized	  the	  management	  
of	   maternal,	   foetal	   and	   neonatal	   conditions	   in	   the	   last	   decade.	   The	   potential	   role	   of	  
kisspeptin	  in	  the	  promotion	  of	  growth	  and	  functional	  development	  of	  the	  foetal	  adrenal	   is	  
an	   area	   for	  much	   future	   research.	   Furthermore,	   the	   roles	   this	   unique	   organ	   plays	   during	  




The	  future	  translational	  aspects	  of	  this	  work	  with	  respect	  to	  the	  potential	  role	  of	  the	  foetal	  
adrenal	  in	  the	  maintenance	  of	  a	  pregnancy,	  are	  also	  important.	  The	  mechanisms	  and	  foeto-­‐
placental	   interactions	   that	   enable	  maintenance	  of	   pregnancy	   and	   survival	   to	   term	   remain	  
unclear,	   as	   reflected	   by	   rising	   rates	   of	   spontaneous	   preterm	  birth	   over	   the	   past	   20	   years	  
(Office	   of	   National	   Statistics	   (released	   October	   2011)	   http://www.ons.gov.uk).	   In	   2009	   in	  
England	  and	  Wales	  ~8%	  of	  babies	  (1	  in	  13)	  were	  born	  prematurely.	  	  
	  
The	   integration	   of	   various	   technologies	   combined	   with	   computational	   and	   mathematical	  
models	   could	   be	   used	   to	   identify	   new	   therapeutic	   agents,	   drug	   targets,	   and	   novel	  
biomarkers	   for	   at	   risk-­‐pregnancies,	   as	   demonstrated	   for	   other	   paradigms	   228–230.	  
Computational	  models	  integrate	  quantitative	  data	  from	  complex	  systems	  and	  could	  be	  used	  
as	   platforms	   to	   investigate	   the	   dynamic	   biochemical	   properties	   of	   cells.	   Studying	   the	  
dynamics	  of	  the	  activity	  of	  a	  pathway	  may	  provide	  prognostically	  relevant	  information	  that	  
differs	   from	   the	   information	  provided	  by	   other	   biomarkers,	   due	   to	   their	   static	   nature	   231.	  
Therefore,	   due	   to	   the	   complexity	   of	   the	   various	   interacting	   pathways	   involved	   in	   the	  
regulation	   of	   adrenocortical	   function,	   and	   the	   dynamic	   partnership	   between	   the	   foetal	  
adrenal	  and	  the	  placenta,	   it	  would	  be	  interesting	  to	  develop	  similar	  models	  to	  explore	  the	  
role	  these	  play	  in	  pregnancy	  and	  the	  timing	  of	  parturition	  85.	  	  
	  
Preterm	  birth	  is	  one	  of	  the	  greatest	  threats	  to	  the	  developing	  foetus	  and	  a	  major	  cause	  of	  
perinatal	  morbidity	  and	  mortality.	  It	  is	  evident	  that	  the	  foetal	  adrenal	  cortex,	  together	  with	  
the	   placenta	   forms	   a	   unique	   foeto-­‐maternal	   endocrine	   unit	   that	   regulates	   oestrogen	  
production	  during	  development,	   and	   is	  modulated	  by	  placental	   regulators.	   Future	   studies	  
may	  be	  warranted,	  examing	  the	  role	  of	  kisspeptin	  as	  a	  potential	  novel	  biomarker	  for	  at-­‐risk	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pregnancies,	   as	   these	   may	   reveal	   targets	   for	   therapeutic	   agents	   which	   could	   arrest	  
threatened	  spontaneous	  preterm	  birth.	  	  
6.5 Conclusion	  
Kisspeptin-­‐Kiss1R	  signalling	  may	  be	  a	  key	  regulator	  of	  HFA	  development	  and	  steroidogenesis	  
and	   therefore	  an	   integral	   component	  of	   the	   foeto-­‐placental	  unit.	   There	   is	   scope	   for	  more	  
research	  into	  further	  defining	  the	  underlying	  molecular	  mechanisms	  involved	  in	  the	  control	  
of	   foetal	  adrenal	  development	  by	  kisspeptin.	   	  As	  well	  as	  being	  critical	   in	   the	   regulation	  of	  
placentation	  in	  early	  pregnancy,	  kisspeptin	  may	  have	  a	  key	  physiological	  role	  in	  intrauterine	  
homeostasis	  and	  the	  maintenance	  of	  pregnancy,	  particularly	  in	  the	  second	  trimester.	  There	  
is	  a	  need	  to	  further	  evaluate	  the	  role	  of	  kisspeptin	   in	  the	  third	  trimester,	  particularly	  with	  
respect	  to	  adverse	  outcomes	  of	  pregnancy,	  and	  this	  information	  may	  help	  in	  directing	  future	  
patient	   surveillance.	   Therefore,	   overall	   this	   data	   suggests	   a	   novel	   functional	   role	   for	  
kisspeptin	  in	  utero.	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APPENDIX	  5:	  PARTICIPANT	  INFORMATION	  SHEET	  
	  
	   	  
	  
Kisspeptin	  and	  CRH:	  Placental	  hormones	  in	  pregnancy	  that	  may	  influence	  premature	  
birth	  and	  newborn	  adaptation	  to	  postnatal	  life	  
	  
Patient	  information	  sheet	  
	  
What	  is	  the	  purpose	  of	  this	  study?	  
The	  way	  in	  which	  normal	  pregnancy	  is	  maintained	  allowing	  an	  unborn	  baby	  to	  remain	  inside	  the	  mother	  
until	  their	  due	  date	  is	  not	  well	  understood.	  Over	  the	  past	  20	  years	  the	  number	  of	  babies	  born	  
prematurely,	  before	  their	  expected	  date	  of	  delivery,	  has	  risen.	  Premature	  birth	  is	  one	  of	  the	  biggest	  
threats	  to	  unborn	  babies	  and	  is	  a	  major	  cause	  of	  sickness	  and	  death	  after	  birth,	  as	  well	  as	  long-­‐term	  
health	  problems.	  
	  
During	  pregnancy	  the	  unborn	  baby	  communicates	  with	  the	  mother	  via	  the	  placenta,	  which	  connects	  the	  
two	  together.	  Signals	  passing	  back	  and	  forth	  between	  mother	  and	  baby	  are	  likely	  to	  help	  maintain	  a	  
pregnancy,	  enabling	  a	  baby	  to	  grow	  and	  develop.	  Hormones	  are	  natural	  chemical	  signals	  produced	  by	  
the	  body,	  and	  we	  think	  that	  hormones	  produced	  by	  the	  placenta	  and	  by	  a	  baby’s	  adrenal	  gland,	  (a	  small	  
gland	  that	  sits	  on	  top	  of	  the	  kidneys)	  may	  be	  important	  in	  this	  process.	  This	  study	  is	  being	  carried	  out	  in	  
order	  to	  better	  understand	  the	  way	  in	  which	  the	  placenta	  and	  the	  adrenal	  gland	  of	  the	  unborn	  baby	  
communicate	  with	  each	  other	  via	  hormone	  signals.	  We	  would	  like	  to	  know	  if	  hormones	  produced	  by	  the	  
placenta	  and	  the	  unborn	  baby’s	  adrenal	  gland	  help	  to	  maintain	  pregnancy	  until	  the	  correct	  gestational	  
due	  date	  as	  well	  as	  helping	  the	  baby	  grow	  and	  mature	  in	  preparation	  for	  life	  after	  birth.	  
	  
It	  is	  already	  known	  that	  hormones	  produced	  by	  the	  unborn	  baby’s	  adrenals	  signal	  to	  the	  placenta,	  
affecting	  the	  way	  the	  placenta	  works	  as	  pregnancy	  progresses.	  We	  would	  like	  to	  know	  if	  a	  mutual	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relationship	  exists:	  if	  hormones	  produced	  by	  the	  placenta	  can	  signal	  to	  the	  unborn	  baby’s	  adrenal	  and	  
affect	  the	  growth,	  development	  and	  the	  way	  this	  organ	  works	  during	  pregnancy,	  as	  well	  as	  progression	  
of	  the	  pregnancy	  itself.	  Two	  hormones	  produced	  by	  the	  placenta	  are	  kisspeptin	  and	  corticotropin	  
releasing	  hormone	  (CRH).	  The	  levels	  of	  both	  these	  hormones	  in	  the	  mother’s	  blood	  increase	  
dramatically	  as	  pregnancy	  progresses	  and	  it	  is	  not	  clear	  why	  this	  happens.	  
	  
We	  would	  like	  to	  measure	  the	  levels	  of	  kisspeptin	  and	  CRH	  at	  different	  stages	  of	  pregnancy	  and	  see	  if	  
these	  levels	  correlate	  with	  the	  growth	  of	  the	  unborn	  baby’s	  adrenal	  glands	  during	  pregnancy,	  and	  
outcomes	  of	  pregnancy	  including	  the	  gestation	  at	  which	  the	  baby	  is	  born,	  the	  production	  of	  steroid	  
hormones	  from	  the	  baby’s	  adrenal	  gland	  after	  birth	  and	  how	  well	  the	  baby	  adapts	  to	  life	  after	  birth.	  
	  
Why	  have	  you	  been	  invited?	  
Previous	  scientific	  studies	  have	  looked	  at	  the	  effect	  of	  CRH	  on	  the	  progression	  of	  pregnancy,	  however	  
many	  unanswered	  questions	  remain,	  as	  CRH	  levels	  do	  not	  always	  correlate	  with	  the	  onset	  of	  labour.	  
The	  reason	  why	  kisspeptin	  levels	  increase	  so	  high	  as	  pregnancy	  progresses	  what	  kisspeptin	  does	  is	  
unknown.	  There	  is	  no	  scientific	  data	  correlating	  levels	  of	  placental	  kisspeptin	  and	  CRH	  with	  growth	  of	  
the	  unborn	  baby’s	  adrenal	  gland	  and	  outcomes	  of	  pregnancy.	  We	  therefore	  aim	  to	  study	  women	  who	  
have	  normal	  pregnancies	  booking	  here	  at	  the	  Royal	  London	  Hospital,	  and	  compare	  this	  group	  to	  
women	  whose	  pregnancies	  are	  complicated	  by	  pre-­‐eclampsia	  (a	  condition	  where	  the	  placenta	  does	  not	  
work	  properly).	  
	  
You	  have	  been	  invited	  because	  at	  your	  12-­‐week	  scan	  your	  Obstetric	  doctor	  noted	  a	  finding	  of	  abnormal	  
uterine	  artery	  Doppler	  measurements.	  Previous	  studies	  carried	  out	  in	  this	  department	  have	  shown	  that	  
this	  finding	  occurs	  in	  1	  in	  5	  of	  all	  pregnant	  women.	  This	  finding	  is	  associated	  with	  an	  increased	  risk	  of	  
pre-­‐eclampsia	  in	  35%	  of	  cases.	  65%	  of	  women,	  however,	  will	  go	  on	  to	  have	  an	  uncomplicated	  normal	  
pregnancy.	  At	  this	  stage	  your	  Obstetric	  doctor	  will	  continue	  to	  follow	  you	  up	  closely.	  In	  conjunction	  with	  
their	  follow	  up	  of	  your	  antenatal	  care	  we	  are	  inviting	  you	  to	  participate	  in	  our	  study,	  which	  is	  being	  run	  in	  





How	  will	  the	  studies	  affect	  your	  treatment?	  
The	  study	  will	  not	  affect	  the	  antenatal	  care	  or	  treatment	  you	  are	  receiving.	  The	  results	  from	  the	  study	  
may	  improve	  our	  understanding	  of	  factors	  that	  can	  influence	  pregnancy,	  which	  can	  be	  useful	  in	  the	  
future.	  
	  
What	  are	  the	  side	  effects	  of	  any	  treatment	  received	  when	  taking	  part?	  
There	  are	  no	  treatments	  included	  in	  this	  study.	  You	  will	  be	  required	  to	  attend	  additional	  appointments	  
for	  extra	  ultrasound	  scans	  and	  blood	  tests	  however	  these	  will	  not	  harm	  your	  baby	  or	  you	  in	  any	  way.	  
	  
Do	  you	  have	  to	  take	  part?	  
It	  is	  up	  to	  you	  to	  decide	  whether	  to	  take	  part	  or	  not	  because	  participation	  in	  the	  research	  study	  is	  
completely	  voluntary.	  If	  you	  do	  agree	  to	  take	  part	  you	  will	  be	  given	  this	  information	  sheet	  to	  keep.	  In	  
addition,	  you	  will	  also	  be	  given	  a	  consent	  form	  to	  sign.	  You	  are	  under	  no	  obligation	  to	  participate	  in	  any	  
part	  of	  this	  study,	  and	  you	  may	  withdraw	  at	  any	  time	  without	  giving	  a	  reason.	  This	  will	  not	  affect	  the	  care	  
you	  are	  receiving	  in	  any	  way.	  
	  
What	  will	  happen	  if	  you	  take	  part?	  
You	  have	  been	  invited	  back	  for	  your	  second	  trimester	  anomaly	  ultrasound	  scan	  at	  18–22	  weeks.	  At	  this	  
time	  if	  you	  give	  your	  consent	  to	  participate	  in	  this	  study	  you	  will	  be	  asked	  to	  sign	  a	  written	  consent	  form.	  
You	  will	  have	  your	  anomaly	  scan	  performed	  in	  the	  Foetal	  Medicine	  Unit	  by	  a	  trained	  specialist	  senior	  
obstetric	  doctor	  who	  will	  also	  perform	  a	  detailed	  scan	  to	  measure	  the	  size	  of	  the	  adrenal	  gland	  that	  sits	  
on	  top	  of	  your	  baby’s	  kidneys.	  This	  will	  not	  cause	  discomfort	  to	  you	  nor	  will	  it	  affect	  your	  baby	  in	  any	  
way.	  The	  detailed	  scan	  will	  take	  around	  an	  extra	  10	  minutes	  in	  addition	  to	  your	  routine	  scan.	  
	  
After	  the	  scan,	  you	  will	  be	  seen	  by	  a	  member	  of	  the	  research	  team	  who	  will	  take	  extra	  samples	  of	  
blood	  (total	  ~10ml	  of	  blood)	  for	  the	  research	  study.	  
	  
The	  detailed	  scans	  along	  with	  the	  blood	  tests	  will	  be	  repeated	  on	  3	  further	  occasions:	  at	  28	  weeks,	  34	  
weeks,	  38	  weeks	  gestation.	  These	  additional	  scans	  and	  blood	  tests	  may	  require	  extra	  hospital	  visits	  
and	  each	  appointment	  could	  last	  up	  to	  30	  minutes.	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If	  your	  obstetric	  doctor	  wishes	  to	  follow	  you	  up	  more	  closely	  in	  the	  event	  of	  any	  complications,	  such	  as	  
pre-­‐eclampsia,	  the	  timing	  of	  these	  additional	  investigations	  will	  be	  adjusted	  to	  coincide	  with	  your	  follow	  
up	  and	  minimise	  any	  inconvenience	  to	  you.	  You	  will	  be	  seen	  in	  the	  Foetal	  Medicine	  Unit	  at	  the	  Royal	  
London	  Hospital	  by	  a	  doctor	  from	  the	  Obstetric	  team	  and	  a	  member	  of	  the	  research	  team	  on	  each	  
occasion.	  
	  
After	  delivery,	  a	  final	  blood	  test	  will	  be	  taken	  from	  you	  prior	  to	  discharge	  home.	  With	  your	  consent,	  at	  
the	  time	  of	  delivery,	  we	  would	  also	  like	  to	  take	  a	  biopsy	  sample	  from	  the	  placenta,	  and	  some	  blood	  from	  
the	  umbilical	  cord	  once	  the	  cord	  has	  been	  clamped	  and	  cut.	  These	  samples	  will	  be	  frozen	  and	  stored	  
for	  future	  research.	  Any	  future	  research	  studies	  will	  be	  carried	  out	  only	  once	  ethical	  approval	  has	  been	  
obtained.	  
	  
About	  5-­‐7	  days	  after	  the	  birth	  of	  your	  baby,	  we	  will	  invite	  you	  back	  to	  attend	  the	  hospital	  in	  order	  for	  
your	  baby	  to	  have	  an	  abdominal	  ultrasound	  scan	  to	  again	  measure	  the	  adrenal	  gland.	  The	  scan	  will	  be	  
performed	  by	  a	  specialist	  paediatric	  radiology	  consultant	  in	  the	  radiology	  department	  at	  the	  Royal	  
London	  Hospital.	  This	  will	  not	  harm	  your	  baby	  or	  influence	  any	  medical	  care	  they	  may	  be	  receiving.	  
Prior	  to	  discharge	  from	  hospital,	  you	  will	  have	  been	  provided	  with	  a	  urine	  bag	  and	  instructions	  on	  how	  
to	  collect	  a	  urine	  sample	  from	  your	  baby.	  A	  member	  of	  the	  research	  team	  will	  take	  the	  urine	  sample	  
from	  you	  after	  the	  scan.	  This	  sample	  will	  be	  used	  to	  measure	  hormone	  levels	  produced	  by	  your	  baby’s	  
adrenal	  gland.	  At	  this	  time	  we,	  with	  your	  consent,	  we	  would	  also	  like	  to	  take	  a	  whole	  blood	  sample	  (total	  
~2ml	  of	  blood)	  from	  your	  baby	  for	  storage.	  Your	  baby’s	  Guthrie	  test	  can	  be	  performed	  by	  a	  trained	  
senior	  paediatrician	  at	  the	  same	  time	  as	  the	  study	  blood	  sample	  is	  taken	  if	  you	  would	  like	  this	  to	  be	  
done	  in	  hospital.	  Taking	  a	  blood	  sample	  can	  be	  uncomfortable	  for	  your	  baby	  but	  is	  done	  routinely	  at	  this	  
age.	  The	  newborn	  screening	  test	  (Guthrie	  test),	  which	  is	  done	  at	  5-­‐7	  days	  of	  life,	  usually	  by	  a	  midwife,	  
is	  recommended	  for	  all	  babies.	  It	  tests	  babies	  for	  serious	  disorders	  for	  which	  early	  treatment	  can	  
prevent	  mental	  retardation,	  physical	  disability,	  or	  death.	  The	  test	  is	  performed	  by	  pricking	  your	  baby’s	  
heel	  or	  taking	  blood	  from	  a	  vein	  to	  obtain	  5	  spots	  of	  blood	  on	  a	  special	  filter	  paper.	  
	  
At	  6-­‐8	  weeks	  we	  will	  invite	  you	  back	  again	  to	  attend	  the	  hospital	  in	  order	  for	  your	  baby	  to	  have	  a	  2nd	  
abdominal	  ultrasound	  scan	  and	  provide	  a	  urine	  sample.	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If	  for	  whatever	  reason	  your	  baby	  is	  still	  in	  hospital,	  we	  will	  arrange	  for	  investigations	  to	  take	  place	  in	  the	  
hospital	  depending	  on	  where	  your	  baby	  is.	  
	  
Will	  my	  taking	  part	  in	  this	  study	  be	  kept	  confidential?	  
Only	  the	  medical	  team	  taking	  care	  of	  you	  and	  the	  individuals	  doing	  the	  research	  will	  have	  access	  to	  
your	  personal	  information	  and	  the	  data	  collected	  during	  the	  study.	  If	  you	  consent	  to	  take	  part	  in	  the	  
research	  the	  people	  conducting	  the	  study	  will	  abide	  by	  the	  Data	  Protection	  Act	  1998,	  and	  the	  rights	  you	  
have	  under	  this	  Act.	  You	  will	  be	  asked	  on	  the	  consent	  form	  whether	  you	  agree	  to	  your	  clinical	  
information	  being	  shared	  with	  the	  research	  team.	  All	  the	  information	  that	  is	  collected	  about	  you	  during	  
the	  course	  of	  the	  study	  will	  be	  kept	  strictly	  confidential.	  We	  will	  not	  share	  the	  clinical	  data	  or	  results	  with	  
anyone	  other	  than	  the	  obstetric	  doctors	  involved	  in	  your	  care.	  All	  the	  clinical	  details	  and	  results	  will	  be	  
kept	  on	  a	  secure,	  password	  protected	  computer	  database	  at	  Queen	  Mary	  University	  of	  London.	  This	  
information	  will	  only	  be	  used	  for	  research	  purposes.	  We	  will	  notify	  your	  GP	  that	  you	  are	  taking	  part	  in	  
the	  study	  unless	  you	  ask	  us	  not	  to.	  
	  
What	  will	  be	  done	  with	  the	  information	  and	  samples	  used	  in	  the	  research?	  
All	  clinical	  information	  and	  samples	  that	  are	  collected	  during	  the	  course	  of	  this	  research	  will	  be	  used	  to	  
gain	  further	  information	  about	  factors	  that	  may	  influence	  the	  timing	  of	  birth	  and	  the	  way	  a	  baby	  adapts	  
to	  life	  after	  birth.	  Samples	  and	  the	  data	  will	  be	  stored	  securely.	  Only	  the	  study	  doctors	  will	  have	  access	  
to	  your	  identity,	  the	  study	  data	  and	  study	  samples.	  The	  samples	  will	  be	  kept	  for	  future	  ethically	  
approved	  research	  projects	  only	  if	  you	  consent	  for	  use	  of	  your	  stored	  sample	  for	  future	  research	  
purposes.	  Your	  clinical	  data	  will	  be	  securely	  destroyed	  at	  the	  end	  of	  the	  research	  studies.	  
	  
What	  if	  relevant	  new	  information	  becomes	  available?	  
If	  the	  study	  is	  stopped	  for	  any	  reason,	  we	  will	  tell	  you	  and	  arrange	  your	  continuing	  care	  with	  the	  relevant	  
medical	  team.	  Likewise	  if	  any	  of	  the	  scans	  reveal	  any	  abnormalities,	  you	  will	  be	  referred	  to	  the	  
appropriate	  team	  for	  further	  management	  as	  per	  routine.	  As	  there	  is	  limited	  information	  regarding	  
normal	  levels	  of	  kisspeptin	  and	  CRH	  in	  pregnancy,	  and	  it	  is	  very	  unclear	  what	  these	  levels	  mean,	  this	  
information	  will	  not	  be	  shared	  until	  completion	  of	  the	  study.	  Similarly	  growth	  of	  your	  unborn	  baby’s	  
adrenal	  gland	  will	  be	  monitored	  but	  again	  standardised	  normal	  measurements	  do	  not	  exist,	  so	  this	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information	  will	  not	  be	  made	  available	  until	  completion	  of	  the	  study.	  The	  urine	  results	  from	  your	  baby	  
will	  be	  shared	  with	  you	  and	  your	  GP	  if	  any	  abnormalities	  are	  detected	  and	  your	  baby	  will	  be	  referred	  to	  
the	  appropriate	  team	  for	  further	  management.	  
	  
What	  happens	  if	  there	  is	  a	  problem?	  
If	  you	  have	  a	  concern	  about	  any	  aspect	  of	  this	  study,	  you	  should	  ask	  to	  speak	  to	  the	  researchers	  who	  
will	  do	  their	  best	  to	  answer	  your	  questions	  [see	  contact	  details	  below].	  If	  however	  you	  would	  like	  to	  
pursue	  this	  formally	  then	  please	  contact	  Patient	  Advice	  and	  Liaison	  Service	  (PALS)	  if	  you	  have	  any	  
concerns	  regarding	  the	  care	  you	  have	  received,	  or	  as	  an	  initial	  point	  of	  contact	  if	  you	  have	  a	  
complaint	  (telephone	  020	  359	  42040	  /	  42050,	  or	  email	  PALS@bartsandthelondon.nhs.uk).	  You	  can	  
also	  visit	  PALS	  in	  person	  at	  the	  Royal	  London	  Hospital.	  
	  
What	  will	  happen	  to	  the	  results	  of	  this	  study?	  
The	  results	  of	  this	  research	  may	  be	  presented	  at	  scientific	  meetings	  and	  published	  in	  scientific	  
journals.	  No	  identifiable	  patient	  information	  will	  be	  included	  and	  all	  data	  will	  be	  anonymised	  before	  
presentation	  or	  publication.	  
	  
Who	  is	  funding	  the	  research?	  
The	  Central	  and	  East	  London	  Comprehensive	  Local	  Research	  Network	  is	  currently	  meeting	  the	  cost	  
of	  this	  study.	  No	  payment	  is	  being	  given	  to	  the	  doctors	  or	  researchers	  for	  including	  you	  in	  this	  study.	  
	  
Who	  has	  reviewed	  the	  research?	  
The	  research	  proposal	  has	  been	  reviewed	  by	  a	  Local	  Ethics	  Committee,	  which	  has	  approved	  this	  
study.	  The	  project	  is	  registered	  with	  the	  Research	  and	  Development	  Office	  at	  Barts	  Health	  NHS	  
Trust.	  
	  
Who	  can	  I	  contact	  to	  find	  out	  more	  about	  this	  study?	  
If	  you	  have	  any	  questions	  please	  contact	  the	  following	  research	  team	  members:	  
Dr	  Harshini	  Katugampola,	  Dr	  Muriel	  Meso	  (Tel:	  020	  78826243	  E-­‐mail:	  endocrinology@qmul.ac.uk)	  
Thank	  you	  for	  considering	  taking	  part	  in	  this	  important	  study.	  We	  very	  much	  appreciate	  your	  help.	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